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Abstract
Investigations on the role of efflux pumps in drug resistance of human
cancer cells
Cathal Elliott
The toxicity of a specific group of chemotherapeutic drugs was demonstrated to 
be enhanced in the presence of non-toxic concentrations of a number of non­
steroidal anti-inflammatory drugs (NSAIDs). This was found to occur in the drug 
sensitive A549 human lung adenocarcinoma and D LKP human lung squamous 
carcinoma cell lines.
The chemotherapeutic drugs for which the toxicity enhancement effect was found 
to occur (adriamycin, daunorubicin, epirubicin, vincristine and VP-16) share the 
property of being potential substrates for the multidrug resistance associated 
protein (MRP). The toxicity of drugs which were not MRP-substrates, was 
unaffected by NSAID treatment. The toxicity of non-chemotherapeutic drug 
substrates for MRP, such as the heavy metal sodium arsenate was also found to 
be enhanced in the presence of a suitable NSAID.
NSAIDs are believed to exert their anti-inflammatory, analgesic and antipyretic 
effects in vivo as a result of their ability to inhibit the enzyme prostaglandin H 2 
synthase (PGHS), which is also known as cyclooxygenase (COX). The only 
NSAIDs found to possess chemotherapeutic drug toxicity enhancing abilities 
were: indomethacin, sulindac, sulindac sulfide, sulindac sulfone, tolmetin, 
acemetacin, mefenamic acid and zomepirac. The mechanism by which these 
NSAIDs enhanced the toxicity of a suitable chemotherapeutic drug was 
demonstrated to be independent of any effects of NSAIDs on PGHS. This was 
conclusively demonstrated by the ability of sulindac sulfone (a metabolite of 
sulindac which is devoid of inhibitory effects on PGHS) to enhance 
chemotherapeutic drug toxicity to the same extent as achieved using sulindac 
sulfide (a metabolite of sulindac with potent inhibitory effects on PGHS).
M R P  protein was demonstrated by Western blotting to be present in low levels in 
DLKP plasma membrane-derived inside-out vesicles (10Vs). The M R P  in DLKP 
IOVs was demonstrated to actively transport the M R P  substrate leukotriene C 4 
(LtC4). This transport was shown to be inhibited by NSAIDs with drug toxicity 
enhancing abilities such as indomethacin, but was unaffected by NSAIDs which 
were without influence on chemotherapeutic dmg toxicity. These results 
suggested that NSAID-mediated enhancement of chemotherapeutic drug toxicity 
was dependent on the ability of an NSAED to interfere with the drug efflux 
activity of MRP.
The presence of M R P  protein in 10 Vs facilitated investigation into the cytotoxic 
drug transporting characteristics of MRP. The LtC4 transport activity of M R P  in 
IOVs from the MRP-overexpressing cell line HL60-ADR was found to be 
significantly inhibited by vincristine (an M R P  substrate) but not by Taxol or 
cisplatin (non-MRP substrates). This inhibition in LtC4 transport with vincristine 
was synergistically enhanced in the presence of non-inhibitory concentrations of 
reduced glutathione (GSH). These results suggested that M R P  substrate drugs 
such as vincristine may be actively transported by M R P  in the presence of GSH.
Demonstration of the presence of active M R P  protein in DLKP suggested that 
M R P  may also have been present in resistant variants of DLKP. Active M R P  
protein was shown to be present in a variety of DLKP-related drug resistant cell 
lines namely DLKP-A10, DLKPA2B, DLKPA1 IB, DLKPA6B and DLKPA5F. 
Preliminary evidence suggested that M R P  may be involved in certain aspects of 
the cytotoxic drug accumulation characteristics of these drug resistant variants of 
DLKP.
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Introduction
1.1 General introduction
The failure of cancer cells to respond to cytotoxic chemotherapy in the laboratory 
as well as in the clinic continues to be a significant problem for cancer researchers 
and clinical oncologists. It is estimated that cancer is responsible for 
approximately 22% of all deaths in the United States, with 1 million cases 
diagnosed each year (Cooper, 1992). Cancer may be treated by surgery, 
radiotherapy or chemotherapy. Approximately half of all cancer patients can be 
cured by surgery and radiation therapy if tumors have not spread to other sites in the 
body. (Davey and Davey, 1997). Significant developments have been made in the 
field of cancer chemotherapy over the years but in many cases it is still found that 
although a tumor may be initially sensitive to chemotherapy, a relapse after 
treatment can occur. Often clinical drug resistance may involve the development 
of resistance to several mechanistically and structurally unrelated cytotoxic drugs 
simultaneously, which can cause treatment failure when the cancer recurs. In 
addition to this form of resistance, some tumors may be intrinsically resistant to 
chemotherapy (Lehnert, 1996). Multidrug resistance implies that structurally and 
functionally unrelated lipophilic drugs are recognised and processed by the molecular 
system which protects multidrug resistant cells against lipophilic cytotoxic drugs 
(Lehnert, 1996; Clynes, 1993; Kartner and Ling, 1989).
A  number of mechanisms of drug resistance have been characterised in multidrug 
resistant cancer cell lines. These mechanisms include expression of energy 
dependent transmembrane drug efflux pumps such as P-glycoprotein (Pgp) and 
multidrug resistance associated protein (MRP), reduced expression of 
topoisomerase II, and overexpression of the drug detoxifying enzyme family, the 
glutathione S-transferases (Bellamy, 1996; Clynes, 1993). The knowledge 
developed from studying the resistance mechanisms in cellular models of 
multidrug resistance (MDR), has resulted in trials using novel chemotherapeutic 
strategies which aim to overcome the drug resistance possessed by some tumors 
(Ferry et al., 1996). A  number of these trials involve the use of drug efflux pump 
modulators such as verapamil in combination with cytotoxic drugs such as 
adriamycin. The results of these trials have been disappointing as these
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compounds have been found to lack the potency to completely reverse the M D R  
phenotype at clinically relevant concentrations. Many of the modulators currently 
being investigated in clinical trials have unacceptable toxic side effects and this 
seriously limits their potential for use as modulators of clinical drug resistance 
(Fisher and Sikic, 1995).
1.2 Cancer chemotherapy
The origins of modem cancer chemotherapy date from 1942 when Gilman, Goodman, 
Lindskog and Dougherty used nitrogen mustard in a patient with lymphosarcoma 
(Pratt et a/.., 1994). Since that first treatment a large number of chemotherapeutic 
drugs have been developed for clinical use. These drugs may be classified into a 
number of specific drug classes primarily based on their mode of activity. These 
classes include the anthracyclines, epipodophyllotoxins, the vinca alkaloids, the 
antimetabolites, as well as the covalent and non-covalent inhibitors of D N A  (Pratt et 
al., 1994).
Tumours with a high rate of growth such as in human lymphomas and childhood 
leukaemias, can generally be effectively treated by chemotherapy (Cooper, 1992). 
The majority of chemotherapeutic drugs either inhibit D N A  synthesis, cause D N A  
damage or in some way interfere with cell division. For this reason, one of the limiting 
factors in chemotherapy is the relative drug sensitivity of the cancer cells compared to 
the patient’s normal cells which possess a high growth rate such as in the bone 
marrow. Colorectal, lung and breast tumors account for almost half of all cancer 
deaths in the United States (Cooper, 1992). These tumors possess a low fraction of 
dividing cells and this contributes to them being relatively resistant to treatment by 
chemotherapy alone. Cancers of the colon and rectum are among the most common 
cancers in developed countries, accounting for 13% of all cancers diagnosed and 11% 
of all cancer deaths (Weiss and Forman, 1996), with the incidence rate remaining 
relatively constant in recent years. The morbidity from lung cancer has increased 
considerably over the past 50 years. The prognosis is very poor with nearly 80% of 
lung cancer patients dying within 1 year of diagnosis. Despite advances in
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chemotherapy, long term survival is obtained in only 5-10% of the patients (Mattem 
and Volm, 1995). Breast cancer is one of the most frequent cancers in women, 
accounting for approximately 30% of all cancers in females with the mortality rate 
second only to lung cancer in American women (Cooper, 1992). The relative 
inability of current chemotherapy regimes to significantly reduce the mortalities 
resulting from colorectal, lung, breast and other cancers has stimulated the 
development of novel strategies to overcome the resistance of these cancers to 
chemotherapy.
1.2.1 The anthracyclines
The anthracyclines are among the most commonly used cancer chemotherapeutic 
drugs. This group describes a class of antitumor antibiotics isolated from various 
Stixplomyces species and includes adriamycin (also known as doxorubicin), 
daunorubicin and epirubicin. Adriamycin is used in the treatment of a variety of 
carcinomas including lung, bladder, breast, endometrium, stomach, ovarian and 
thyroid, soft tissue sarcomas, paediatric solid tumours as well as lymphoid and 
myelogenous tumours (Pratt et a l, 1994). It is administered intravenously at a dose of 
60 mg/m2 which is repeated after a period of 21 days. This is associated with a rapid 
uptake of the drugs in the lungs, heart, kidney, liver and spleen. Adriamycin is 
metabolised in the liver and excreted in the bile resulting in the elimination of 
adriamycin from the body. This elimination follows a 2 phase pharmokinetic profile 
with a initial half life (a t'A) of approximately 10 minutes and a second half life (13 t'A) 
of approximately 30 hours (Pratt et al., 1994). As with all cancer chemotherapeutic 
drugs, adriamycin has serious side effects. This drug is a carcinogen and a mutagen, 
but in addition it may also cause immunosuppression (Pratt et al., 1994). Adriamycin 
also possesses significant cardiotoxic effects and this cardiotoxicity is shared by other 
anthracyclines (Gaudin et al., 1993; Unverferth et al., 1982) and is believed to be due 
to the generation of active oxygen species from oxygen (Pratt et a l, 1994).
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The therapeutic advantage in the use of anthacyclines in cancer chemotherapy is a 
result of the ability of these drugs to bind to D N A  and RNA. These drugs bind tightly 
to D N A  and during their intercalation, their amino sugar moiety becomes located 
within the minor groove of DNA. This causes extensive interaction between the 
hydrophobic faces of the base pairs and the drug. Intercalation of the aglycone moiety 
between adjacent D N A  base pairs can cause an inhibition of D N A  replication as well 
as R N A  synthesis and transcription. A  stabilisation of the topoisomerase It-DNA 
complex, which causes protein associated D N A  strand breaks has also been reported 
to occur in the presence of anthracyclines (Pratt et a l, 1994). Anthracyclines have 
been shown to undergo metabolism to form a free radical molecule with the ability to 
form superoxides which can cause single strand D N A  breaks, lipid peroxidation and 
disruption of cell membrane function and integrity (Skladanowski and Konopa, 1994; 
Skladanowski and Konopa, 1993; Bachur et al., 1977). The cytotoxicity induced by 
adriamycin has been reported as occurring even in the absence of significant D N A  
damage (Triton and Lee, 1982). This does not appear to be the dominant mechanism 
of action of anthracyclines, as when adriamycin is altered so that the ability of the drug 
to bind D N A  and R N A  is decreased, the level of cytotoxicity achieved by the drug is 
significantly reduced (Pratt et al., 1994).
1.2.2 Vinca alkaloids
The vinca alkaloids are derived from extracts isolated from the periwinkle plant 
Catharanthus roseus and include chemotherapeutic drugs such as vincristine and 
vinblastine. Vincristine is often used in the treatment of childhood leukemia and 
vinblastine is regularly used in a variety of combination chemotherapy regimes often 
involving cisplatin or bleomycin (Pratt et al., 1994). Vincristine can also be used to 
treat acute leukaemia, aggressive non-Hodgkin's lymphoma, Hodgkin's lymphoma, 
small cell lung cancer, Wilm's tumour and neuroblastoma (Pratt et a l, 1994). 
Vincristine is administered intravenously and is eliminated from the body with 
characteristic triexponential kinetics, with a and 13 half lives of 3 minutes and 100 
minutes respectively, and a terminal half life of over 85 hours (Pratt et al., 1994).
5
Vincristine is eliminated from the body after metabolism in the liver and by biliary 
excretion. Only a fraction of vinca alkaloid end products are found to be present in the 
urine (Owellan et al., 1977).
Vinca alkaloids can cause cell cycle metaphase arrest and a resultant block in mitosis. 
Vincristine disrupts the mitotic spindle which results in the cells becoming blocked in 
the mitotic phase of the cell cycle. The disruption of the mitotic spindle is caused by 
the binding of vincristine to free tubulin dimers. This results in the formation of 
paracrystalline aggregates which interfere with microtubule polymerisation and 
ultimately cause dissolution of the microtubules (Pratt et a l, 1994). In the absence of 
an intact mitotic spindle, the chromosomes become unable to segregate correctly and 
this eventually results in cell death. Mutations involving alterations in tubulin proteins 
have been shown to effect the ability of vinca alkaloids to achieve their cytotoxic 
effects (Cabral et al., 1980; Ling et al., 1979). The vinca alkaloids have also been 
shown to indirectly affect DNA, R N A  and lipid biosynthesis (Jordan et al., 1992; 
Jordan et al., 1991).
1.2.3 Epipodophyllotoxins
The plant Podophylhm peltatum (American mandrake) produces podophyllotoxin, a 
mitotic inhibitor that acts by binding to tubulin and that prevents the formation of 
microtubules by blocking polymerisation of tubulin (Long, 1992). Podophyllotoxin 
was evaluated in the clinic in the early 1950s but had poor antitumor activity and 
excessive toxicity. Semi-synthetic derivatives of podophyllotoxin are now available 
and these include etoposide (VP-16) and teniposide (VM-26). These semisynthetic 
derivatives have been used in the treatment of a number of different types of cancers. 
VP-16 is used in the treatment of small cell bronchogenic carcinoma, testicular 
carcinoma, lymphoma, leukaemia and Kaposi’s sarcoma (Van Maanen et al., 1988a; 
Van Maanen et al., 1988b).
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VP-16 and VM-26 are normally administered intravenously with at a dose of 60-120 
mg/m2 daily for 5 days (Carter et al., 1987). Metabolism follows biphasic kinetics with 
a half lives o f 3 and 15 hours. Approximately 50% of the drug can be recovered 
unchanged in urine with a significant fraction recovered in the bile as hydroxy acid, 
glucuronide and sulphate conjugate metabolites (Pratt et a l, 1994). Haematologic 
toxicity is usually the dose limiting factor in the treatment of cancer patients with 
epipodophyllotoxins. The use of these drugs can result in leukopenia and 
thrombocytopenia. Gastrointestinal toxicity results in nausea and mild vomiting, but in 
addition alopecia can occur in of 8-20% of patients (Carter et a l, 1987).
The primary target of VP-16 and VM-26 is cellular DNA. Topoisomerase II binds to 
double stranded DNA making a transient double strand break. Topoisomerase II is 
activated by sites on chromosomes where two double helices become crossed over 
one another. When the topoisomerase binds, it causes a reversible breakage in one 
double helix to create a DNA gate. This allows the second double helix to pass 
through this break. Topoisomerase II then reseals the breakage in DNA and finally 
dissociates from the DNA, (Alberts etal., 1994). The epiodophyllotoxins achieve their 
cytotoxic effects by stabilising the complex formed between topoisomerase II and the 
newly cleaved DNA. This causes an interference in the activity of topoisomerase II 
which ultimately results in double strand breaks and cell death.
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1.3 The arachidonic acid Cascade
The arachidonic acid cascade is a cascade of events that results in the formation of 
prostaglandins (Pgs), leukotrienes (Lts), thromboxanes (Txs) and various hydroxy 
(HETEs) and hydroperoxy fatty acids (HPETEs). The end products of the arachidonic 
acid cascade are collectively referred to as eicosanoids and the biochemical pathway 
required for their formation is shown in simplified schematic form in Figure 1.3.1. In 
humans the most important precursor for eicosanoid biosynthesis is arachidonic acid 
(AA), a C20 polyunsaturated fatty acid with four non-conjugated double bonds which 
is derived directly from the diet or via modification of linoleic acid (Burgoyne and 
Morgan, 1990). The rate limiting step in the arachidonic acid cascade is the initial step 
involving the calcium dependent release of free AA from the cell phospholipid pool by 
phospholipases such as phospholipase A2 (Lapetina, 1982). This cytosolic enzyme 
hydrolyses acyl groups at C2 of phopholipids such as phosphatidylcholine, 
phophatidylethanolamine and phosphatidylinositol, (Lauritsen et. a/., 1994). An 
increase in free AA levels within the cell can also be generated directly or indirectly by 
phospholipid breakdown by other phospholipases such as phospholipases Ai, C or D 
(Burgoyne and Morgan, 1990). Activation of phospholipase A2 can occur upon 
stimulation of specific cell surface receptors. These stimuli include bradykinin, 
thrombin, ADP, chemotactic peptides and histamine, (Lapetina, 1982). Enzyme 
studies have shown that maximal phospholipase A2 activation is dependent on the 
synergistic action of two factors (Berlin and Preston, 1995). The first of these factors 
involves an increase in intracellular free calcium levels which is necessary for enzyme 
catalysis and translocation to the membrane. The second factor involves specific 
phosphorylation of the enzyme by a mitogen activated protein (MAP) kinase (Berlin 
and Preston, 1995).
Membrane Phospholipids
1 p l a 2
Arachidonic Acid
5-LOX
LtAj
LtB4 LtC4
COX
LtD4
LtE4
Figure 1.3.1: The arachidonic acid cascade. All enzymes are signified by bold type. 
PLA2 indicates phospholipase A2, COX indicates prostaglandin H 2 synthase and LOX 
indicates lipoxygenase. Details of other abbreviations are provided in Section 1.3
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After liberation from cell membrane phospholipids, AA than becomes available for 
enzymatic modification to eicosanoids (Needleman el a l, 1986). The most extensively 
characterised branches of the arachidonic acid cascade are the prostaglandin 
endoperoxide synthase (also known as PGHS, cyclooxygenase or COX) and the 
lipoxygenase (LOX) catalysed branches of the arachidonic acid cascade, (Needleman 
el a l, 1986). The COX or PGHS catalysed branch of the AA cascade results in the 
formation of prostaglandins (such as PgE2), thromboxanes (TxA2 and TxB2) and 
prostacyclin (Pgl2), which are collectively known as the prostanoids (Needleman el 
a l, 1986). The lipoxygenase catalysed branch of the arachidonic acid cascade may 
result in the formation of leukotrienes (such as LtC4), as well as hydroxy and 
hydroperoxy fatty acids (HETEs and HPETEs), (Henderson, 1994).
Prostaglandins possess a cyclopentane ring and two side chains with a carboxyl group 
in one side chain (Needleman et a l, 1986). The first prostaglandins to be discovered 
were designated PgE and PgF respectively because of their preferential solubility in 
ether (E) and phosphate buffer (F for fosfat, or phosphate in Swedish). A subscript 
number such as in PgE2 denotes the number of double bonds in the two chains, with 
two double bonds being most common for prostaglandins derived from arachidonic 
acid (Mathews and van Holde, 1990). A subscript a  such as in the case of PgF2tx 
indicates that the hydroxyl group at C9 (carbons are numbered from the carboxyl 
group at the end of the side chain) is on the same side of the ring as the adjacent C8 to 
C7 bond, (Mathews and van Holde, 1990). Similar nomenclature is used for 
thromboxanes and prostacyclin.
The labile intermediate PgH2 is the immediate precursor of all series-2 prostaglandins 
(such as PgE2), thromboxanes and prostacyclin. The fate of PgH2 is dependent on the 
relative activities of the enzymes catalysing the specific inter-conversions to either of 
the series-2 prostaglandins, thromboxanes and prostacyclin, (Hubbard el a l, 1988). 
The primary prostaglandins (PgE2, D2 and F2o)  can be formed by non-enzymatic 
degradation of the endoperoxides (PgG2 and PgH2), but formation of PgE2 and PgD2 
can also be catalysed by an isomerase (Vane, 1987). The intermediate PgH2 can also 
be metabolised to TxA2 by thromboxane synthase and to Pgl2 by Pgl2 synthase
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(Needleman et a l, 1986). These labile compounds are subsequently and rapidly 
converted to TxB2 and 6 -keto-PgFia which are stable but usually biologically inactive.
The relative amounts of individual prostanoids formed from PgH2 depend on the cell 
type in question (Lau el a l, 1987). Prostanoids exert a wide variety of effects on 
diverse tissues and cells through specific cell surface receptors (Negishi et a l, 1995). 
Prostanoid receptors are classified into five basic types on the basis of sensitivity to the 
five primary prostanoids PgE2, D2, F2(Xj, I2 and TxA2. These receptors are termed EP, 
DP, FP, IP and TP respectively. The EP family of receptors is composed of four 
subtypes namely EPi to EP4 which are produced through alternative RNA splicing 
from a single gene and which differ only in their carboxy terminal tails (Negishi et al.,
1995). The prostanoid receptors are G-protein linked and so prostanoid receptor 
binding can have a wide variety of signal transduction effects, (Di Marzo, 1995).
Leukotrienes are products of the AA cascade formed through the action of the 5- 
lipoxygenase (5-LOX) enzyme pathway (Ford-Hutchinson, 1994). To date, three 
animal lipoxygenases have been identified namely 5, 12- and 15-lipoxygenase, which 
are named after the position where oxygen is inserted into AA (Honn et al., 1994). 
The 5-LOX enzyme resides in the cytosol until cell activation induces a calcium 
dependent translocation to a putative cell membrane receptor. This enzyme and a 18 
kDa membrane protein named 5-LOX activating protein, (FLAP), are required for 
leukotriene biosynthesis in intact cells, (Brooks and Day, 1991). The activity of 5- 
LOX initially results in the formation of 5-HPETE and then in the formation of the 
unstable epoxide LtA>. This may then serve as the substrate for two enzymes namely 
LtAi hydrolase or LtC4 synthase (Needleman et al., 1986). The LtAt hydrolase 
enzyme catalyses the production of LtB4. LtC4 synthase catalyses conjugation of 
glutathione to LtA(, resulting in LtC4 production (Nelson and Seitz, 1994). The 
leukotriene LtC4 can be further metabolised to LtD4 by a glutamyl transferase enzyme 
and this can subsequently be converted to LtE4 by a dipeptidase enzyme (Eberhart and 
DuBois, 1995). The leukotrienes C4, D4 and E4 are collectively known as the cysteinyl 
leukotrienes or the slow reacting substances of anaphylaxis (SRS-A), (Needleman et 
al., 1986). The precise number as well as the specificity o f receptors for cysteinyl
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leukotrienes is currently unclear. It is known that LtD4 binds to a specific receptor that 
differs from LtB4 receptors and LtC4 receptors (Snyder and Fleisch, 1989). There 
have been no reports of a specific receptor for LtE4. These receptors are similar to 
prostanoid receptors as they are G protein linked and so receptor activation can give 
rise to a variety of cellular effects (Henderson, 1994).
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1.3.1 Prostaglandin endoperoxide H synthases -1 and -2
Prostaglandin endoperoxide H synthase (PGHS) or cyclooxygenase (COX) is one of 
the most important enzymes involved in the production of prostanoids from 
arachidonic acid. This enzyme possesses two enzymatic activities namely a 
cyclooxygenase activity, which inserts two molecules of 0 2 into arachidonic acid to 
yield PgG2, and a peroxidase activity which reduces PgG2 to the corresponding 15- 
hydroxy analogue PgH2, (Needleman et a l, 1986). This enzyme is now known to 
exist in two separate isoforms namely PGHS-1 and PGHS-2, also known as COX-1 
and COX-2. The PGHS-1 isozyme is produced constitutively in many cell types but 
synthesis of the PGHS-2 isozyme in inducible by a wide range of extracellular and 
intracellular stimuli including interleukins (Croxtall et a l, 1996), lipopolysaccharide 
(Geisel et a l, 1994), tumor necrosis factor (Geng et a l, 1995) and other factors such 
as serum, retinoic acid, epidermal growth factor, transforming growth factor-a and 
platelet activating factor (Williams and DuBois, 1996). PGHS-1 is believed to be a 
ubiquitous constitutive enzyme whereas PGHS-2 seems to be present in only a select 
number of tissues such as fibroblasts, endothelial cells, monocytes and ovarian follicles 
in response to an appropriate stimulus (Smith et a l, 1996). The PGHS-2 enzyme is 
expressed constitutively in a number of locations including tracheal epithelia, brain and 
testes (Smith ei a l, 1996).
The human PGHS-1 gene is 22.5 kb in length and composed of 11 exons and 10 
introns and is located on chromosome 9 at locus 9q32-33.3, (Kosaka et a l, 1994). 
The human PGHS-2 gene has been mapped to chromosome Iq25.2-q25.3, and is 
approximately 8.3 kB in size with 10 exons, (Kosaka et a l, 1994). The PGHS-1 gene 
lacks a TATA box but little is known of the regulation of expression of this gene. 
Expression of the PGHS-2 gene can be induced through multiple signalling pathways 
involving protein kinase C, protein kinase A, tyrosine kinases and src, (Smith et a l,
1996). The transcription of PGHS-1 and PGHS-2 gives rise to mRNAs that are 2.7 
and 4.5 kb in size (O’Banion et al., 1991). The PGHS-1 mRNA codes for the 
production of homodimer of 70 kDa subunits with 565 amino acid residues as well as 
a short signal peptide and four N-linked glycosylation sites. The PGHS-2 mRNA
13
codes for a homodimer protein composed of 70 kDa subunits, which is approximately 
75% homologous to PGHS-1 at the protein level (Williams and DuBois, 1996).
The crystallographic structure of ovine PGHS-1 has been characterised by Picot et al., 
(1994). This group showed that the enzyme possesses three independent folding units 
namely an epidermal growth factor domain, a membrane binding motif and an 
enzymatic domain. It was found that the cyclooxygenase active site was created by a 
long hydrophobic channel which was the site of NSAID (non-steroidal anti­
inflammatory drug) binding. The peroxidase active site was located within a wide cleft 
on the exterior surface of the protein, (Picot et a l, 1994). The enzyme was also 
shown to be located in a single leaflet of the lipid bilayer (Picot et a l, 1994). The 
crystal structure of PGHS-2 has been recently been reported and has been shown to 
be extremely similar to that of PGHS-1 (Smith et a l, 1996). The PGHS-1 and PGHS- 
2  isozymes are integrated into the lumenal surface of the endoplasmic reticulum and 
into the contiguous outer membrane of the nuclear envelope (Otto and Smith, 1994),
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1.3.2 Eicosanoids in cancer
A wide range of eicosanoids have been shown to be involved in the regulation, 
initiation and promotion steps in tumor development (Marnett, 1992). These 
potent biological mediators have also been shown to have important roles in the 
rate o f tumor growth and dissemination in many tumor types (Young et al.,
1985). A wide variety o f human and animal tumor types have been shown to 
produce abnormally high levels of eicosanoids, (Bennett, 1986). It is estimated 
that PGHS-2 protein levels are increased in 90% of human colon cancers and 
40% of pre-malignant colorectal adenomas, but PGHS-2 protein is not expressed 
in non-tumor colon tissue (Boolbol et al., 1996). There is no specific relationship 
between type o f tumor and the range or quantities of eicosanoids produced (Milas 
and Hanson, 1995). Hubbard et al., (1988) characterised the profile of 
prostanoids formed from endogenous arachidonic acid in 16 cell lines from 
different histological classes of carcinomas (colorectal adenocarcinomas, ovarian 
adenocarcinomas, prostate adenocarcinoma, non-small cell lung carcinoma and 
small cell lung carcinoma). It was found that PgE2 and PgF2a were the only 
prostanoids synthesised in detectable quantities and that only one of three 
colorectal adenocarcinoma derived cell lines, one of three ovarian 
adenocarcinomas derived cell lines and four of five non-small cell lung carcinoma 
cell lines produced significant levels of eicosanoids, (Hubbard et al., 1988). None 
o f the other cell lines tested produced significant levels o f prostanoids.
Eicosanoids have been shown to exert both stimulatory (Qiao et al., 1995; Zhang 
and Fulton, 1994; De Asua et al., 1975) and inhibitory effects on tumor cell 
growth (Ellis et al., 1990; Santoro et al., 1976). Studies carried out into the 
effects o f eicosanoids on tumor cell growth in vivo are complicated by the fact 
that it is often unclear if the tumor cell is responsible for eicosanoid production, or 
if the eicosanoids in question originate from other cell types in the vicinity of the 
tumor. Marnett, (1992) has reviewed studies involving human colon tumors which 
appeared to produce higher levels o f PgE2 than the surrounding mucosa. A 
number o f these studies found that enhanced prostaglandin production was due to 
host peripheral mononuclear cell activity rather than due to enhanced PgE2
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production by the tumor cells. For this reason, assessments o f the direct 
eicosanoid producing abilities of tumor cells are most effectively carried out using 
tumor cell lines (Lau et al., 1987).
Eicosanoids have been shown to be involved in tumor promotion, initiation and 
regulation as well as mutagenesis, immune suppression and metastasis (Marnett,
1992). The peroxidase activity o f PGHS is primarily responsible for the 
involvement of eicosanoids in mutagenesis (Marnett, 1994). This activity catalyses 
the oxidation of a wide range of xenobiotics including several classes o f chemical 
carcinogens (Eling and Curtis, 1992). This oxidation can result in the formation of 
mutagenic derivatives (Eling et a l., 1990). The PGHS catalysed branch of the 
arachidonic acid cascade is also responsible for the production o f a direct acting 
mutagen, malondialdehyde which has been shown to be mutagenic in bacterial and 
mammalian models as well as being carcinogenic in rats (Marnett, 1994). This 
mutagen is produced as a result of both enzymatic and non-enzymatic breakdown 
o f PgH2 (Needleman et al., 1986). Malondialdehyde has been shown to cause 
frame-shift and base-pair substitution mutations in Salmonella typhimurium 
(Mukai and Goldstein, 1976) and is known to form adducts with deoxyguanosine, 
deoxycytosine and deoxyadenosine residues (Marnett, 1994). In addition to 
generating the direct acting mutagen malondialdehyde, PGHS can generate peroxy 
radicals as reactive intermediates during the catalysis process, (Marnett, 1994). These 
radicals can oxidise the double bonds of pre-carcinogens such as benzopyrene-7,8-diol 
to the carcinogenic form (Levy, 1997).
Tumor growth is often associated with immune suppression and it has been shown 
that eicosanoids can have critical roles in this immune suppression process 
(Plescia et. al., 1975). Tumors can directly suppress host immune defences 
(directly effecting tumor infiltrating lymphocytes, circulating T-cells, natural killer 
cells and macrophages) through production of soluble immune suppressive factors 
such as PgE2. Alternatively tumors can indirectly cause immune suppression by 
stimulating host immune suppressor cells such as CD8 + suppressor T-cells, 
(Young, 1994). Prostanoids such as PgE2 have the ability when present in high levels 
in areas surrounding tumors, to diminish immune surveillance. Inhibition of this
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synthesis due to the presence of an NSAID, can cause this immune suppression to be 
reversed, (Taffet and Russell, 1981).
The influence of eicosanoids on the immune response is intricately linked to the 
role of eicosanoids in metastasis. A wide range of eicosanoids have been shown to 
be involved in metastasis (Honn et al., 1994) but the involvement if Pgl2 and 
TxA2 illustrate the complexity of the relationship between eicosanoids and 
metastasis (Honn et al., 1981a). Formation of aggregates o f tumor cells and 
platelets has been suggested as one possible activation mechanism for tumor cell 
attachment to vascular endothelium, providing an immunological shield for tumor 
cells and aiding in the installation of tumor cells in small capillary beds, (Marnett,
1992). Any of these events could partially facilitate tumor cell metastasis. 
Prostacyclin, Pgl2 is a product of arachidonic acid metabolism in vascular 
endothelial cells and TxA2 is produced by platelets. Prostacyclin is a potent 
inhibitor of platelet aggregation whereas TxA2 promotes platelet aggregation 
(Marnett, 1992). For this reason the balance between TxA2 and Pgl2 levels 
becomes a critical factor in determining if platelets aggregate. Studies carried out 
with the potent inhibitor o f platelet aggregation, Pgl2 have shown that this 
eicosanoid can inhibit, metastasis in colon, lung, breast, pancreas and prostate 
carcinomas (Honn et al., 1981b; Marnett, 1992). A significant amount o f interest 
has recently arisen in the use of aspirin in the treatment o f digestive tract cancers, 
(Thun, 1994). There are a number of possible explanations for the relative 
successes achieved in epidemiological studies. One of the possible explanations 
for the anti-tumor activity o f aspirin involves the influence o f aspirin on TxA2 and 
Pgl2 production in vascular endothelial cell and in platelets. The acetylation o f 
PGHS by aspirin is irreversible and so cells such as platelets with a low protein 
synthetic ability have their PGHS activity irreversibly inhibited. This results in an 
absence of platelet derived TxA2 until new platelets are synthesised (which can 
take a number of days). The vascular endothelial cells have a superior level o f 
protein synthetic ability and so Pgl2 returns to normal levels a short period after 
aspirin treatment. This results in Pgl2 levels predominating over TxA2 levels which 
ultimately results in an effective inhibition of platelet aggregation. The eicosanoid 
12-FETE is derived from 12-lipoxygenase catalysed insertion o f oxygen into the
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AA moiety and has also been shown to have some important involvement in 
cancer metastasis. Honn et a l ,  (1994) have shown that the ability of certain tumor 
cell types to generate 12-HETE is directly related to their metastatic potential. 
This eicosanoid has been shown to have involvement in tumor cell motility, 
angiogenesis and vasculature-tumor cell interactions (Honn et al., 1994). In 
addition, Tang et a l ,  (1996) have shown that 12-HETE is a critical regulator of 
cell survival and apoptosis in rat Walker 256 carcinosarcoma cells.
1.4 Nonsteroidal anti-inflammatory drugs (NSAIDs)
NSAIDs are a group of compounds prescribed for use as anti-inflammatories, 
antipyretics or analgesics and are believed to account for 3% to 9% of the total 
numbers of prescriptions issued world-wide (Alhava, 1994). In the United Kingdom 
over 20 million prescriptions for NSAIDs are issued each year for a variety of 
conditions including management of cancer pain (Pace, 1995). NSAIDs may be 
classified by chemical structure and so may be subdivided into five main groups, 
namely the salicylates (such as aspirin and diflunisal), oxicams (such as piroxicam and 
tenoxicam), 5-pyrazolone derivatives (such as phenylbutazone), arylacetic acid 
derivatives (such as indomethacin, acemetacin, sulindac, tolmetin and zomepirac) and 
the fenamates and isoteres (such as mefenamic and flufenamic acid), (Korolkovas, 
1988).
NSAIDs are believed to achieve their therapeutic effects by inhibition of PGHS which 
ultimately results in a reduction in prostanoid production (Vane, 1994). NSAIDs vary 
in the mechanism by which they inhibit the cyclooxygenase activity of PGHS. Aspirin 
transfers an acetyl moiety to a single serine (Ser530 in the case of PGHS-1 and Ser516 in 
the case of PGHS-2) hyroxyl group of PGHS. This inhibits PGHS activity by denying 
arachidonic acid entry to the cyclooxygenase active site of PGHS (De Witt et a l,
1990). Aspirin totally inhibits prostanoid synthesis by PGHS-1 but causes the activity 
of PGHS-2 to be altered so that an overproduction of 15-HETE results (Meade et a l,
1993). The majority of NSAIDs such as ibuprofen compete competitively with AA for 
binding to the cyclooxygenase site of PGHS (Mitchell et al., 1994). NSAIDs such as
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indomethacin bind to the cyclooxygenase active site and induce a conformational 
change which makes the active site inaccessible to AA (Levy, 1997).
NSAIDs show significant variation in their respective abilities to inhibit either the 
PGHS-1 or PGHS-2 isozymes (Frolich, 1997). Aspirin preferentially inhibits PGHS-1 
but the majority of NSAIDs such as ibuprofen, indomethacin, diclofenac and 
piroxicam show both intermediate levels of PGHS-1 inhibitory activity and low levels 
of PGHS-2 inhibitory activity (Vane and Botting, 1996). Few NSAIDs possess highly 
significant PGHS-2 inhibitory activity but Meloxicam has recently been shown by 
Engelhardt et a l, (1996a) to possess a high preference in intact cells for inhibition of 
PGHS-2 rather than for the PGHS-1 isozyme. Meloxicam has also been shown to 
preferentially inhibit PGHS-2 in vivo when tested in the rat pleurisy model of the 
inflammatory process (Engelhardt et a l, 1996b). The PGHS isozyme preference of 
NSAIDs is important in terms of the ability of an NSAID to achieve their anti­
inflammatory, antipyretic and analgesic effects. In achieving the desired therapeutic 
effect, a given NSAID must not cause serious side effects such as ulceration. This can 
be caused by the inhibition of constitutive prostanoid production in healthy tissue 
(Fries, 1996). The side effects associated with NSAIDs are unfortunately very 
common and are responsible for the largest number of adverse effect reports to the 
FDA in the United States (Pace, 1995). Eicosanoids have a variety of roles in 
conditions such as inflammation where eicosanoid production is increased as a result 
of some form of inflammatory stimulus (Samuelsson, 1983). This increased eicosanoid 
production can often be the result of PGHS-2 induction whereas PGHS-1 levels 
remain unchanged (Munroe and Lau, 1995). Ideally one would aim to inhibit PGHS-2 
by NSAID treatment and so eliminate the abnormally high levels of prostanoid 
production. PGHS-1 activity should not be affected so that the normal physiological 
activities of prostanoids such as cytoprotection of the gastric mucosa would remain 
unaffected (Whittle etal., 1980).
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1.4.1 The effects of NSAIDs on tumor cell growth
There have been numerous reports over the last 10 years describing the ability of 
NSAIDs to significantly reduce or in some cases eliminate the occurrence and 
development of various types of cancer. Three related areas of research have provided 
evidence of the anti-tumor activity of NSAIDs. Firstly, in animal models of colon 
carcinogenesis, NSAIDs such as sulindac, indomethacin and piroxicam, when 
administered at high concentrations (often up to 80% of maximum tolerated dose), 
have been repeatedly shown to cause a reduction in the number of tumors per animal 
as well as an overall reduction in the number of tumor bearing animals (Reddy et a l, 
1990; Moorghen et a l, 1988; Narisawa et a l , 1981). The second line of evidence 
comes from studies of familial adenomatous polyposis (FAP), an autosomal dominant 
disorder characterised by the formation of hundreds of colorectal adenomas and 
eventually development of colon cancer. Numerous studies such as performed by 
Giardiello et a l, (1993) have shown that sulindac can prevent the formation of 
colorectal polyps in FAP patients. In addition there is some evidence that NSAIDs 
such as sulindac can also cause the regression of sporadic colorectal adenomatous 
polyps (Matsuhashi et al., 1997). A mouse model of FAP was used by Boolbol et al.,
(1996) where a strain containing a dominant mutation in the APC (adenomatous 
polyposis coli) tumor suppressor gene was developed. This strain (known as Min 
mice) developed gastrointestinal adenomas by 110 days of age. It was found that the 
Min animals produced increased levels of PGHS-2 and PgE2 compared to wild type 
mice. Treatment with sulindac inhibited tumor formation and decreased PGHS-2 and 
PgR2 levels to baseline as well as restoring normal levels of apoptosis (normally at a 
level of 27-47% of the levels in wild-type mice). The third indication of the ability of 
NSAIDs to influence tumor growth comes from epidemiological studies (Weiss and 
Forman, 1996). Results of 15 colorectal cancer studies are now available and the 
results illustrate that patient treatment with NSAIDs, particularly aspirin results in a 
significant reduction in colorectal cancer risk (Berkel et al., 1996).
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The mechanism by which a number of individual NSAIDs can in some cases influence 
tumor growth is presently unclear. In addition it is has not yet been fully proven if the 
effects of NSAIDs in the three types of studies listed above are a result of only one or 
even a number of aspects of a given NSAID’s activities. There are a number of 
possible explanations for the anti-tumor activity of NSAID and these include inhibition 
of prostanoid biosynthesis, interference with tumor cell cycle and induction of 
apoptosis (Krishnan and Brenner, 1997) as well as effects of NSAIDs on the immune 
system (Gilman and Chang, 1987).
The influence of NSAIDs on eicosanoid production from arachidonic acid was 
examined in Section 1.4, but basically it can be generalised that NSAIDs can reduce 
prostanoid biosynthesis by inhibiting the cyclooxygenase activity of PGHS. Many 
tumor types overproduce prostanoids and these prostanoids have been shown to 
increase the proliferation rate of tumor cell lines and related cells in vivo (Qiao et al.,
1995). Inhibition of this growth stimulatory activity due to the presence of an NSAID 
such as indomethacin, obviously can cause a resultant reduction in tumor cell growth 
(Tripathi et al., 1996; Tanaka el al., 1989). It is known that the influence of NSAIDs 
on tumor cell growth is not entirely dependent on PGHS inhibition because of a 
number of factors. The first of these factors stems from studies which have shown no 
correlation between the ability of an NSAID to inhibit tumor cell growth and the 
potency of that NSAID as an inhibitor of PGHS (DeMello et al., 1980). Secondly, 
sulindac sulfone, which is devoid of any PGHS inhibitory activity has been shown to 
inhibit HT-29 colon carcinoma cell growth to an extent comparable to that achieved 
with sulindac sulfide, a potent inhibitor of PGHS (Piazza et al., 1995). In addition, a 
number of studies such as performed by Planchón et al., (1995) with the MCF-7 
breast carcinoma cell line have shown that exogenous addition of prostanoids such as 
PgE2 was ineffective for achieving a reversal of NSAID mediated growth inhibition. 
Hanif et al., (1996) carried out a detailed investigation into the effects o f sulindac 
sulfide and piroxicam on the growth of the HT-29 and HCT-15 human colon 
adenocarcinoma cell lines. The HT-29 cell line produces PgE2, PgF2a and Pgl2, but 
HCT-15 does not possess PGHS and hence is devoid of prostanoid synthesising ability 
(Hanif et al., 1996). It was found that treatment of these cell lines with sulindac sulfide
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and piroxicam had comparable growth inhibitory effects and that these effects could 
not be reversed by exogenous addition of PgE2, PgF2(X and Pgl2. For this reason, it 
was obvious that both sulindac sulfide and piroxicam exerted their growth inhibitory 
effects independently of any inhibition of PGHS (Hanif el al., 1996).
NSAIDs have recently been shown to have effects on the cell cycle progression and 
apoptosis of tumor cells (Piazza el al., 1997a; Goldberg, 1996; Pasricha el al., 1995; 
Piazza et a l, 1995). Shiff el a l, (1996) investigated the effects of aspirin, 
indomethacin, naproxen and piroxicam on proliferation, cell cycle phase distribution 
and apoptosis in HT-29 cells. It was found that these NSAIDs reduced the 
proliferation and altered the morphology of HT-29 in a time dependent and 
concentration dependent fashion. Only indomethacin and aspirin increased the fraction 
of cells in the Go/Gi phase and accordingly reduced the fraction of cells in the S and 
G2/M phases of the cell cycle. In addition, these NSAIDs were shown to reduce the 
levels of the cdks (cyclin dependent kinases), p34cdc2 and p33cdk2 which have critical 
roles in the Gi/S and G2/M transitions respectively (Shiff el a l, 1996). Indomethacin, 
piroxicam and naproxen but not aspirin were shown in this study to induce apoptosis 
in the HT-29 colon adenocarcinoma cell line. The HT-29 cell line expresses mutant 
p53 protein only (Rodrigues el al., 1990) and so this apoptosis occurred 
independently of wild-type p53 protein.
The tumor suppressor gene p53 is critical in the regulation of the Gi/S checkpoint of 
the cell cycle (Kastan et al., 1991). The levels of the p53 protein have been shown to 
increase in response to DNA damage, which ultimately results in a Gi cell cycle arrest 
(allowing for DNA repair to occur) or apoptosis (Shaw el al., 1992). It has been 
reported that over 50% of human lung, breast and colon tumors possess missense p53 
mutations (Hollstein et al., 1991; Nigro et al., 1989) with mutant p53 unable to cause 
Gi arrest or apoptosis. The p21 tumor suppressor gene is induced during activation of 
the p53 mediated Gi/S checkpoint but it can also be regulated by p53 independent 
mechanisms. The p21 protein has the ability to inhibit the kinase activity of a variety of 
cdks which can prevent phosphorylation of a variety of substrates including pRb 
(retinoblastoma protein) (Harper et al., 1993). The pRb tumor suppressor gene 
product causes cell cycle arrest in late Gi by regulating the activity of the E2F family of
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transcription factors (Weinberg, 1995). The pRb protein also possesses the ability to 
inhibit apoptosis (Haas-Kogan et a l , 1995) but the role of pRb in carcinogenesis has 
not been fully elucidated. Goldberg et a l, (1996) investigated the influence o f sulindac 
and sulindac sulfide on p53, p21 and pRb protein levels in HT-29 cell line. It was 
found that these compounds caused a Go/Gi cell cycle block and exit from the cell 
division cycle. This was associated with an initial increase followed by an abrupt 
decrease in the levels of p34cdc2, a reduction in the levels o f the mitotic cyclins A and 
Bi, an increase in p21 levels, a reduction in total pRb and an increase in 
hypophosphorylated pRb as well as a reduction in the levels of p53 (Goldberg et a l,
1996). Piazza et a l, (1995) showed that sulindac sulfide and sulindac sulfone inhibited 
the growth of a variety of cell lines but these compounds also were growth inhibitory 
for normal fibroblasts and normal epithelial cells. Both of these sulindac derivatives 
induced apoptosis in the HT-29 cell line, and this was shown to be independent of 
their inhibitory effect on cell cycle progression (Piazza et a l, 1997a; Piazza et a l, 
1995). It was recently reported by Thompson et a l, (1997) that sulindac sulfone 
inhibited the occurrence of mammary carcinoma which were classified as having either 
the wild type or mutant Ha-ras gene, but with significantly more potent inhibition in 
the case of carcinomas with the mutant Ha-ras gene. This group suggested that the 
effect of sulindac sulfone on mammary carcinogenesis involved interference in the 
signal transduction cascade involving Ha-ras, (Thompson eta l., 1997).
The relationship between NSAID treatment and apoptosis in rat intestinal epithelial 
(RIE) cells was examined by Tsujii and DuBois, (1995). These RIE cells were 
permanently transfected with a PGHS-2 expression vector. The transfected cells 
showed high levels of PGHS-2 protein and were resistant to butyrate-induced 
apoptosis. In addition, these transfected cells possessed elevated bcl-2 protein and 
reduced transforming growth factor (TGF-(3) levels, all of which are indications of 
increased tumorigenic potential. It was found that the resistance to apoptosis was 
overcome by sulindac sulfide treatment. In a related study, Tsujii et a l, (1997) 
reported that PGHS-2 transfected human colon cancer cells (CaCo-2) possessed 
significantly increased RNA levels for activated metalloproteinase-2, and that this 
resulted in increased metastatic potential. This increased invasiveness and the
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increased prostanoid production due to overexpression of PGHS-2 was shown to be 
eliminated by sulindac sulfide.
1.4.2 NSAIDs in cancer chemotherapy
NSAIDs have been extensively shown to inhibit the growth of some tumors in 
vivo and in vitro. NSAIDs have also been shown to potentiate tumor 
radioresponse, (Furata et a l, 1988), but only a select number o f studies have 
investigated the possibility of NSAID-mediated enhancement of chemotherapeutic 
drug toxicity.
Powles et a l, (1978) reported that indomethacin and flurbiprofen rendered a 
chemo-resistant variant of the Walker tumor more resistant to chlorambucil 
treatment in vivo. Bennett et al., (1982) showed that flurbiprofen and 
indomethacin decreased cancer development and spread in mice bearing a 
transplanted mammary adenocarcinoma when treated in combination with 
methotrexate and melphalan. This toxicity enhancement effect was also shown in 
vitro using indomethacin in combination with methotrexate, (Gaffen et al.., 1985). 
Flurbiprofen, unlike indomethacin, was unable to enhance methotrexate 
cytotoxicity in vitro (Bennett et al., 1987). Indomethacin was also shown to 
increase methotrexate accumulation in vitro (Bennett et al., 1987).
The toxicity of methotrexate in LoVo human colon cancer cells was unaffected by 
co-treatment with indomethacin, (Gaffen et al., 1989). Indomethacin increased the 
cytotoxicity of methotrexate to the human breast cell lines DU4475 and T47D, 
(Bennett et al., 1989). The mechanism of enhancement of methotrexate toxicity 
by indomethacin has not been conclusively proven. A number of interesting 
observations have been made namely that the toxicity enhancement effect is 
unlikely to be due to displacement of methotrexate from binding sites on serum 
proteins, inhibition o f prostaglandin synthesis, inhibition o f cAMP 
phosphodiesterase or calcium transport, (Yazici et al., 1992). Indomethacin does 
not have a beneficial interaction with all cytotoxic drugs. Sato et al., (1983)
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reported that indomethacin in combination with 5-fluorouracil was no more 
effective at killing a mouse colon adenocarcinoma in vivo than 5-fluorouracil 
treatment alone. A select number o f other drugs have been successfully used in 
combination with indomethacin. Hall et al., (1989) showed that the toxicity of 
chlorambucil was potentiated 5.5 fold in a resistant Chinese Hamster Ovary cell 
line following exposure to indomethacin.
A study by Maca, (1991) showed that non-toxic concentrations o f indomethacin 
enhanced the sensitivity to V P-16 and Methotrexate in a variety o f cell lines. 
Cultured Lewis lung carcinoma (LLC) cells, mouse lymphoma cells, a human 
acute lymphoblastic leukaemia cell line and human chronic myelogenous 
leukaemia cells were tested. These cell lines are relatively insensitive to V P-16 
alone but indomethacin was found to enhance V P-16 cytotoxicity in all cases. 
Indomethacin also increased the response of LLC cells to methotrexate but not to 
bleomycin. It was concluded that indomethacin enhances V P-16 cytotoxicity by 
increasing the cellular concentration of VP-16. Draper et a l ,  (1997) reported that 
indomethacin increased multidrug susceptibility of both murine and human cell 
lines overexpressing MRP, but not those displaying Pgp associated resistance. 
This report suggested that indomethacin acted as a specific inhibitor o f MRP and 
so modulated drug resistance as a result o f this activity. Hollo et a l,  (1996) 
characterised the transport properties of MRP in MRP-transfected and drug 
selected MRP overexpressing cells and found that indomethacin at concentrations 
of 10-20 (xM inhibited MRP activity by approximately 50%. Kobayashi et al.,
(1997) examined the drug sensitivity of two pulmonary adenocarcinoma cell lines 
to a variety o f chemotherapeutic drugs in the presence of various NSAIDs. It was 
found that indomethacin, mefenamic acid, sulindac and tolmetin enhanced the 
toxicity of both adriamycin and vincristine. Indomethacin was shown to enhance 
the toxicity of methotrexate, adriamycin, VP-16 and vincristine but not 
cyclophosphamide, mitomycin C, 5-fluorouracil, cisplatin, vindestine or cytarabine 
(Kobayashi et a l ,  1997).
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A number of additional NSAIDs have been used in combination with a select 
number of cytotoxic drugs. The use of piroxicam in a cytotoxic drug treatment 
regimen was reported by Braun et al, (1987). Patients with lung cancer receiving 
mitomycin C, vinblastine and cisplatin treatment were treated with piroxicam for 
31 days. This group found that the immuno-modulatory effects of cytotoxic 
chemotherapy were ameliorated by adding piroxicam to the cytotoxic drug 
treatment regimen.
Teicher et al., (1994) reported on the use of mefenamic acid, diflunisal, sulindac 
and indomethacin as modulators of cytotoxic drug therapies in the treatment of 
the Lewis lung carcinoma in mice. A mixture consisting of indomethacin or 
sulindac combined with phenidone (a lipoxygenase inhibitor) and cisplatin was 
2.5-fold more effective in causing tumor growth delay than was cisplatin 
treatment alone. Sulindac in combination with either minocycline (a collagenase 
inhibitor) or phenidone increased the tumor growth delay achieved by 
cyclophosphamide by 2.0-fold. Sulindac in combination with minocycline or 
phenidone and mefenamic acid in combination with minocycline caused a 4.5-fold 
increase in tumor growth delay achieved by melphalan. Sulindac or diflunisal in 
combination with minocycline caused a 3.0-fold increase in the tumor growth 
delay caused by carmustine.
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1.5 Multiple drug resistance (MDR) in cancer
1.5.1 P-glycoprotein in MDR
Kessel et a l,  (1968) reported that anthracycline selected drug resistant cells exhibited 
a drug accumulation deficit relative to the drug sensitive parental cell line. Since that 
initial report, a wide variety of multidrug resistant (MDR) cell lines have been isolated 
as a result of exposure to chemotherapeutic drugs such as anthracyclines, 
epipodophyllotoxins, vinca alkaloids, actinomycin D and colchicine (Germann, 1996; 
Clynes, 1993; Beck and Danks, 1991). These resistant cell lines may be obtained in 
three ways namely by adaptation to gradually increasing concentrations of an 
appropriate drug, transfection with an appropriate drug resistance cDNA or 
alternatively by establishment of the cell line from an inherently resistant tumor 
(Clynes, 1993). These cell lines generally exhibit cross resistance to a range of 
structurally unrelated drugs but are relatively sensitive to 5-fluorouracil and platinum 
compounds (Hill, 1993; Beck and Danks, 1991). Overexpression of a plasma 
membrane efflux pump, known as P-glycoprotein or Pgp has been shown to be 
involved in the resistance of many of these MDR cell lines (Germann, 1996). The 
physiological role of Pgp in normal tissues is presently unclear, but it is known to be 
highly expressed in the adrenal cortex, proximal tubules of the kidney, bile canaliculi of 
the liver, colon and jejunum (Izquierdo, 1996a; Favrot el a l, 1991; Sugawara el al., 
1988). The Pgp protein may have a role in normal tissues as a detoxifying transporter 
of xenobiotics (foreign organic compounds not produced by metabolic cellular 
activity), (Garberoglio et a l, 1992; Cordon-Cardo et al., 1989) and as a steroid 
transporter in the adrenal gland (Van Kalken et a l, 1993; Van Kalken et a l, 1992). 
The overexpression of Pgp is often found in the case of tumors derived from tissues 
which normally express Pgp such as carcinomas of the adrenal gland, lung, colon, 
kidney, liver and pancreas (Izquierdo, 1996a). A study involving over 400 human 
cancers showed that elevated expression of the mdrl gene responsible for Pgp 
synthesis, occurred in the case of colon cancer, renal cell carcinoma, and hepatoma 
(Goldstein et a l, 1989). In many cases, Pgp expressing tumors have been shown to 
have a poor prognosis (Fisher and Sikic, 1995).
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1.5.1.1 Structure of the gene encoding P-glycoprotein
The Pgp protein in humans is encoded by the mdrl gene, which is present on the long 
arm of chromosome 7, band q21.1 (Chen et a l, 1986). Transfection experiments have 
shown that a full length cDNA clone coding for mdrl conferred drug resistance when 
transfected into drug sensitive cell lines (Gros et al., 1986). This gene possesses 27 
exons in the protein coding region of the gene and 14 of these exons code for the left 
and 13 for the right half of the Pgp molecule (Roninson, 1991). The nomenclature 
used to describe mdrl related genes (the MDR gene family) in different species, 
according to a scheme involving sequence similarity of the 3 ’ untranslated regions, is 
summarised in Table 1.5.1.1, (Heenan, 1994). This illustrates that humans only have 
two, while mice and hamsters possess three classes of members of the MDR gene 
family. In hamsters and mice only class I and II are believed to be involved in drug 
resistance but in humans only class I is believed to convey drug resistance to cells. As 
mentioned above, transfection of full length cDNA for mdrl conferred drug resistance 
when transfected into drug sensitive cell lines (Gros et al., 1986). In addition 
transfection of human mdr3 or mouse mdr2 cDNA did not result in drug resistance 
(Van der Bliek et a l, 1988). The mdrl locus is 230 kb in length and is approximately 
300 bp upstream of the mdr3 gene (Lincke et al., 1991; van der Bliek et al., 1988). 
The mdrl and mdr3 genes encode 4.1 to 4.5 kb mRNA transcripts which share a 
significant level of homology (Roninson, 1991).
Class Human Hamster Mouse -Scheme 
A
Mouse -Scheme 
B
I m drl pgpl mdr3 mdr la
II pgpl mdrl m drlb
m mdr 3/2 pgpl mdr2 mdr2
Table 1.5.1.1: Classification and nomenclature of mammalian P-glycoproteins
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Increases in mdrl mRNA have been shown to occur in the presence and absence of 
gene amplification (Bradley et al., 1989; Shen et al., 1986; Roninson et a l, 1986). 
Two promoter regions for this gene have been identified (Ueda et a l, 1987a, b) one of 
which is upstream and the other which is downstream. This downstream promoter is 
preferentially used by the majority of resistant cells in vitro (Ueda et al., 1987b). A 
wide variety of agents have been shown to influence transcription of the mdrl gene. 
The treatment of a number of colon carcinoma cell lines with dimethyl sulfoxide, 
sodium butyrate or dimethyl formamide have been shown to increase mRNA and 
protein levels of Pgp (Mazzanti et al., 1996; Mickley et al., 1989). Treatment of 
human cell lines with chemotherapeutic drugs or UV radiation has also been shown to 
increase mdrl expression (Chaudhary and Roninson, 1993; Uchiumi et al., 1993). 
Phorbol ester response element and a number of heat shock consensus elements have 
also been shown to be involved in the transcription of mdrl under appropriate 
conditions (Angel et a l, 1997; Chin et al., 1990; Angel et a l, 1987).
I.5.1.2 P-glycoprotein protein structure
The mdrl gene product is a 170 kDa membrane associated protein of 1280 amino 
acids which contains 12 transmembrane domains with 6 extracellular loops and 2 
cytoplasmic ATP binding domains. (Gros et al., 1986). A  model predicted by 
computer assisted hydropathy analysis and amino acid sequence comparisons with 
bacterial transport proteins (Chen et al., 1986; Gros et al., 1986) suggests that both 
the N- and C-terminal membrane associated domains possess 6 transmembrane 
regions. The N- and C-termini and nucleotide binding folds are predicted to be present 
intracellularly with the overall structure composed of two halves of similar structure 
bridged by a linker region (Van der Bliek et a l, 1987). In addition, the first 
extracellular loop is predicted to be glycosylated (Chen et al., 1986; Gros et al.,
1986). The Pgp protein is predominately localised in the plasma membrane of MDR 
cells (Izquierdo, 1996a) but low levels of expression have been shown to be present in 
association with the endoplasmic reticulum and Golgi apparatus (Germann, 1996).
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The human Pgp protein is produced as a 120-140 kDa non-glycosylated precursor 
which can be processed to the 170 kDa form within 1-2 hours (Richert et al., 1988). 
The primary structure of mammalian Pgp suggests the presence of several potential N- 
linked glycosylation sites within the first extracellular loop with Asn91, Asn94 and Asn" 
the relevant sites in human Pgp (Schinkel et al., 1993). The precise role of 
glycosylation of Pgp is unclear but it has been suggested that it is not critical for Pgp 
mediated drug efflux (Germann, 1996). For example, multidrug resistant sublines have 
been established from a glycosylation defective hamster mutant cell line (Ling et al.,
1983). In addition, tunicamycin, an inhibitor of glycosylation did not affect the drug 
resistance characteristics of the human T-cell leukemia resistant cell line CCRF-CEM 
(Beck and Cirtain, 1982). It has been suggested that glycosylation is required for 
translocation of the Pgp protein to the plasma membrane and this suggestion has 
developed from studies such as performed by Kramer et al., (1995) where a 
tunicamycin treated human colon carcinoma cell clone was shown to possess reduced 
levels of plasma membrane associated Pgp.
P-glycoprotein is a phosphorylated glycoprotein but a number of the details related to 
the phosphorylation mechanisms involving this protein require further investigation. 
Pgp has the ability to undergo rapid cycles of phosphorylation and dephosphorylation 
(Ma et al., 1991). Studies carried out by Chambers et al., (1990) using the human 
MDR KB-V1 carcinoma cell line showed that protein kinase C (PKC) and type 1 or 
2A phosphatases were responsible for this activity. Increased phosphorylation of Pgp 
was shown to cause an increase in Pgp-mediated drug efflux activity and inhibition of 
phosphorylation was shown to decrease this activity (Chambers et al., 1990). The 
phosphorylation of Pgp by PKC was believed to occur on serine residues only, namely 
Ser661 and Ser671 and one or more of Ser667, Ser675 and Ser683 which occur in the linker 
domain of Pgp (Chambers et al., 1993). The Ser667 residue is now known to be the 
third site for PKC phosphorylation of Pgp (Chambers et al., 1994). The cAMP 
dependent protein kinase (PKA) has also been shown to phosphorylate Pgp in vitro 
(Mellado and Horwitz, 1987). Treatment of Pgp overexpressing cells with protein 
kinase inhibitors such as staurosporine and calphostin C, causes a reduction in the 
levels of phosphorylation of Pgp and in some cases a resultant inhibition of the drug 
efflux activity of Pgp (Bates et al., 1993; Ma et al., 1991). These kinase inhibitors are
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relatively non-specific, exerting a variety of effects on cells and so results such as these 
should be interpreted with caution. Mutational analysis performed with Ser661, Ser671, 
Ser667, Ser675 and Ser683 residues on Pgp, where these residues were substituted with 
alanine residues (which cannot be phosphorylated), showed that non-phosphorylated 
Pgp possessed the same ability to confer MDR as the wild-type phosphorylated form 
(Germann, 1996). It is now believed that phosphorylation may have an indirect role in 
certain aspects of Pgp activity including the kinetics of drug transport, Pgp protein 
stability and drug resistance pattern of Pgp overexpressing cells.
1.5.1.3 P-glycoprotein mediated transport
The role of Pgp in normal tissues is currently unclear but it is believed to have a role in 
protection against natural xenobiotics (Cordon-Cardo et a l, 1989). It has been shown 
to be induced with cytochrome P-450 genes in rat liver after xenobiotic administration 
(Burt and Thoreirsson, 1988), and is proposed as being a modulator of an endogenous 
chloride channel (Hardy et al., 1995). The overexpression of Pgp in tumor cells can 
confer cross-resistance to a broad range of chemically and mechanistically unrelated 
drugs including anthracyclines, vinca alkaloids, epipodophyllotoxins, actinomycin D 
and Taxol (Clynes, 1993). It is believed that Pgp is a transmembrane pore forming 
protein with an energy dependent drug effluxing ability. It has also been suggested that 
Pgp can lower intracellular drug concentrations by regulating the plasma membrane 
pH gradient and electric membrane potential (Roepe et al., 1994; Roepe et al., 1993). 
The potential drug binding sites of Pgp have been identified using azidopine in 
photoaffinity labelling experiments with proteolytic fragments of Pgp (Skach et al.,
1993), The binding was shown to occur primarily in the cytoplasmic domain in the 
region adjacent to transmembrane region number 6 and in the cytoplasmic region 
immediately following transmembrane region number 12. This suggests that one 
binding site is formed by the two homologous halves of Pgp. A number of point 
mutations have been shown to influence the drug transporting abilities of Pgp. Dhir et 
a l, (1993) showed that alterations in Ser939 of the mouse mdr3 gene product 
conferred a significant reduction in the levels of vinblastine resistance. Replacing this 
residue with alanine or cysteine had no effects on adriamycin and colchicine cross
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resistance. Replacement of the serine residue with aspartic acid practically caused a 
complete loss of adriamycin and cholchicine resistance, (Dhir et al., 1993). The 
suggestions of direct involvement of Pgp in drug transport have been supported by the 
results of a number of related studies as discussed by Germann, (1996). As described 
earlier transfection of full length cDNA for mdrl conferred drug resistance when 
transfected into drug sensitive cell lines (Gros et a l, 1986). In addition, cellular Pgp 
levels often correlate with drug resistance levels in MDR cell lines (Fojo et a l, 1985). 
Pgp has been shown to directly bind to cytotoxic drugs, as demonstrated by 
photoaffinity labelling experiments with a photoactive analogue of vinblastine and 
mutations in critical transmembrane regions can interfere with this binding (Cornwell 
et a l, 1986). Plasma membrane vesicles from Pgp overexpressing cells have the ability 
to transport [3H]-labelled drug in an ATP dependent manner (Horio et al, 1988).
1.5.1.4 Modulation of Pgp mediated drug resistance
Verapamil was the first agent to be shown successfully to reverse the MDR phenotype 
in Pgp expressing cells in vitro (Tsuruo et a l, 1981). Since this initial study a large 
number of compounds have been shown to be potential modulators of Pgp activity. 
Clinical studies have shown that in general, the maximum tolerated dose of the 
clinically available modulators yielded serum levels significantly below those required 
for Pgp inhibition (Fisher et al., 1996). MDR modulators may interfere with cytotoxic 
drug efflux by acting as competitive or non-competitive inhibitors or by binding to 
chemosensitiser binding sites that cause allosteric changes. These allosteric changes 
can result in the inhibition of cytotoxic drug binding to the relevant efflux pump (Ford,
1995). The majority of chemosensitisers described to date may be grouped into six 
categories (Ford, 1995) namely immunosuppressive drugs (cyclosporin A and SDZ 
PSC833), calcium channel blockers (verapamil), calmodulin antagonists 
(trifluoroperazine), steroidal agents (tamoxifen), vinca alkaloid analogues (vindoline), 
and miscellaneous compounds (quinidine).
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The MDR modulator verapamil has been shown to inhibit Pgp mediated drug 
efflux. This modulating effect is independent of this compound’s ability to directly 
affect calcium channels (Robert et al., 1987). Verapamil inhibits the binding of 
various chemotherapeutic drugs to Pgp (Ford, 1995). This has been confirmed by 
photoaffinity labelling experiments which showed that this calcium channel 
blocker binds directly to the Pgp protein (Safa, 1988). Cyclosporin A is a cyclic 
hydrophobic peptide of 11 amino acids and it has been found to reverse drug 
resistance in MDR cells. Cyclosporin A may act as a substrate for P-glycoprotein and 
antagonises Pgp activity through competitive inhibition of cytotoxic drug efflux 
(Twentyman, 1988). The direct binding of cyclosporin A to Pgp has been shown by 
photoaffinity labeling experiments (Foxwell et al., 1989). A  number of less 
immunosuppressive cyclosporin analogues such as PSC 833 and PSC 280-446 have 
also been developed and are being examined as possible modulators of Pgp in vivo 
(Ford, 1995; Gaveriaux et al., 1991).
Research into the area of MDR modulators is continuing, but the compounds used to 
date in vivo have been shown to be required in very high doses. These high doses 
often exceed the maximum tolerated doses of these compounds, causing unacceptable 
toxic side effects (Erlichman el al., 1993). Ferry et al., (1996) reported on the results 
of a randomised trial of verapamil in a chemotherapeutic regime for the treatment of 
small cell lung cancer. Patients were treated with cyclophosphamide, adriamycin, 
vincristine and VP-16. Verapamil at a dose of 480 mg/day (the maximum tolerated 
dose) was also included in the treatment, and at this dose verapamil reached a serum 
level of 0.8 |aM. This level is approximately 8-fold lower than the verapamil 
concentration needed to reverse Pgp mediated resistance in vitro, (Ferry et al., 1996). 
Twentyman and Versantvoort, (1996), stated that any strategy designed to suppress 
efflux of cytotoxic drugs by a drug efflux pump was highly probable to increase 
normal tissue toxicity. Even if this was the case, the development of novel 
circumventing and drug modulating strategies would permit the accumulation of 
information which would ultimately lead to a successful therapeutic treatment for drug 
resistant cancer.
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1.5.1.5 PgP as a member of the ATP-binding cassette superfamily
The MDR gene family in mammals is related to the ATP-binding cassette (ABC) 
superfamily with can exist in non-mammalian species. The (ABC) superfamily are 
structurally diverse with over 50 members, but all contain at least one 
hydrophobic transmembrane region and a cytoplasmic nucleotide binding domain 
(NBD), (Higgins, 1992). These proteins are involved in energy dependent 
transport o f a variety o f substrates across membranes. In eukaryotic cells, ABC 
genes often encode four domains composed of two NBDs and two 
transmembrane regions, (Leveille-Webster and Arias, 1995). The ATP binding 
NBDs contain conserved residues (termed Walker A and B motifs) spaced by 90- 
120 amino acids (Walker C motif). There is wide variation in the chemical nature 
of the molecules transported by ABC proteins, which vary from chloride ions to 
antigenic peptides associated with the endoplasmic reticulum of immune cells, 
(Bellamy, 1996). The Pgp protein in humans shows a significant degree of homology 
with the Hly B protein of Escherichia coli with 50% amino acid sequence identity 
between the two proteins, (Juranka ei a/.,, 1989). P-glycoprotein is also homologous 
with the leukotoxin secretion protein lkt in Pasteurella Haemolytica, (Strathdee and 
Lo, 1989). The human Pgp protein exhibits significant homology to the ndvA protein 
in Rhizobium Meliloti which possesses glycan transporting abilities, (Stansfield et al., 
1988). The STE 6 gene product in Saccharomyces cerevisiae shares homologous 
regions with Pgp in their nucleotide binding regions and transmembrane domains 
(McGrath and Varshavsky, 1989). Several mammalian homologues of Pgp have been 
identified including the TAPI and TAP2 proteins (Section 1.5.3), CFTR (cystic 
fibrosis transmembrane conductance regulator protein) which is an ATP dependent 
cAMP regulated chloride channel and PMP 70, which when mutated results in a fatal 
cerebro-hepato-renal dysfunction known as Zellweger syndrome, (Leveille-Webster 
and Arias, 1995).
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1.5.2 Multidrug Resistance-associated Protein
The drug transporter Pgp has been shown to be present in a variety o f human 
tumors and multidrug resistant cell lines. Numerous examples now exist o f 
multidrug resistant cell lines and tumors which have Pgp-independent drug 
resistance mechanisms (Broxterman et a l , 1995). One of these mechanisms 
involves the multidrug resistance-associated protein, MRP. Since the initial 
discovery of MRP in the drug resistant, small cell lung cancer cell line, H69AR, 
(Cole et a l ,  1992), this transporter molecule has been shown to be present in non- 
Pgp multidrug resistant cell lines from a variety o f tumor types. These tumors 
include leukaemias, fibrosarcoma, small cell and non-small cell lung carcinomas, 
breast, cervix, prostate and bladder carcinomas (Izquierdo et al., 1996c; Loe et 
al., 1996a). There have also been reports of co-expression of Pgp and MRP in a 
number o f drug selected cell lines (Brock et al., 1995). MRP has been detected 
either at the protein or mRNA level in normal human tissues including lung, 
stomach, colon, peripheral blood macrophages, thyroid, testis, nerve, bladder, 
adrenal, ovary, pancreas, gall-bladder, duodenum, heart, muscle, placenta, brain, 
kidney, liver and spleen (Sugawara et al., 1997; Loe et al., 1996a; Zaman et al., 
1993; Cole e ta l ,  1992).
Cell lines overexpressing MRP are typically cross-resistant to anthracyclines, 
epipodophyllotoxins and vinca alkaloids (Loe et a l,  1996a). Although the 
resistance profiles o f drug-selected MRP or Pgp overexpressing cell lines are 
similar, considerable differences exist particularly with regard to Taxol resistance 
(Loe et a l,  1996a). The explanation for a cell developing MRP rather than Pgp- 
mediated resistance during drug exposure remains unclear, but it is believed that 
overexpression o f MRP may confer initial levels of resistance, while Pgp 
overexpression develops as higher levels o f resistance are required for survival. A 
study by Brock et a l ,  (1995) showed that in the small cell lung cancer cell line, 
H69, MRP is over-expressed during selection in low concentrations of VP-16. 
Following further selection in higher concentrations of drug, MRP expression 
remained relatively constant, but Pgp overexpression developed. The expression 
of MRP protein and mRNA is not limited to drug selected MRP-overexpressing
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cells. Berger et a l, (1997) reported that a significant number o f drug sensitive 
non-small cell lung cancer cell lines expressed MRP mRNA and protein.
1.5.2.1 MRP gene structure
The MRP gene is distantly related to the mdrl gene, and has been localised to 
chromosome 16p 13.1 (Cole et al. 1992). Cloning and sequence analysis 
performed by Zhu and Center, (1994), of a 2.2 kb 5’-flanking sequence of 
genomic MRP, (a region of strong promoter activity) of HL60-ADR cells 
indicated the presence o f a number of regulatory elements. These included AP-1, 
AP-2, SP-1, ERE (estrogen response element), GRE (glucocorticoid response 
element) and CRE (cyclic AMP response element). The MRP gene has been 
shown to be amplified in a number of drug selected cell lines (Cole et al., 1992). 
In other cases MRP mRNA levels have been shown to increase in the absence of 
gene amplification (Slapak et al., 1994) and this is believed to be due to 
alterations in transcriptional control of the MRP gene. It is suggested that the 
major promoter activity of MRP resides in a highly GC-rich region of 194 
nucleotides (Zhu and Center, 1994). This region does not contain a TATA box 
for directing site-specific transcriptional initiation, but contains multiple start sites 
for transcription. This is similar to the situation found in the case o f Pgp (Ueda et 
al., 1987b). The MRP gene codes for a message of 6.5 kb which is capable of 
encoding the 1531 amino acid protein. Transfection studies using flail length MRP 
cDNA have shown that MRP can confer resistance to drug sensitive cells (Grant 
e ta i ,  1994).
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1.5.2.2 MRP protein structure
After MRP mRNA had been isolated from the H69AR cell line (Cole et a l  1992), 
analysis showed that this mRNA coded for a member of the ABC superfamily of 
transmembrane transporters. The MRP protein was predicted to be 171 kDa, 
containing two nucleotide binding domains, each preceded by a multi-spanning 
transmembrane region. A number of models have been proposed (reviewed by 
Loe et a l ,  1996a) for the secondary structure o f MRP, but it is now believed that 
the transporter contains 12 transmembrane segment in the NH2-proximal half and 
six transmembrane segments in the COOH-proximal half. Three other ABC 
transporters may also have topologies similar to MRP, namely the p cell 
sulfonylurea receptor (SUR) which is involved in regulating insulin secretion, the 
MOAT (multispecific organic anion transporter) molecule and the yeast cadmium 
resistance factor YCF1 (Lautier et a l,  1996).
MRP was initially believed to be predominately located in the endoplasmic 
reticulum of resistant cells but significant levels are now known to be present in 
the plasma membrane (Krishnamachary and Center, 1993). The phenotypes o f 
MDR cell lines with high levels of MRP vary significantly with regards to their 
drug accumulation characteristics. Some drug-selected MRP-overexpressing cell 
lines can accumulate less drug or have higher rates of efflux than the sensitive 
cells from which they were derived, (Coley et a l,  1991). A number o f MRP 
expressing cell lines also appear to sequester drug into cytoplasmic vesicles 
(Marquardt and Center 1992). If this vesicular sequesterisation occurs, it may 
divert drug from the relevant cellular target without affecting cellular 
accumulation levels. This could possibly explain some o f the unusual drug 
accumulation characteristics of MRP-expressing cell lines. This also complicates 
any potential attempt to correlate MRP expression with total drug accumulation 
characteristics of MRP expressing cells. Analysis of subcellular distribution of 
MRP, as performed by Almquist et a l ,  (1995), using isopyknic density gradient 
centrifugation, showed that 80% of MRP in HeLa transfectants was associated 
with a low density plasma membrane fraction. The comparable fraction in drug-
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selected MRP-overexpressing H69AR cells contained 50% of the protein. The 
remaining MRP and plasma membrane markers were co-distributed in higher 
density fractions which indicated the presence o f MRP in endocytotic vesicles in 
H69AR cells. The MRP-transfected HeLa cells accumulated less drug over time 
than the parental HeLa cell line, but H69AR drug resistant cells and H69 parental 
cells accumulated comparable levels of drug over time. The presence o f MRP- 
containing endocytotic vesicles in H69AR was believed to contribute to drug 
resistance in this cell line. Encapsulation of drug in these vesicles was suggested 
as having prevented drugs from reaching their target destination in the cell. This 
would explain both the drug resistance o f MRP-overexpressing H69AR cells and 
the fact that both H69AR and H69 cells accumulated comparable levels of drug 
over time.
The amino acid sequence of MRP contains various sites known to be relevant for 
ATP binding and post-translational modification (Loe et a l, 1996a). MRP has 
been detected immunologically as a 190 kDa N-glycosylated phosphoprotein 
which binds ATP. Various studies have shown that the unmodified MRP 
polypeptide has an apparent mass of 170 kDa and is processed into a mature 190 
kDa form by addition of N-linked oligosaccharides (Almquist et al., 1995). It is 
known to take approximately 90 minutes to produce the 190 kDa MRP molecule 
from the 170 kDa polypeptide, with the.mature protein possessing a half life o f 20 
hours (Almquist et al., 1995). Human MRP contains twelve potential sites for N- 
linkod glycosylation, but it is believed that only three o f these sites are external to 
the plasma membrane and so ultimately glycosylated (Almquist et al., 1995). The 
effect of glycosylation on MRP activity is not fully known. It has been 
demonstrated that tunicamycin-induced inhibition of glycosylation has little effect 
on the cellular drug accumulation characteristics of MRP expressing cells 
(Almquist et al., 1995).
The precise location and functional role o f the phosphorylated residues on MRP 
are also unclear. In Pgp and CFTR (cystic fibrosis transmembrane conductance 
regulator), phosphorylation occurs predominately in the linker region (Chambers 
et a l,  1993) and it is believed that this is also the case for phosphorylation of
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MRP. Serine is the single amino acid phosphorylated in MRP and the phosphate 
groups are contained in nine tryptic peptides (Ma et a l,  1995). The 
phosphorylation of these amino acids was shown to be blocked by compounds 
such as staurosporine. This resulted in an increase in drug accumulation in MRP 
overexpressing HL60-ADR cells (Ma et a l ,  1995). The protein kinases involved 
in this phosphorylation have not yet been clearly identified, partly because o f the 
fact that agents such as staurosporine simultaneously inhibit a variety o f protein 
kinases with varying levels of potency. There are potential sites for 
phosphorylation of MRP by cyclic AMP/cyclic GMP-dependent protein kinases, 
protein kinase C, casein kinase II and tyrosine kinases (Almquist et a l ,  1995). 
The primary sequence requirements for many o f these sites are not strict and their 
presence is not necessarily indicative that they are functional. In addition, 
comparison of the linker region amino acid sequences of human and murine MRP 
have shown that there is only a low level o f conservation of potential PKC 
(believed to be particularly important for MRP phosphorylation) phosphorylation 
sites between these two homologs, which otherwise share a very high proportion 
of conserved sequences (Lautier et al., 1996).
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1.5.2.3 MRP Transport Activity
The MRP transporter has the ability to transport cysteinyl leukotrienes such as 
leukotriene C4 (LtC4) and glutathione conjugates such as glutathione disulphide 
(GSSG), (Loe et a l, 1996a). A wide variety of organic anions are believed to 
serve as possible physiological substrates of MRP including anionic conjugates of 
bile salts and steroid hormones (Loe el a l ,  1996a). Transport o f heavy metal 
oxyanions by MRP has also been demonstrated (Cole et al., 1994).
The mechanism of MRP mediated transport of chemotherapeutic drugs is 
presently unclear. It was known that MRP had the ability to transport glutathione 
conjugates and so it was suggested that cytotoxic drugs became conjugated to 
glutathione and in this way became potential substrates for MRP transport. This 
suggestion was complicated by the fact that glutathione conjugation is not known 
to occur for natural product drugs. In addition, MRP transfectants do not exhibit 
increased resistance to alkylating agents, the class of drugs for which glutathione 
conjugation is known to occur (Loe et al., 1996a). Although MRP has been 
indirectly shown to reduce cellular accumulation o f drugs such as adriamycin, 
only a limited number of reports have described the direct transport o f these drugs 
by MRP. Studies carried out by Paul et al., (1996c) showed that MRP isolated 
from MRP-transfected NIH 3T3 fibroblasts, could serve as an ATP dependent 
pump for a spectrum of natural product, unconjugated cytotoxic drugs including 
anthracyclines, vincristine and etoposide. Paul et al., (1996b) demonstrated that 
MRP isolated from the HL60-ADR human leukaemia drug resistant cell line 
actively transported daunorubicin, V P-16 and vincristine but not vinblastine or 
Taxol. Shen et a l ,  (1996) reported that the activity of MRP isolated from the 
HL60-ADR cell line was potently inhibited by daunorubicin, vincristine and VP- 
16. Heijn, et a l ,  (1997) reported that MRP activity in the GLC4/ADR small cell 
lung carcinoma drug resistant cell line was inhibited by daunorubicin and V P-16.
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Loe et a l,  (1996b) demonstrated that transport of vincristine by MRP occurred 
only in the presence of glutathione. It was suggested that either MRP co­
transports glutathione and cytotoxic drugs, or that glutathione causes some form 
of conformational change in MRP which enables cytotoxic drugs to bind to the 
transporter (Loe et al., 1996b). Stride et al., (1997) also provided evidence that 
MRP-transfected cells only possess the ability to transport vincristine when 
glutathione is present.
The analysis of drug resistance profiles o f MRP-overexpressing drug selected cell 
lines has generated information on the potential drug transporting abilities of 
MRP, (Versantvoort et al., 1992; Coley et a l, 1991). This information is 
complicated by the fact that these cell lines were obtained by a stepwise selection 
in drug, which facilitates the development of multiple collateral resistance 
mechanisms. This may result in the simultaneous expression of a variety of drug 
resistance mechanisms which ultimately results in difficulties in interpreting the 
contribution o f any individual mechanism to drug resistance levels, (Brock et a l, 
1995, Hasegawa et a l ,  1995). Studies carried out with MRP-transfected cell lines 
serve as more useful models for definition of the profile of drugs transported by 
MRP as the use of cell systems such as these should avoid the interference from 
multiple resistance mechanisms found in drug selected cell lines.
A study carried out by Breuninger et a l,  (1995) using NIH 3T3 fibroblasts, which 
had been transfected with MRP cDNA, showed that these transfectants displayed 
increased resistance to several lipophilic drugs. These included adriamycin (9.4- 
fold more resistant than negative control transfectant), daunorubicin (7.8 -fold 
resistance), VP-16 (11.4-fold resistance), actinomycinD (2.3-fold resistance) and 
vincristine (3.8-fold resistance). These tranfectants showed very low to negligible 
levels o f resistance to vinblastine (1.2-fold resistance) and Taxol (1.3-fold 
resistance), but were more sensitive to cisplatin (0.9-fold resistance). The absence 
of high level resistance to Taxol in MRP-transfected cells is significant as this 
drug is a high affinity substrate for transport by Pgp. In a similar study carried out 
by Cole et a l ,  (1994) it was found that MRP-transfected cell populations
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possessed a moderate level of resistance to adriamycin (6.9-fold resistance), 
daunorubicin (6 .3-fold resistance), epirubicin (8 .6 -fold resistance), vincristine 
(11.6-fold resistance) and V P-16 (10.3-fold resistance). These cells showed only 
low level o f resistance to Taxol (1.7-fold resistance), vinblastine (3-fold 
resistance) and colchicine (2.1-fold resistance). In addition, these transfectants 
were not resistant to 9-alkyl anthracyclines (1.0-fold resistance), mitoxantrone 
(1.0-fold resistance) or cisplatin (0.9-fold resistance). The MRP transfected cells 
were also resistant to a selection of heavy metal anions including arsenite, 
arsenate and trivalent and pentavalent antimonials, but were not resistant to 
cadmium chloride, (Cole et a l ,  1994).
1.5.2.4 Modulation of MRP mediated drug resistance
As was the case for defining the drug substrate menu o f MRP, identification of 
specific modulators o f MRP is complicated by the fact that this transporter 
exhibits various similarities to other drug transporter molecules such as Pgp. In 
drug selected cell lines, co-expression o f various drug resistance mechanisms 
makes it extremely difficult to conclusively deduce if a given modulator influences 
drug accumulation due to interference with MRP activity only. In many cases, 
potential modulators of MRP can have significant effects on drug transporters 
such as Pgp. For this reason, ideally all screening of potential modulators of MRP 
should be performed in MRP-transfected cell lines. Studies performed with MRP 
transfected HeLa-T5 cells showed that the cytotoxic effects of vincristine and 
adriamycin could be enhanced in a dose dependent fashion by co-administration of 
verapamil, (Cole et a l,  1994). In addition, it was found that cyclosporin A also 
increased vincristine toxicity but that it had less of an effect on adriamycin 
toxicity. This chemosensitisation was believed to be independent o f interference 
with MRP activity as the degree of chemosensitisation by these agents was similar 
in MRP-transfected cells and in cells transfected with the vector alone. Both 
verapamil and cyclosporin A caused a slight increase in vincristine accumulation in 
resistant cells, but did not return the level of accumulation to that achieved by the 
drug sensitive cells. A further study by Breuninger et al., (1995) showed that
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verapamil increased the sensitivity of MRP-transfected HeLa-pSRa-MRP16 cells 
relative to control transfectants, to adriamycin and VP-16.
The chemosensitisers verapamil and cyclosporin A are known to be much less 
effective at reversing drug resistance in MRP overexpressing drug selected cell 
lines, rather than in Pgp overexpressing drug selected cell lines, (Coley et a l,
1991). In addition, MRP could not be labelled with a photoaffinity analogue of 
verapamil in the MRP-overexpressing drug selected HL60-ADR cell line, 
(McGrath et al., 1989). This suggests that verapamil does not directly interact 
with MRP, whereas in the case of Pgp, verapamil is known to bind directly to the 
protein and interfere with transport in this manner, (Safa, 1988).
A significant number of compounds have now been suggested as having the ability 
to modulate MRP activity. Practically all of these studies have been carried out 
using drug selected MRP-expressing cells and so the selectivity o f inhibition may 
be questioned as many of these compounds can have effects on a variety of 
cellular drug resistance mechanisms. The use of these compounds as modulators 
of MRP has been reviewed by Twentyman and Versantvoort, (1996). The two 
most interesting compounds to emerge as potentially selective MRP modulators 
include the anionic quinoline LtD4 receptor antagonist MK571 and the 
bisindolylmaleimide protein kinase C inhibitor GF109203X. The leukotriene D4 
receptor antagonist MK571 has been extensively characterised by Gekeler et a l ,  
(1995a) in drug selected Pgp and MRP expressing cell lines. A complete reversal 
o f vincristine resistance was achieved by co-incubation with a non-toxic level (40 
(J,M) of MK571 in an MRP-expressing cell line. This compound was found to 
have no effect on the level of toxicity achieved in a Pgp-overexpressing cell line. 
MK571 has been shown to completely inhibit LtC4 transport by MRP in 
membrane vesicles prepared from MRP-overexpressing cells and has also been 
shown to totally inhibit photoaffinity labelling of MRP by [3H]-LtC4, (Jedlitschky 
et a l ,  1994). Gekeler et a l, (1995b) showed that the specific bisindolylmaleimide 
protein kinase C inhibitor GF109203X totally reversed vincristine resistance in 
one MRP-overexpressing cell line, but only partially reversed adriamycin and 
vincristine resistance in a second MRP-overexpressing cell line. The effect of this
43
compound on drug resistance of a Pgp-overexpressing cell line was not examined 
in this study (Gekeler et al., 1995b). The bisindolylmaleimide GF109203X is 
reported as being a highly selective inhibitor o f PKC isozymes, with inhibitory 
effects on other kinases only at very high concentrations. It was assumed by 
Gekeler et al., (1995b) that this compound exerted an inhibitory influence on 
MRP activity due to interference with phosphorylation and so activity o f the 
transporter, or that it interacted directly with the transporter. No explanation was 
offered for the inability o f this compound to reverse adriamycin resistance.
Although the majority of studies into modulation of MRP involve the use of 
compounds such as verapamil, the use of antisense oligonucleotides to reduce 
MRP protein expression has also been reported, (Stewart et a l, 1996). A 
sequence was identified, ISIS 7597, complementary to nucleotides 2107-2126 of 
MRP that reduced levels of MRP mRNA and protein in transfected HeLa cells by 
90% and 70% respectively. Cells treated with ISIS 7597 have been shown to 
enhance sensitivity to adriamycin (Stewart et al., 1996), but the decreases in MRP 
mRNA and protein levels were short lived and only a partial sensitisation to 
adrhmycin was achieved.
1.5.2.5 MRP as a member of the ATP-binding cassette superfamily
The ATP-binding cassette (ABC) superfamily are structurally diverse but all 
contain at least one hydrophobic transmembrane region and a cytoplasmic 
nucleotide binding domain (NBD) as described earlier. These proteins are 
involved in energy dependent transport of a variety of substrates across 
membranes. In eukaryotic cells, ABC genes often encode four domains composed 
of two NBDs and two transmembrane regions. The ATP binding NBDs contain 
conserved residues (termed Walker A and B motifs) spaced by 90-120 amino 
acids (Walker C motif). There is wide variation in the chemical nature of the 
molecules transported by ABC proteins, which vary from chloride ions to 
antigenic peptides associated with the endoplasmic reticulum of immune cells, 
(L o ee ta l., 1996a).
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A total o f 21 new genes from the human ABC superfamily have recently been 
identified, bringing the total number of characterised human ABC genes to 33, 
(Allikmets et a l,  1996). A number of the previously characterised human ABC 
proteins have been well characterised and these include proteins involved in drug 
transport (Pgp and MRP), peptide transporters involved in antigen presentation 
(TAP), and those involved in inherited human diseases (CFTR (cystic fibrosis 
transmembrane conductance regulator), ALD (adrenoleukodystrophy), SUR 
(sulfonylurea receptor) and PMP70 (human peroxisomal membrane protein)). 
Members of the ABC superfamily with which MRP has greatest degree of 
sequence homology include CFTR (19% amino acid identity) which mediates 
chloride conductance in airway epithelia and other tissues, rat SUR (29% amino 
acid identity), ItpgpA (32% amino acid identity), a Leishmania protein which 
confers resistance to arsenic and antimony centred oxyanions, YORI (33% amino 
acid identity) a yeast protein that mediates oligomycin resistance and YCF1 (43% 
amino acid identity), which is a yeast protein that mediates cadmium resistance 
(Loe et al., 1996a). It has been suggested that MRP may be involved in the 
regulation of endogenous ion channels. As described above, MRP possesses 
significant sequence homology with CFTR (outwardly rectifying Cl' channel), 
SUR (inwardly rectifying K+ channel) and Pgp (volume regulated Cl’ channel), but 
there have been only a limited number o f reports describing MRP’s influence on 
ion channel activity. Jirsch et a l,  (1994) reported that Cl' and K+ channel activity 
was increased in MRP expressing H69AR cells relative to the drug sensitive 
parent.
The MRP transporter has the ability to transport a wide variety of hydrophobic 
anionic compounds such as oxidised glutathione and a number o f different steroid 
glucuronides and bile salt derivatives, (Leier et a l,  1996). The multispecific 
organic anion transporter (MOAT) in liver canicular membranes and other tissues 
(Mayer et a l,  1995) also has the ability to transport molecules of this nature, and 
it was suggested that the MRP-1 gene was responsible for cMOAT synthesis. The 
extremely low expression of M RP-1 protein in the liver and the localisation of 
MRP-1 in the basolateral hepatocyte membrane indicated that this suggestion was
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incorrect. Recent studies by Paulusma et a l, (1996) provided evidence that MRP- 
1 and cMOAT are encoded by two different genes namely MRP-1 and MRP-2.
The role of glutathione and glutathione S-transferases will be described briefly in 
Section 1.5.5.2. It has been shown relatively conclusively that increased levels of 
GST are involved in resistance to alkylating agents (Puchalski and Fahl, 1990) but 
it has proven more difficult to conclusively prove involvement in other forms of 
resistance such as to cisplatin and anthracyclines. Ishikawa and Ali-Osman, (1993) 
showed that cisplatin resistance is complex as it involves two steps, namely the 
initial formation o f a glutathione (GSH) S-conjugate and the subsequent removal 
of the toxic conjugate from the cell by a glutathione conjugate pump, which this 
group describes as the GS-X pump. It is now also known as a MOAT protein or 
the leukotriene C4 transporter (Leier et al., 1994). Conjugation of cisplatin and 
GSH can occur non-enzymatically but export from the cell requires the GS-X 
pump. The activity of the GS-X pump has been shown to be enhanced in one 
cisplatin resistant mutant (Ishikawa et al., 1994). Muller et al., (1994) found no 
increased activity o f the GS-X pump in a cisplatin resistant cell line, but found a 
substantial increase in GS-X pump activity in the MRP-overexpressing 
GLC4/ADR cell line, relative to the sensitive parental cells. The GS-X pump is 
described as being an ATP-dependent export pump for organic anions such as 
cysteinyl leukotrienes and certain organic anions such as methotrexate. The 
studies by Muller et al., (1994) and Leier et al., (1994) showed that 
overexpression o f the MRP gene in cells resulted in increased ATP dependent 
GS-conjugate transport. Ishikawa et al., (1996) assumes from this evidence that 
the MRP gene product is a GS-X pump and that the MRP and GS-X pumps 
possess similar if not identical substrate specificity. The sensitivity of the vast 
majority o f MRP overexpressing cell lines to cisplatin was explained by Ishikawa 
et al., (1996) as being a result of insufficient intracellular levels of GSH in these 
cells,. This group concludes that simultaneously elevated expression of the GS-X 
pump and increased GSH biosynthesis, are the critical factors in determining 
resistance levels to cisplatin, alkylating agents and heavy metals.
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Database screening has permitted the identification of three new homologues o f 
the MRP-1 gene, which is responsible for the MRP-1 gene product, and the 
MRP2 gene, which is responsible for cMOAT production. These newly 
discovered genes have been designated MRP-3, MRP-4 and MRP-5. The MRP-3 
protein, like cMOAT is mainly expressed in the liver, with MRP-4 expressed at 
very low levels in a number of different tissues, and MRP-5 expressed in almost 
all tissues analysed (Kool et al., 1997). Preliminary investigations have also been 
carried out to investigate the role of these MRP homologues in drug resistance. It 
was found that MRP-4 was not over-expressed in any o f the cell lines tested. The 
MRP-3 and MRP-5 transporters were only over-expressed in a limited number of 
cell lines but mRNA levels in these cell lines did not correlate with levels o f 
adriamycin or cisplatin resistance. In addition, it was found that cMOAT was 
over-expressed in a number of cell lines and that mRNA levels correlated with 
cisplatin but not adriamycin resistance (Kool et al., 1997). Further investigations 
are necessary in order to investigate the exact contribution of these homologues 
of MRP to drug resistance in MRP expressing cells.
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1.5.3 Transporter associated with Antigen Presentation
The transporter associated with antigen presentation (TAP) is a recently discovered 
member of the ABC superfamily which has been found to be over-expressed in a 
number of MDR cell lines (Izquierdo et al., 1996d). TAP is a heterodimer formed by 
the products of the TAPI and TAP2 genes. This protein is involved in MHC (major 
histocompatibility complex) class I antigen presentation where it facilitates peptide 
translocation over the endoplasmic reticulum membrane (Neeles et al., 1993). Pgp 
has also been reported as having the ability to transport peptides (Sarkadi et al.,
1994). The TAPI and Pgp proteins share highly homologous regions among their 
transmembrane sections (Manavalan et al., 1993). The transfection of the TAP genes 
into mutant lymphoblastoid cells lacking TAP caused the levels of resistance of these 
cells to VP-16, adriamycin and vincristine to increase 2-fold. It was also demonstrated 
that high VP-16 or vincristine concentrations inhibited the transport of a model 
peptide by TAP into the endoplasmic reticulum, (Izquierdo et al., 1996d). It has been 
suggested that TAP may have a role in low levels of MDR but further investigations 
will be necessary in order to obtain more definitive information on the possible 
involvement of TAP in MDR, (Izquierdo et al., 1996d).
1.5.4 Lung Resistance-related Protein
The lung resistance related protein (LRP) was identified by Scheper et al., (1993) as a 
110 kDa vesicular protein over-expressed in a non-Pgp expressing MDR lung cell line. 
LRP protein expression has been demonstrated in the epithelia of the bronchus, 
digestive tract, as well as in keratinocytes, macrophages and the adrenal cortex 
(Izquierdo et al., 1996b). The LRP gene is localised on chromosome 16p 11.2 which is 
close to the locus for the MRP gene (16pl3.1), (Izquierdo, 1996a). LRP has been 
shown to be over-expressed in a large number of Pgp negative drug selected MDR 
cell lines including small cell lung cancer cell lines such as GLC4-ADR, breast cancer 
lines such as MCF7-MR, fibrosarcoma derived lines such as HT1080-DR4 and 
myeloma cell lines such as 8226-MR40 (Scheper et al., 1993). When the LRP gene
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was cloned and sequenced it was found to share over 87% amino acid identity with 
the major vault protein in Rattus norvigecus (SchefFer et al., 1995).
Vaults have been isolated from a variety of species and are highly conserved among 
these different species, (Kedersha el al, 1990). Vaults in other species are most 
abundant in epithelial cells and macrophages, as is found in the case of LRP in normal 
human tissues, (Kedersha el al., 1990). Vaults are ribonucleoprotein particles that in 
the rat are composed of a major vault protein of 104 kDa (accounting for over 70% of 
the mass of the particle), three minor proteins of 210, 192 and 54 kDa and a small 
RNA molecule (Izquierdo, 1996a). These vault constituents are constructed into a 
barrel-like structure of approximately 57 x 32 nm. The vault particle has 2-fold 
symmetry and each half of the vault particle can be opened into a flower-like structure 
which contains eight petals surrounding a central ring (Kedersha et a l, 1991). Most 
vaults are present in the cytoplasm and it is believed that the majority of cell types 
possess thousands of vaults (Chugani et a l, 1993). Vault structure and localisation 
support a transport function for this particle which could involve a variety of 
substances, but the precise function of vaults is currently unknown (Izquierdo, 1996a).
In a study conducted by Izquierdo et al, (1996b), relatively low levels of LRP protein 
were shown to be present in tissue samples from acute myeloid neuroblastoma, 
leukaemia, and testicular cancer. Intermediate levels of LRP were present in ovarian 
cancer and high levels present in colon, renal and pancreatic carcinomas. The 
simultaneous overexpression of MRP and LRP was reported by Izquierdo et a l, 
(1996c) as being a frequent event in non-Pgp MDR cell lines. In this study, MRP and 
LRP were found to be widely expressed in a panel of 61 human cancer cell lines. 
These cell lines possessed a low level of expression of P-glycoprotein. LRP was found 
to be a more accurate indicator of in vitro drug resistance of these cell lines, compared 
to P-glycoprotein and MRP (Izquierdo et a l, 1996c). Expression of LRP in primary 
ovarian cancer was significantly associated with a poor response to chemotherapy and 
shorter overall survival (Izquierdo el al, 1995). It has been suggested that LRP may 
be a potentially useful marker of clinical drug resistance particularly in the case of 
acute lyphoblastic leukaemia (ALL), acute myeloid leukaemia (AML) and in some 
cases of ovarian carcinoma (Izquierdo et al., 1996e). The extent of the involvement of
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LRP in the manifestation of MDR requires further investigations but it has been 
suggested by Izquierdo el a l, (1996e) that vaults regulate the cytoplasmic 
redistribution and nucleocytoplasmic transport of drugs. Scheffer el al., (1995) 
showed that transfection of the LRP gene did not confer the MDR phenotype on the 
transfected cells.
1.5.5 Additional mechanisms of resistance in MDR
In addition to Pgp. MRP, TAP and LRP expression in multidrug resistant cells, a 
number of alternative mechanisms of resistance have been identified as potentially 
being involved in MDR. These mechanisms can include alterations in the levels of 
topoisomerase II, glutathione S-transferases or metallothionein expression. 
Metallothioneins are proteins of 6-7 kDa molecular weight which have the ability to 
bind heavy metal ions (Mattem and Volm, 1995). The production of metallothioneins 
by tumor cells has been suggested as a possible mechanism for the intracellular 
inactivation of metal containing chemotherapeutic agents such as cisplatin (Mattem 
and Volm, 1995). Kasahara el al., (1991) showed that metallothionein content 
correlated with the sensitivity of human small cell lung cancer cell lines to cisplatin. 
Kelley et a l, (1988) showed that overexpression of metallothioneins in a cell line 
contributed to resistance to cisplatin, chlorambucil, melphalan and adriamycin.
1.5.5.1 Topoisomerase II
The type I and type II DNA topoisomerases are highly conserved enzymes that 
catalyse the critical steps in DNA replication, transcription, chromosome segregation 
and DNA recombination. All cells possess the type I topoisomerase which makes 
single stranded cuts in DNA and the type II topoisomerase which cut and pass double 
stranded DNA (Wang, 1985). Inhibitors of DNA topoisomerases can often interfere 
with enzyme catalysis at a variety of stages of the process (Nitiss and Beck, 1996). 
The activity of the topoisomerase II enzyme is affected by certain categories of 
chemotherapeutic drugs (De Isabella el al., 1990). These drugs stabilise the cleavable
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complex formed between topoisomerase II and DNA, resulting in increased DNA 
excision. It has been shown that alterations in topoisomerase II levels can lead to 
resistance to anthracyclines and the epipodophyllotoxins (De Isabella et al., 1990) but 
not to the vinca alkaloids. A correlation between topoisomerase II gene expression 
and sensitivity to adriamycin, VP-16 and cisplatin has been shown in non-drug 
selected lung cancer cell lines (Giaccone et al., 1992). A number of cell lines selected 
for resistance to VP-16 have decreased topoisomerase II content (Heenan, 1994) and 
this may contribute significantly to the levels of resistance to specific drugs. This 
decrease in topoisomerase II content can result in a decreased number of drug induced 
DNA strands breaks. This ultimately can result in the conferral of resistance to 
topoisomerase II specific drugs. The decrease in topoisomerase II content can be 
caused by gene inactivation (Tan et al., 1989) or may also be a post-translational event 
(Deffie et al., 1992). Additional factors such as topoisomerase II activity, isoform 
expression and degree o f phosphorylation can also contribute to the development of 
the MDR phenotype (De Isabella et al., 1990).
1.5.5.2 Glutathione S-transferases
Glutathione is a tripeptide that can protect the cell against two forms of metabolic 
stress (Mathews and van Holde, 1990). The first form involves free radicals or 
peroxides that can accumulate in cells under oxidising conditions. Glutathione has the 
ability to non-enzymatically reduce these potentially damaging free radicals. 
Glutathione can also be conjugated to xenobiotics or electrophiles (which can be 
produced by the activity of cytochrome P-450 enzymes) and this conjugation can be 
catalysed by the glutathione-S-transferase enzymes (GSTs). This conjugation can 
result in a potentially toxic compound becoming less toxic against cellular targets. In 
addition the compound becomes more hydrophilic which aids the excretion and 
elimination of the toxin in question. The GSTs are ubiquitously present in many 
normal tissues as well as in tumors (O’Brien and Tew, 1996). GSTs are the products 
of a multigene family and consist of different isozymes namely a , 71, [a. and 0 which 
have the ability to conjugate reduced glutathione to a wide variety of electrophilic 
compounds (O’Brien and Tew, 1996). The ultimate result of GST metabolism as
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stated above is the conversion of lipophilic compounds to more polar derivatives 
which enables elimination from the body. These enzymes catalyse the conjugation of 
electrophiles to the sulphur atom of the cysteine residue of glutathione (which is 
composed of cysteine, glutamate and glycine), (Alberts et a l, 1994). A  number of the 
common cancer chemotherapeutic agents are electrophiles and can be conjugated with 
molecules such as glutathione and glucuronic acid to facilitate transport, metabolism 
and ultimately excretion. Known chemotherapeutic drug substrates of GST include 
chlorambucil, melphalan and cyclophosphamide (Cheng et a l, 1997; O ’Brien and 
Tew, 1996). Eastman, (1987) reported on the direct conjugation of cisplatin to 
glutathione.
Many of the various forms of human cancer exhibit overexpression of GSTs, although 
a significant proportion of liver and breast carcinomas may show no expression 
despite being resistant to drugs metabolised by these enzymes (Harrison, 1995). 
Overexpression of GST could be potentially detrimental to a patient undergoing 
chemotherapeutic drug treatment as it may result in a more rapid detoxification and so 
a reduction in the efficacy of treatment of any drug that is potentially a substrate for 
GST. The GST-71 isozyme has been shown to be present in abnormally high levels in a 
number of solid tumors including colon, ovary, oesophagus, pancreas and bladder, 
(Hayes et a l, 1991; Singh et al., 1990). The cellular levels of glutathione are also 
believed to be important factors in GST mediated diug resistance because GST can 
only act as a detoxification mechanism if there are adequate levels of glutathione for 
conjugation to the appropriate drug. An inhibitor of the y-glutamylcysteine synthase 
enzyme which is critical for glutathione synthesis, (buthionine-S-sulphoximine or 
BSO), has been shown reduce cellular G S H  levels and in some cases a reversal in the 
resistance of M D R  cell lines (Kunzmich et a l, 1992; Mistry et al., 1991; Green et a l,
1984). Significant increases in glutathione have also been shown to be present in some 
ovarian, breast, small cell and non-small cell lung carcinomas (Singh et al., 1994; 
Buser el al., 1991). Agents such as ethacrynic acid (a diuretic drug with the ability to 
conjugate with GSH) have been shown to reverse chlorambucil resistance in a CLL 
(chronic lymphocytic leukaemia) patient (O’Dwyer et al., 1991).
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The role of GSTs in M D R  requires further investigation, but a number of transfection 
studies have shown that GSTs may be involved in drug resistance, (O’Brien and Tew,
1996). Greenbaum et a l, (1994) showed that transfection of GSTa cDNA into NIH 
3T3 fibroblasts conferred increased levels of resistance to chlorambucil. In a similar 
study, Nakagawa et al., (1990) showed that when NIH 3T3 fibroblasts were 
transfected with GSTtu, the cells exhibited resistance to adriamycin and ethacrynic acid 
(an inhibitor of GST isozymes) but did not develop resistance to cisplatin, melphalan 
and chlorambucil. The results of these transfection studies are encouraging but have 
generated some unexpected results such as found by Nakagawa et a l, (1990). This 
group found that resistance to known GST substrates did not develop and that 
resistance to non-GST substrates such as adriamycin did develop.
The conjugation of electrophilic chemotherapeutic drugs to glutathione is only an 
efficient method of detoxification if these conjugates can be efficiently eliminated from 
the cell. The GS-X pump is an ATP dependent glutathione-conjugate export pump 
for organic anions such as cysteinyl leukotrienes and certain organic anions such 
as methotrexate, as has already been described in Section 1.5.2.5. This pump is 
closely associated with the M R P  protein which is believed to have the ability to pump 
a variety of natural product drugs such as anthracyclines, epipodophyllotoxins and 
vinca alkaloids. M R P  mediated resistance is not normally associated with resistance to 
alkylating agents, the category of drugs which are known to undergo glutathione 
conjugation. This has been explained for the case of cisplatin sensitivity by Ishikawa et 
al., (1996) as being a result of a cell being deficient in some aspect of the 
glutathione conjugation system such as low GST or G S H  levels. This can explain 
the sensitivity to agents such as cisplatin, but the simultaneous M R P  mediated 
resistance to other drugs such as anthracyclines, epipodophyllotoxins or vinca 
alkaloids in these cells requires further explanation if M R P  is assumed to be acting as a 
glutathione conjugate pump.
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1.6 Aims of thesis
The initial aim of the research described in this thesis was the identification of 
chemotherapeutic drugs whose toxicity was enhanced in the drug sensitive A549 
human lung adenocarcinoma cell line, in the presence of non-toxic levels of the 
NSAIDs indomethacin and sulindac. This was performed in order to identify a 
characteristic which was shared by all chemotherapeutic drugs which had their toxicity 
enhanced in the presence of indomethacin or sulindac but which was not possessed by 
drugs from other categories. Once this had been performed, further in vitro toxicity 
assay screening was performed with a wide range of NSAIDs in order to identify the 
specific NSAIDs which possessed the ability to enhance the toxicity of adriamycin and 
vincristine in the A549 cell line. The therapeutic effects of NSAIDs are generally 
attributed to the ability of these compounds to inhibit the activity of the prostaglandin 
endoperoxide H  synthase (PGHS) enzyme. Studies were conducted in order to 
investigate if this activity was involved in the ability of an NSAID such as 
indomethacin to enhance the toxicity of a chemotherapeutic drug such as adriamycin.
The profile of NSAIDs with the ability to enhance the toxicity of adriamycin and 
vincristine was shown to be exactly similar in both the A549 human lung 
adenocarcinoma and DLKP human lung squamous carcinoma cell lines. This indicated 
that these compounds affected a drug resistance mechanism common to both of these 
cell lines. The specific group of chemotherapeutic drugs with which the NSAID- 
mediated toxicity enhancement effect could be demonstrated suggested the 
involvement of the multidrug resistance associated protein (MRP). The demonstration 
of NSAID-mediated chemotherapeutic drug toxicity enhancement in DLKP appeared 
to contradict this suggestion, as M R P  protein had not been detected in whole cell 
extracts of DLKP. For this reason, plasma membrane derived inside-out vesicles were 
isolated from DLKP in order to demonstrate that active M R P  protein was present in 
DLKP and to investigate the mechanisms by which NSAIDs interfered with M R P  
activity in this cell line.
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The presence of M R P  in DLKP suggested that some of the unusual drug 
accumulation characteristics of DLKP-related drug resistant cell lines may have been 
explainable by the presence of M R P  in these cell lines. The DLKP-A10 drug resistant 
cell line was known to possess non-P-glycoprotein related drug accumulation 
characteristics. Experiments were conducted in order to determine if active M R P  
protein was present in this cell line and if this drug transporter was involved in the 
unusual drug accumulation characteristics possessed by DLKP-A10.
A  number of clonal subpopulations of the DLKP-derived DLKP-A drug resistant cell 
line exhibited drug resistance characteristics that were not fully explainable by the 
levels of P-glycoprotein or topoisomerase II present in the cells. Inside-out vesicles 
were isolated from these clones and their M R P  protein levels and activities 
characterised in an attempt to explain if this drug resistance mechanism contributed to 
the drug resistance characteristics of these clones.
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Materials and Methods
2.1 Ultrapure water
Ultrapure water, (UHP) was used for the preparation of all media and solutions. This 
water was purified by a reverse osmosis system (Millipore Milli-RO 10 Plus, Elgastat 
UHP) to a standard of 12-18 M Q  / cm resistance. The quality of U H P  was 
continuously monitored by a conductivity meter in the system.
2.2 Treatment of glassware
Solutions used in all stages of cell culture were stored in sterile glass bottles. Bottles 
and all other glassware used for cell culture related applications were prepared using 
the following protocol: glassware and lids were soaked in a 2% solution of RBS-25 
(AGB Scientific) for 1 hour. After this time they were cleaned and rinsed in tap water. 
Materials were then washed in an industrial dishwasher, using Neodisher detergent 
and rinsed twice with ultrapure water, (UHP). Materials were finally sterilised by 
autoclaving as described in Section 2.3.
2.3 Sterilisation
Water, glassware and all thermostable solutions were sterilised by autoclaving at 
121°C for 20 min. at 15 p.s.i.. Thermolabile solutions were filtered through 0.22 (im 
sterile filters (Millipore, Millex-GV SLGV025BS). Large volumes (up to 10 litres) of 
thermolabile solutions were filter sterilised through a micro-culture bell filter (Gelman, 
12158).
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2.4 Preparation of cell culture media
The basal media used during cell culture were prepared according to the formulations 
illustrated in Table 2.4. 10X media were added to sterile UHP water, buffered with 
HEPES and NaHCC >3 as required and adjusted to pH 7.5 using sterile 1.5 N  NaOH 
and 1.5 N  HCl. The media were then filtered through sterile 0.22 ¡am bell filters 
(Gelman, 12158) and stored in sterile 500 m L  bottles at 4°C. Sterility checks were 
performed on each bottle of media using the protocol described in Section 2.5.5. Basal 
media were stored at 4°C for up to 3 months. The HEPES buffer was prepared by 
dissolving 23.8 g HEPES in 80 mL UHP water followed by autoclaving. Following 
autoclaving, 5 m L  sterile 5 N  NaOH was added to give a final volume of 100 mL. 
NaHCOs was prepared by dissolving 7.5 g in 100 m L  of UH P  water followed by 
autoclaving. Volumes of 100 mL of basal media were in the majority of cases, 
supplemented with 2 m M  L-glutamine (Gibco, 043-05030) and 5% foetal calf serum 
(Sigma, F7524). Volumes of 1 mL 100X non-essential amino acids (Gibco, 11140- 
035) and 100 m M  sodium pyruvate (Gibco, 11360-035) were also added to MEM. 
Complete media was maintained at 4°C for up to a maximum of 1 week
DM EM
(Gibco 042-02501M)
Hams F I2
(Gibco 042-01430M)
M EM
(Gibco 074-01700N)
10X M edium 500 mL Powder 500 mL
U ltrapure w ater 4300 mL 4700 mL 4300 mL
1M H E PE S '
(Sigma H9136)
100 mL 100 mL 100 mL
7.5%  N allC O j 
(BDH 30151)
45 mL 45 mL 45 mL
* HEPES = N-(2-Hydroxyethyl) piperazine-N'-(2-etlianesulfonic acid)
Table 2.4: Preparation of basal media for cell culture
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2.5 Cells and cell culture
All cell culture manipulations were performed in a class II laminar air-flow cabinet 
(Nuaire Biological Laminar Air-Flow Cabinet). Any experiments involving cytotoxic 
compounds were conducted in a cytogard laminar air-flow cabinet (Gelman Sciences, 
C G  Series). The laminar air-flow cabinet was cleaned with 70% industrial methylated 
spirits (IMS) before and after use. This was also performed for any all items brought 
into the laminar air-flow cabinet. Only one cell line was used in the laminar air-flow 
cabinet at any given time. After using a given cell line, the laminar air-flow cabinet was 
allowed to clear for 20 minutes in order to eliminate any possibilities of cross 
contamination. The cabinet was cleaned weekly with industrial detergents. The 
detergents used were alternated every month (Virkon, Antec or TEGO, Goldschmidt). 
Details pertaining to the cell lines used for the experiments detailed in this thesis are 
provided in Table 2.5.1. For experiments conducted with DLKP in serum free media, 
the media components were insulin (10 (imol/L), transferrin (5 ¡imol/L), L-glutamine 
(1 x 1 O'2 (imol/L), selenium (3 x 10‘2(imol/L) and linoleic acid (3 x 10'1 ¡imol/L). All 
cell lines were incubated at 37°C in an atmosphere of 5% C 0 2 where required. Cells 
were fed with fresh media every 2-3 days in order to maintain active cell growth. The 
cell lines listed in Table 2.5.1 are anchorage dependent cell lines with the exception of 
the HL60-ADR cell line which was grown in suspension in vented 75 cm2 flasks 
(Costar, 3276) at 37°C in an atmosphere of 5% C02 in RPMI media (Gibco, 52400- 
025) containing 10% serum.
2.5.1 Subculturing of cell lines
1. The waste cell culture medium was removed from the tissue culture flask and 
discarded into a sterile bottle. The flask was then rinsed with 1 m L  of a 
trypsin/EDTA solution (0.25% trypsin (Gibco, 043-05090), 0.01% E D T A  
(Sigma, E9884) solution in PBS (Oxoid. BR14a)).
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2. A  volume of 4 m L  trypsin was added to the flask, which was then incubated
at 37°C until the cells were seen to have detached from the surface of the flask 
(approximately 5 minutes).
3. Trypsin was inactivated by addition of an equal volume of complete medium 
to the flask.
4. This cell suspension was then added to a sterile universal container (Sterilin, 
128a) and centrifuged at 1,000 r.p.m. for 5 minutes.
5. Supernatant was discarded and the cell pellet resuspended in growth 
medium. A  cell count was performed and an aliquot of cells used to reseed a 
flask at the desired cell density.
Cell line Basal medium1’4 Cell type Source1'3
A549 DME Human lung 
adenocarcinoma
ATCC
DLKP ATCC Human lung squamous 
carcinoma
NCTCC
DLKP-A ATCC Adrianiycin resistant 
variant o f DLKP
NCTCC
DLKP-VP3 ATCC V P-16 selected variant 
of DLKP
NCTCC
DLKP-VP8 ATCC V P-16 selected variant 
of DLKP
NCTCC
DLKP-A10 ATCC Adrianiycin selected 
variant of DLKP-A
NCTCC
DLKPA2B ATCC Clonal subpopulation 
of DLKP-A
NCTCC
DLKPA6B ATCC Clonal subpopulation 
of DLKP-A
NCTCC
DLKPA11B ATCC Clonal subpopulation 
of DLKP-A
NCTCC
DLKPA5F ATCC Clonal subpopulation 
of DLKP-A
NCTCC
SKMES-1 M EM Human lung squamous 
carcinoma
ATCC
SKMES-1/ADR MEM Adrianiycin resistant 
variant of SKMES-1
NCTCC
HL60-ADR RPMI 1640 Adrianiycin resistant 
variant of HL60 human 
leukaemia cell line
Dr. M. Center 
Univ. Kansas 
USA
: ATCC basal media consists of a 1:1 mixture of DM EM  and Hams F12.
2: ATCC = American Tissue Culture Collection.
3: NCTCC = National Cell and Tissue Culture Centre.
4: R P M I1640 media supplied as a IX  stock (Gibco, 52400-025).
Table 2.5.1 Source, description and media requirements of cell lines.
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2.5.2 Assessment of cell number
1. Cells were trypsinised, pelleted and resuspended in media. An aliquot of the 
cell suspension was then added to trypan blue (Gibco, 525) at a ratio of 5:1.
2. The mixture was incubated for 3 minutes at room temperature. A  10 (xL 
aliquot of the mixture was then applied to the chamber of a glass coverslip 
enclosed haemocytometer
3. Cells in the 16 squares of the four grids of the chamber were counted. The 
average cell numbers per 16 squares were multiplied by a factor of 104 and the 
relevant dilution factor to determine the number of cells per m L  in the 
original cell suspension.
4. Non-viable cells stained blue, while viable cells excluded the trypan blue dye 
as their membrane remained intact, and remained unstained. On this basis,
%  viability could be calculated.
2.5.3 Cryopreservation of cells
1. Cells for cryopreservation were harvested in the log phase of growth and 
counted as described in Section 2.5.2.
2. Cell pellets were resuspended in a suitable volume of serum. An equal volume 
of a 10% DMSO/serum solution was added dropwise to the cell suspension.
3. A  total volume of 1 m L  of this suspension (which should contain 
approximately 7x106 cells) was then placed in cryovials (Greiner, 122278). 
These vials were then placed in the vapour phase of a liquid nitrogen 
containers which was equivalent to a temperature of -80°C.
4 After a period of 3 hours, vials were removed from the vapour phase and
transferred to the liquid phase for storage (-196°C).
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2.5.4 Thawing of cryopreserved cells
1. A  volume of 9 m L  of fresh growth medium was added to a sterile universal. 
The cryopreserved cells were removed from the liquid nitrogen and thawed at 
37°C. The cells were removed from the vials and transferred to the aliquoted
media.
2. The resulting cell suspension was centrifuged at 1,000 r.p.m. for 5 minutes.
The supernatant was removed and the pellet resuspended in fresh cell culture 
medium.
3. An assessment of cell viability on thawing was then carried out (Section
2.5.2).
4. Thawed cells were then added to an appropriately sized tissue culture flask
with a suitable volume of growth medium and allowed to attach overnight.
2.5.5 Monitoring of sterility of cell culture solutions
Sterility testing was performed in the case of all cell culture media and cell culture 
related solutions. Samples of prepared basal media were inoculated into Columbia 
blood agar plates (Oxoid, CM331), Sabauraud dextrose (Oxoid, CM217) and 
Thioglycollate broths (Oxoid, C M  173), These facilitated the detection of bacteria, 
fungus and yeast contamination. Complete cell culture media were sterility tested at 
least 4 days prior to use using Columbia blood agar.
2.6 Mycloplasma analysis of cell lines
Cell lines were tested for possible Mycoplasma contamination by Dr. Mary Heenan at 
the National Cell and Tissue Culture Centre, Glasnevin, Dublin 9. The protocol used is 
detailed in the following Sections 2.6.1 and 2.6.2.
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2.6.1 Indirect staining procedure for Mycloplasma analysis
M yco p lasm a  negative N R K  (normal rat kidney fibroblast) cells were used as indicator 
cells for this analysis. The cells were incubated with a sample volume of supernatant 
from the cell lines in question and then examined for M yco p la sm a  contamination. A  
fluorescent Hoechst stain was used in this analysis. This stain binds specifically to 
D N A  and so stains the nucleus of the cell in addition to any M yco p lasm a  D N A  
present. M yco p lasm a  infection was indicated by fluorescent bodies in the cytoplasm of 
the N R K  cells.
2.6.2 Direct Staining procedure for Mycloplasma analysis
Direct staining for M yco p lasm a  analysis involved inoculating samples onto a 
M yco p lasm a  culture broth (Oxoid, CM403). This was supplemented with 16% serum,
0.002% D N A  (BDH, 42026), 2 |lg/mL fungizone (Gibco, 042 05920), 2x103 units 
penicillin (Sigma, Pen-3) and 10 m L  of a 25% yeast extract solution. Incubation was 
carried out at 37°C for a period of 48 hours. Samples of this broth were then streaked 
onto plates of M yco p lasm a  agar base (Oxoid, CM401) which had been supplemented 
as described above. The plates were incubated for 3 weeks at 37°C while exposed to 
C 0 2. The plates were examined microscopically every 7 days. The appearance of 
small oval shaped colonies indicated the presence o f M yco p lasm a  infection.
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2.7 Minitiaturised in vitro toxicity assays
2.7.1 In vitro toxicity assay experimental procedure
1. Cells in the exponential phase of growth were harvested by trypsinisation as 
described in Section 2.5.1.
2. Cell suspensions containing lxl04 cells/mL were prepared in cell culture 
medium. Volumes of 100 ¡iL of these cell suspensions were added into 96- 
well plates (Costar; 3599) using a multichannel pipette. Plates were agitated 
gently in order to ensure even dispersion of cells over a given well. Cells were 
then incubated overnight at 37°C in an atmosphere containing 5% C O 2.
3. Cytotoxic drug dilutions were prepared at 2X their final concentration in cell 
culture medium. Volumes of the drug dilutions (100 (iL) were then added to 
each well using a multichannel pipette. Plates were then mixed gently as 
above.
4. Cells were incubated for 6 days at 37°C and 5% C 0 2. At this point the 
control wells would have reached approximately 80% confluency.
5. Assessment of cell survival in the presence of drug was determined by acid 
phosphatase assay (Section 2.7.2). The concentration of drug which caused 
50% cell kill, (the IC50 of the drug) was determined from a plot of% survival 
(relative to control cells ) versus cytotoxic drug concentration.
2.7.2 Assessment of cell number - Acid phosphatase assay
1. Following the incubation period of 6 days, media was removed from the 
plates.
2. Each well on the plate was washed with 100 |lL PBS. This was then removed 
and 100 (iL of freshly prepared phosphatase substrate (10 m M  /»-nitrophenol 
phosphate (Sigma, 104-0) in 0.1 M  sodium acetate (Sigma, S8625), 0.1% 
triton X-100 (BDH, 30632), pH 5.5) was added to each well.
3. The plates were then incubated in the dark at 37°C for 2 hours.
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4. The enzymatic reaction was stopped by the addition of 50 jiL of 1 N  NaOH.
5. The plate was read in a dual beam plate reader at 405 nm with a reference 
wavelength of 620 nm.
2.7.3 NSAID mediated drug toxicity enhancement assays
1. Cells were trypsinised from the flask in the exponential phase of growth as 
described in Section 2.5.1.
2. Cell suspensions containing lxl 04 cells/mL were prepared in cell culture 
medium. Volumes of 100 |xL of this cell suspension were added into 96- 
well plates (Costar; 3599) using a multichannel pipette. Plates were agitated 
gently in order to ensure even dispersion of cells over a given well. Cells were 
then incubated overnight at 37°C in an atmosphere containing 5% C O 2 .
3. Cytotoxic drug dilutions and NSAID dilutions were prepared at 4X their final 
concentration in media. Volumes of 50 |xL of the drug dilution and 50 (iL of 
the NSAID dilution were then added to each relevant well so that a total final 
volume of200 (XL was present in each well. All potential toxicity enhancing 
agents were dissolved in D M  SO, ethanol or media as illustrated in Table 
2.7.3.1. Stock solutions were prepared at approximately 15 mg/10 m L  media, 
filter sterilised with a 0.22 Llm filter (Millex-GV, SLGV025BS) and then used 
to prepare all subsequent dilutions. Solvent control experiments showed that 
no toxicity enhancement effects were due to the presence of D M S O  or 
ethanol. The sulindac sulfide and sulfone analogues were synthesised by Dr. 
Robert O ’ Connor at the NCTCC as described by Hucker et a l, (1973). In 
assays where more than two compounds were used in combination (such as 
adriamycin, indomethacin and PgE2), 8X concentrations of the relevant agents 
were individually prepared in media and 25 pL of these compounds added to 
the appropriate wells. The final volume in each well was always maintained at 
200 |i,L.
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4. Cells were incubated for 6 days at 37°C and 5% C 0 2. At this point the 
control wells would have reached approximately 80% confluency.
5. Cell number was assessed using the acid phosphatase assay (Section 2.7.2).
6. Statistical analysis of the data was performed as detailed in Section 2.13.
NSA1D Stock solution .solubility Signut product 
number
Working concentrations 
(jJ-tVinL)
Acetaminophen 1 mL DMSO + 9 mL DME A5000 60, 30,15
Acemctacin 1 mL DMSO + 9 mL DME A1674 40, 20, 10
Aspirin lOm LDM E A3160 150, 75, 30
Aurothioglucose 10 mL DME A0632 3.0, 1.5, 0.8
Chloroquine 10 mL DME C8138 10, 5, 2.5
Diclofenac 1 mL EtOH + 9 mL DME D6899 12, 6, 3
Fenoprofen 1 mL DMSO + 9 mL DME F1517 50, 25, 13
Flufenamic acid 1 mL DMSO + 9 mL DME F9005 6 ,3 ,2
Flurbirprofen 1 mL DMSO + 9 mL DME F8514 6 ,3 ,2
Ibuprofen 1 mL EtOH + 9 mL DME 14883 16, 8, 4
Indomelhacin 1 mL DMSO + 9 mL DME 17378 2.50, 1.25, 0.60
Ketoprofen 1 mL DMSO + 9 mL DME K1751 50, 25, 13
Levamisole lOm LDM E L9756 30, 15, 8
Meclofenamic acid 1 mL DMSO + 9 mL DME M4531 8, 4 ,2
Mefenamic acid 1 mL DMSO + 9 mL DME M4267 6 .3 ,2
Naproxen lOm LDM E M1275 100,50,30
Phenylbutazone 1 mL DMSO + 9 mL DME P8386 12,6,3
Piroxicam 1 mL DMSO + 9 mL DME P5654 20, 10, 5
Sulindac 1 mL DMSO + 9 mL DME S8139 6, 3, 1.5
Sulindac sulfide 1 mL DMSO + 9 mL DME N/A 6 ,3 , 1.5
Suhndac sulfone 1 mLDM SO + 9 mLDM E N/A 20,10, 5
Tolmetin 10 mL DME T6779 20, 10, 5
Zomcpirac 1 mL DMSO + 9 mL DME Z2625 40, 20, 10
Table 2.7.3.1: Solubility data for NSAIDs and related compounds
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The concentration of PgE2 in cell culture supernatants was analysed as follows:
1. Cells were seeded at high density (2.5 x 105 cells per well) in 6 well plates 
(Falcon, 3046).
2. Plates were then incubated overnight in serum containing media.
3. Media was removed and cells washed twice with DME. The compounds 
of interest (such as NSAIDs) were then added to the cells, at a 
concentration appropriate for the cell density present. Control wells were 
treated with media only.
4. At appropriate timepoints, 150 (iL aliquots were removed and then stored 
at -80°C.
5. Samples were analysed using a PgE2 enzyme immunoassay kit (Cayman 
Chemical, 514010). Concentrations of PgE2 present in the samples were 
determined from a standard curve of absorbance at 405 nm versus PgE2 
concentration.
The PgE2 assay kit was based on the competition between PgE2 and a PgE2- 
acetylcholinesterase conjugate for a limited amount of PgE2 monoclonal antibody. 
Because the concentration of the PgE2 tracer was held constant while the 
concentration of PgE2 varied, the amount of the detectable PgE2 tracer that was 
able to bind to the PgE2 monoclonal antibody was inversely proportional to the 
concentration of PgE2 present. For analysis of PgE2 levels released by cells into 
the media during incubation in 175 cm2 flasks, a 1 m L  media aliquot was taken at 
the appropriate timepoint and 50 |iL of this volume subjected to analysis as 
described above.
2.8 ELISA for assessment of PgE2 production
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2.9 Western blotting
2.9.1 Sample preparation
1. Cells were seeded at a density of 3x106 cells per 175 cm2 flask two days 
before the experiment.
2. Media was removed and replaced with media containing the agents of 
interest (such as a cytotoxic drug).
3. After an appropriate time period, media was removed (aliquot taken for 
PgE2 ELISA if necessary) and cells were trypsinised as described in 2.5.1.
4. Cells were washed twice with ice cold PBS. All procedures from this point 
forward were performed on ice.
5. Cells were resuspended in 1 m L  of NP-40 lysis buffer. Table 2.9.1 below 
provides the details of lysis buffer. Immediately before use, 10 ¡xL of the 
100X stocks listed in Table 2.9.2 were added to 1 m L  of lysis buffer.
Addition required per 500 mL stock Final concentration
425 m L  UHP water -
25 m L  1 M  Tris-HCl (pH 7.5) 50 m M  Tris-HCl (pH 7.5)
15 m L  5 M  NaCl 150 m M N a C l
2.5 m L  NP-40 0.5% NP-40
Table 2.9.1 : NP-40 lysis buffer
100X Stock Preparation instructions
100 m M  Na3VC>4 1.83 g Na3V 0 4 in 100 m L  U H P
lOOmMDTT 154 mg in 10 m L  U H P
l O O m M P M S F 174 mg in 10 m L  100 %  ethanol
100X Protease inhibitors 2.5 mg/mL leupeptin, 2.5 mg/mL 
aprotinin, 15 mg/mL benzamidine and 1 
mg/mL trypsin inhibitor in U H P  water.
Table 2.9.2: NP-40 lysis buffer 100X stocks
6. Cells were sonicated immediately with 9 pulses lasting 0.9 seconds at 50% 
power.
7. Lysed cells were transferred to an eppendorf and pelleted at 13,000 r.p.m 
for 10 minutes.
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8. Supernatant was removed and protein concentration quantified as detailed
in Section 2.9.2. Samples were then stored in aliquots at -80°C.
2.9.2. Protein quantification
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad,
5000006) as follows:
1. A  2 mg/mL bovine serum albumin (BSA) solution (Sigma, A9543) was 
prepared freshly in lysis buffer.
2. A  protein standard curve was prepared from the B S A  stock with dilutions 
made in lysis buffer.
3. The Bio-Rad reagent was diluted 1:5 in U H P  water and filtered through 
Whatman paper before use.
4. A  20 |xL volume of protein standard dilution or sample (1:2 dilution) was 
added to 1 m L  of diluted dye reagent and the mixture vortexed.
5. After 5 minutes incubation, absorbance was assessed at 570 nm.
6. The concentration of the protein samples was determined from the plot of 
the absorbance at 570 nm versus concentration of the protein standard.
2.9.3 Gel electrophoresis
Proteins for analysis by Western blotting were resolved using SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE). The stacking and resolving gels were prepared 
as illustrated in Table 2.9.3.1. The gels were set in clean 10 cm x 8 cm gel 
cassettes which consisted of a glass plate and an aluminium plate. These plates 
were separated by 0.75 cm plastic spacers. The resolving gel was added to the gel 
cassette and allowed to set while covered with 0.1% SDS. Once set, the 0.1% 
SDS was removed and the stacking gel was then added. A  comb was placed into 
the stacking gel after pouring, in order to create wells for sample loading 
(maximum sample loading volume of 15-20 ¡xL).
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7.5%  Resolving Gel 15%  Resolving G el 5 %  S tacking  Gel
Acrylamide stock 3.8 mL 5.0 mL 0.8 mL
UHP W ater 8.0 mL 6.8 mL 3.6 mL
1.875 M  Tris-HCl pH 
8.8
3.0 mL 3.0 mL -
1.25 M  Tris-HCl pH
6.8
- - 0.5 mL
10 % SDS 150 |xL 150 M-L 50 fa.L
1 0 % N H < -
Persulfate
60 |J,L 50 |j.L 17 p.L
TEMED 9 |iL 10 fiL 8 p.L
Table 2.9.3.1: Preparation protocol for SDS-PAGE gels (2 x 0.75 m m  gels).
The acrylamide stock in Table 2.9.3.1 was composed of 29.1 g Acrylamide 
(Sigma, A8887) and 0.9 g NN'-methylene bis-acrylamide (Sigma, N7256) made 
up to 100 m L  with U H P  water. In advance of samples being loaded into the 
relevant sample wells, 15 |ig of protein was diluted in 5X loading buffer (2.5 m L  
1.25 M  Tris-HCl, 1.0 g SDS, 2.5 m L  mercaptoethanol (Sigma, M6250), 5.8 m L  
glycerol (BDH, 44305) and 0.1% bromophenol blue (Sigma, B8026) made up to 
10 m L  with distilled water). The molecular weight markers (Sigma, PI677) and 
protein samples (for PGHS-2 analysis) were heated to 95°C for 2 minutes. 
Following heating, equal amounts (15 (ig in 5X loading buffer in a total volume of 
10 (iL) of protein were loaded into each well. The gels were run at 250 V  and 45 
in A until the bromophenol blue dye front was found to have reached the end of 
the gel, at which time sufficient resolution of the molecular weight markers was 
achieved.
2.9.4 Western blotting - Transfer of protein to nitrocellulose
1. Once electrophoresis had been completed, the SDS-PAGE gel was
equilibrated in transfer buffer (25 m M  Tris (Sigma, T8404), 192 m M  glycine 
(Sigma, G7126) pH 8.3-8.5) for approximately 30 minutes.
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2. Protein was transferred from the gel to Hybond ECL nitrocellulose 
membranes (Amersham, RPN 2020D) by semi-dry electroblotting. Five sheets 
of Whatman 3 mm filter paper were soaked in freshly prepared transfer buffer. 
These were then placed on the cathode plate of a semi-dry blotting apparatus 
(Bio-rad). Air pockets were then removed from between the filter paper. 
Nitrocellulose was also soaked in transfer buffer and placed over the filter 
paper on the cathode plate. Air pockets were once again removed. The 
acrylamide gel was layered gently on top of the nitrocellulose. Five additional 
sheets of transfer buffer soaked filter paper were placed on top of the gel and 
all air pockets removed. The proteins were transferred from the gel to the 
nitrocellulose at a current of 34 inA at 15 V for 35 minutes.
3. The protocol used for MRP protein analysis is summarised in Section 2.9.6. 
For analysis of PGHS-1 and PGHS-2, the membranes were blocked overnight 
using 5% milk powder (Cadburys; Marvel skimmed milk) in TBS (125 mM 
NaCl, 2 0  mM Tris pH 7.5) at 4°C.
4. Membranes were treated with primary antibody overnight at 4°C (with 
prostaglandin H synthase 1 monoclonal antibody (Cayman Chemicals,
160110) or prostaglandin H synthase 2 (human) polyclonal antibody 
(Cayman Chemicals, 160107) diluted 1 in 1,000). A negative control where 
the gel was exposed to antibody diluent or animal pre-bleed was also 
performed.
5. Primary antibody was removed after this period and the membranes rinsed 5 
times with TBS for a total of 30 minutes.
6 . Secondary antibody (1 in 1,000 dilution of anti-mouse IgG peroxidase 
conjugate (Sigma; A6782) in TBS or a 1 in 1,000 dilution of anti-rabbit IgG 
(Sigma; A4914) in TBS) was added for 1 hour at room temperature.
7. The membranes were washed thoroughly in the wash buffer (TB S containing
0.5% Tween 20 (Sigma, P7949)) for 15 minutes.
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2.9.5 Enhanced chemiluminescence (ECL) detection
Immunoblots were developed using an Enhanced Chemiluminescence kit (Amersham,
RPN2109) which facilitated the detection of bound peroxidase-conjugated secondary
antibody.
1. Following final washings nitrocellulose filters were subjected to ECL.
2. A layer of parafilm was flattened over a glass plate and the nitrocellulose 
placed gently upon the plate.
3. A volume of 3 mL of a 50:50 mixture of ECL reagents was used to cover the 
nitrocellulose.
4. The ECL reagent mixture was completely removed after a period of one 
minute and the membrane wrapped in cling film. All excess air bubbles were 
removed.
5. The nitrocellulose was then exposed to autoradiographic film (Kodak; X- 
OMAT S) for various times (from 1 to 15 minutes depending on the signal).
6 . The exposed autoradiographic film was developed for 3 minutes in developer 
(Kodak; LX24).
7. The film was then washed in water for 15 seconds and transferred to a fixative 
(Kodak; FX-40) for 2 minutes.
8 . The film was washed with water for 5-10 minutes and left to dry at room 
temperature.
2.9.6 Western blot analysis of MRP in inside-out vesicles (IOVs)
Western blotting for MRP protein detection in IOVs was performed as described
in Sections 2.9.1 to 2.9.5 with the following modifications:
1. A total o f 20 |0g  IOV protein was diluted in 5X loading buffer and loaded
onto the 5% stacking gel and 7.5% resolving gel.
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Molecular weight markers (New England Biolabs, 7708S) were heated to 
95-100°C for 3-5 minutes or heated for 40°C for 1 minute (Bio-Rad, 161 - 
0309).
Membranes were blocked using 5% milk (Cadburys; Marvel skimmed milk) 
in TBS (125 mM NaCl, 20 mM Tris pH 7.5) for 4 hours at room temperature. 
Anti-human MRP monoclonal primary antibody (TCS Biologicals, ZUMC- 
201) was added (1:50 dilution in TBS) to membranes overnight at 4°C.
Rabbit anti-rat secondary antibody (Dako, P0450) was added at a 1:12,000 
dilution in TBS for 2 hours at room temperature. Membranes were then 
washed 5 times in TBS containing 0.5% Tween-20 (Calbiochem, 655205).
A SuperSignal ULTRA Chemiluminescence kit (Pierce, 34075) was used for 
the development of immunoblots. This involved mixing 1.5 mL SuperSignal 
Reagent 1 with 1.5 mL SuperSignal Reagent 2 and addition of this mixture to 
the membranes as described in 2.9.5. After 5 minutes, the reagents were 
removed and the membrane wrapped in cling film. This was then exposed to 
autoradiographic film for 30 seconds. Autoradiograph film was processed as 
described in Section 2.9.5.
2.10 Inside-out vesicle (IOV) preparation
2.10.1 Spinner flask preparation
Spinner flasks were soaked in a warm solution of 2% RBS for one hour and then 
scrubbed vigorously with a scrubbing brush. They were then rinsed three times in 
tap water and then three times in UHP water. Spinner flasks were then allowed to 
completely dry at 37°C, and after this point were treated with 10 mL of 
dimethylchlorosilane (Sigma, D6258). The vessel was rotated to ensure exposure 
of all glass surfaces to the siliconising agent. Surplus fluid was then removed and 
the vessel left in a fume hood to dry. Once completely dry, the flask was rinsed 
three times in UHP water. The spinner flasks were then autoclaved (121°C for 20 
minutes).
2.10.2 Large scale culture of cells
1. Cells were subcultured into 75 cm2 flasks at a density of 2x105 cells per 
flask.
2. Once cells reached 70% to 80% confluency, the cells were trypsinised 
and used to seed a 175 cm2 flask.
3. Cells were cultured for 4-5 days until they reached 70% to 80% 
confluency. The cells were then trypsinised, and used to seed a large 
500 mL spinner flask (Techne, TR174-30) containing 250 mL of media.
4. Spinner flasks were incubated at 37°C and placed on a spinner apparatus 
set at a rotational speed of 25 r.p.m.
5. After a period o f 24 hours, the agitation rate was increased to 35 r.p.m.
6 . Cells were fed with 100 mL of media after three days of growth in the 
spinner flasks.
7. Cells were harvested after seven days at which time cell number was 
approximately 1.5 x 108 cells per flask.
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8 . When 10Vs were isolated from HL60-ADR, cells (in RPMI media
supplemented with 1 0 % serum) were cultured in five vented 75 cm2 flasks 
(Costar, 3276) until 70-80% confluent. The media containing the 
anchorage independent HL60-ADR cell line was removed from the flasks 
and centrifuged at 1,000 r.p.m. for 5 minutes. The pellets were then 
resuspended in 5 mL media and used to seed a roller bottle (Falcon,
3027) containing 500 mL of media. Cells were cultured in the roller 
bottle until 60%) confluent. Once this had been achieved, cells were split 
equally into an additional four roller bottles and the final volume in each of 
the five roller bottles made up to 500 mL with complete media. Cells were 
harvested upon reaching 70% confluency.
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2.10.3 Isolation of IOYs
The isolation of IOVs from various cell lines was performed as described by
Ishikawa et al., (1994) and as detailed below:
1. Approximately 7x10s cells were pelleted at 5,000 r.p.m (1,200 g) for 10 
minutes at 4°C in a Sorvall refrigerated centrifuge.
2. The supernatant was decanted and the pellets resuspended in 50 mL ice 
cold PBS. The combined pellets were then transferred to a 50 mL tube 
and spun at 4,000 r.p.m for 5 minutes.
3. The resulting cell pellet was then resuspended in 230 mL hypotonic 
buffer, (Table 2.10.3.1). The PMSF was added to the buffer immediately 
before use.
Buffer constituent Preparation instructions
0.5 mM Sodium phosphate (pH 7.0) 30 mg NaP in 500 mL UHP
0.1 m M EGTA 19.2 mg EGTA added to NaP solution
0.1 mM PMSF 100 mM stock prepared in EtOH
Table 2.10.3.1: Hypotonic buffer for IOY isolation
4. Cells were lysed by gentle agitation at 4°C for 1.5 hours.
5. The cell lysate was then centrifuged at 28,000 r.p.m (100,000 g) for 35 
minutes at 4°C with a Beckman SW28 rotor in a Beckman XL-80 
ultracentrifuge.
6 . The resulting pellets were then resuspended in 10 mL of hypotonic buffer 
and then homogenised for 15 minutes at 4°C with a Braun potter S8 8 6  
homogeniser.
7. The homogenised cell extract was diluted to a final volume of 20 mL with 
incubation buffer which was prepared as shown in Table 2.10.3.2.
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Buffer constituent Preparation instructions
10 mM Tris-HCl (pH 7.4) 1.211 g Tris in 1 L UHP water
250 mM Sucrose 42.79 g Sucrose in 500 mL 10 mM Tris- 
HCl (pH 7.4)
Table 2.10.3.2: Incubation buffer for 10V isolation
8 . A 100 |xL aliquot of this crude membrane fraction was then retained for 
marker enzyme assays.
9. The crude membrane fraction was layered over 38% sucrose/10 mM Tris- 
HC1 pH 7.4, (38 g sucrose in 100 mL 10 mM Tris-HCl pH 7.4) and 
centrifuged at 28,000 r.p.m (100,000 g) for 35 minutes at 4 °C with a 
SW28 rotor. A volume of 10 mL crude membrane fraction was layered 
over 28.5 mL 38% sucrose/10 mM Tris-HCl pH 7.4. The interface was 
marked to specify the location of the plasma membrane band which 
developed after the sucrose centrifugation step.
10. A thin white band became localised at the interface after centrifugation 
and this was removed with a pasteur pipette and diluted to a total volume 
of 20 mL with incubation buffer.
11. The suspension was then centrifuged at 38,200 r.p.m (100,000 g) for 35 
minutes at 4°C using a Beckman 70.1 rotor.
12. The pellets were then resuspended in 0.2 mL incubation buffer. Vesicles 
were formed by passing resuspended pellets through a 27-gauge needle 2 0  
times using a 1 mL syringe.
13. A protein assay was then performed (Section 2.10.4) and the IOV 
preparation was then diluted to a concentration of 5 mg protein/mL with 
incubation buffer. Volumes of 50 (i.L IOVs were then frozen at -80°C.
14. Before freezing, a 50 (iL aliquot was taken for the marker enzyme assays. 
These assays had to be performed on the day of the IOV preparation in 
order to ensure that enzyme activity remained intact.
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2.10.4 Protein assay
This assay was performed in the same manner as described in Section 2.9.2. For 
the IOVs and crude membrane preparation, samples were diluted 1 in 5 before 
analysis.
2.10.5 Marker enzyme assays - Plasma membrane
1. The solutions listed in Table 2.10.5.1 were prepared freshly in advance of 
the assay.
Buffer constituent Preparation instructions
90 mM 2-amino-2-methyl-l-propanol (pH 
10.5)
0.34 g in 30 mL UHP water.
2 2 .0  mM MgCl2 10.5 mg in 5 mL of 90 mM 2-amino-2- 
methyl-1-propanol (pH 10.5).
Table 2.10.5.1: Plasma membrane assay buffers
2. A solution o f 8 .0  mMp-nitrophenylphosphate was prepared by dissolving
26.3 mgp-nitrophenylphosphate in 9.55 mL 90 mM 2-amino-2-methyl-l- 
propanol (pH 10.5) and 0.45 mL 22.0 mM MgCl2.
3. A volume of 5 mL of 8.0 mM /;-nitrophenylphosphate solution was 
removed and a volume of 5 [iL Triton X-100 (Sigma, T-9284), added to 
the reaction buffer. This was used to disrupt the IOVs and so allow 
assessment of the % IOVs in the preparation.
4. To perform the assay, 100 uL of the reaction buffer (one volume without 
Triton X-100 and a second volume containing Triton X-100) was added 
to a 96-well plate and 10 (XL of the IOV preparation or crude membrane 
extract added to each relevant well. A reagent blank was also included on 
the plate.
5. The plates were incubated in the dark at 37°C for 35 minutes.
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6 . Absorbance was then analysed at 405 nm on a dual beam ELISA plate 
reader.
2.10.6 Marker enzyme assays - Lysosome
1. This assay was performed in exactly the same manner as the acid 
phosphatase assay detailed in Section 2.7.2. In this case, 0.0263 g o fp-  
nitrophenylphosphate was added to i 0 mL o f acid phosphatase buifer.
2. Volumes of 100 |xL of this reagent were added to a 96-well plate and 10
pL of 10V or crude membrane was then added. Reagent blanks were also
included on the plate.
3. The plates were incubated in the dark at 37°C for 35 minutes and then 
analysed at 405 nm on the ELISA plate reader.
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2.11 Transport assays with IOVs
Transport assays with IOVs were performed as described by Ishikawa et al., 
(1994). The protocol used in these assays was as follows:
1. A number of solutions were prepared in advance of the assay. The
protocol used for the preparation of the incubation buffer has already been 
provided in Table 2.10.3.2. An ATP/creatine phosphate/MgCl2/10 mM 
Tris-HCl (pH 7.4) solution is prepared as detailed in Table 2.11.1.
Volumes of 200 |lL were then frozen at -80°C.
Buffer constituent Preparation instructions
MgCl2 6H20 203.3 mg in 30 mL Incubation buffer
ATP (Disodium salt) 6.05 mg ATP in 3 mL MgCl2. 6H20  
solution
Creatine phosphate 32.7 mg in 3 mL ATP solution
Table 2.11.1: ATP/Creatine phosphate/MgCl2/10 mM Tris-HCl (pH 7.4)
preparation protocol.
2. For the AMP solution, 4.99 mg AMP (Sigma, A1752) was substituted for 
the ATP (Sigma, A7699). Once prepared as in Table 2.11.1 above, 100 
(lL volumes were frozen at -80°C.
3. A creatine kinase solution (2 mg/mL), (Sigma, C3755) was prepared in 
incubation buffer and 50 ¡J.L aliquots frozen at -80°C.
4. Prior to performing the assay, filters (Millipore, GSWP-02500) were 
soaked in the incubation buffer for one hour at 4°C. Once soaked, the 
filters were applied to the filter apparatus (Millipore, 12-25 Sampling 
Manifold) and vacuum was applied to the system.
5. An Eppendorf thermomixer (Eppendorf, 5436) was allowed to equilibrate 
at 37°C and once at this temperature, the ATP, AMP, creatine kinase and 
IOV solutions were thawed rapidly at 37°C. After thawing, solutions were 
immediately placed on ice.
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6 . An eppendorf was placed in the thermomixer and the following added 
sequentially: 60 |iL incubation buffer, 30 [XL ATP, 5 |iL creatine kinase, 5 
(iL [3H]-LtC4 (DuPont NEN, NET-1018, 0.01 mCi/mL) and 10 |xL IOVs. 
After every sequential addition the thermomixer was adjusted to half speed 
mixing to allow agitation of the various components of the mixture.
7. Aliquots o f 20 p,L were removed at appropriate timepoints and added into 
1 mL volumes of ice cold incubation buffer.
8 . These were then washed through the filter apparatus. The eppendorf was 
washed out with 1 mL of ice cold incubation buffer. The filter was finally 
washed with 2 mL of ice cold incubation buffer.
9. Filters were removed and placed in 8 mL scintillation cocktail (ICN, 
882475) in a scintillation vial. After allowing 12 hours for the filters to 
fully dissolve, the vials were counted for [3H] content using a Beckman 
LS-6500 scintillation counter using a 1 minute count time.
10. For an AMP negative control, the above procedure was repeated with 
ATP replaced by AMP. For a total negative control, neither ATP nor 
AMP were included but were instead replaced with 30 |iL  incubation 
buffer.
11. For assessment o f a compounds ability to inhibit LtC4 transport ability, the 
compound of interest was dissolved in incubation buffer at 1.83X the 
final desired concentration. An aliquot of 60 \xL of this volume was then 
added to an eppendorf. The standard volumes o f ATP, AMP, creatine 
kinase, LtC4 and IO V were then added to a total final volume o f 1 1 0  |iL. 
The final concentration of solvent used for dissolution of the compound of 
interest was maintained below 0.5% in all cases possible. Indomethacin 
(Sigma, 17378), Taxol (Sigma, T7402), verapamil (Sigma, V4629),
MK571 (Cayman Chemicals, 70720-M010) and antimycin A (Sigma, 
A8674) were prepared as 10 mM stocks in ethanol before final dissolution 
to the desired concentration in incubation buffer. Naproxen (Sigma, 
M1275), glutathione (Sigma, 6529) and sodium azide (S8032) were 
prepared as 10 mM stocks in incubation buffer.
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Water based formulations of vincristine (David Bull Laboratories), 
adriamycin (Farmitalia Carlo Erba Ltd.), cyclosporin A (Sandoz) and 
cisplatin (David Bull Laboratories) were used in all LtC4 transport 
inhibition experiments. These compounds were dissolved in incubation 
buffer to the desired final concentration. In control experiments it was 
demonstrated that at the concentrations used in these studies, the 
solvent used to dissolve these compounds did not have any significant 
effects on transport of LtC4 into 10Vs.
2.11.1 Determination of kinetic parameters of [3H]-LtC4 transport.
1. An eppendorf was placed in the thermomixer and the following added
sequentially: 60 jiL incubation buffer, 30 (iL ATP and 5 (iL creatine 
kinase. A volume of 1 (iL unlabelled LtC4 (Sigma, L4886), at the desired 
final concentration was then added to the reaction mixture. The unlabelled 
LtC4 was supplied at a stock concentration of 54 |0g/mL ( 8 6  |xM) in 70% 
ethanol. A volume of 4 |lL [3H]-LtC4 (DuPont NEN, NET-1018, 0.01 
mCi/mL, 165 Ci/mmol) was then added to the reaction mixture. Final LtC4 
concentration (labelled and unlabelled LtC4) in the reaction mixture was 
varied from 3 nM to 750 nM by preparation of various concentrations of 
unlabelled LtC4 in 70% ethanol and using 1 \iL of this unlabelled LtC4 in 
the mixture as described above. A  volume of 10 (XL IOVs was then added 
to the reaction mixture. After every sequential addition the thermomixer 
was adjusted to half speed mixing to allow agitation o f the various 
components of the mixture.
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2. Aliquots of the mixture were then removed at appropriate timep oints and 
added to 1 mL ice cold incubation buffer. For determination of kinetic 
parameters, only initial rates o f LtC4 transport were monitored. A 
timepoint of 1 minute was used in the case of DLKP and 20 seconds in the 
case of HL60-ADR for all LtC4 transport rate determinations.
3. The removed aliquot was then washed through the filter apparatus. The 
eppendorf was subsequently washed with 1 mL o f ice cold incubation 
buffer. The filter was finally washed with 2 mL of ice cold incubation 
buffer.
4. Filters were then removed and placed in 8 mL scintillation cocktail (ICN, 
882475) in a scintillation vial. After allowing 12 hours for the filters to 
fully dissolve, the vials were counted for [3H] content using a Beckman 
LS-6500 scintillation counter.
5. Total LtC4 uptake (labelled plus unlabelled) was calculated by dividing the 
amount of accumulated [3H]-labelled LtC4 (in pmol/mg) as found from 
scintillation counting, by the quantity of [3H]-labelled LtC4 initially added. 
This was then multiplied by the total quantity of LtC4 (labelled and 
unlabelled) initially added in order to approximate the total uptake of 
LtC4-
6 . Data was plotted as initial rate (V0) of LtC4 transport (pmol/mg/min) 
versus total final LtC4 concentration (nM). Kinetic parameters were 
determined from regression analysis of the Lineweaver-Burk 
transformation o f the data. This involved plotting (Vo)" 1 versus [L^ ] ' 1 
with the values of Vmax and Km determined from the Y- and X-axes 
intercepts (Y-axis intercept of (Vmax) ’ 1 and X-axis intercept of (-Km)'1).
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1. Assessment of fH]-vincristine transport into IOVs was performed as 
described for [3H]-LtC4. Modifications to the procedure detailed in 
Section 2.11 were made in order to minimise non-specific binding of [3H]- 
vincristine to the filters. This involved the use of glass fiber (type A/E) 
filters (Gelman sciences, 61630) which had been soaked in incubation 
buffer for 2  hours in advance of the assay.
2. [3H]-Vincristine (Amersham, TRK478, 3 .7xl0 'n mol/[jL, 6.7 Ci/mmol) 
was added to the reaction mixture at a final concentration o f 200 nM. The 
addition of ATP, AMP, creatine kinase and IOV was performed as 
described in Section 2.11. Filters were washed with 5 x 1 mL volumes of 
ice cold incubation buffer in order to minimise any non-specific binding to 
the glass fiber filters. Quantification of [3H]-vincristine transport into the 
IOVs was performed by scintillation counting. Results were corrected for 
non-specific binding of [3H]-vincristine to the filters.
2.12 Assessment of [14C]-Indomethacin accumulation in DLKP and
DLKP-A.
1. Cells in the exponential phase o f growth were trypsinised and set up at a 
density of lx l0 5 cells per well on 6 -well plates. These plates were then 
incubated at 37°C, 5% C 0 2 for 48 hours.
2. Labelled indomethacin (DuPont NEN, NEC-786, 22.3 mCi/mmol) at a 
concentration of 7 |Xg/mL, ([14C]-labelled) and unlabelled indomethacin 
(94 |_lg/mL) were added to the cells for an appropriate time period.
3. At various time points, media was removed from the cells. The cells were 
then washed twice with ice cold PBS and the plates blotted dry.
4. Cells were solubilised by overnight treatment with 0.2 N NaOH at room
temperature. The cell lysates were then neutralised with 0.2 N HC1.
2.11.2 Assessment of [3H]-vincristine transport into IOVs
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5. The levels of [14C]-indomethacin present in the cell lysates was then
determined by scintillation counting following mixing of cell lysates with 
Ecolite scintillation cocktail (ICN, 882475). A standard curve o f c.p.m 
due to [I4C]-indomethacin present, versus [14C]-indomethacin 
concentration was used to convert c.p.m values obtained for the cell 
lysates into the equivalent [14C]-indomethacin concentration accumulated 
in the cells.
2.13 Fractional product method
Analysis o f experiments investigating possible synergy between cytotoxic drugs 
and compounds such as NSAIDs was performed initially using the fractional 
product method. This method involves using the following equation:
Equation 2.13.1: Fractional product equation
(fu)l,2 = (f«)i x ( f u) 2
where: (f u)i,2 = Expected fraction unaffected by combining compounds 1 and 2. 
(f u)i = Actual fraction unaffected by compound 1 treatment.
(f 11)2 = Actual fraction unaffected by compound 2 treatment.
If it was found that (f u)i,2 was significantly greater than the actual fraction 
unaffected by combining compounds 1  and 2 , a synergistic level of cell kill was 
demonstrated. Mutually exclusive drugs share a common mechanism of action, 
such as binding to the same target in the cell. Mutually non-exclusive drugs have 
independent mechanisms of action. The fractional product method is only 
theoretically applicable in cases involving mutually exclusive drugs, and so was 
only used as a rapid approximation to investigate possible synergy between drugs.
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For this reason, results obtained from the analysis of data using the fractional 
product method were confirmed using a computer package for multiple drug 
effect analysis, “Dose - Effect Analysis with Microcomputers”, (Chou and Chou, 
1987).
2.14 Bioluminescent ATP assay
The concentration of ATP in the incubation mixture used in the LtC4 transport 
assays was quantified using a bioluminescent ATP assay (Labsystems, 5080200). 
The assay is based on the quantitative measurement of light produced as a result 
of firefly luciferase activity in the presence of ATP. The conditions used in the 
ATP assay kit are designed so that the light emitted is directly proportional to the 
ATP concentration present.
1. Unlabelled LtC4 (Sigma, L4886) was diluted in incubation buffer so that a 
final concentration of 2.75 nM LtC4 was achieved in the 110 |0.L 
volume of the LtC4 transport assay incubation mixture.
2. The incubation mixture was composed of 60 |lL incubation buffer, 30 |±L 
ATP, 5 \lL creatine kinase (in the case of the negative control, this was 
replaced by 5 (XL incubation buffer), 5 |lL o f the above LtC4 dilution and 
10 jxL IOVs. The reaction mixture was incubated at 37°C as described in 
Section 2.11.
3. At the relevant timepoints, 9 |iL of the reaction mixture was removed and 
dissolved in 4 mL ice cold incubation buffer. A total o f 100 [iL was 
subsequently removed from this volume and added to 900 |xL o f ice cold 
incubation buffer.
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4. A 50 |xL aliquot of the final dilution of the sample was added to 110 (xL of 
0.1 M tris-acetate buffer in a well of 96-well assay plate (Labsystems, 
95029510). A volume of 40 |xL ATP monitoring reagent (containing 
firefly luciferase) was then added and the assay plate loaded into a 
luminometer (Luminoskan RS).
5. The luminescent signal was then quantified using a 2 second lagtime and 
1 0  second integration time.
6 . The concentration of ATP in the IOV incubation mixture was calculated 
from a standard curve constructed using an ATP standard (Labsystems, 
1620140).
2.15 Quantification of adriamycin accumulation in DLKP-A10
1. DLKP or DLKP-A10 cells were seeded into 75 cm2 flasks (Costar, 3375) 
at 0.5xl06 cells per flask. Cells were incubated for 48 hours, after which 
time medium was removed and fresh medium containing adriamycin ( 1 0  
|xM) added. In some cases, DLKP-A10 cells were treated with adriamycin 
and verapamil (60 jxM) or adriamycin and cyclosporin A (8  fxM).
At relevant timepoints, medium was removed and the flasks washed twice 
with PBS. Cells were then trypsinised as described in Section 2.5.1. Pellets 
were then washed with PBS and frozen at -20°C. SKMES-1 and SKMES- 
1/ADR cells were treated in the manner described above for DLKP and 
DLKP-A10.
2. For adriamycin accumulation experiments involving antimycin A 
(Sigma, A8674) and sodium azide (Sigma, S8032), DLKP and DLKP-A10 
cells were treated with glucose free medium. Cells were seeded at 0 .5xl06 
cells per flask and incubated at 37°C for 48 hours as described above.
Cells were then washed twice in PBS and then pre-incubated for 2 hours 
in glucose free medium only (Gibco, 11963-022).
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Cells were then treated with adriamycin (10 (iM), adriamycin and 
antimycin A (10 [iM) or adriamycin and sodium azide (10 niM) in glucose 
free medium. At relevant timepoints, cells were trypsinised and pellets 
washed and frozen as described above.
The frozen pellets were thawed and resuspended in 100 pL water. A 
volume o f 100 |iL 33% silver nitrate (Sigma, S6506) was then added to 
the pellets, followed by mixing for 5 minutes. A quantity o f 1 .5 ¡xg 
daunorubicin (Farmitalia Carlo Erba Ltd.), dissolved in 300 |iL of 
methanol (Labscan) was then added to the mixture as an internal 
standard. Mixing was then continued for a further 5 minutes.
A volume of 1.3 mL acetonitrile (Labscan) was added to the mixture, 
which was then maintained at 4°C for 1 hour. This was followed by 
centrifugation at 4000 r.p.m. for 40 minutes.
The supernatant (1.1 mL) was removed and added to HPLC autosampler 
vials. All solvent was then removed under a stream of nitrogen gas.
The remaining solids were resuspended in 50 pL o f HPLC mobile phase. 
The HPLC mobile phase was prepared as follows: 32 mL of 0.1 M 
phosphoric acid (Sigma, P6560) was added to 244 mL UHP water. The 
pH was then adjusted to 2.3 with 1 N potassium hydroxide (Sigma,
P6310). A volume of 124 mL acetonitrile was added finally and the 
completed mobile phase allowed to degas at 4°C overnight.
The samples for analysis were automatically injected into the HPLC 
system (Beckman System Gold 507 autosampler, 125 pump and 166 
detector). Mobile phase flow rate was set at 1 mL per minute with a total 
run time of 15 minutes. The column used for HPLC analysis of adriamycin 
in DLKP and DLKP-AI0 was a Cjg reversed phase Prodigy 5 pm particle 
size ODS-3 column (Phenomenex, U.K.). Absorbance was monitored 
at 253 nm.
A standard curve of (adriamycin peak area/daunorubicin internal standard 
peak area) versus adriamycin concentration was used to quantify the levels 
of adriamycin present in the samples.
2.16 Materials
The product numbers of materials used, but which have not already been 
provided, are as follows: sodium fluoride (Sigma, S I504), sodium orthovanadate 
(Sigma, S6508), DTT (Sigma, D5545), PMSF (Sigma, P7626), leupeptin (Sigma, 
L2023), aprotinin (Sigma, A6279), benzamidine (Sigma, B6506), trypsin inhibitor 
(Sigma, T9003), SDS (Sigma, L4509), ammonium persulfate (Sigma, A6761), 
TEMED (Sigma, T9281), sodium phosphate (Sigma, P5379), EGTA (Sigma, 
E4378), sucrose (Sigma, S7903), amino-methyl-propanol (Sigma, A9199), MgCl2 
(Sigma, M8266), MgCl2. 6H20  (Sigma, M2670), PgE2 (Sigma, P5640), PgD2 
(Sigma, P5172), GF109203X (Calbiochem, 203290).
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Results
3.1 Cytotoxic drug resistance profiles of cell lines used in NSAID 
screening experiments.
The A549 human lung adenocarcinoma and DLKP human lung squamous 
carcinoma cell lines were used for the identification o f NSAIDs with 
chemotherapeutic drug toxicity-enhancing abilities. The drug resistance profile of 
the A549 cell line is provided in Table 3.1.1. The DLKP and A549 cell lines are 
regarded as drug sensitive as they do not exhibit the high level o f drug resistance 
found for multidrug resistant cell lines such as DLKP-A, (Clynes el al., 1992),
Anticancer drug category Drug A549 lC5u,
Antimetabolites 5-Fluorouracil 0.13 ±0.01 |xg/mL
Covalent DNA binding drugs Carboplatin 3.50 ± 0 .20  |xg/mL
Noncovalent DNA binding drugs Adriamycin 55.00 ± 3.00 ng/mL
Daunorubicin 15.00 ± 0.60 ng/mL
Epirubicin 12.00 ±0 .40  ng/mL
Mitoxantrone 2.00 ± 0.30 ng/mL
Inhibitors o f  chromatin function Etoposide (VP-16) 0.28 ± 0.05 [xg/mL
Vincristine 9.00 ± 0.50 ng/mL
Taxol 1.20 ±  0.10 ng/mL
Table 3.1.1: I C 50 values of chemotherapeutic drugs in A549. These values were 
identified as the drug concentrations giving rise to 50% cell kill relative to 
untreated control cells according to the protocol detailed in Section 2.7.
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3.2 Chemotherapeutic drug in vitro toxicity assay screening with 
indomethacin and sulindac in the A549 cell line
Non-toxic levels o f the NSAIDs, indomethacin and sulindac have been shown to 
enhance the toxicity o f adriamycin in a number o f drug sensitive cell lines, (Duffy 
et al., 1997). An enhancement in chemotherapeutic drug toxicity, caused as a 
direct result of the presence of an NSAID was regarded as significant if the level 
of cell kill achieved by the combination was significantly greater than the product 
of the individual toxicities of the drug and NSAID (as described in Section 2.13). 
Drug screening experiments illustrated the ability of indomethacin and sulindac to 
significantly enhance the toxicity o f adriamycin in the A549 cell line (Tables 3.2.2 
and 3.2.3). The toxicity enhancing abilities of these NSAIDs occurred when the 
NSAIDs were added at relatively non-toxic levels (causing only 0-5% cell kill). A 
certain degree of toxicity appeared to be necessary for achievement of the toxicity 
enhancement effect. The data in Table 3.2.6 illustrates this fact as it can be seen 
that minor toxicity was caused due to the presence of 3.20 (ig/mL indomethacin. 
This concentration of indomethacin was found to enhance epirubicin induced cell 
kill. At a concentration of 0.90 |lg/niL indomethacin, cell kill is negligible and no 
significant synergistic cell kill is observed in the presence o f a variety of epirubicin 
concentrations (11, 6 or 4 ng/mL).
Further drug screening experiments with indomethacin and sulindac showed that 
in addition to adriamycin, the toxicity of vincristine, V P-16, daunorubicin and 
epirubicin could be enhanced in the presence of non-toxic levels of these NSAIDs. 
It was also discovered that indomethacin and sulindac did not enhance the toxicity 
of carboplatin, 5-fluorouracil or Taxol. The results are shown in summary in Table 
3.2.1 with the relevant screening results in Tables 3.2.2 to 3.2.13 inclusive. As can 
be seen from Table 3.2.1, no differences were found between indomethacin and 
sulindac as regards their ability to enhance the toxicity of a given 
chemotherapeutic drug. Drug and NSAID combinations where the toxicity 
enhancement effect was observed have been included in Tables 3.2.2 to 3.2.11. In 
Tables 3.2.12 and 3.2.13 sample data is provided where a drug (Taxol) and
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NSAID combination give rise to an additive rather than a synergistic level of cell 
kill. All other drug and NSAID combinations where the toxicity enhancement 
effect was not observed generated similar results
Drug NSAID Toxicity
enhancement
*
Drug NSAID Toxicity
enhancement*
Adriamycin Indomethacin ( + ) Adriamycin Sulindac ( + )
Carboplatin Indomethacin ( - ) Carboplatin Sulindac ( - )
Daunorubicin Indomethacin ( + ) Daunorubicin Sulindac ( + )
Epirubicin Indomethacin ( + ) Epirubicin Sulindac ( + )
5-Fluorouracil Indomethacin ( - ) 5-Fluorouracil Sulindac ( - )
Taxol Indomethacin ( - ) Taxol Sulindac ( - )
Vincristine Indomethacin ( + ) Vincristine Sulindac ( + )
VP-16 Indomethacin ( + ) VP-16 Sulindac ( + )
*: Toxicity enhancement is scored with a ( + ) if  a level of toxicity is achieved with a drug plus 
NSAID combination, which is significantly greater than the level of toxicity predicted by the 
fractional product method and as described in Section 2.13.
Table 3.2.1: Chemotherapeutic drug toxicity enhancement abilities of
indomethacin and sulindac as found in the A549 cell line.
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A549 (P 98), Adriamycin and Indomethacin
Adriamycin conc. 1 0.04 (j.g/mL 
Adriamycin conc. 2 0.02 /xg/mL 
Adriamycin conc. 3 :-0.01 jig/mL
Indomethacin conc. 1 2.40 (ig/mL 
Indomethacin conc. 2 1.20 frg/mL 
Indomethacin conc. 3 0.60 (xg/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 60.60 7.96
Indo 1 control 92.18 7.09
Adriamycin 1 + Indo 21.00* 3.56
Adriamycin 2 control 81.54 7.26
Adriamycin 2 + Indo 30.54* 3.74
Adriamycin 3 control 84.89 10.98
Adriamycin 3 + Indo 56.48* 5.58
Adriamycin 1 control 53.40 10.37
Indo 2 control 87.54 13.07
Adriamycin 1 + Indo 23.20* 4.25
Adriamycin 2 control 70.18 11.09
Adriamycin 2 + Indo 30.28* 5.51
Adriamycin 3 control 85,40 13.11
Adriamycin 3 + Indo 55.07 10.72
Adriamycin 1 control 49.71 4.99
Indo 3 control 92.38 13.30
Adriamycin 1 + Indo 25.48* 2.99
Adriamycin 2 control 78.90 13.92
Adriamycin 2 + Indo 40.43 8.96
Adriamycin 3 control 79.92 11.95
Adriamycin 3 + Indo 60.89 8.26
Table 3.2.2: Survival of A549 cells in the presence of various concentrations of 
adriamycin and indomethacin (Indo) as found using the protocol detailed in 
Section 2.7.3. Survival is represented as a % relative to the control untreated cells 
± S.D. Statistically significant results are indicated by an asterisk. Results are the 
average o f triplicate determinations in a single experiment. Similar results were 
obtained in at least one additional experiment.
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A549 (P 98), Adriamycin and Sulindac
Adriamvciii conc. 1 0.04 ug/mL
Adriamycin conc. 2 0.02 (xg/mL
Adriamycin conc. 3 0.01 jxg/mL
Sulindac conc. 1 6.30 |-ig/mL
Sulindac conc. 2 3.20 |xg/mL
Sulindac conc. 3 1.50 p,g/mL
Treatment % Cell Survival S.D.
Cell Control 100
Adriamycin 1 control 49.87 4.74
Sul 1 control 96.01 5.36
Adriamycin 1 + Sul 27.14* 3.64
Adriamycin 2 control 72.41 6.65
Adriamycin 2 + Sul 35.27* 6.44
Adriamycin 3 control 83.21 6.14
Adriamycin 3 + Sul 59.72* 7.58
Adriamycin 1 control 47.56 5.57
Sul 2 control 101.0 12,14
Adriamycin 1 + Sul 27.72* 4.57
Adriamycin 2 control 69.75 8.57
Adriamycin 2 + Sul 50.50 7.70
Adriamycin 3 control 83.95 9.17
Adriamycin 3 + Sul 70.02 7.29
Adriamycin 1 control 42.11 6.89
Sul 3 control 100.0 13.20
Adriamycin 1 + Sul 28.51 5.17
Adriamycin 2 control 65.99 10.27
Adriamycin 2 + Sul 55.94 6.18
Adriamycin 3 control 84.61 11.86
Adriamycin 3 + Sul 79.29 9.37
Table 3.2.3: Survival of A549 cells in the presence of various concentrations o f 
adriamycin and sulindac (Sul) as found using the protocol detailed in Section
2.7.3. Survival is represented as a % relative to the control untreated cells ±  S.D. 
Statistically significant results are indicated by an asterisk. Results are the average 
o f triplicate determinations in a single experiment. Similar results were obtained in 
at least one additional experiment.
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A549 (P 95), Daunorubicin and Indomcthacin
Daunorubicin conc. 1 0.012 |ig/mL
Daunorubicin conc. 2 0.006 |Xg/mL
Daunorubicin conc. 3 >0.003 |ig/mL
Indomethacin conc. 1 3.20 |xg/mL
Indomethacin conc. 2 1.60 |ig/mL
Indomethacin conc. 3 0,90 |0.g/mL
Treatment % Cell Survival S.D.
Celi control 100
Daunorubicin 1 control 51.31 3.78
Indomethacin 1 control 95.75 5.64
Dauno 1 + Indo 23.80* 1.92
Dauno 2 control 83.44 8.04
Dauno 2 + Indo 31.77* 3.57
Dauno 3 control 94.12 4.00
Dauno 3 + Indo 73.40 5.69
Daunorubicin 1 control 47.90 3.40
Indomethacin 2 control 106.21 14.75
Dauno 1 +  Indo 21.03* 1.52
Dauno 2 control 78.30 5.07
Dauno 2 + Indo 39.79* 5.78
Dauno 3 control 91.48 8.08
Dauno 3 + Indo 78.87 7.59
Daunorubicin 1 control 46.64 3.47
Indomethacin 3 control 100.87 7.51
Dauno 1 + Indo 20.69* 3.15
Dauno 2 control 77.04 4.61
Danno 2 + Indo 53.77* 3.75
Dauno 3 control 95.70 7.31
Dauno 3 + Indo 89.27 6.83
Table 3.2.4: Survival of A549 cells in the presence o f various concentrations of 
daunorubicin (Dauno) and indomethacin (Indo) as found using the protocol 
detailed in Section 2.7.3. Survival is represented as a % relative to the control 
untreated cells ± S.D. Statistically significant results are indicated by an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P 95), Daunorubicin and Sulindac
Daunorubicin conc. 1 0.012 |xg/mL
Daunorubicin conc. 2 0.006 (xg/mL
Daunorubicin conc. 3 0.003 (ig/mL
Sulindac conc. 1 8.40 (Xg/mL
Sulindac conc. 2 4.40 jxg/mL
Sulindac conc. 3 2.20 |xg/mL
Treatment % Cell Survival S.D.
Cell control 100
Daunorubicin 1 control 53.05 19.03
Sulindac 1 control 87.27 25.79
Dauno 1 + Sul 25.65* 16.80
Daunorubicin 2 control 61.36 15.72
Dauno 2 + Sul 44.42 15.94
Daunorubicin 3 control 65.15 16.54
Dauno 3 + Sul 56.17 18.46
Daunorubicin 1 control 58.79 20.16
Sulindac 2 control 94.09 20.57
Dauno 1 + Sul 38.83* 8.90
Daunorubicin 2 control 65.09 10.51
Dauno 2 + Sul 53.34 9.28
Daunorubicin 3 control 69.72 9.64
Dauno 3 + Sul 66.82 6.14
Daunorubicin 1 control 55.35 17.43
Sulindac 3 control 92.91 23.80
Dauno 1 + Sul 46.20 16,33
Daunorubicin 2 control 70.61 22.63
Dauno 2 + Sul 61.38 17.04
Daunorubicin 3 control 72.34 20.39
Dauno 3 + Sul 70.81 24.09
Table 3.2.5: Survival of A549 cells in the presence of various concentrations of 
daunorubicin (Dauno) and sulindac (Sul) as found using the protocol detailed in 
Section 2.7.3. Survival is represented as a % relative to the control untreated cells 
±  S.D. Statistically significant results are indicated by an asterisk. Results are the 
average of triplicate determinations in a single experiment. Similar results were 
obtained in at least one additional experiment.
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A549 (P 95), Epirubicin and Indomethacin
Epirubicin conc. 1 0.011 (ig/mL 
Epimbicin conc. 1 0.006 |xg/mL 
Epirubicin conc. 1 0.004 ug/rnL
Indomethacin conc. 1 3.20 jxg/mL 
Indomethacin conc. 2 1.60 (ig/'mL 
Indomethacin conc. 3 0.90 )J,g/mL
Treatment % Cell Survival S.D.
Cell control 100
Epirubicin 1 control 44.62 4.20
Indomethacin 1 control 89.01 6.47
E p i1 + Indo 17.15* 1.46
Epi 2 control 68.62 5.38
Epi 2 + Indo 20.42* 3.32
Epi 3 control 80.30 8.17
Epi 3 + Indo 26.72* 3.04
Epirubicin 1 control 49.70 4.39
Indomethacin 2 control 90.55 12.05
Epi 1 + Indo 22.88* 1.74
Epi 2 control 70.37 6.17
Epi 2 + Indo 30.01* 2.94
Epi 3 control 78.16 6.38
Epi 3 + Indo 48.22 5.14
Epirubicin 1 control 53.11 4.86
Indomethacin 3 control 99.77 18.14
Epi 1 + Indo 26.76 2.16
Epi 2 control 73.71 10.55
Epi 2 + indo 42.70 4.20
Epi 3 control 82.78 6.02
Epi 3 + Indo 66.40 6.48
Table 3.2.6: Survival o f A549 cells in the presence o f various concentrations o f 
epirubicin (Epi) and indomethacin (Indo) as found using the protocol detailed in 
Section 2.7.3. Survival is represented as a % relative to the control untreated cells 
±  S.D. Statistically significant results are indicated by an asterisk. Results are the 
average of triplicate determinations in a single experiment. Similar results were 
obtained in at least one additional experiment.
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A549 (P 95), Epirubicin and Sulindac
Epirubicin conc. 1 0.011 jxg/mL
Epirubicin conc. 2 0.006 (.i.g/mL
Epirubicin conc. 3 0.004 jig/mL
Sulindac conc. 1 8.40 (j,g/mL
Sulindac conc. 2 4.40 |xg/niL
Sulindac conc. 3 2.20 jxg/mL
Treatment % Cell Survival S.D.
Cell control 100
Epirubicin 1 control 56.24 1.33
Sulindac 1 control 92.03 4.08
Epi 1 + Sul 25.69* 5.67
Epirubicin 2 control 67.80 8.84
Epi 2 + Sul 44.64* 8.52
Epirubicin 3 control 75.57 12.17
Epi 3 + Sul 52.07 9.60
Epirubicin 1 control 59.20 13.93
Sulindac 2 control 103.88 19.55
Epi 1 + Sul 45.92 8.67
Epirubicin 2 control 88.95 13.67
Epi 2 + Sul 71.09 13.90
Epirubicin 3 control 91.31 12.98
Epi 3 + Sul 81.39 13.24
Epirubicin 1 control 53.42 7.84
Sulindac 3 control 96.14 14.94
Epi 1 + Sul 46.02 9.04
Epiiubicin 2 control 64.87 11.63
Epi 2 + Sul 61.46 11.25
Epirubiciu 3 control 71.68 11.61
Epi 3 + Sul 70.61 10.68
Table 3.2.7: Survival of A549 cells in the presence of various concentrations of 
epirubicin (Epi) and sulindac (Sul) as found using the protocol detailed in Section 
2.7.3. Survival is represented as a % relative to the control untreated cells ±  S.D. 
Statistically significant results are indicated by an asterisk. Results are the average 
of triplicate determinations in a single experiment. Similar results were obtained in 
at least one additional experiment.
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A549 (P 100), Vincristine and Indomethacin
Vincristine conc. 1 0.008 jag/mL 
Vincristine conc. 2 0.004 jxg/mL 
Vincristine conc. 3 0.002 )xg/niL
Indomethacin conc. 1 2.60 fxg/mL 
Indomethacin conc. 2 1.30 |.ig/inL 
Indomethacin conc. 3 0.60 p.g/inL
Treatment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 67.33 6.07
Indo 1 control 92.89 6.74
Vincristine 1 + Indo 16.78* 2.17
Vincristine 2 control 89.05 7.22
Vincristine 2 + Indo 31,20* 3.86
Vincristine 3 control 90.99 7.97
Vincristine 3 + Indo 57.08* 8.19
Vincristine 1 control 59.71 7.05
Indo 2 control 92.23 6.37
Vincristine 1 + Indo 21.52* 3.84
Vincristine 2 control 87.36 7.50
Vincristine 2 + Indo 39.61* 5.27
Vincristine 3 control 88.28 6.50
Vincristine 3 + Indo 72.28 7.88
Vincristine 1 control 60.88 11.00
Indo 3 control 98.50 7.03
Vincristine 1 + Indo 27.75* 4.03
Vincristine 2 control 89.43 6.55
Vincristine 2 + Indo 60.53* 9.38
Vincristine 3 control 98.54 10.82
Vincristine 3 + Indo 90.46 8.83
Table 3.2.8: Survival of A549 cells in the presence of various concentrations of 
vincristine and indomethacin (Indo) as found using the protocol detailed in 
Section 2.7.3. Survival is represented as a % relative to the control untreated cells 
± S.D. Statistically significant results are indicated by an asterisk. Results are the 
average of triplicate determinations in a single experiment. Similar results were 
obtained in at least one additional experiment.
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A549 (P 101), Vincristine and Sulindac
Vincristine conc. 1 0.008 jxg/mL
Vincristine conc. 2 0.004 |J.g/mL
Vincristine conc. 3 0.002 (xg/mL
Sulindac conc. 1 6.20 jig/mL
Sulindac conc. 2 3.10 (.ig/mL
Sulindac conc. 3 1.60 |xg/mL
Treatment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 74.07 6.99
Sul 1 control 89.56 9.73
Vincristine 1 + Sul 28.47* 3.57
Vincristine 2 control 90.18 11.10
Vincristine 2 + Sul 45.32* 9.71
Vincristine 3 control 90.60 10.38
Vincristine 3 + Sul 67.17 13.82
Vincristine 1 control 57.95 4.00
Sul 2 control 95.01 8.25
Vincristine 1 + Sul 31.61* 7.28
Vincristine 2 control 84.20 11.02
Vincristine 2 + Sul 61.47 8.62
Vincristine 3 control 92.93 11.45
Vincristine 3 + Sul 75.72 11.43
Vincristine 1 control 47.20 2.95
Sul 3 control 97.28 5.90
Vincristine 1 + Sul 32.92* 5.59
Vincristine 2 control 78.42 9.01
Vincristine 2 + Sul 64.36 4.66
Vincristine 3 control 75.85 8.70
Vincristine 3 + Sul 68.32 6.83
Table 3.2.9: Survival of A549 cells in the presence of various concentrations of 
vincristine and sulindac (Sul) as found using the protocol detailed in Section 
2.7.3. Survival is represented as a % relative to the control untreated cells ± S.D. 
Statistically significant results are indicated by an asterisk. Results are the average 
of triplicate determinations in a single experiment. Similar results were obtained in 
at least one additional experiment.
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A549 (P 102), VP-16 and Indomethacin
VP-16 conc. 1 0.080 ¡ig/mL
VP-16 conc. 2 :- 0.040 |U.g/inL
VP-16 conc. 3 0.020 |ig/mL
Indomethacin conc. 1 :- 4.50 ixg/mL
Indomethacin conc. 2 2.10 jxg/mL
Indomethacin conc. 3 :-1.20 |xg/mL
Treatment % Cell Survival S.D.
Cell control 100
VP-16 1 control 97.14 3.50
Indomethacin 1 control 99.46 10.20
VP-16 1 + Indo 53.45* 7.95
VP-16 2 control 105.01 12.39
VP-16 2 + Indo 77.87* 8.23
VP-16 3 control 100.73 11.98
VP-16 3 + Indo 82.60 34.65
VP-16 1 control 96.24 8.20
indomethacin 2 control 100.30 8.05
VP-16 1 + Indo 60.92* 3.86
VP-16 2 control 100.73 12.96
VP-16 2 + Indo 86.84 8.51
VP-16 3 control 99.80 13.68
VP-16 3 + Indo 93.46 11.07
VP-16 1 control 93.03 10.07
Indomethacin 3 control 98.92 14.64
VP-16 1 + Indo 76.90 5.17
VP-16 2 control 98.23 10.60
VP-16 2 + Indo 92.91 9.31
VP-16 3 control 95.04 8.75
VP-16 3 + Indo 96.91 12.46
Table 3.2.10: Survival of A549 cells in the presence of various concentrations of 
V P-16 and indomethacin (Indo) as found using the protocol detailed in Section 
2.7.3. Survival is represented as a % relative to the control untreated cells ±  S.D. 
Statistically significant results are indicated by an asterisk. Results are the average 
o f triplicate determinations in a single experiment. Similar results were obtained in 
at least one additional experiment.
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A549 (P 106), VP-16 and Sulindac
VP-16 conc. 1 > 0 .1 0  |ig/mL
VP-16 conc. 2 > 0.05 jxg/niL
VP-16 conc. 3 > 0.03 jig/mL
Sulindac conc. 1 > 5.80 (xg/rnL
Sulindac conc. 2 > 2.90 jj,g/mL
Sulindac conc. 3 > 1.50 |ig/mL
Treatment % Cell Survival S.D.
Cell Control 100
VP-16 1 control 72.26 6.28
Sul 1 control 99.24 3.45
VP-16 1 + Sul 46.59* 4.56
VP-16 2 control 94.30 14.27
VP-16 2 + Sul 77.36 6.57
VP-16 3 control 96.39 12.84
VP-16 3 + Sul 90.40 8.61
VP-16 1 control 64,80 3.10
Sul 2 control 98.36 2.40
VP-16 1 + Sul 49.11* 5.80
VP-16 2 control 86.22 5.50
VP-16 2 + Sul 76.86 5.46
VP-16 3 control 92.54 7.36
VP-16 3 + Sul 89.13 10.94
VP-16 1 control 59.62 5.55
Sul 3 control 102.7 9.82
VP-16 1 + Sul 56.95 8.75
VP-16 2 control 82.99 11.84
VP-16 2 + Sul 82.91 7.61
VP-16 3 control 95.01 9.39
VP-16 3 + Sul 86.92 9.33
Table 3.2.11: Survival of A549 cells in the presence o f various concentrations of 
VP-16 and sulindac (Sul) as found using the protocol detailed in Section 2.7.3. 
Survival is represented as a % relative to the control untreated cells ±  S.D. 
Statistically significant results are indicated by an asterisk. Results are the average 
of triplicate determinations in a single experiment. Similar results were obtained in 
at least one additional experiment.
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A549 (P 100), Taxol and Indomcthacin
Taxol conc. 1 1.80 ng/mL
Taxol conc. 2 0.90 ng/mL
Taxol conc. 3 0.50 ng/mL
Indomethacin conc. 1 2.60 (ig/mL
Indomethacin conc. 2 1.30 (xg/inL
Indomethacin conc. 3 0.65 |xg/mL
Treatment % Cell Survival S.D.
Cell control 100
Taxol 1 control 17.25 1.79
Indo 1 control 96.43 10.79
Taxol 1 + Indo 16.48 2.05
Taxol 2 control 39.24 4.22
Taxol 2 + Indo 41.46 6.00
Taxol 3 control 69.84 8.05
Taxol 3 + Indo 76.83 7.01
Taxol 1 control 16.45 2.44
Indo 2 control 99.05 10.83
Taxol 1 + Indo 14.83 2.13
Taxol 2 control 36.49 3.60
Taxol 2 + Indo 38.73 6.18
Taxol 3 control 72.62 6.79
Taxol 3 + Indo 69.43 7.31
Taxol 1 control 16.25 2.20
Indo 3 control 100.03 5.82
Taxol 1 + Indo 16.22 2.41
Taxol 2 control 35.51 5.65
Taxol 2 + Indo 35.71 3.84
Taxol 3 control 73.05 6.10
Taxol 3 + Indo 74.15 6.85
Table 3.2.12: Survival of A549 cells in the presence of various concentrations of 
Taxol and indomethacin (Indo) as found using the protocol detailed in Section 
2.7.3. Survival is represented as a % relative to the control untreated cells ±  S.D. 
Statistically significant results are indicated by an asterisk. Results are the average 
of triplicate determinations in a single experiment. Similar results were obtained in 
at least one additional experiment.
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A549 (P 101), Taxol and Sulindac
Taxol conc. 1 2.25 ng/mL
Taxol conc. 2 1.10 ng/mL
Taxol conc. 3 0.60 ng/mL
Sulindac conc. 1 > 6 .39  (Xg/mL
Sulindac conc. 2 > 3 .10  ug/mL
Sulindac conc. 3 > 1.64 jig/mL
Treatment % Cell Survival S.D.
Cell control 100
Taxol 1 control 10.90 1.37
Sul 1 control 101.36 9.86
Taxol 1 + Sul 9.89 0.83
Taxol 2 control 53.85 7.46
Taxol 2 + Sul 46.43 5.66
Taxol 3 control 69.56 7.26
Taxol 3 + Sul 70.37 8.14
Taxol 1 control 11.60 1.37
Sul 2 control 102.05 8.32
Taxol 1 + Sul 10.39 1.15
Taxul 2 control 60,08 7.33
Taxol 2 + Sul 54.80 8.18
Taxol 3 control 75.00 7.33
Taxol 3 + Sul 77.04 7.54
Taxol 1 control 11.05 1.80
Sul 3 control 101.95 10.64
Taxol 1 + Sul 10.89 1.17
Taxol 2 control 52.84 6.26
Taxol 2 + Sul 51.75 7.24
Taxol 3 control 70.24 8.59
Taxol 3 + Sul 62.41 9.40
Table 3.2.13: Survival o f A549 cells in the presence of various concentrations of 
Taxol and sulindac (Sul) as found using the protocol detailed in Section 2.7.3. 
Survival is represented as a % relative to the control untreated cells ±  S.D. 
Statistically significant results are indicated by an asterisk. Results are the average 
o f triplicate determinations in a single experiment. Similar results were obtained in 
at least one additional experiment.
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3.3 Identification of NSAIDs with an ability to enhance the toxicity of 
adriamycin and vincristine in the A549 cell line.
The data provided in Tables 3.2.1 to 3.2.13 illustrated that indomethacin and 
sulindac had the ability to enhance the toxicity of a specific group of 
chemotherapeutic drugs. Further studies were conducted to investigate if the 
toxicity enhancement abilities of indomethacin and sulindac in the A549 cell line 
were shared by other NSAIDs. The results of these studies are summarised in 
Table 3.3.1 with relevant individual data in Tables 3.3.2. to 3.3.14. It was found 
that acemetacin, indomethacin, mefenamic acid, sulindac, sulindac sulfide, 
suliddac sulfone, tolmetin and zomepirac enhanced the toxicity of both adriamycin 
and vincristine in the A549 cell line. None of these NSAIDs enhanced the toxicity 
of only one o f these drugs. This indicated that these NSAIDs interfered with a 
cellular resistance mechanism which is common for both adriamycin and 
vincristine. As found in the case of indomethacin and sulindac, the toxicity 
enhancement effect appeared to be concentration dependent as the effect was 
highly significant at higher concentrations of drug and NSAID. In some cases, the 
effect was absent at lower concentrations of drugs and NSAIDs. For example 
5.80 [ig/mL mefenamic acid significantly enhanced the toxicity of 15 ng/mL 
adriamycin from approximately 22% to 66%). This dose of mefenamic acid is 
insufficient to enhance the level of toxicity achieved using 4 ng/mL adriamycin 
(Table 3.3.3). Sample data has been included in Tables 3.2.13 and 3.2.14 to 
illustrate the level of cell survival achieved in the presence of an NSAID such as 
acetaminophen which is ineffective for enhancement o f the toxicity o f drugs such 
as adriamycin. In the presence of this NSAID an additive rather than a synergistic 
level of cell kill, as determined from the fractional product method (Section 2.13), 
was achieved. The NSAIDs tested in combination with adriamycin and vincristine 
may be classified into a number o f structural categories as described in Section 
1.4. It was found that with the exception o f mefenamic acid, all NSAIDs with the 
ability to enhance the toxicity of adriamycin and vincristine were members o f the 
heteroarylacetic acid NSAIDs. This suggests that a characteristic structural 
feature may be required for an NSAID to enhance the toxicity o f a given drug.
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This situation is complicated by the fact that mefenamic acid but not other 
fenamic acid NSAlDs (such as meclofenamic acid) had the ability to enhance 
adriamycin and vincristine toxicity in the drug sensitive A549 cell line.
Ding NSAID Toxicity
enhancement
•*:,* *
Dnij* NSAID Toxicity
enhancement* *-*
Adriamycin Acemetacin ( + ) Vincristine Acemetacin ( + )
Adriamycin Acetamino­
phen
( - ) Vincristine Acetamino­
phen
( - )
Adriamycin Aspirin ( - ) Vincristine Aspirin N.D.
Adriamycin Aurothio-
glucose
( • ) Vincristine Aurothio-
glucose
( - )
Adriamycin Chloroquine ( - ) Vincristine Chloroquine N.D.
Adriamycin Diclofenac ( - ) Vincristine Diclofenac N.D.
Adriamycin Etodolac ( - ) Vincristine Etodolac ( - )
Adriamycin Flufenamic
acid
( - ) Vincristine Flufenamic
acid
( - )
Adriamycin Flurbiprofen ( - ) Vincristine Flurbiprofen ( - )
Adriamycin Ibuprofen ( - ) Vincristine Ibuprofen ( - )
Adriamycin Indomethacin ( + ) Vincristine Indomethacin ( + )
Adriamycin Levamisole ( - ) Vincristine Levamisole N.D.
Adriamycin Meclofenamic
acid
( - ) Vincristine Meclo-fenamic
acid
( - )
Adriamycin Mefenamic
acid
( + ) Vincristine Mefenamic
acid
( + )
Adriamycin Naproxen ( - ) Vincristine Naproxen N.D.
Adriamycin Pheylbulazone ( - ) Vincristine Pheyl-butazone ( - )
Adriamycin Sulindac ( + ) Vincristine Sulindac ( + )
Adriamycin Sulindac
sulfide
( + ) Vincristine Sulindac
sulfide
( + )
Adriamycin Sulindac
sulfone
( + ) Vincristine Sulindac
sulfone
( + )
Adriamycin Tolmetin ( + ) Vincristine Tolmetin N.D.
Adriamycin Zomepirac ( + ) Vincristine Zomepirac ( + )
* Toxicity enhancement is scored with a ( +  ) if  a level of toxicity is achieved with a drug plus 
NSAID combination, which is significantly greater than the level of toxicity predicted by the 
fractional product method as described in Section 2.13.
** N.D. = Not determined.
Table 3.3.1: Summary table of ability of various NSAIDs to enhance adriamycin 
or vincristine toxicity in the drug sensitive A549 cell line.
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A549 (P109), Aüriamycin and Acemetacin
Adriamycin conc. 1 0.015 |xg/mL
Adriamycin conc. 2 0.007 (.ig/niL
Adriamycin conc. 3 0.004 p-g/mL
Acemelacin conc. 1 37.5 ag/niL
Acemetacin conc. 2 19.2 ug/mL
Acemetacin conc. 3 11.5 |Jg/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 68.99 6.69
Acemetacin 1 control 85.04 10.13
Adriamycin 1 + Ace 19.25* 1.80
Adriamycin 2 control 89.24 16.14
Adriamycin 2 + Ace 29.33* 2.66
Adriamycin 3 control 93.16 11.91
Adriamycin 3 + Ace 54.82* 3.17
Adriamycin 1 control 61.43 4.73
Acemetacin 1 control 97.30 8.46
Adriamycin 1 + Ace 25.73* 2.65
Adriamycin 2 control 82.14 6.55
Adriamycin 2 + Ace 51.07* 3.95
Adriamycin 3 control 94.61 6.79
Adriamycin 3 + Ace 83.58 6.65
Adriamycin 1 control 53.14 4.07
Acemetacin 1 control 102.08 8.76
Adriamycin 1 + Ace 30.66* 3.82
Adriamycin 2 control 81.10 6.27
Adriamycin 2 + Ace 68.55 6.22
Adriamycin 3 control 96.68 9.29
Adriamycin 3 + Ace 92.20 6.72
Table 3.3.2: Survival o f A549 cells in the presence of various concentrations of 
adriamycin and acemetacin (Ace). Survival is represented as a % o f control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average o f triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P106), Adriamycin and Mefenamic Acid
Adriamycin conc. 1 0.015 jj,g/mL
Adriamycin conc. 2 0.007 |a.g/mL
Adriamycin conc. 3 0.004 |X.g/mL
Mefenamic Acid conc. 1 5.80 |xg/mL
Mefenamic Acid conc. 2 2.90 fj,g/mL
Mefenamic Acid conc. 3 1.50 |j,g/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 78.19 7.23
Mefenamic Acid 1 control 99.95 8.40
Adriamycin 1 + M ef 34.77* 4.05
Adriamycin 2 control 97.87 13.41
Adriamycin 2 + M ef 70.55 7.33
Adriamycin 3 control 103.34 17.39
Adriamycin 3 + Mef 95.41 16.32
Adriamycin 1 control 65.52 5.52
Mefenamic Acid 2 control 100.07 10.12
Adriamycin 1 + M ef 36.65* 4.59
Adriamycin 2 control 87.56 5.38
Adriamycin 2 + M ef 73.73 6,99
Adriamycin 3 control 93.49 8.76
Adriamycin 3 + M ef 91.86 7.63
Adriamycin 1 control 72.99 4.08
Mefenamic Acid 3 control 103.47 10.70
Adriamycin 1 + Mef 59.19* 4,16
Adriamycin 2 control 93.84 6.44
Adriamycin 2 + M ef 90.50 6.85
Adriamycin 3 control 98.79 7.28
Adriamycin 3 + Mef 97.82 7.27
Table 3.3.3: Survival of A549 cells in the presence o f various concentrations of 
adriamycin and mefenamic acid (Mel). Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P 96), Adriamycin and Sulindac Sulfide
Adriamycin conc. 1 0.015 |ig/mL
Adriamycin conc. 2 0,008 p,g/mL
Adriamycin conc. 3 0.004 |ig/mL
Sulindac sulfide conc. 1 6.00 p,g/mL
Sulindac sulfide conc. 2 2.70 |0g/mL
Sulindac sulfide conc. 3 1.40 jxg/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 74.21 4.29
Sulindac sulfide 1 control 90.19 9.63
Adriamycin 1 + Sul sulfide 26.79* 1.99
Adriamycin 2 control 85.46 5.95
Adriamycin 2 + Sul sulfide 34.12* 2.86
Adriamycin 3 control 88.23 7.89
Adriamycin 3 + Sul sulfide 48.86* 5.63
Adriamycin 1 control 69.66 3.43
Sulindac sulfide 2 control 104.91 5.57
Adriamycin 1 + Sul sulfide 34.80* 2.39
Adriamycin 2 control 92.93 4.90
Adriamycin 2 + Sul sulfide 39.02* 2.94
Adriamycin 3 control 101.55 6.81
Adriamycin 3 + Sul sulfide 62.56 4.32
Adriamycin 1 control 68.49 6.73
Sulindac sulfide 3 control 105.83 6.50
Adriamycin 1 + Sul sulfide 26.74* 1.76
Adriamycin 2 control 83.99 5.89
Adriamycin 2 + Sul sulfide 39.34* 3.79
Adriamycin 3 control 90.77 6.44
Adriamycin 3 + Sul sulfide 65.59 4.23
Table 3.3.4: Survival of A549 cells in the presence of various concentrations of 
adriamycin and sulindac (Sul) sulfide. Survival is represented as a % o f control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P 96), Adriamycin and Sulindac Sulfone
Adriamycin conc. 1 0.015 ¡xg/mL
Adriamycin conc. 2 0.008 |xg/mL
Adriamycin conc. 3 0.004 fxg/mL
Sulindac sulfone conc. 1 19.50 jxg/mL
Sulindac sulfone conc. 2 8.90 (.ig/inL
Sulindac sulfone conc. 3 4.50 |xg/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 66.68 6.90
Sulindac sulfone 1 control 76.77 6.49
Adriamycin 1 + Sul sulfone 22.16* 1.78
Adriamycin 2 control 81.15 5.90
Adriamycin 2 + Sul sulfone 30.93* 2.90
Adriamycin 3 control 99.80 9.25
Adriamycin 3 + Sul sulfone 49.45 4.51
Adriamycin 1 control 70.50 5.85
Sulindac sulfone 2 control 102.21 8.88
Adriamycin 1 + Sul sulfone 26.60* 2.87
Adriamycin 2 control 86,69 7.74
Adriamycin 2 + Sul sulfone 41.88* 4.10
Adriamycin 3 control 96.38 8.67
Adriamycin 3 + Sul sulfone 64.71 8.28
Adriamycin 1 control 66.18 4.98
Sulindac sulfone 3 control 101.87 10.52
Adriamycin 1 + Sul sulfone 36.67* 2.68
Adriamycin 2 control 81.24 5.35
Adriamycin 2 + Sul sulfone 60.77* 5,30
Adriamycin 3 control 97.91 10.23
Adriamycin 3 + Sul sulfone 79.48 12.34
Table 3.3.5: Survival of A549 cells in the presence of various concentrations of 
adriamycin and sulindac (Sul) sulfone. Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A54i> (P 104 ), Adriamycin and Tolmetin
Adriamycin conc. 1 0.02 jxg/mL 
Adriamycin conc. 2 0.01 (j,g/mL 
Adriamycin conc. 3 0.005 p.g/mL
Tolmetin conc. 1 24.20 fxg/mL 
Tolmetin conc. 2 14.10 ug/mL 
Tolmetin conc. 3 8.50 jxg/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 79.64 3.95
Tol 1 control 99.24 10.35
Adr 1 + Tol 31.82* 2.73
Adr 2 control 98.73 14.08
Adr 2 + Tol 52.83 4.33
Adr 3 control 101.32 11.33
Adr 3 + Tol 86.36 5.82
Adriamycin 1 control 81.10 5.17
Tol 2 control 97.59 9.85
Adr 1 + Tol 38.83* 3.07
Adr 2 control 94.37 8.70
Adr 2 + Tol 73.74 3.55
Adr 3 control 96.94 10.01
Adr 3 + Tol 92.23 9.41
Adriamycin 1 control 73.38 5.58
Tol 3 control 91.84 4.30
Adr 1 + Tol 44.66* 3.13
Adr 2 control 94.40 11.86
Adr 2 + Tol 76.54 6.69
Adr 3 control 95.87 11.00
Adr 3 + Tol 92.04 9.55
Table 3.3.6: Survival of A549 cells in the presence of various concentrations of 
adriamycin and tolmetin (Tol). Survival is represented as a % o f control untreated 
cells ±  S.D. Statistically significant results are indicated with an asterisk. Results 
are the average o f triplicate determinations in a single experiment. Similar results 
were obtained in at least one additional experiment.
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A549 (P108), Adriamycin and Zomepirac
Adriamycin conc. 1 0.015 |xg/mL 
Adriamycin conc. 2 0.007 (xg/mL 
Adriamycin conc. 3 0.004 jxg/mL
Zomepirac conc. 1 39.40 |xg/niL 
Zomepirac conc. 2 19.80 p,g/niL 
Zomepirac conc. 3 9.30 jxg/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 78.82 7.65
Zomepirac 1 control 88.82 8.25
Adriamycin 1 + Zorn 21.40* 2.67
Adriamycin 2 control 90.80 9.53
Adriamycin 2 + Zom 30.94* 2.23
Adriamycin 3 control 94.42 7.58
Adriamycin 3 + Zom 54.56 4.32
Adriamycin 1 control 72.39 5.45
Zomepirac 2 control 95.26 11.73
Adriamycin 1 + Zom 20.88* 1.90
Adriamycin 2 control 90.59 10.84
Adriamycin 2 + Zom 31.94* 2.89
Adriamycin 3 control 98.00 10.70
Adriamycin 3 + Zom 58.20 5.17
Adriamycin 1 control 73.62 8.47
Zomepirac 3 control 98.25 13.72
Adriamycin 1 + Zom 26.25* 2.15
Adriamycin 2 control 90.48 11.79
Adriamycin 2 + Zom 40.52* 3.71
Adriamycin 3 control 97.98 12.86
Adriamycin 3 + Zom 71.45 4.93
Table 3.3.7: Survival of A549 cells in the presence of various concentrations of 
adriamycin and zomepirac. Survival is represented as a % of control untreated 
cells ±  S.D. Statistically significant results are indicated with an asterisk. Results 
are the average of triplicate determinations in a single experiment. Similar results 
were obtained in at least one additional experiment.
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A549 (P106), Vincristine and Acemetacin
Vincristine conc. 1 0.010 |xg/mL
Vincristine conc. 2 0.005 |xg/mL
Vincristine conc. 3 0.002 (J,g/mL
Acemetacin conc. 1 37.5 jig/mL 
Acemetacin conc. 2 19.2 jxg/mL 
Acemetacin conc. 3 > 11 .5  (xg/mL
Treatment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 71.57 5.80
Acemctacin 1 control 76.27 5.85
Vincristine 1 + Ace 13.48* 1.02
Vincristine 2 control 95.41 7.55
Vincristine 2 + Ace 24.77* 2.34
Vincristine 3 control 97.31 11.40
Vincristine 3 + Ace 50.00 5.17
Vincristine 1 control 71.99 7.28
Accmetacin 2 control 99.74 7.10
Vincristine 1 + Ace 28.38* 3.97
Vincristine 2 control 99.67 6.79
Vincristine 2 + Ace 64.09 6.85
Vincristine 3 control 100.65 6.59
Vincristine 3 + Ace 96.49 10.42
Vincristine 1 control 80.08 4.30
Acemetacin 3 control 96.96 6.26
Vincristine 1 + Ace 46.51* 3.02
Vincristine 2 control 95.55 7.63
Vincristine 2 + Ace 85.91 3.56
Vincristine 3 control 101.52 10.10
Vincristine 3 + Ace 97.84 6.32
Table 3.3.8: Survival o f A549 cells in the presence o f various concentrations of 
vincristine and acemetacin (Ace). Survival is represented as a % of control 
untreated cells ±  S.D. Statistically significant results are indicated with an asterisk. 
Results are the average o f triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P 98), Vincristine and Mefenamic acid
Vincristinc conc. 1 0.010 jxg/mL
Vincristinc conc. 2 0.005 ug/mL
Vincristinc conc. 3 0.002 (ig/inL
Mefenamic acid conc. 1 7.90 (xg/mL
Mefenamic acid conc. 2 4.00 |xg/mL
Mefenamic acid conc. 3 2.30 |xg/mL
Treatment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 35.78 2.83
Mefenamic acid 1 control 85.57 5.03
Vincristine 1 + Mef 14.01* 1.06
Vincristine 2 control 79.18 4.24
Vincristine 2 + Mef 28.83* 1.95
Vincristine 3 control 91.24 4.99
Vincristine 3 + Mef 72.98 5.44
Vincristinc 1 control 29.57 2.87
Mefenamic acid 2 control 94.19 5.08
Vincristinc 1 + M ef 14.83* 1.32
Vincristine 2 control 73.21 4.53
Vincristine 2 + Mef 38.57* 3.16
Vincristine 3 control 94.20 5.83
Vincristine 3 + Mef 88.26 6.91
Vincristinc 1 control 32.50 3.76
Mefenamic acid 3 control 97.35 13.49
Vincristine 1 + Mef 21.25 1.90
Vincristine 2 control 73.76 6.54
Vincristine 2 + Mef 54.49 5.03
Vincristine 3 control 90.78 4.68
Vincristine 3 + Mef 91.68 4.00
Table 3.3.9: Survival of A549 cells in the presence of various concentrations of 
vincristine and mefenamic acid (Mef). Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average o f triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P 99), Vincristine and Sulindac Sulfide
Vincristine conc. 1 0.010 jxg/mL
Vincristine conc. 2 0.006 p,g/niL
Vincristine conc. 3 0.003 jig/mL
Sulindac sulfide conc. 1 9.50 jxg/mL
Sulindac sulfide conc. 2 4.70 |u.g/mL
Sulindac sulfide conc. 3 2.40 )ig/niL
Treatment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 44.71 3.02
Sulindac sulfide 1 control 99.01 13.58
Vincristine 1 + Sul sulfide 18.34* 1.08
Vincristine 2 control 91.79 10.05
Vincristine 2 + Sul sulfide 24.09* 1.30
Vincristine 3 control 94.70 8.89
Vincristine 3 + Sul sulfide 51.80* 3.31
Vincristine 1 control 44.34 2.99
Sulindac sulfide 2 control 92.11 10.93
Vincristine 1 + Sul sulfide 19.16* 1.60
Vincristine 2 control 91.97 21.04
Vincristine 2 + Sul sulfide 25.83* 2.33
Vincristine 3 control 99.47 14.68
Vincristine 3 + Sul sulfide 59.35* 3.78
Vincristine 1 control 49.16 3.92
Sulindac sulfide 3 control 107.65 12.50
Vincristine 1 + Sul sulfide 22.09* 1.76
Vincristine 2 control 99.08 10.57
Vincristine 2 + Sul sulfide 31.62* 2.23
Vincristine 3 control 101.53 11.17
Vincristine 3 + Sul sulfide 74.32 3.72
Table 3.3.10: Survival of A549 cells in the presence of various concentrations of 
vincristine and sulindac (Sul) sulfide. Survival is represented as a % of control 
untreated cells ±  S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P 99), Vincristine and Sulindac Sulfone
Vincristine conc. 1 0.010 )ig/inL
Vincristine conc. 2 0.006 ji.g/mL
Vincristine conc. 3 0.003 |xg/mL
Sulindac sulfone conc. 1 20.70 )ig/mL
Sulindac sulfone conc. 2 10.00 jig/niL
Sulindac sulfone conc. 3 6.10 ug/mL
T reatinent % Cell Survival S.D.
Cell control 100
Vincristine 1 control 43.76 3.77
Sulindac sulfone 1 control 102.91 8.50
Vincristine 1 + Sul sulfone 18.42* 1.83
Vincristine 2 control 92.44 12.62
Vincristine 2 + Sul sulfone 24.29* 2.50
Vincristine 3 control 97.29 5.64
Vincristine 3 + Sul sulfone 46.27* 4.35
Vincristine 1 control 46.13 6,09
Sulindac sulfone 2 control 98.99 17.53
Vincristine 1 + Sul sulfone 23.34* 2.51
Vincristine 2 control 90.80 17.36
Vincristine 2 + Sul sulfone 34.81* 3.20
Vincristine 3 control 100.53 13.49
Vincristine 3 + Sul sulfone 85.34 13.78
Vincristine 1 control 40.43 4.62
Sulindac sulfone 3 control 104.95 14.02
Vincristine 1 + Sul sulfone 27.91* 2.61
Vincristine 2 control 87.06 6.43
Vincristine 2 + Sul sulfone 43.91* 3.59
Vincristine 3 control 103.86 13.06
Vincristine 3 + Sul sulfone 99.81 13.10
Table 3,3.11: Survival o f A549 cells in the presence of various concentrations o f 
vincristine and sulindac (Sul) sulfone . Survival is represented as a % of control 
untreated cells ±  S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P 97), Vincristine and Zomepirac
Vincristinc conc. 1 0.010 pg/mL
Vincristine conc. 2 0.005 jxg/mL
Vincristine conc. 3 0.002 ug/niL
Zomepirac conc. 1 38.80 )xg/mL
Zomepirac conc. 2 20.70 jxg/mL
Zomepirac conc. 3 11.40 (xg/niL
Treatment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 80.11 6.68
Zomepirac 1 control 93.49 9.05
Vincristine 1 + Zom 20.86* 2.39
Vincristine 2 control 101.32 15.14
Vincristine 2 + Zom 39.96* 2.50
Vincristine 3 control 99.59 11.23
Vincristine 3 + Zom 82.22 9.76
Vincristine 1 control 86.43 12.92
Zomepirac 2 control 102.60 11.90
Vincristinc 1 + Zom 23.96* 2.12
Vincristine 2 control 96.12 12.19
Vincristine 2 + Zom 51.04* 3.65
Vincristine 3 control 100.62 12.52
Vincristine 3 + Zom 95.93 9.50
Vincristine 1 control 87.91 10.55
Zomepirac 3 control 103.38 14.77
Vincristine 1 + Zom 26.66* 2.32
Vincristinc 2 control 107.94 13.98
Vincristine 2 + Zom 63.71* 5.15
Vincristine 3 control 102.73 16.10
Vincristine 3 + Zom 98.55 17.98
Table 3.3.12: Survival of A549 cells in the presence of various concentrations of 
vincristine and zomepirac (Zom). Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average o f triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P 98), Adriamycin and Acetaminophen
Adriamycin conc. 1 >0.015 )ag/mL 
Adriamycin conc. 2 > 0.007 |Xg/mL 
Adriamycin conc. 3 > 0.004 (xg/mL
Acetaminophen conc. 1 > 0.01 (ig/mL 
Acetaminophen conc. 2 > 0.005 |xg/mL 
Acetaminophen conc. 3 > 0.002 p,g/mL
T rcatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 68.53 6.42
Acetaminophen 1 control 82.91 7.30
Adriamycin 1 + Acet 55.04 3.86
Adriamycin 2 control 91.74 13.68
Adriamycin 2 + Acet 60.83 10.39
Adriamycin 3 control 97.57 12.03
Adriamycin 3 + Acet 77.13 8.16
Adriamycin 1 control 59.52 8,42
Acetaminophen 2 control 89.44 19.78
Adriamycin 1 + Acet 40.70 5.21
Adriamycin 2 control 88.23 13.34
Adriamycin 2 + Acet 66.76 10,90
Adriamycin 3 control 93.17 10.30
Adriamycin 3 + Acet 76.33 15.25
Adriamycin 1 control 79.09 4.63
Acetaminophen 3 control 99.39 8.85
Adriamycin 1 + Acet 69.76 7.38
Adriamycin 2 control 93.84 13.38
Adriamycin 2 + Acet 90.72 8,05
Adriamycin 3 control 97.46 6.30
Adriamycin 3 + Acet 92.48 9.57
Table 3.3.13: Survival of A549 cells in the presence of various concentrations of 
adriamycin and acetaminophen (Acet). Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P 98), Vincristine and Acetaminophen
Vincristine conc. 1 0.010 |ig/mL
Vincristine conc. 2 0.005 |j.g/mL
Vincristine conc. 3 0.002 |Xg/mL
Acetaminophen conc. 1 :-0.01 |J,g/niL
Acetaminophen conc. 2 0.005 |xg/mL
Acetaminophen conc. 3 0.002 jj,g/mL
T icatment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 60.05 6.31
Acetaminophen 1 control 94.01 8.43
Vincristine 1 + Acet 55.56 5.74
Vincristine 2 control 93.96 10.50
Vincristine 2 + Acet 84.35 9.56
Vincristine 3 control 104.54 12.37
Vincristine 3 + Acet 95.32 12.28
Vincristine 1 control 63.89 7.62
Acetaminophen 2 control 94.29 9.08
Vincristine 1 + Acet 61.62 9.55
Vincristine 2 control 96.22 12.24
Vincristine 2 + Acet 91.61 10.50
Vincristine 3 control 99.34 9.02
Vincristine 3 + Acet 102.39 11.04
Vincristine 1 control 68.77 9.80
Acetaminophen 3 control 104.21 11.28
Vincristine 1 + Acet 72.52 12.15
Vincristine 2 control 101.64 9.24
Vincristine 2 + Acet 100.09 10.87
Vincristine 3 control 105.08 9.00
Vincristine 3 + Acet 101.11 8.81
Table 3.3.14: Survival o f A549 cells in the presence of various concentrations of 
vincristine and acetaminophen (Acet). Survival is represented as a % of control 
untreated cells ±  S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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3.4 Ability of NSAEDs to enhance the toxicity of heavy metals in the A549 
cell line
It was known that the toxicity of a suitable chemotherapeutic drug could be 
enhanced in the presence of various NSAIDs. but it was unclear if this effect was 
a result o f the NSAID interfering with a resistance mechanism unique for 
chemotherapeutic drugs or if the NSAID affected an intrinsic cellular resistance 
mechanism common to toxins other than chemotherapeutic drugs. Further in vitro 
toxicity assay screening was carried out with the A549 cell line in order to 
investigate the ability of NSAIDs such as indomethacin and tolmetin to enhance 
the toxicity of heavy metals such as sodium arsenate or potassium antimony 
tartrate. Heavy metals such as these compounds have been shown to be substrates 
for the drug transporter molecule MRP, (Cole et a l ,  1994). Interference with 
their transport out of MRP-expressing cells should result in an increase in cellular 
accumulation and an augmentation of heavy metal-induced cell kill. As can be 
seen from Tables 3.4.1 and 3.4.2, indomethacin and tolmetin, when present in 
high concentrations (3 and 24 |ig/mL respectively) enhanced the toxicity of 
sodium arsenate in A549 cells. This result suggested that indomethacin and 
to lmetin may have in some way interfered with MRP-mediated transport of 
sodium arsenate out of the cell and so caused the enhancement of heavy metal 
toxicity. This suggestion was complicated by the fact that the cytotoxicity of 
potassium antimony tartrate was unaffected by the presence of indomethacin or 
tolmetin (Tables 3.4.3 and 3.4.4). The influence of an NSAID such as 
acetaminophen which did not possess chemotherapeutic drug toxicity enhancing 
abilities, to influence heavy metal toxicity was not investigated.
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A549 (P 99), Sodium Arsenate and Indomethacin
Sodium arsenate conc. 1 15.20 )J,g/niL
Sodium arsenate conc. 2 7.70 ug/mL
Sodium arsenate conc. 3 4.00 ¡ig/mL
Indomethacin conc. 1 3.00 pig/mL 
Indomethacin conc. 2 1.50 fXg/mL 
Indomethacin conc. 3 1.00 jig/mL
Treatment % Cell Survival S.D.
Cell control 100
Na Arsenate 1 control 68.88 5.20
Indomethacin 1 control 98.95 3.99
Na Arsenate 1 + Indo 35.10* 2.20
Na Arsenate 2 control 67.58 8.13
Na Arsenate 2 + Indo 54.81 5.22
Na Arsenate 3 control 78.17 9.32
Na Arsenate 3 + Indo 71.41 6.18
Na Arsenate 1 control 69.85 2.65
Indomethacin 2 control 100.36 3.89
Na Arsenate 1 + Indo 40.33* 5.99
Na Arsenate 2 control 64.98 6.54
Na Arsenate 2 + Indo 66.86 5.41
Na Arsenate 3 control 79.50 6.31
Na Arsenate 3 + Indo 80.23 6.29
Na Arsenate 1 control 63.29 7.97
Indomethacin 3 control 95.74 5.35
Na Arsenate 1 + Indo 54.31 3.51
Na Arsenate 2 control 64.74 5.35
Na Arsenate 2 + Indo 65.70 4.81
Na Arsenate 3 control 79.15 5,23
Na Arsenate 3 + Indo 80.83 5.10
Table 3.4.1: Survival of A549 cells in the presence o f various concentrations of 
sodium arsenate and indomethacin (Indo). Survival is represented as a % of 
control untreated cells ± S.D. Statistically significant results are indicated with an 
asterisk. Results are the average of triplicate determinations in a single 
experiment. Similar results were obtained in at least one additional experiment.
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A549 (P 98), Sodium Arsenate and Tolmetin
Sodium arsenate conc. 1 14.50 jj,g/mL
Sodium arsenate conc. 2 7.50 |xg/mL
Sodium arsenate conc. 3 4.20 jig/mL
Tolnietin conc. 1 24.30 jug/mL
Tolmetin conc. 2 11.90 jxg/mL
Tolmetin conc. 3 6.10 |J,g/mL
Treatment % Cell Survival S.D.
Cell control 100
Na Arsenate 1 control 85.97 7.01
Tolmetin 1 control 96.58 9.92
Na Arsenate 1 + Tol 48.77* 4.26
Na Arsenate 2 control 93.22 8.21
Na Arsenate 2 + Tol 73.23 3.99
Na Arsenate 3 control 99.30 11.49
Na Arsenate 3 + Tol 89.72 9.08
Na Arsenate 1 control 91.02 9.10
Tolmetin 2 control 97.29 8.61
Na Arsenate 1 + Tol 58.29* 7.10
Na Arsenate 2 control 94.82 13.96
Na Arsenate 2 + Tol 87.34 7.84
Na Arsenate 3 control 92.39 12.89
Na Arsenate 3 +  Tol 91.41 9.61
Na Arsenate 1 control 93.30 7.81
Tolmetin 3 control 100.99 11.04
Na Arsenate 1 + Tol 86.88 8.59
Na Arsenate 2 control 99.51 13.90
Na Arsenate 2 + Tol 97.88 11.90
Na Arsenate 3 control 100.92 9.25
Na Arsenate 3 + Tol 101.92 15.25
Table 3.4.2: Survival of A549 cells in the presence of various concentrations of 
sodium arsenate and tolmetin (Tol). Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P 95), Potassium Antimony Tartrate and Indomethacin
Potassium Antimony Tartrate conc. 1:- 3.00 fig/mL 
Potassium Antimony Tartrate conc. 2:-1.50 (xg/'mL 
Potassium Antimony Tartrate conc. 3:- 0.75 |_ig/mL
Indomethacin conc. 1 2.60 |j,g/mL 
Indomethacin conc. 2 1.30 |j,g/mL 
Indomethacin conc. 3 0.80 |ig/mL
T reatment % Cell Survival S.D.
Cell control 100
Pott antimony tartrate 1 control 38.27 7.61
Indomethacin 1 control 90.49 6,43
Pott antimony tartrate 1 + Indo 66.12 5.59
Pott antimony tartrate 2 control 53.02 9.09
Pott antimony tartrate 2 + Indo 75.25 7.60
Pott antimony tartrate 3 control 76.12 7.83
Pott antimony tartrate 3 + Indo 83.48 6,05
Pott antimony tartrate 1 control 34.39 9.33
Indomethacin 2 control 96.58 10.07
Pott antimony tartrate 1 + Indo 66.34 7.10
Pott antimony tartrate 2 control 46.86 10.41
Pott antimony tartrate 2 + Indo 67.42 7.30
Pott antimony tartrate 3 control 76.09 6.01
Pott antimony tartrate 3 + Indo 86.40 6.88
Pott antimony tartrate 1 control 45.21 5.71
Indomethacin 3 control 96.73 4.55
Poll antimony tartrate 1 + Indo 76.27 6.27
Pott antimony tartrate 2 control 64.24 7.76
Pott antimony tartrate 2 + Indo 80.29 7.55
Pott antimony tartrate 3 control 83.72 7.89
Pott antimony tartrate 3 + Indo 87.12 5.63
Table 3.4.3: Survival o f A549 cells in the presence o f various concentrations of 
Potassium antimony tartrate and indomethacin (Indo). Survival is represented as a 
% of control untreated cells ±  S.D. Statistically significant results are indicated 
with an asterisk. Results are the average of triplicate determinations in a single 
experiment. Similar results were obtained in at least one additional experiment.
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A549 (P 98), Potassium Antimony Tartrate and Tolmetin
Potassium Antimony Tartrate conc. 1:- 3.50 jxg/mL 
Potassium Antimony Tartrate conc. 2:-1.70 jxg/mL 
Potassium Antimony Tartrate conc. 3:- 0.90 |ig/mL
Tolmetin conc. 1 24.30 (Xg/mL 
Tolmetin conc. 2 11.90 |Xg/mL 
Tolmetin conc. 3 6.10 jig/mL
Treatment % Cell Survival S.D.
Cell control 100
Pott antimony tartrate 1 control 99.19 14.30
Tolmetin 1 control 101.32 14.63
Pott antimony tartrate 1 + Tol 87.40 6.37
Poll antimony tartrate 2 control 97.49 14.87
Pott antimony tartrate 2 + Tol 94.44 12.27
Pott antimony tartrate 3 control 98.02 12.76
Pott antimony tartrate 3 + Tol 92.73 10.58
Pott antimony tartrate 1 control 90.24 9.17
Tolmetin 2 control 98.51 11.78
Pott antimony tartrate 1 + Tol 89.72 8.57
Pott antimony tartrate 2 control 93.03 10.21
Pott antimony tartrate 2 + Tol 93.14 9.48
Pott antimony tartrate 3 control 94.21 8.61
Pott antimony tartrate 3 + Tol 93.23 8.97
Pott antimony tartrate 1 control 92.52 9.81
Tolmetin 3 control 99.02 12.23
Pott antimony tartrate 1 + Tol 89.38 10.53
Pott antimony tartrate 2 control 94.42 10.22
Pott antimony tartrate 2 + Tol 94.71 12.81
Pott antimony tartrate 3 control 92.81 9.41
Poll antimony tartrate 3 + Tol 94.26 6.98
Table 3.4.4: Survival of A549 cells in the presence of various concentrations o f 
Potassium antimony tartrate and tolmetin (Tol). Survival is represented as a % of 
control untreated cells ± S.D. Statistically significant results are indicated with an 
asterisk. Results are the average of triplicate determinations in a single 
experiment. Similar results were obtained in at least one additional experiment.
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3.5 Identification of NSAIDs with an ability to enhance the toxicity of 
adriamycin and vincristine in the DLKP cell line.
The NSAID screening performed with the A549 cell line identified a select 
number o f NSAIDs with an ability to enhance the toxicity o f adriamycin and 
vincristine. In order to investigate if this profile of toxicity enhancing NSAIDs 
was unique to the A549 cell line, further in vitro toxicity assay screening was 
performed using a second drug sensitive cell line, the human lung squamous 
carcinoma cell line DLKP. It was found that in DLKP, adriamycin and vincristine 
toxicity could be enhanced in the presence of acemetacin, indomethacin, sulindac, 
tolmetin, mefenamic acid and zomepirac. The toxicity o f these cytotoxic drugs 
was unaffected by the presence of an NSAID such as etodolac (Table 3.5.9). As 
described in Section 3.3, these NSAIDs also enhance adriamycin and vincristine 
toxicity in the A549 cell line. This suggested that the NSAIDs in question directly 
affected a drug resistance mechanism which is common to the DLKP and A549 
cell lines. The NSAID screening results for the DLKP cell line are summarised in 
Table 3.5.1 with the specific screening results presented in Tables 3.5.3 to 3.5.16. 
From the data it can be seen that the toxicity enhancement effect occurs to the 
greatest extent at the highest concentrations of drug and NSAID tested. For 
example in Table 3.5.4, a concentration of 2.5 (ig/mL indomethacin (a non-toxic 
dose) significantly enhances the toxicity of 10 ng/mL adriamycin from 
approximately 26% to 85%. This concentration of indomethacin has no effect on 
the level o f toxicity achieved by a dose of 3 ng/mL adriamycin. The magnitude of 
the toxicity enhancement effect in the DLKP cell line is comparable to the effect in 
the A549 cell line. For example in the A549 cell line (Table 3.2.3), a non-toxic 
dose of sulindac (6.3 |ig/mL) enhanced the toxicity of 20 ng/mL adriamycin from 
approximately 28% to 65%, In DLKP (Table 3.5.6) a non-toxic dose of sulindac 
(7.6 (J,g/mL) enhanced the toxicity o f 20 ng/mL adriamycin from approximately 
35% to 75%.
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A  serum free medium has been developed for the DLKP cell line, (Meleady, 
1997). NSAID in vitro toxicity assay screening was carried out using serum free 
conditions (media composition detailed in Section 2.5) in order to investigate the 
possible dependence of the toxicity enhancement effect on the various growth 
factors present in serum. It was found that chemotherapeutic drug toxicity was 
enhanced under serum free conditions to an extent comparable to that found 
under standard serum containing conditions. The results are provided in summary 
in Table 3.5.2. This illustrated that the ability of a suitable NSAID to enhance the 
toxicity of a drug such as adriamycin was independent o f any potential activities 
o f the various growth factors present in serum.
Drug NSAID Toxicity
enhancement
*
Drug NSAID Toxicity
enhancement
*
Adriamycin Acemetacin ( + ) Vincristine Acemetacin ( + )
Adriamycin Etodolac ( - ) Vincristine Etodolac ( - )
Adriamycin lndomethacin ( + ) Vincristine lndomethacin ( + )
Adriamycin Mefenamic acid ( + ) Vincristine Mefenamic
acid
( + )
Adriamycin Sulindac ( + ) Vincristine Sulindac ( + )
Adriamycin Tolmetin ( + ) Vincristine Tolmetin ( + )
Adriamycin Zomepirac ( + ) Vincristine Zomepirac ( + )
* Toxicity enhancement is scored with a ( + ) if  a level of toxicity is achieved with a drug plus 
NSAID combination, which is significantly greater than the level of toxicity predicted by the 
fractional product method as described in Section 2.3. A ( - ) indicates no significant toxicity 
enhancement effects.
Table 3.5.1: Ability of various NSAIDs to enhance the toxicity o f adriamycin and 
vincristine in the DLKP cell line.
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Drug NSAID Toxicity enhancement’
Adriamycin Indomethacin ( + )
Adriamycin Sulindac ( + )
Adriamycin Tolmetin ( + )
Adriamycin Naproxen ( - )
* Toxicity enhancement is scored with a ( + ) if a level o f toxicity is achieved with a drug +  
NSAID combination, which is significantly greater than the level of toxicity predicted by the 
fractional product method. A  ( - )  indicates no significant toxicity enhancement cffects.
Table 3.5.2: Ability o f various NSAIDs to enhance the toxicity of adriamycin and 
vincristine in the DLKP cell line under serum free medium growth conditions as 
described in Section 2.5.
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Adriamycin conc. 1 0.010 |xg/mL
Adriamycin conc. 2 0.005 p.g/mL
Adriamycin conc. 3 0.003 jxg/mL
Acemetacin conc. 1 37.50 |ig/mL
Acemetacin conc. 2 18.30 p.g/mL
Acemelacin conc. 3 7.50 |xg/mL
DLKP (P 16), Adriamycin and Acemetacin
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 63.00 4.93
Acemelacin 1 control 76.82 9.90
Adriamycin 1 + Ace 14.93* 1.92
Adriamycin 2 control 88.64 5.34
Adriamycin 2 + Ace 28.91* 2.98
Adriamycin 3 control 95.17 6.23
Adriamycin 3 + Ace 32.72* 3.39
Adriamycin 1 control 59.58 4.96
Acemetacin 2 control 89.33 8.45
Adriamycin 1 + Ace 11.38* 1.72
Adriamycin 2 control 83.68 4.56
Adriamycin 2 + Ace 60,50 5.35
Adriamycin 3 control 93.76 7.93
Adriamycin 3 + Ace 83.67 7.21
Adriamycin 1 control 56.38 5.30
Acemetacin 3 control 96.41 6.73
Adriamycin 1 + Ace 10.77* 2.00
Adriamycin 2 control 86.80 8.51
Adriamycin 2 + Ace 62.22 3.73
Adriamycin 3 control 92.29 5.77
Adriamycin 3 + Ace 91.65 8.79
Table 3.5.3: Survival of DLKP cell in the presence o f various concentrations of 
adriamycin and acemetacin (Ace). Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average o f triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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DLKP (P 17), Adriamycin and Indomcthacin
Adriamycin conc. 1 0 . 0 1 0  |ig/mL
Adriamycin conc. 2 0.005 jxg/mL
Adriamycin conc. 3 0.003 )Xg/mL
Indomethacin conc. 1 2.50 (ig/mL
Indomethacin conc. 2 1.40 |ig/mL
Indomethacin conc. 3 0.70 |xg/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 73.52 5.41
Indomcthacin 1 control 96.70 4.93
Adriamycin 1 + Indo 14.63* 4.58
Adriamycin 2 control 94.85 5.72
Adriamycin 2 + Indo 69.83* 4.02
Adriamycin 3 control 102.02 5.57
Adriamycin 3 + Indo 96.70 8.61
Adriamycin 1 control 70.44 5.26
Indomethacin 2 control 98.05 6.00
Adriamycin 1 + Indo 23.47* 3.35
Adriamycin 2 control 90.46 6.37
Adriamycin 2 + Indo 76.92 6.39
Adriamycin 3 control 96.47 9.13
Adriamycin 3 + Indo 93.46 7.40
Adriamycin 1 control 70.69 11.75
Indomethacin 3 control 102.18 15.08
Adriamycin 1 + Indo 36.24* 8.12
Adriamycin 2 control 90.98 12.42
Adriamycin 2 + Indo 85.74 11.35
Adriamycin 3 control 97.68 9.03
Adriamycin 3 + Indo 89.50 8.53
Table 3.5.4: Survival of DLKP cells in the presence of various concentrations of 
adriamycin and indomethacin (Indo). Survival is represented as a % of control 
untreated cells ±  S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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DLKP (P 21), Adriamycin and Mefenamic acid
Adriamycin conc. 1 0.010 ag/mL
Adriamycin conc. 2 0.005 ug/mL
Adriamycin conc. 3 0.003 /xg/mL
Mefemamic acid conc. 1 > 7 .60  jig/mL
Mefemamic acid conc. 2 > 4.00 |ig/mL
Mefemamic acid conc. 3 > 2.00 (ig/inL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 91.08 13.76
Mefenamic acid 1 control 96.12 11.58
Adriamycin 1 + Mef 30.46* 3.82
Adriamycin 2 control 99.59 13.55
Adriamycin 2 + Mef 85.69 6.16
Adriamycin 3 control 97.48 9.08
Adriamycin 3 + Mef 95.58 12.72
Adriamycin 1 control 91.67 8.66
Mefenamic acid 2 control 100.67 12.04
Adriamycin 1 + M ef 46.77* 4.08
Adriamycin 2 control 99.33 13.46
Adriamycin 2 + Mef 100.90 12.58
Adriamycin 3 control 98.58 8.48
Adriamycin 3 + Mef 99.56 12.98
Adriamycin 1 control 86.49 8.60
Mefenamic acid 3 control 95.24 13.15
Adriamycin 1 + M ef 67.64 4.61
Adriamycin 2 control 96.80 11.01
Adriamycin 2 + M ef 94.02 10.67
Adriamycin 3 control 92.65 8.92
Adriamycin 3 + Mef 93.69 11.42
Table 3.5.5: Survival o f DLKP cells in the presence of various concentrations of 
adriamycin and mefenamic acid (Mef). Survival is represented as a % of control 
untreated cells ±  S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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D LK P (P 18), A driam ycin  and  Sulindac
Adriamycin conc. 1 0.020 jxg/mL
Adriamycin conc. 2 0.010 fxg/mL
Adriamycin conc. 3 0.005 (.ig/mL
Sulindac conc. 1 7.60 (ig/mL
Sulindac conc. 2 3.90 jxg/mL
Sulindac conc. 3 2.00 (xg/mL
T rea tm en t %  Cell Survival S.D.
Cell control 100
Adriamycin 1 control 64.84 3.40
Sulindac 1 control 103.04 8.41
Adriamycin 1 + Sul 24.35* 1.90
Adriamycin 2 control 87.06 15.18
Adriamycin 2 + Sul 58.68* 3.66
Adriamycin 3 control 95.37 16.29
Adriamycin 3 + Sul 88.74 12.41
Adriamycin 1 control 56.52 5.15
Sulindac 2 control 102.10 8.37
Adriamycin 1 + Sul 22.26* 2.23
Adriamycin 2 control 94.15 11.20
Adriamycin 2 + Sul 64.17* 4.36
Adriamycin 3 control 95.24 10.55
Adriamycin 3 + Sul 94.28 13.69
Adriamycin 1 control 64.68 4.93
Sulindac 3 control 101.25 8.40
Adriamycin 1 + Sul 37.55* 2.72
Adriamycin 2 control 98.71 8.29
Adriamycin 2 + Sul 83.16 4.01
Adriamycin 3 control 104.01 13,87
Adriamycin 3 + Sul 104.26 13.77
Table 3.5.6: Survival of DLKP cells in the presence of various concentrations of 
adriamycin and sulindac (Sul). Survival is represented as a % of control untreated 
cells ± S.D. Statistically significant results are indicated with an asterisk. Results 
are the average o f triplicate determinations in a single experiment. Similar results 
were obtained in at least one additional experiment.
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DLKP (P 19), Adriamycin and Tolmetin
Adriamycin conc. 1 0.010 jxg/mL
Adriamycin conc. 2 0.005 jig/mL
Adriamycin conc. 3 0.003 (Xg/mL
Tolmetin conc. 1 26.80 jag/mL
Tolmetin conc. 2 13.40 (Xg/mL
Tolmetin conc. 3 6.50 jxg/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 54.72 4.82
Tolmetin 1 control 94.72 6.00
Adriamycin 1 + Tol 18.44* 1.44
Adriamycin 2 control 81.61 6.51
Adriamycin 2 + Tol 65.51* 4.64
Adriamycin 3 control 92.37 7.01
Adriamycin 3 + Tol 87.33 6.64
Adriamycin 1 control 51.03 3.42
Tolmetin 2 control 99.00 5.15
Adriamycin 1 + Tol 22.90* 2.56
Adriamycin 2 control 82.79 5.00
Adriamycin 2 + Tol 71.86 4.48
Adriamycin 3 control 95.35 5.97
Adriamycin 3 + Tol 93.85 4.36
Adriamycin 1 control 48.64 3.73
Tolmetin 3 control 97.48 5.71
Adriamycin 1 + Tol 30.83* 3.43
Adriamycin 2 control 80.32 6.17
Adriamycin 2 + Tol 75.45 4.17
Adriamycin 3 control 91.76 6.04
Adriamycin 3 + Tol 90.76 6.01
Table 3.5.7: Survival o f DLKP cells in the presence of various concentrations of 
adriamycin and tolmetin (Tol). Survival is represented as a % of control untreated 
cells ± S.D. Statistically significant results are indicated with an asterisk. Results 
are the average of triplicate determinations in a single experiment. Similar results 
were obtained in at least one additional experiment.
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DLKP (P 19), Adriamycin and Zomepirac
Adriamycin conc. 1 0.010 ixg/mL 
Adriamycin conc. 2 0,005 (J.g/mL 
Adriamycin conc. 3 0.003 (ig/mL
Zomepirac conc. 1 37.20 |xg/mL 
Zomcpirac conc. 2 17.20 (xg/mL 
Zomepirac conc. 3 8.40 ixg/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 61.11 5.52
Zomepirac 1 control 89.20 8.20
Adriamycin 1 + Zom 12.05* 1.89
Adriamycin 2 control 92.03 21.41
Adriamycin 2 + Zom 54.14* 3.76
Adriamycin 3 control 99.93 20.02
Adriamycin 3 + Zom 76.62 8.86
Adriamycin 1 control 55.73 6.25
Zomcpirac 2 control 90.71 17.22
Adriamycin 1 + Zom 9.06* 1.40
Adriamycin 2 control 87.95 14.65
Adriamycin 2 + Zom 53.93* 8.82
Adriamycin 3 control 94.32 13.73
Adriamycin 3 + Zom 80.18 13.40
Adriamycin 1 control 53.87 10.08
Zomepirac 3 control 87.08 6.64
Adriamycin 1 + Zom 10.27* 2.35
Adriamycin 2 control 84.63 6.55
Adriamycin 2 + Zom 51.78 7.64
Adriamycin 3 control 94.62 14.30
Adriamycin 3 + Zom 76.03 12.33
Table 3.5.8: Survival of DLKP cells in the presence o f various concentrations o f 
adriamycin and zomepirac (Zom). Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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DLKP (P 21), Adriamycin and Etodolac
Adriamycin conc. 1 0.010 jig/mL
Adriamycin conc. 2 0.005 jxg/mL
Adriamycin conc. 3 0,003 |xg/mL
Etodolac conc. 1 >15 .20  jig/mL
Etodolac conc. 2 > 7.60 (.ig/niL
Etodolac conc. 3 > 3.70 |_ig/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 72.88 10.50
Etodolac 1 control 100.06 9.81
Adriamycin 1 + Etod 73.78 6.48
Adriamycin 2 control 97.16 6.85
Adriamycin 2 + Etod 91.97 8.64
Adriamycin 3 control 102.96 12.16
Adriamycin 3 + Etod 98.21 10.35
Adriamycin 1 control 76.82 4.18
Etodolac 2 control 99.26 5.05
Adriamycin 1 4- Etod 74.69 5.00
Adriamycin 2 control 92.83 5.12
Adriamycin 2 + Etod 93.73 5.29
Adriamycin 3 control 97.17 6.57
Adriamycin 3 + Etod 94.46 5.54
Adriamycin 1 control 66.27 5.49
Etodolac 3 control 94.60 5.86
Adriamycin 1 + Etod 66.91 3.19
Adriamycin 2 control 85.42 6.36
Adriamycin 2 + Etod 89.53 6.18
Adriamycin 3 control 91.12 4.93
Adriamycin 3 + Etod 90.87 5.02
Table 3.5.9: Survival o f DLKP cells in the presence of various concentrations o f 
adriamycin and etodolac (Etod). Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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DLKP (P16), Vincristine and Acemetacin
Vincristine conc. 1 0.002 jxg/mL
Vincristine conc. 2 0.001 |ig/inL
Vincristine conc. 3 0.003 (ig/mL
Acemetacin conc. 1 37.50 fXg/mL
Acemetacin conc. 2 18.30 )xg/mL
Acemetacin conc. 3 7.50 jxg/mL
Treatment %  Cell Survival S.D.
Cell control 100
Vincristinc 1 control 10.08 1,63
Acemetacin 1 control 71.83 5.24
Vincristine 1 + Ace 5.31 0.33
Vincristine 2 control 77.40 5.05
Vincristine 2 + Ace 12.33* 2.50
Vincristine 3 control 87,22 5.16
Vincristine 3 + Ace 20.39* 6.57
Vincristine 1 control 11.58 2.72
Acemetacin 2 control 93.39 9.08
Vincristinc 1 + Ace 0.72 0.48
Vincristine 2 control 87.54 7.87
Vincristinc 2 + Ace 3.83* 0.76
Vincristine 3 control 95.19 10.36
Vincristine 3 + Ace 17.90* 3.52
Vincristine 1 control 17.57 3.88
Acemetacin 3 control 98.02 5.94
Vincristine 1 + Ace 0.71 0.33
Vincristine 2 control 91.09 6.08
Vincristine 2 +  Ace 12,09* 1.61
Vincristine 3 control 101.06 17.61
Vincristinc 3 + Ace 51.13* 6.13
Table 3.5.10: Survival o f DLKP cells in the presence of various concentrations of 
vincristine and acemetacin (Ace). Survival is represented as a % o f control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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DLKP (P 17), Vincristine and Indomethacin
Vincristine conc. 1 0.0014 jig/mL
Vincristine conc. 2 0.0010 jig/mL
Vincristine conc. 3 0.0007 )ig/mL
indomethacin conc. 1 2.50 )u.g/mL
Indomethacin conc. 2 1.40 (xg/niL
Indomethacin conc. 3 0.70 |Xg/mL
Treatment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 31.10 3.25
Indomethacin 1 control 95.07 5.06
Vincristine 1 + Indo 1.60* 0.49
Vincristine 2 control 66.26 5.51
Vincristine 2 + Indo 3.02* 0.66
Vincristine 3 control 87.39 6.64
Vincristine 3 + Indo 10.52* 1.05
Vincristine 1 control 34.71 5.90
Indomethacin 2 control 98.84 5.97
Vincristine 1 + Indo 1.87* 0.39
Vincristine 2 control 64.28 4.17
Vincristine 2 + Indo 4.34* 0.90
Vincristine 3 control 86.50 8.15
Vincristine 3 + Indo 17.48* 2.99
Vincristine 1 control 37.27 6.72
Indomethacin 3 control 95.81 9.08
Vincristine 1 + Indo 2.21* 0.44
Vincristine 2 control 68.00 8.13
Vincristine 2 + Indo 7.75* 1.66
Vincristine 3 control 89.35 12.88
Vincristine 3 + Indo 36.24* 7.61
Table 3.5.11: Survival of DLKP cells in the presence of various concentrations of 
vincristine and indomethacin (Indo). Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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DLKP (P 21), Vincristine and Mefenamic acid
Vincristine cone. 1 0.0015 ug/mL
Vincristine conc. 2 0.0012 jig/mL
Vincristine conc. 3 0.0070 fxg/mL
Mcfemamic acid conc. 1 7.60 j-ig/inL
Mefemamic acid conc. 2 4.00 (ig/inL
Mefemamic acid conc. 3 2.00 )xg/niL
T refitment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 70.51 5.23
Mefcnamic acid 1 control 96.46 16.65
Vincristine 1 + M ef 2.33* 0.42
Vincristine 2 control 88.77 14.47
Vincristine 2 + M ef 6.36* 0.90
Vincristine 3 control 98.26 11.96
Vincristine 3 + M ef 56.45* 10.26
Vincristine 1 control 76.27 7.28
Mefenamic acid 2 control 96.21 10.27
Vincristine 1 + M ef 10,28* 2.12
Vincristine 2 control 85.95 9.71
Vincristine 2 + M ef 34.88* 4.99
Vincristine 3 control 95.21 11.36
Vincristine 3 + M ef 86.93 7.39
Vincristine 3 control 82.43 5.63
Mefenamic acid 3 control 100.93 10.49
Vincristine 1 + M ef 41.44* 6.11
Vincristine 2 control 94.02 7.81
Vincristine 2 + M ef 80.57 7.76
Vincristine 3 control 99.03 8.42
Vincristine 3 + M ef 95.84 7.04
Table 3.5.12: Survival of DLKP cells in the presence of various concentrations of 
vincristine and mefenamic acid (Mef). Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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D LK P (P 18), Vincristine and Sulindac
Vincristine conc. 1 0.002 |ig/mL
Vincristine conc. 2 0.001 (ig/mL
Vincristine conc. 3 0,005 p,g/mL
Sulindac conc. 1 -1 .60  fig/mL
Sulindac conc. 2 3.90 (Xg/mL
Sulindac conc. 3 2.00 (0,g/inL
Treatment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 74.08 7.23
Sulindac 1 control 94.26 9.30
Vincristine 1 + Sul 6.23* 1.02
Vincristine 2 control 92.62 6.89
Vincristine 2 + Sul 26.67* 3.09
Vincristine 3 control 99.87 10.28
Vincristine 3 + Sul 87.24 7.32
Vincristine 1 control 74.37 6.20
Sulindac 2 control 100,05 13.96
Vincristine 1 + Sul 9.43* 1.30
Vincristine 2 control 97.97 8,13
Vincristine 2 + Sul 51.75* 3.61
Vincristine 3 control 100.70 9.73
Vincristine 3 + Sul 97.98 7.72
Vincristine 1 control 75.37 5,35
Sulindac 3 control 103.56 11.67
Vincristine 1 +  Sul 25.86* 3.71
Vincristine 2 control 97.13 5.95
Vincristine 2 + Sul 86.06 8.10
Vincristine 3 control 103.56 8.10
Vincristine 3 + Sul 102.79 8.85
Table 3.5.13: Survival of DLKP cells in the presence of various concentrations of 
vincristine and sulindac (Sul). Survival is represented as a % of control untreated 
cells ± S.D. Statistically significant results are indicated with an asterisk. Results 
are the average o f triplicate determinations in a single experiment. Similar results 
were obtained in at least one additional experiment.
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DLKP (P 19), Vincristine and Tolmetin
Vincristine conc. 1 0.0015 jig/mL
Vincrislinc conc. 2 0,0012 (xg/inL
Vincristine conc. 3 0.0007 |Xg/mL
Tolmetin conc. 1 26.80 (xg/mL
Tolmetin conc. 2 13.40 Jig/mL
Tolmetin conc. 3 6.50 (Xg/mL
Treatment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 54.86 4.56
Tolmetin 1 control 93.11 6.16
Vincristine 1 +  Tol 5.93* 1.08
Vincristine 2 control 68.57 6.31
Vincristine 2 + Tol 16.00* 2.09
Vincristine 3 control 90.16 5.59
Vincristine 3 + Tol 65.45* 4.75
Vincristine 1 control 52.08 4.23
Tolmetin 2 control 97.40 5.60
Vincristine 1 + Tol 12.70* 2.14
Vincristine 2 control 66.33 4.34
Vincristine 2 + Tol 26.76* 2.24
Vincrislinc 3 control 90.35 6.41
Vincristine 3 + Tol 79.28 6.08
Vincristine 1 control 55.21 5.50
Tolmetin 3 control 98.93 7.29
Vincristine 1 + Tol 25.66* 3.88
Vincristine 2 control 67.27 5.34
Vincristine 2 + Tol 44.73 4.93
Vincristine 3 control 90.90 7.01
Vincristine 3 + Tol 87.43 9.70
Table 3.5.14: Survival of DLKP cells in the presence o f various concentrations of 
vincristine and tolmetin (Tol). Survival is represented as a % of control untreated 
cells ± S.D. Statistically significant results are indicated with an asterisk. Results 
are the average o f triplicate determinations in a single experiment. Similar results 
were obtained in at least one additional experiment.
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DLKP (P 19), Vincristine and Zomepirac
Vincristine conc. 1 0.0015 ug/mL
Vincristine conc. 2 0.0012 (Xg/mL
Vincristine conc. 3 0.0006 fig/inL
Zomepirac conc. 1 37.20 ug/mL
Zomepirac conc. 2 17.20 |ig/mL
Zomepirac conc. 3 8.40 )ig/mL
Treatment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 61.37 18.65
Zomepirac 1 control 78.95 5.67
Vincristine 1 + Zom 1.73* 0.46
Vincristine 2 control 82.09 4.70
Vincristine 2 + Zom 2.90* 0.67
Vincristine 3 control 96.31 6.32
Vincristine 3 + Zom 22.28* 4.80
Vincristine 1 control 66.19 5.86
Zomepirac 2 control 91.60 4.53
Vincristine 1 + Zom 2.03* 0.28
Vincristine 2 control 86.79 6.11
Vincristine 2 + Zom 4.46* 0.48
Vincristine 3 control 95.30 7.73
Vincristine 3 + Zom 33.89* 3.96
Vincristine 1 control 62.79 5.89
Zomepirac 3 control 93.54 6.39
Vincristine 1 + Zom 1.99* 0.39
Vincristine 2 control 81.20 4.47
Vincristine 2 + Zom 4.67* 0.80
Vincristine 3 control 95.75 5.51
Vincristine 3 + Zom 43.63 5.93
Table 3.5.15: Survival of DLKP cells in the presence of various concentrations 
of vincristine and zomepirac (Zom). Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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DLKP (P 21), Vincristinc and Etodolac
Vincristine conc. 1 >0.0015 jxg/mL
Vincristine conc. 2 > 0.0012 )ig/mL
Vincristinc conc. 3 > 0,0007 )j,g/mL
Etodolac conc. 1 > 15.20 (xg/niL
Elodolac conc. 2 > 7.60 \xglmL
Etodolac conc. 3 > 3.70 ug/mL
Treatment % Cell Survival S.D.
Cell control 100
Vincristine 1 control 64.35 13.21
Etodolac 1 control 83.94 5.48
Vincristine 1 + Etod 72.87 11.71
Vincristinc 2 control 72.38 11.37
Vincristinc 2 + Etod 80.86 9.41
Vincristine 3 control 87.30 8.76
Vincristine 3 + Etod 84.36 8.51
Vincristine 1 control 69.82 7.15
Etodolac 2 control 98.67 8.15
Vincristine 1 + Etod 82.34 8.25
Vincristine 2 control 79.34 6.68
Vincristine 2 + Etod 91.48 10.35
Vincristine 3 control 94.30 8.83
Vincristinc 3 + Etod 96.18 7.28
Vincristine 1 control 66.03 5.10
Etodolac 3 control 99.79 6.69
Vincristine 1 + Etod 71.52 4.27
Vincristine 2 control 77.77 7.32
Vincristine 2 + Etod 82.26 6.10
Vincristinc 3 control 94.12 8.09
Vincristine 3 + Etod 97.44 4.79
Table 3.5.16: Survival o f DLKP cells in the presence of various concentrations of 
vincristine and etodolac (Etod). Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average o f triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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3.6 Effect of exogenous prostaglandin addition on NSAID mediated 
chemotherapeutic drug toxicity enhancement.
The A549 cell line produces a variety of eicosanoids such as PgE2, PgF2a, TxB2 
and 15-HETE (Asano et al., 1996; Claria et a l ,  1996). It is estimated that PgE2 
and PgF2a can account for approximately 80% of total eicosanoid production by 
this cell line (Hubbard et a l, 1988). NSAIDs are believed to exert their anti­
inflammatory, antipyretic and analgesic properties as a result o f their inhibition o f 
the prostaglandin H synthase (PGHS) enzyme. This inhibition ultimately results in 
a reduction in prostanoid synthesis. For this reason an investigation was 
conducted in order to see if NSAID-mediated inhibition o f prostanoid synthesis 
was involved in the enhancement of drug toxicity effect. This investigation 
involved co-treatment of cells with cytotoxic drug, NSAID and PgE2 or PgD2 
using the protocol described in Section 2.7.3. PgD2 is not known to be produced 
by A549 under stimulated or unstimulated conditions and so for this reason served 
as a negative control for these experiments. The results are summarised in Table
3.6.1 with sample data provided in Table 3.6.2 for adriamycin and indomethacin 
in combination with PgE2, and Table 3.6.3 for adriamycin and indomethacin in 
combination with PgD2. From Table 3.6.2 it can be seen that indomethacin at a 
non-toxic level enhanced the toxicity of adriamycin (10 ng/inL) from 
approximately 10% to 6 6 % but simultaneous exogenous addition of 0.60 (Xg/mL 
PgE2 had no significant effects on cell survival. This concentration of PgE2 is non­
toxic and is significantly higher than the levels of PgE2 produced by A549 even 
under stimulated conditions. Lowering the concentration o f exogenously added 
PgE2 in these experiments to more physiologically relevant levels (A549 can 
produce 150 pg PgE2/mL under IL-1[3 stimulated conditions; Croxtall and Flower, 
1994) was found to have no effect on the combined toxicity o f adriamycin and 
indomethacin. The fact that the exogenous addition o f the eicosanoid (PgE2) 
which is predominantly formed by the A549 cell line had no effect on NSAID 
mediated drug toxicity enhancement, strongly suggested that NSAIDs possessed 
drug toxicity enhancing abilities independently of any inhibitory effects on the 
synthesis of these eicosanoids. This was confirmed directly by further studies
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detailed in Section 3.7 and 3.8. Related experiments using other NSAIDs or 
cytotoxic drugs generated similar data (Table 3.6.1).
Drug NSAID Eicosanoid Reversal of 
toxicity 
enhancement*
Adriamycin Indomethacin PgE2 ( - )
Adriamycin Sulindac PgE2 ( - )
Vincristine Indomethacin PgE2 ( - )
Vincristine Sulindac PgE2 ( - )
Adriamycin Indomethacin ( - )
Adriamycin Sulindac PgD2 ( - )
Vincristine Indomethacin PgD2 ( - )
Vincristine Sulindac PgD2 ( - )
* Toxicity enhancement is defined as a level of toxicity achieved w ith the drug plus NSAID 
combination, which is significantly greater than the level of toxicity predicted by the fractional 
product method. A  ( - ) in  Table 3.6.1 indicates that this toxicity level was unchanged by Pg 
treatment.
Table 3.6.1: Investigation into the potential for toxicity enhancement effect 
reversal with eicosanoid (PgE2 or PgD2) treatment of A549.
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A549 (P 104) : Adriamycin and Indomethacin and PgE2
Adriamycin conc. :-().()] jig/tnL
Indomethacin conc. 2.37 jig/mL
Prostaglandin E2 conc. 1 0.60 )ig/mL 
Prostaglandin E2 conc. 2 0.06 jUg/tnL
T rcatniciit % Cell Surviv al S.D.
Cell Control 100
Adriamycin control 90.41 5.39
Indomethacin control 95.75 9.55
PgE2 1 control 97.78 7.45
Adriamycin +  lndo 33.66 2.74
Adriamycin + PgE2 1 89.48 7.32
Indo + PgE; 1 99.89 11.26
Adriamycin + Indo + PgE2 1 35.67 3.30
Adriamycin control 89.35 10.17
Indomethacin control 101.44 11.54
PgE2 2 control 103.37 13.93
Adriamycin + Indo 36.34 4.68
Adriamycin + PgE2 2 89.28 7.83
lndo + PgE2 2 101.15 11.98
Adriamycin + Indo + PgE22 29.64 4.74
Table 3.6.2: Survival o f A549 cells in the presence of adriamycin, indomethacin 
(Indo) or PgE2. Survival is represented as a % of the control untreated cells ± 
S.D. Results are the average of triplicate determinations using the experimental 
protocol detailed in Section 2.7.3.
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A549 (P 100) : Adriamycin and Indomethacin and PgD2
Adriamycin conc. 0.01 jxg/mL
Indomethacin conc. > 2 .40  (xg/mL
Prostaglandin D2 conc. 1 > 0.60 |ig/mL 
Prostaglandin D2 conc. 2 > 0.06 |j,g/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin control 70.11 6.16
Indomethacin control 74.76 5.02
PgD2 conc. 1 control 97.81 3.48
Adriamycin + Indo 27.89 1.89
Adriamycin + PgD21 75.06 4.49
Indo + PgD2 1 72.15 2.08
Adr + Indo + PgD2 1 25.39 1.47
Cell control 100
Adriamycin control 67.83 7.73
Indomethacin control 98.15 6.31
PgD2 conc. 2 control 100.94 6.56
Adriamycin + Indo 17.79 2.84
Adriamycin + PgD2 2 70.03 8.57
Indo + PgD2 2 101.94 5.12
Adr + Indo + PgD2 2 19.01 2.1
Table 3.6.3: Survival of A549 cells in the presence o f adriamycin, indomethacin 
(Indo) or PgD2. Survival is represented as a % of the control untreated cells ± 
S.D. Results are the average of triplicate determinations using the experimental 
protocol detailed in Section 2.7.3
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3.7 In vitro toxicity assay screening of non-NSAID inhibitors of the 
arachidonic acid cascade.
NSAIDs are known inhibitors o f prostanoid biosynthesis due to their inhibitory 
effects on the PGHS enzyme. Investigations were conducted to elucidate if non- 
NSAID-mediated inhibition of prostanoid synthesis could contribute to the 
toxicity enhancement effect. This investigation involved using inhibitors o f the 
critical steps o f the arachidonic acid cascade. As described in Section 1.3, the 
most critical step in eicosanoid biosynthesis involves the liberation of arachidonic 
acid from cell membranes as a result of phospholipase (PL) activity. In the A549 
cell line, cytosolic PLA2 is the most critical PL involved in this process (Croxtall 
et a l,  1996). Inhibition of PLA2 activity causes inhibition of the synthesis o f 
prostanoids and HETEs and this inhibition can be caused by agents such as 4- 
bromophenacyl bromide, manoalide and quinacrine. If  inhibition o f prostanoid 
synthesis was critical for achievement of chemotherapeutic drug toxicity 
enhancement, then one would expect that total inhibition of eicosanoid synthesis 
due to the presence of a PL inhibitor would be sufficient to achieve the toxicity 
enhancement effect. As can be seen from Table 3.7.1 and Tables 3.7.2, 3.7.5 and 
3.7.6, none of the PLA2 inhibitors studied (4-bromophenacyl bromide, manoalide 
and quinacrine) had any effects on the toxicity of adriamycin. These compounds 
were added at non-toxic concentrations rather than at concentrations known to be 
effective for total PLA2 inhibition. The specific effects o f these PLA2 inhibitors on 
PLA2 activity at the concentrations used in these experiments was not 
investigated. This was not performed as it was required to add these agents at 
relatively non-toxic concentrations, which potentially affected cell growth in an 
equivalent fashion to that achieved in the presence o f an NSAID. As expected the 
PLA2 inhibitors were highly toxic (quinacrine IC50 of 4.0 ¡ig/mL). The 
concentrations reported in the literature as being effective for total PLA2 
inhibition (quinacrine inhibits macrophage membrane-associated PLA2 activity by 
20% at 400 (ig/mL; Lister et a l,  1989) were highly toxic for A549 cells . As it 
was unclear as to the extent o f prostanoid synthesis inhibition required for the 
toxicity enhancement effect to occur, it was decided to use the PLA2 inhibitors at 
non-toxic doses. The use o f 4-bromophenacyl bromide, manoalide and quinacrine
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at these concentrations may be questionable for the purposes o f this experiment as 
the exact extent o f PL inhibition was unknown.
NSAIDs are not believed to exert any direct inhibitory effects on the lipoxygenase 
(LOX) catalysed branch of the AA cascade as described in Section 1.4. Screening 
was carried out using a 5- and 12-LOX inhibitor, esculetin, in order to see if 
inhibition of the LOX catalysed branch was sufficient to enhance 
chemotherapeutic drug toxicity. As can be seen from Table 3.7.4, inhibition o f 5- 
LOX and 12-LOX due to the presence of non-toxic levels of esculetin had no 
effect on the toxicity o f adriamycin in the A549 cell line. This result illustrates that 
as expected the LOX catalysed branch of the AA cascade was not involved in the 
NSAID-mediated drug toxicity enhancement effect. As described in Section 1.3.1, 
PGHS is known to exist in constitutive and inducible forms. NSAIDs vary in their 
ability to preferentially inhibit either or both of the PGHS-1 and PGHS-2 
isoforms. The NSAIDs which had been identified from in vitro toxicity screening 
as possessing the ability to enhance the toxicity of a suitable chemotherapeutic 
drug in the A549 and DLKP cell lines are known to inhibit both PGHS-1 and 
PGHS-2 (Frolich, 1997). It was also known that aspirin, an NSAID with 
negligible effects on PGHS-2, was unable to enhance the toxicity o f adriamycin or 
vincristine. This suggested that preferential inhibition of the PGHS-2 isozyme may 
have been important in achievement of the drug toxicity enhancement effect by a 
given NSAID. Dexamethasone has a large variety of cellular effects including 
inhibition of induction of PGHS-2 mRNA synthesis (Croxtall and Flower, 1994). 
From Table 3.7.3 it can be seen that this compound had no effects on adriamycin 
toxicity. This indicates that PGHS isozyme preference of an NSAID may not be 
critical for the ability of that NSAID to enhance drug toxicity. This result is in no 
way definitive as dexamethasone has a wide variety of effects on cellular 
metabolism.
148
Drug Inhibitor Inhibitor description Toxicity
enhancement*
Adriamycin 4-Bromophenacyl
bromide
Phospholipase A2 
inhibitor
( - )
Adriamycin Dexamethasone PGHS-2 synthesis 
inhibitor
C /
Adriamycin Esculetin 5- and 12- 
lipoxygenase inhibitor
( - )
Adriamycin Manoalide Phospholipase A2 
inhibitor
\ )
Adriamycin Quinacrine Phospholipase A2 
inhibitor
( " J
* Toxicity enhancement is scored with a ( + )  if  a level of toxicity is achieved w ith a drug plus 
inhibitor combination, w hich is significantly greater than the level o f toxicity predicted by the 
fractional product method. A ( - )  indicates no significant toxicity enhancement effects.
Table 3.7.1: Investigation into potential ability o f inhibitors o f critical steps o f the 
arachidonic acid cascade to enhance the toxicity of adriamycin.
149
A549 (P102), Adriamycin and 4-Bromophenacyl bromide
Adriamycin conc. 1 0.015 )ig/mL 
Adriamycin conc. 2 0.008 jxg/mL 
Adriamycin conc. 3 0.004 fig/mL
4-Bromophenacyl bromide conc. 1 1.25 jig/mL 
4-Bromophenacyl bromide conc. 2 :- 0.90 ug/mL 
4-Bromophenacyl bromide conc. 3 0.60 jxg/mL
Treatment % Cell Survival S.D.
Cel I control 100
Adriamycin 1 control 69.71 5.32
4BrPhAcBr 1 control 83.16 12.79
Adriamycin 1 + 4-BrPhAcBr 53.58 5.26
Adriamycin 2 control 89.79 11.83
Adriamycin 2 + 4-BrPhAcBr 67.39 6.12
Adriamycin 3 control 97.35 12.06
Adriamycin 3 + 4-BrPhAcBr 70.45 9.17
Adriamycin 1 control 59.52 8.11
4BrPhAcBr 2 control 78.88 13.62
Adriamycin 1 + 4-BrPhAcBr 58.90 10.20
Adriamycin 2 control 86.95 12.12
Adriamycin 2 + 4-BrPhAcBr 61.33 12.59
Adriamycin 3 control 95.21 13.24
Adriamycin 3 + 4-BrPhAcBr 67.13 14.05
Adriamycin 1 control 66.21 4.23
4BrPhAcBr 3 control 90.33 7.80
Adriamycin 1 + 4-BrPhAcBr 55.00 6.54
Adriamycin 2 control 90.19 6.13
Adriamycin 2 + 4-BrPhAcBr 86.74 8.04
Adriamycin 3 control 96,00 6.59
Adriamycin 3 + 4-BrPhAcBr 85.27 8.52
Table 3.7.2: Survival of A549 cells in the presence o f adriamycin and 4- 
bromophenacyl bromide (4-BrPhAcBr). Survival is represented as a % of the 
control untreated cells ± S.D. Results are the average o f triplicate determinations 
in a single experiment. Similar results were obtained in at least one additional 
experiment.
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A549 (P104), Adriamycin and Dexamethasone
Adriamycin conc. 1 0.015 jig/mL
Adriamycin conc. 2 0.007 |xg/mL
Adriamycin conc. 3 0.004 ag/mL
Dexamethasone conc. 1 0.020 ).ig/mL
Dexamethasone conc. 2 0.010 jo,g/mL
Dexamethasone conc. 3 0.005 jxg/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 68.39 5.09
Dexamethasone 1 control 49.58 3.14
Adriamycin 1 + Dex 37.47 6.44
Adriamycin 2 control 86.64 8.57
Adriamycin 2 + Dex 38.69 1.83
Adriamycin 3 control 93.77 11.18
Adriamycin 3 + Dex 44.44 3.09
Adriamycin 1 control 62.90 8.86
Dexamethasone 2 control 48.65 5.26
Adriamycin 1 + Dex 46.39 9.98
Adriamycin 2 control 82.07 12.56
Adriamycin 2 + Dex 36.95 10.23
Adriamycin 3 control 71.06 9.74
Adriamycin 3 + Dex 43.08 2.92
Adriamycin 1 control 67.36 5.29
Dexamethasone 3 control 64.89 4.11
Adriamycin 1 + Dex 36.07 2.37
Adriamycin 2 control 85.91 8.81
Adriamycin 2 + Dex 50.36 2.58
Adriamycin 3 control 95.21 13.78
Adriamycin 3 + Dex 59.86 4.23
Table 3.7.3: Survival of A549 cells in the presence of adriamycin and 
dexamethasone (Dex). Survival is represented as a % of the control untreated 
cells ±  S.D. Results are the average o f triplicate determinations in a single 
experiment. Similar results were obtained in at least one additional experiment.
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A549 (P103), Adriamycin and Esculetin
Adriamycin conc. 1 0.015 (ig/iriL 
Adriamycin conc. 2 0.007 (ig/mL 
Adriamycin conc. 3 0.004 |ig/mL
Esculetin conc. 1 1.90 jig/mL 
Esculetin conc. 2 0.95 |xg/mL 
Esculetin conc. 3 0.50 (ig/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 84.78 3.99
Esculetin 1 control 89.01 4.65
Adriamycin 1 + Esc 68.03 3.90
Adriamycin 2 control 93.16 5.58
Adriamycin 2 + Esc 81.97 4.46
Adriamycin 3 control 97.09 5.36
Adriamycin 3 + Esc 89.89 5.91
Adriamycin 1 control 66,11 4.85
Esculetin 2 control 100.90 8.07
Adriamycin 1 + Esc 71.62 3.78
Adriamycin 2 control 88.75 6.33
Adriamycin 2 + Esc 88.77 8.54
Adriamycin 3 control 92.85 4.99
Adriamycin 3 + Esc 92.63 3,86
Adriamycin 1 control 79.47 5.32
Esculetin 3 control 100,05 7.99
Adriamycin 1 + Esc 78.99 3.25
Adriamycin 2 control 90.71 5.84
Adriamycin 2 + Esc 93.61 4.60
Adriamycin 3 control 98.51 5.87
Adriamycin 3 + Esc 97.90 8.22
Table 3.7.4: Survival of A549 cells in the presence o f adriamycin and esculetin 
(Esc). Survival is represented as a % of the control untreated cells ±  S.D. Results 
are the average o f triplicate determinations in a single experiment. Similar results 
were obtained in at least one additional experiment.
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A549 (P 9 7 ): Adriamycin and Manoalide
Adriamycin conc. 1 >0.015 |i,g/mL 
Adriamycin conc. 2 > 0.0075 |ig/mL 
Adriamycin conc. 3 > 0.0040 jxg/inL
Manoalide conc. 1 > 0.10 (J,g/mL 
Manoalide conc. 2 > 0.035 p.g/mL 
Manoalide conc. 3 > 0.015 jxg/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 71.06 4.82
Mano 1 control 100.79 8.11
Adr 1 + Mano 84.67 5.79
Adr 2 control 83.47 11.85
Adr 2 + Mano 101.93 11.54
Adr 3 control 101.81 10.92
Adr 3 + Mano 100.19 8.23
Adriamycin 1 control 77.33 9.41
Mano 2 control 103.69 9.20
Adr 1 + Mano 76.32 6.65
Adr 2 control 83.36 8.17
Adr 2 + Mano 102.24 10.44
Adr 3 control 104.51 12.35
Adr 3 + Mano 104.00 12.11
Adriamycin 1 control 75.67 10,40
Mano 3 control 97.41 11.69
Adr 1 + Mano 81.23 11.29
Adr 2 control 84.53 8.40
Adr 2 + Mano 96.29 13.05
Adr 3 control 95.64 10.00
Adr 3 + Mano 98.09 10.55
Table 3.7.5: Survival o f A549 cells in the presence of adriamycin and manoalide 
(Mano). Survival is represented as a % o f the control untreated cells ± S.D. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P110), Adriamycin and Quinacrine
Adriamycin conc. 1 0.015 fxg/mL 
Adriamycin conc. 2 0,007 (xg/mL 
Adriamycin conc. 3 0.004 |i.g/mL
Quinacrine conc. 1 1.00 (Xg/mL 
Quinacrine conc. 2 0.50 (ig/mL 
Quinacrine conc. 3 0.30 |u,g/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 91.06 21.55
Quinacrine 1 control 96.46 20.08
Adriamycin 1 + Quin 82.37 23.38
Adriamycin 2 control 99.23 21.12
Adriamycin 2 + Quin 87.60 23.13
Adriamycin 3 control 100.24 17.09
Adriamycin 3 + Quin 89.74 21.78
Adriamycin 1 control 88.57 9.40
Quinacrine 2 control 106.56 10.20
Adriamycin 1 + Quin 90.25 11.82
Adriamycin 2 control 101.56 14.38
Adriamycin 2 + Quin 97.23 28.08
Adriamycin 3 control 97.41 10.31
Adriamycin 3 + Quin 93.03 8.77
Adriamycin 1 control 85.29 22.37
Quinacrine 3 control 102.30 12.37
Adriamycin 1 + Quin 102.22 19.30
Adriamycin 2 control 106.45 12.41
Adriamycin 2 + Quin 111.55 16.39
Adriamycin 3 control 111.20 15.10
Adriamycin 3 + Quin 123.53 11.48
Table 3.7.6: Survival of A549 cells in the presence of adriamycin and quinacrine 
(Quin). Survival is represented as a % of the control untreated cells ±  S.D. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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3.8 PgE2 synthesis by A549 cells exposed to chemotherapeutic
drugs and NSAIDs
As described in Section 1.4, NSAIDs are believed to exert their therapeutic 
effects by means of their inhibition of the PGHS enzymes. A study was carried out 
to investigate if co-treatment of the A549 cell line with a cytotoxic drug and 
NSAID, such as adriamycin and indomethacin caused any significant alterations in 
prostanoid production which could contribute to enhancement of drug toxicity. A 
PgE2 ELISA assay was used to quantify the PgE2 production by A549 cells 
during treatment with cytotoxic drugs and NSAIDs. The experimental protocol 
used in these experiments is detailed in Section 2.8. In summary, cells were 
seeded at a density o f 2.5 x 1 0 5 cells per well in 6 -well plates and allowed to 
attach overnight. The waste media was then removed and replaced with freshly 
prepared media containing the compounds o f interest. Aliquots of media for PgE2 
analysis were removed after 24 hours incubation in the agents of interest. The 
results o f this study are summarised in Table 3.8.1. In the unstimulated state A549 
cells produced only approximately 5 pg PgE2 per 105 cells whereas EL-1(3 
stimulated A549 cells produced approximately 304 pg PgE2 per 105 cells. From 
Table 3.8.1 it can be seen that the unstimulated PgE2 production by A549 was 
practically negligible when one corrects for errors and the media blank (media 
which had not been exposed to cells). The level of PgE2 synthesis by A549 cells 
was unchanged from unstimulated PgE2 levels following treatment with 
adriamycin (0.5 (ig/mL) or Taxol (35.9 ng/mL). These concentrations o f drug 
were optimised for use with the cell densities used in these experiments. At these 
concentrations, the drugs caused equivalent levels of cell kill to that achieved with 
the concentrations o f drug used in the in vitro toxicity assay screening 
experiments (approximately 30% toxicity after 7 days). The results suggests that, 
under these conditions, prostanoid production was unaffected by 
chemotherapeutic drug treatment. In the A549 cell line, adriamycin toxicity was 
enhanced in the presence of an NSAID such as indomethacin. The toxicity of 
Taxol was known to be unaffected by NSAID treatment (Section 3.2). No 
significant difference in PgE2 synthesis was found between adriamycin treated, 
Taxol treated or untreated cells, all of which produced negligible levels o f PgE2 
(Table 3.8.1). For this reason it was not surprising to find that indomethacin or
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flurbiprofen treatment (39.50 (ig/mL and 39.90 [ig/mL respectively) had no effect 
on adriamycin treated, Taxol treated or untreated cells.
Treatment Prostaglandin E2 production, 
(pg/105 cells)
Media blank 3.90 ±2 .00
Media treated cells 5 .10± 2.50
Adriamycin (0.46 (lg/inL) 5.00 ± 3.30
Indomethacin (39.50 |Xg/mL) 4.00 ± 4.10
Adriamycin + Indomethacin 3.50 ± 3.80
Flurbiprofen (39.90 |_lg/mL) 4.30 ±2.90
Adriamycin + Flurbiprofen 6.50 ± 4.90
Taxol (35.90 ng/mL) 7.20 ±3 .70
Indomethacin (39.50 (Xg/niL) 3.50 ± 2.80
Taxol + Indomethacin 5.20 ±4.20
IL -ip  (10 ng/mL) 304.00 ±65.60
Table 3.8.1: PgE2 production by A549 cells in the presence o f cytotoxic drugs 
and NSAIDs. Cells were seeded at 2.5 x 105 cells in 6 -well plates and incubated 
for 24 hours in the compounds of interest. Aliquots of media were then removed 
and analysed for PgE2 content as described in Section 2.8. Results are represented 
as means ± S.D for duplicate determinations carried out on two separate 
occasions.
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3.9 Ability of sulindac sulfide and sulfone to enhance adriamycin and 
vincristine toxicity in the A549 cell line.
Sulindac sulfide is the active metabolite of sulindac in vivo and is a potent 
inhibitor of PGHS. Sulindac sulfone is an oxidation product of sulindac sulfoxide 
and is known to be at least 5000-fold less potent than the sulfide for inhibiting 
cyclooxygenase (Piazza et al., 1997a). These compounds were analysed in in 
vitro toxicity screening assays in combination with adriamycin and vincristine. It 
was found that these sulindac analogues enhanced the toxicity o f adriamycin and 
vincristine. The results from these experiments have already been provided in 
Tables 3.3.4 and 3.3.10 for sulindac sulfide and Tables 3.3.5 and 3.3.11 in the 
case o f sulindac sulfone. This immediately suggests that potential ability for 
inhibition of PGHS activity is not necessary for an NSAID to enhance the toxicity 
of a suitable chemotherapeutic drug. This is due to the fact that sulindac sulfone, 
which is devoid o f PGHS inhibitory activity, enhances the toxicity of adriamycin 
and vincristine to the same extent found in the case of the potent PGHS inhibitor 
sulindac sulfide. From the data it can be seen that sulindac sulfide enhances 
adriamycin and vincristine toxicity at concentrations equivalent to those used in 
the case o f sulindac (approximately 7 to 1 |Xg/mL). Sulindac sulfone was found to 
be effective when used at relatively high concentrations (from 20 to 5 |ig/mL). 
The IC50 values for sulindac sulfide and sulfone in A549 are 12 ±  1  and 40 ± 5 
(ig/mL respectively.
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3.10 Effect of drug treatment on PGHS-2 isozyme expression and PgE2 
production in the A549 cell line.
There is evidence to suggest that drug treatment can have an influence on the 
arachidonic acid cascade (discussed in Section 4.6). Many tumor types produce 
eicosanoids in elevated levels relative to related normal tissue. These eicosanoids 
can have a variety o f roles in promoting tumor cell survival (Section 1.3.2), but 
the potential involvement o f eicosanoids in promoting cell survival in the presence 
of chemotherapeutic drugs has not been extensively investigated. It was known 
from investigations into the variations in PgE2 levels during NSAID mediated 
chemotherapeutic drug toxicity enhancement (Section 3.8), that under the 
experimental conditions examined, cytotoxic drug treatment had no effects on the 
PgE2 synthesis by A549. The study detailed in Section 3.8 was relatively limited 
as it only investigated drug concentrations relevant for the NSAID-mediated drug 
toxicity enhancement effect. In addition it also only investigated PgE2 production 
after a 24 hour period. For this reason a series of experiments were conducted to 
investigate the effects on the arachidonic acid cascade o f treating A549 cells with 
various concentrations o f chemotherapeutic drugs for varying lengths o f time. 
A549 can produce PgE2 in relatively high levels under suitable conditions. 
Elevations in PgE2 synthesis in A549 are attributable to induction of the PGHS-2 
isozyme. A549 has not been shown to express significant levels o f PGHS-1 
mRNA or protein under stimulated (phorbol ester stimulation) or unstimulated 
conditions, (Asano et al., 1996). One ideally would aim to analyse all eicosanoids 
produced by A549 when attempting to investigate the effect of chemotherapeutic 
drug treatment on the arachidonic acid cascade. Due to the obvious analytical 
difficulties in attempting to simultaneously quantify PgE2, PgF2a, TxB2 and 15- 
HETE in cell culture media, studies focused upon PgE2 production by A549. The 
protein levels o f the PGHS isozyme responsible for the synthesis of PgE2, namely 
PGHS-2 were also examined.
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Three related experiments were conducted into the effect of drug treatment on 
PgE2 synthesis and PGHS-2 protein levels. The first experiment investigated 
variations in the levels of PGHS-2 protein and PgE2 production during treatment 
with 0.35 fXg/mL adriamycin for various periods o f time. An adriamycin 
concentration o f 0.35 |_ig/mL adriamycin was shown to be non-toxic over a 24 
hour period at the cell density used in these experiments (Section 2.9). If  cells 
were permitted to grow for a period of 7 days in this concentration o f drug, it was 
found that approximately 70% of A549 cells were killed relative to a control non­
drug treated cells. The results of these studies are summarised in Table 3.10.1 and 
Figure 3.10.1. As can be seen from the data, adriamycin treatment (0.35 (Xg/mL) 
for 2 , 4 or 24 hours caused no significant increases in PgE2 production relative to 
control (media treated) cells. No PGHS-2 protein was found in unstimulated 
media treated cells or in drug treated cells (Figure 3.10.1). A549 cells treated with 
3.0 ng/mL IL-1[3 for 24 hours produced high levels o f PgE2 (approximately 490 
pg/106 cells) and PGHS-2 protein as expected.
Sample
Number
Treatment PgE2, (p g /1 0 6 cells) PGHS-2
protein
levels*
1 Adriamycin for 2 hours 1 . 2 0  ± 2 . 1 0 ( - )
2 Adriamycin for 4 hours 2 .30±  1.50 ( - )
3 Adriamycin for 8 hours 1.20 ±2 .30 ( - )
4 Adriamycin for 24 hours 0.20 ±2 .30 ( - )
5 3.0 ng/mL EL-1 (3 for 24 hours 490 ±56.80 ( + + )
6 Media treated cells 2 . 2 0  ± 1.80 ( - )
* High level PGHS-2 expression is signified by a ( ++ ) and moderate PGHS-2 expression is 
signified by a ( + ). No PGHS-2 expression if  signified by a ( - ) .  For the PgE2 ELISA it was 
found that media which had not been exposed to cells contained 6.00 ± 1.20 pg PgE2 /20 mL 
media. All PgE2 data in the above table has been corrected for this amount of PgE2.
Table 3.10.1: Effect of adriamycin treatment (0.35 |Xg/mL) on PgE2 and PGHS-2 
protein levels produced by A549. PgE2 concentrations are represented as the 
mean ± S.D. for duplicate determinations carried out on two separate occasions.
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Figure 3.10.1: PGHS-2 expression in IL -1 (3 control (lane 5), adriamycin (lanes 1- 
4) and untreated A549 cells (lane 6 ). Corresponding PgE2 data for each sample is 
shown in Table 3.10.1. The details of the incubation times and concentrations of 
the various agents are provided in Table 3.10.1.
From the results shown with IL-1(3 in Table 3.10.1 and Figure 3.10.1 it was 
obvious that PgE2 synthesis and PGHS-2 protein synthesis induction was readily 
detectable after a period of 24 hours incubation with a suitable agent. For this 
reason all subsequent experiments involved analysis after a 24 hour incubation 
period with the compound of interest. The experiment shown in Table 3.10.1 and 
Figure 3.10.1 investigated the effect of only one adriamycin concentration on 
PgE2 and PGHS-2 levels. For this reason a subsequent experiment was conducted 
to elucidate if there was any potential concentration-dependent relationship 
between drug treatment and eicosanoid production by A549. Cells were treated 
with a variety of adriamycin concentrations for a period of 24 hours. Adriamycin 
concentrations of 0.25, 0.35 and 0.45 |jg/mL were investigated. These drug 
concentrations would cause 60, 75 and 85% toxicity respectively after a 7 day 
incubation period in drug. As can be seen from Table 3.10.2 adriamycin treatment 
at these concentrations had negligible effects on PgE2 synthesis or PGHS-2 
protein levels (Figure 3.10.2). Cells treated with 3 ng/mL IL-1|3 produced high 
levels of PgE2 (approximately 620 pg/106 cells) and PGHS-2. Co-treatment of 
cells with adriamycin and IL-1(3 was found to have variable effects on the levels of 
PgE2 synthesis and PGHS-2 protein synthesis. No relationship was found to exist 
between drug concentration and ability to vary IL-l(3-induced PgE2 synthesis. The 
variation in PgE2 levels found with varying concentrations of adriamycin, in the 
adriamycin and IL-1P co-treatment regime was found to be more a result of
Sample Number 1 2 3 4 5 6
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variation in the PgE2 synthetic capabilities of A549 cells rather than a result o f a 
significant influence o f adriamycin on IL -ip  induced PgE2 synthesis. From Figure 
3.10.2 it can be seen that this was the case, as co-treatment of cells with 
adriamycin and IL -ip  had no significant effects on PGHS-2 synthesis relative to 
IL -ip  treated cells.
Sample
Number
Treatment PgE2, (pg/106 cells) PGHS-2
protein
levels*
1 Media treated cells 14.80 ± 10.60 ( - )
2 0.25 (lg/mL adriamycin 10.00 ± 10.90 ( - )
3 0.35 |lg/mL adriamycin 9.01 ±5 .30 ( - )
4 3 ng/mL IL -ip 620.00 ±46.90 ( + + )
5 0.25 |Xg/mL adriamycin + 
3 ng/mL IL -ip
770.00 ±80.14 ( + + )
6 0.35 [ig/mL adriamycin + 
3 ng/mL IL-1(3
790.20 ± 99.70 ( + + )
7 0.45 |ig/mL adriamycin + 
3 ng/mL IL -ip
527.10 ± 100.78 ( + + )
* High level PGHS-2 expression is signified by a ( ++ ) and moderate PGHS-2 expression is 
signified by a ( + ). No PGHS-2 expression if  signified by a ( - ). For the PgE2 ELISA it was 
found that media which had not been exposed to cells contained 6.00 ±  1.20 pg PgE2 /20 mL 
media. All PgE2 data in the above table has been corrected for this level of PgE2.
Table 3.10.2: Effect of adriamycin treatment for 24 hours on PgE2 and PGHS-2 
protein levels produced by A549. PgE2 concentrations are represented as the 
mean ± S.D. for duplicate determinations carried out on two separate occasions.
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Figure 3.10.2: PGHS-2 expression in A549 cells treated for 24 hours with 3 
ng/mL IL-1[3 (lane 4), media (lane 1), 0.25 and 0.35 jig/mL adriamycin (lanes 2 
and 3) or IL-1 (3 and adriamycin (lanes 5-7). Corresponding PgE2 data for each 
sample is shown in Table 3.10.2.
Sample Number 1 2 3 4 5 6 7
A drug from a totally separate mechanistic category of chemotherapeutic drugs, 
V P-16 (an epipodophyllotoxin) has been shown to be activated to a toxic 
metabolite as a result of PGHS activity (discussed in Section 4.6). In order to 
investigate if PGHS activity in A549 was altered in the presence of this cytotoxic 
drug, the experiment documented in Table 3.10.2 and Figure 3.10.2 was 
performed using VP-16 in place of adriamycin. Cells were treated with 2.5, 0.5 
and 0.1 |i.g/mL VP-16 which are non-toxic over 24 hours but which would cause 
70, 40 and 20% toxicity respectively if growth was permitted to continue for 7 
days. The results are represented in Table 3.10.3 and Figure 3.10.3. As can be 
seen, V P-16 at the three concentrations analysed had no effects on PgE2 synthesis 
or PGHS-2 levels. IL -ip  treated cells produced approximately 510 pg PgE2 per 
106 cells and high levels of PGHS-2. VP-16 had no significant effects on IL -ip  
induced PgE2 or PGHS-2 levels. Variations in PgE2 levels formed during co­
incubation with VP-16 and IL-1 (3 can be attributed to non-specific variability in 
PgE2 synthesising abilities of A549 cells rather than a specific effect on PgE2 
synthesis.
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Sample
Number
Treatment PgE2, 
(pg/106 ceils)
PGHS-2
protein
levels*
1 2.50 [ig/mL VP-16 14.00 ± 10.00 ( - )
2 0.50 (xg/mL VP-16 12.10 ± 12.30 ( - )
3 0.10|Xg/mL VP-16 6.70 ±9 .30 ( - )
4 3 ng/mL IL-1 (3 510.30 ± 98.10 (+ + )
5 2.50 |lg/mL V P-16 + 
3 ng/mL IL-1 (3
667.80 ±85.30 (+ + )
6 0.50 (ig/mL V P-16 + 
3 ng/mL IL-1 (3
603.20 ±  109.80 (+ + )
7 Media treated cells 11.80 ± 10.70 ( - )
* High level PGHS-2 expression is signified by a ( ++ ) and moderate PGHS-2 expression is 
signified by a ( + ). No PGHS-2 expression if  signified by a ( - ). For the PgE2 ELISA it was 
found that media which had not been exposed to cells contained 6.00 ± 1.20 pg PgE2 /20 niL 
media. All PgE2 data in the above table has been corrected for this amount of PgE2.
Table 3.10.3: Effect of V P-16 treatment for 24 hours on PgE2 and PGHS-2
protein levels produced by the A549 cell line. PgE2 concentrations are represented 
as the mean ± S.D. for duplicate determinations carried out on two separate 
occasions.
PGHS-2 
(75 kDa)
Sample Number 1 2  3 4 5 6
Figure 3.10.3: PGHS-2 expression in A549 cells treated for 24 hours with 3 
ng/mL IL-1(3 (lane 4), 2.50, 0.50 or 0.10 |xg/mL VP-16 (lanes 1, 2 and 3), media 
(lane 7) or VP-16 and IL-1 (3 (lanes 5 and 6 ). Corresponding PgE2 data for each 
sample is shown in Table 3.10.3.
163
3.11 PGHS-2 isozyme expression and PgE2 production in DLKP
and DLKP derived resistant variants.
The investigations detailed in Section 3.10 focused upon the effect o f 
chemotherapeutic drug treatment on PgE2 production and PGHS-2 expression in 
the A549 drug sensitive cell line. There have been isolated reports o f drug 
resistant tumors with altered eicosanoid synthesising abilities (Section 4.7). For 
this reason, PgE2 and PGHS-2 were analysed in the case o f two drug-selected cell 
lines DLKP-VP3 and DLKP-VP 8 . These cell lines are derived from the drug 
sensitive DLKP cell line, (Heenan, 1994), The VP-16 selected VP3 and VP8 cell 
lines were chosen for analysis as there is evidence to suggest that PGHS can be 
involved in the activation of VP-16 to a metabolically active form, (Section 4.7). 
If this was the case and if a cell developed V P-16 resistance, one would predict 
that alterations in PGHS levels in resistant cell line relative to the parental 
sensitive cells could develop as a possible mechanism o f desensitising the cell to 
drug. As in Section 3.10 only PGHS-2 and not PGHS-1 was investigated. Asano 
et a l ,  (1996) reported that PGHS-2 is the dominant PGHS isoform in 
unstimulated and stimulated lung tumor cell lines in vitro. The levels of PgE2 
synthesis by the DLKP, DLKP-VP3 and DLKP-VP 8 cell lines under a variety o f 
conditions was also investigated. This particular eicosanoid was chosen for 
analysis as it is the most commonly formed eicosanoid in lung cancer cell lines 
(Hubbard et a l,  1988). Figure 3.11.1 shows that neither DLKP, VP-3 or VP-8  
express PGHS-2 protein when stimulated with 3 ng/mL IL-1(3 whereas A549 cells 
demonstrated high level expression of this protein. DLKP, VP-3 and VP-8  
produce negligible levels of PgE2 under these conditions whereas A549 cells 
produce approximately 2 0 0  pg/1 0 6 cells.
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Figure 3.11.1: PGHS -2 expression in IL-1 (3 (3 ng/mL) treated DLKP (lane 1), 
DLKP-VP3 (lane 2), DLKP-VP8 (lane 3) and A549 (lane 4) cells. Corresponding 
PgE2 data for each sample is shown in Table 3.11.1.
Sample Number 1 2  3 4
Sample
Number
Treatment PgE2, 
(pg/106 cells)
PGHS-2
protein
levels*
1 DLKP
(3 ng/mL IL-1 (3)
4.00 ± 11.00 ( - )
2 DLKP-VP3 
(3 ng/mL IL-1 (3)
8.16 ± 4.20 ( - )
3 DLKP-VP 8 
(3 ng/mL IL-1 (3)
9.80 ±2.40 ( - )
4 A549 
(3 ng/mL IL-1 (3)
205.30 ± 68.10 (+ + )
* High level COX-2 expression is signified by a ( ++ ) and moderate PGHS-2 expression is 
signified by a ( + ). No PGHS-2 expression if signified by a ( - ). For the PgE2 ELISA it was 
found that media which had not been exposed to cells contained 6.00 ±  1.20 pg PgE2 /20 mL 
media. All PgE2 data in the above table has been corrected for this amount of PgE2.
Table 3.11.1: Effect o f IL-1 j3 treatment for 24 hours on PgE2 and PGHS-2 levels 
in DLKP, DLKP-VP3, DLKP-VP8 and A549. PgE2 concentrations are 
represented as the mean ± S.D. for duplicate determinations carried out on two
separate occasions.
As no significant levels of PGHS-2 could be detected in DLKP, DLKP-VP3 or 
DLKP-VP8 after IL-1 (3 treatment it was decided that in subsequent experiments, 
PgE2 levels would be analysed before analysing PGHS-2 levels. This was due to 
the fact that increases in the levels of PgE2 should correlate with increases in 
PGHS-2 protein synthesis (as found in Section 3.10). These experiments are 
detailed in Tables 3.11.2 to 3.11,4. In the first of these experiments DLKP cells 
were treated with adriamycin, IL-1 [3 or a combination o f these agents. It was
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found that treatment o f DLKP cells with 0.15 or 0.25 (ig/mL adriamycin (non­
toxic over 24 hours but causing 40% and 60% toxicity respectively if growth was 
allowed to continue for 7 days) had no effect on PgE2 levels. Treatment with 3 
ng/mL and 5 ng/mL IL-1(3 also had no effect on PgE2 levels. Co-treatment with 
cytotoxic drug and IL-1(3 had no effect on PgE2 levels (which were practically 
negligible). IL-1(3 treated A549 cells produced approximately 360 pg PgE2 per 
106 cells over the same period. This experiment served as a reference for 
equivalent experiments in the VP-3 and VP-8  drug selected cell lines. The results 
o f these experiments are summarised in Tables 3.11.3 and 3.11.4 for DLKP-VP3 
and VP -8  respectively. DLKP-VP3 cells produced negligible levels o f PgE2 in the 
unstimulated state. Treatment of these cells with adriamycin (14 and 22 ¡xg/mL 
which cause 40 and 70% toxicity over a 7 day period in this cell line) had no 
effects on PgE2 synthesis. In addition no significant levels of PgE2 were formed 
after 1L-1 (3 treatment or after co-treatment with adriamycin and IL- I p. Similar 
results were found in the case of the DLKP-VP8 cell line (Table 3.11.4). These 
results illustrated that DLKP, VP-3 and VP-8  cells do not produce PgE2 or 
PGHS-2 protein in the unstimulated, LL-1 (3 stimulated or drug treated state.
Treatment for 24 hours PgE2, 
(pg/106 cells)"
Media treated cells 11.60 ±9.70
0.15 ¡ig/mL adriamycin 11.50 ± 11.70
0.25 (Ig/mL adriamycin 8.40 ±11.50
3 ng/mL IL -1 (3 13.50 ±  12.80
5 ng/mL IL-1(3 17.70 ± 13.70
0.25 (Xg/mL adriamycin 17.70 ± 15.00
+ 3 ng/mL IL -1(3
A549 control . 362.10 ± 25.10
(3 ng/mL IL -1(3)
* For the PgE2 ELISA it was found that media which had not been exposed to cells contained 
6.00 ± 1.20 pg PgE2 /20 mL media. All PgE2 data in the above table has been corrected for this 
amount of PgE2.
Table 3.11.2: Characterisation of eicosanoid synthesising ability of DLKP in the 
presence of various concentrations of adriamycin or IL -lß  for 24 hours. PgE2 
concentrations are represented as the mean ± S.D. for duplicate determinations 
carried out on two separate occasions.
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Treatment for 24 hours PgE2, 
(pg/106 cells)"
Media treated cells 10.20 ± 19.40
14 |lg/mL adriamycin 8.50 ± 18.70
22 |ig/mL adriamycin 9.20 ± 21.50
3 ng/mL IL-1 (3 1 0 . 2 0  ± 12.60
5 ng/mL IL-1 (3 13.70 ± 15.70
14 |lg/mL adriamycin + 3 ng/niL IL-1 (3 12.20 ±25.00
A549 control (3 ng/mL IL-1 (3 ) 430.20 ±45.90
* For the PgE2 ELISA it was found that media which had not been exposed to cells contained 
6.00 ± 1.20 pg PgE2 /20 rnL media. All PgE2 data in the above table has been corrected for this 
amount of PgE2.
Table 3.11.3: Characterisation of eicosanoid synthesising ability of DLKP-VP3 in 
the presence of various concentrations of adriamycin or IL -lß  for 24 hours. PgE2 
concentrations are represented as the mean ± S.D. for duplicate determinations 
carried out on two separate occasions.
Treatment for 24 hours l’gE2, 
(pg/10f' cells)"
Media treated cells 9 .60±  10.10
14 |lg/mL adriamycin 4.60 ± 16.30
28 (Ig/mL adriamycin 8.60 ±20.40
3 ng/mL IL -lß 11.20 ±  13.20
5 ng/mL IL -lß 8.70 ± 12.30
14 (Ig/mL adriamycin + 3 ng/mL IL -lß 11.20 ±  15.10
A549 control (3 ng/mL IL -lß  ) 850.60 ±82.30
* For the PgE2 ELISA it was found that media which had not been exposed to cells contained
6.00 ± 1.20 pg PgE2 /20 mL media. All PgE2 data in the above table has been corrected for this 
amount of PgE2.
Table 3.11.4: Characterisation of eicosanoid synthesising ability of DLKP-VP8 in 
the presence of various concentrations of adriamycin or IL-1 (3 for 24 hours. PgE2 
concentrations are represented as the mean ± S.D. for duplicate determinations 
carried out on two separate occasions.
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The NSAID-mediated enhancement of chemotherapeutic drug toxicity had only 
been shown to occur in the DLKP and not in the Pgp-overexpressing cell line, 
DLKP-A, (Duffy et al., 1997). An experiment was carried out to investigate the 
possibility that one o f the reasons for the toxicity enhancement effect not 
occurring in resistant cells was that the NSAID was not entering or being retained 
within resistant cells such as DLKP-A. The details of the design o f this experiment 
are provided in the Section 2.12, but the experiment essentially consisted of 
treating cells with [14C]-labelled indomethacin for varying lengths of time and then 
monitoring the levels of labelled indomethacin retained by the cells. It was found 
experimentally that there was rapid accumulation o f labelled indomethacin by the 
cells (reaching maximum accumulation by approximately 5 minutes), and that 
there was no significant difference between the level o f labelled indomethacin 
accumulated by DLKP or DLKP-A.
3.12 Indomethacin accumulation in DLKP and DLKP-A.
Incubation time, (min) DLKP Indomethacin 
accumulation, 
(ng/l0° cells)
DLKP-A Indomethacin 
accumulation, 
(ng/106 cells)
0 0 . 0  ± 1 0 . 0 0 . 0  ±  1 0 . 0
4 2 0 0 . 0  ± 2 0 . 0 210.0 ±25.0
60 225.0 ± 15.0 220.0 ±30.0
1 2 0 240.0 ± 10.0 240.0 ±25.0
240 245.0 ±25.0 240.0 ±30.0
Table 3.12.1: Time course of [14C]-Indomethacin accumulation in DLKP and 
DLKP-A cells treated as described in Section 2.12. Data is represented as the 
mean (± S.D.) for triplicate samples carried out on two separate occasions.
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3.13 Investigation into MRP-mediated transport of LtC4 into IOVs
isolated from DLKP in the presence or absence of NSAIDs.
Protein analysis studies failed to show the existence of MRP protein in whole cell 
extracts o f DLKP. It had been demonstrated that all other cell lines in which the 
toxicity enhancement effect had been found to occur, expressed MRP (Duffy et 
a l., 1997). The drug profile for which the NSAID-mediated toxicity enhancement 
effect was found to occur was exactly similar to the range of drugs believed to be 
transported by MRP, (Section 1.5.2.3). This suggested that co-treatment of MRP - 
expressing cells with an MRP-substrate drug and an NSAID with the ability to 
interfere with MRP’s drug pumping ability may have resulted in increased 
retention o f drug within the cell. This ultimately would then cause an 
enhancement o f cytotoxic drug induced cell kill. One significant problem with this 
theory was the fact that the toxicity enhancement effect was found to occur in 
DLKP, but MRP protein expression had not been detected in this cell line. It was 
suggested that DLKP expressed MRP at levels undetectable by Western blotting 
o f whole cell extracts. Isolation of inside-out vesicles (IOVs) from DLKP was 
performed in order to isolate the plasma membranes from these cells and 
specifically target Western blotting analysis to the area in which the MRP 
molecule may have been localised. In addition, isolation of IOVs allowed 
investigation o f potential glutathione-conjugate transport activity in DLKP via the 
glutathione conjugate pump, MRP.
The experimental protocol used for isolation o f the IOVs from DLKP is detailed 
in Section 2.10. It was found that MRP was detectable by Western blotting, in 
IOVs isolated from DLKP (Section 3 .17.4). The level o f MRP protein in DLKP 
was significantly lower than the levels found in IOVs isolated from HL60-Adr. 
This result indicated that DLKP possessed low levels of MRP protein and that this 
level may have been functionally effective for drug transport out of the cell. 
Inhibition o f the pumping activity due to treatment with a suitable NSAID 
ultimately resulted in increased drug accumulation levels and an enhancement in 
chemotherapeutic drug toxicity. Transport assays were performed with [3H]-LtC4 
and the IOVs isolated from DLKP. The glutathione conjugate, LtC4 was found to
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be transported into the vesicles in an ATP dependent manner. This indicated that a 
glutathione-conjugate pump was active in DLKP. The initial rate o f transport o f 
[3H]-LtC4 into DLKP derived 10Vs was 0.8 ± 0.2 pmol/mg protein/minute and in 
HL60-ADR 10Vs was 4.0 ± 1.0 pmol/mg/minute (with maximum LtC4 
accumulation of 2.0 ± 0.3 and 7.0 ± 1 .0  pmol/mg protein respectively). All o f the 
above [3H]-LtC4 transport data expressed above is the mean ± S.D. for duplicate 
determinations carried out on two separate occasions using different vesicle 
preparations from a cell line on each occasion. The initial rate of [3H]-LtC4 
transport and maximum accumulation of [3H]-LtC4 are believed to be dependent 
on the amount of the relevant transporter in the preparation. From Western 
blotting results it was demonstrated that MRP protein levels in HL60-ADR IOVs 
were significantly higher than in DLKP derived IOVs (Section 3.17.4). This 
strongly suggested that the [3H]-LtC4 transporter in DLKP was MRP.
The influence of various NSAIDs on MRP activity in HL60-ADR IOVs has been 
described by Duffy et al., (1997). No data had been previously available for IOVs 
isolated from the DLKP cell line. From Figure 3.13.3 it can be seen that 
concentrations o f 100 and 50 jiM indomethacin inhibit [3H]-LtC4 transport into 
HL60-ADR IOVs by 80 and 50% respectively. Naproxen (Figure 3.13.4) did not 
exert any significant inhibitory effects on MRP activity at 100, 50 or 10 ¡iM 
concentrations. Similar results were found in the case of DLKP-derived IOVs. 
Concentrations o f 100 and 50 |iM indomethacin (Figure 3.13.5) inhibited [3H]- 
LtC4 transport into DLKP-derived IOVs by approximately 60 and 35% 
respectively. Naproxen (Figure 3.13.6) did not exert significant effects on [3H]- 
LtGt transport into DLKP-derived IOVs at 100, 50 or 10 (iM. These results 
illustrated that an NSAID such as indomethacin may act as a potent inhibitor of 
MRP-mediated drug efflux activity in DLKP and so ultimately cause an 
enhancement in chemotherapeutic drug induced cell kill. NSAIDs such as 
naproxen, do not exert any significant effects on MRP transport activity and so do 
not influence chemotherapeutic drug toxicity.
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Figure 3.13.1: Time course o f LtC4 transport into IOVs isolated from the DLKP cell 
line over time in the presence of ATP, AMP or in the absence o f ATP and AMP 
(negative control). Data points represent the means (± S.D.) o f duplicate 
determinations.
Figure 3.13.2: Time course o f transport o f LtC4 transport into IOVs isolated from the 
HL60-ADR cell line in the presence of ATP, AMP or in the absence o f ATP and AMP 
(negative control). Data points represent the means (± S.D.) o f duplicate 
determinations.
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Figure 3.13.3: Inhibition of ATP dependent transport of LtC4 into IOVs isolated from 
the HL60-ADR cell line caused due to the presence o f ATP and 100, 50 or 10 |.iM 
indomethacin. Data points represent the means (± S.D.) of duplicate determinations.
Figure 3.13.4: Inhibition of ATP dependent transport o f LtC4 into IOVs isolated from 
the HL60-ADR cell line caused due to the presence of ATP and 100, 50 and 10 |J.M 
naproxen. Data points represent the means (± S.D.) o f duplicate determinations.
172
Figure 3.13,5: Inhibition o f ATP dependent transport o f U C 4 into 10 Vs isolated from 
the DLKP cell line caused due to the presence of ATP and 100, 50 or 10 |aM 
indomethacin. Data points represent the means (± S.D.) of duplicate determinations.
Figure 3.13,6: Inhibition o f ATP dependent transport of LtGj into lOVs isolated from 
the DLKP cell line caused due to the presence of ATP and 100, 50 or 10 |xM 
naproxen. Data points represent the means (± S.D.) o f duplicate determinations.
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3.14 Verification of the identity of the LtC4 transporter in IOVs
isolated from the DLKP cell line.
Western blot analysis o f the proteins present in IOVs isolated from DLKP, 
demonstrated that MRP protein was present in the DLKP cell line (Section 
3.17.4). From the data presented in Section 3.13, it can be seen that DLKP 
derived IOVs demonstrate ATP-dependent transport of the glutathione-conjugate, 
[3H]-LtC4. This characteristic is typical of MRP-expressing cell lines such as 
HL60-ADR. These results suggested that DLKP contains low levels o f MRP in 
the plasma membrane which is isolated following purification o f plasma membrane 
derived-IOVs. In addition, the results indicated that this glutathione conjugate 
pump transported [3H]-LtC4 in an ATP dependent fashion. The presence o f MRP 
in DLKP derived IOVs was obvious from Western blotting results, but the 
specific identity of the [3H]-LtC4 transporter in DLKP IOVs required further 
investigation. This transporter could potentially be any of a variety o f MRP 
isoforms or alternatively an unrelated LtC4 transporter. For this reason a number 
of experiments were conducted to verify the identity o f the LtC4 transporter in 
DLKP derived IOVs.
3.14.1 Enhancement of drug toxicity in the presence of inhibitors of
MRP activity in the DLKP cell line.
All cell lines with which NSAID mediated chemotherapeutic drug toxicity 
enhancement have been demonstrated have been shown to express MRP protein 
(Duffy et al., 1997). The DLKP cell line possesses significant levels o f MRP 
protein in the plasma membrane. Evidence suggests that the NSAID mediated 
toxicity enhancement effect is achieved by NSAIDs interfering with MRP- 
catalysed transport of cytotoxic drugs (Figures 3.13.5 and 3.13.6). These 
cytotoxic drugs, under normal conditions may serve as substrates for transport by 
MRP out of the cell. If the [3H]-LtC4 transporter in DLKP IOVs was MRP then 
one would predict that an agent which strongly interferes with [3H]-LtC4 
transport activity would also interfere with MRP activity. Interference with MRP
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activity should result in the enhancement of the toxicity o f a suitable drug in the 
DLKP cell line. The leukotriene receptor antagonist, MK571 is a potent inhibitor 
o f[ 3H]-LtC4 transport by MRP (Section 3.16) to the interior o f IOVs. If  the [3H]- 
LtC4 transporter in DLKP IOVs was MRP, one would predict that MK571 should 
interfere with MRP activity to an extent comparable to that found in the case o f a 
suitable NSAID. This should ultimately result in an enhancement o f toxicity o f a 
suitable cytotoxic drug.
From the data presented in Tables 3.14.1.1 and 3.14.1.2 it can be seen that 
MK571 enhances the toxicity of adriamycin and V P-16 in the DLKP cell line. This 
effect was found to occur over a range of MK571 concentrations. The extent of 
adriamycin and V P-16 toxicity enhancement is comparable to that achieved with 
NSAIDs such as indomethacin (Tables 3.2.2 and 3.2.10). The concentration o f 
MK571 required for achievement o f the toxicity enhancement effect is comparable 
to that required for NSAIDs. For example, indomethacin is a potent enhancer o f 
adriamycin toxicity when used at 2.5 fXg/mL or 7 |i,M (Table 3.5.4) and MK571 
potently enhances adriamycin toxicity even at 5 (Xg/mL or 9 ¡xM. MK571 did not 
enhance the toxicity of Taxol (Table 3.14.1.3). Taxol is not believed to be readily 
transported by MRP and so inhibition of MRP by MK571 should have little effect 
on Taxol efflux from cells. MK571 also had comparable effects on adriamycin and 
VP-16 toxicity in a second MRP expressing cell line, A549 (Tables 3.14.1.4 and 
3.14.1.5). No MRP negative cell line was analysed in order to see if the effects of 
MK571 on drug toxicity were isolated to MRP expressing cell lines.
The bisindolylmaleimide, GF109203X is believed to be a selective inhibitor of 
protein kinase C. This compound has been shown to interfere with MRP activity 
(Gekeler et ah, 1995b). This compound is relatively non-specific as regards 
interference with drug efflux activity as it has been shown to have effects on Pgp 
as well as MRP activity, (Gekeler et al., 1995b). GF109203X was shown to 
enhance the toxicity of adriamycin and V P-16 (Tables 3.14.1.6 and 3.14.1.7). This 
compound also enhanced the toxicity of the non-MRP substrate drug Taxol 
(Table 3.14.1.8). This indicates that as expected this compound was not selective 
for MRP activity but due to interference in protein kinase C activity, had a range
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of cellular effects which resulted in enhancement o f  the toxicity o f a variety of 
MRP and Pgp substrate drugs. The results obtained using MK571 strongly 
indicated that the [3H]-LtC4 transporter in DLKP was MRP. In order to obtain 
more direct evidence o f the identity o f [3H]-LtC4 transporter in DLKP, this 
transport was characterised directly in order to identify MRP like characteristics. 
The results from these investigations are provided in Section 3.14.2.
176
DLKP (P 27), Adriamycin and MK571
Adriamycin conc. 1 0.010 j-ig/mL
Adriamycin conc. 2 0.005 fj.g/mL
Adriamycin conc. 3 0.003 |ig/mL
MK751 conc. 1 15.10 |ig/mL
MK751 conc. 2 8.40 |ig/mL
MK751 conc. 3 5.00 (ig/rnL
T rcatmcn t % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 67.17 5.81
MK571 conc. 1 control 38.89 3.01
Adriamycin 1 +MK571 15.78* 1.72
Adriamycin 2 control 102.70 10.97
Adriamycin 2 + MK571 37.37 3.95
Adriamycin 3 control 105.32 9.80
Adriamycin 3 + MK571 45.98 5.95
Adriamycin 1 control 82.35 7.86
MK571 conc. 2 control 100.62 14.84
Adriamycin 1 + MK571 26.84* 4.67
Adriamycin 2 control 99.27 9.06
Adriamycin 2 + MK571 88.90 13.24
Adriamycin 3 control 104.60 12.12
Adriamycin 3 + MK571 101.47 9,01
Adriamycin 1 control 80.21 8.23
MK571 conc. 3 control 99.24 12.18
Adriamycin 1 + MK571 32.98* 5.08
Adriamycin 2 control 95.42 8.84
Adriamycin 2 + MK571 96.36 11.36
Adriamycin 3 control 104.16 14.71
Adriamycin 3 + MK571 100.39 12.64
Table 3.14.1.1: Survival o f the DLKP cell line in the presence o f various 
concentrations o f adriamycin and MK571. Survival is represented as a % of 
control untreated cells ± S.D. Statistically significant results are indicated with an 
asterisk. Results are the average o f triplicate determinations in a single 
experiment. Similar results were obtained in at least one additional experiment.
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DLKP (P 27), VP-16 and MK571
VP-16 conc. 1 :- 0.13 fig/mL
VP-16 conc. 2 0.07 |0.g/mL
VP-16 conc. 3 0.03 (ig/mL
MK751 conc. 1 :-15.10 jxg/mL
MK751 conc. 2 8.40 p,g/mL
MK751 conc. 3 :- 5.00 jJ.g/mL
Treatment % Cell Survival S.D.
Cell control 100
VP-16 1 control 45.81 3.70
MK571 conc. 1 control 36.67 3.23
VP-16 1+M K 571 8.16* 0.85
VP-16 2 control 89.76 8.93
VP16 2 + MK571 21.65* 1.83
VP-16 3 control 99.76 14.26
VP-16 3 + MK571 33.25 2.90
VP-16 1 control 49.97 4.32
MK571 conc. 2 control 103.75 10.43
VP-16 1 +M K571 7.08* 2.23
VP-16 2 control 98.76 18.71
VP16 2+M K 571 45.08* 4.23
VP-16 3 control 102.21 15.48
VP-16 3 + MK571 85.53 19.35
VP-16 1 control 44.82 4.88
MK571 conc. 3 control 95.71 20.71
VP-16 1 +M K571 6.62* 2.15
VP-16 2 control 93.47 20.48
VP 16 2 + MK571 51.04* 8.87
VP-16 3 control 101.90 17.60
VP-16 3 +M K571 85.72 22.39
Table 3.14.1.2: Survival of the DLKP cell line in the presence o f various 
concentrations of V P-16 and MK571. Survival is represented as a % of control 
untreated cells ±  S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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DLKP (P 30), Taxol and MK571
Taxol conc. 1 1.20 ng/niL
Taxol conc. 2 0.60 ng/mL
Taxol conc. 3 0.30 ng/mL
MK751 conc. 1 15.10 jj,g/mL
MK751 conc. 2 8.00 (ig/mL
MK751 conc. 3 5.00 |ig/mL
Treatment % Cell Survival S.D.
Cell control 100
Taxol 1 control 54.70 5,00
MK571 conc. 1 control 37.64 4.11
Taxol 1+M K 571 18.74 1.99
Taxol 2 control 44.93 3.32
Taxol 2 + MK571 18.70 2.63
Taxol 3 control 95.60 16.43
Taxol 3 + MK571 35.66 8.05
Taxol 1 control 54.81 6.15
MK571 conc. 2 control 89.51 12.55
Taxol 1 +MK571 40.26 8.50
Taxol 2 control 44.22 2.91
Taxol 2 + MK571 40.81 3.72
Taxol 3 control 95.71 16.01
Taxol 3 + MK571 85.52 15.73
Taxol 1 control 56.50 5.07
MK571 conc. 3 control 98.27 12.78
Taxol 1 + MK571 56.92 6.15
Taxol 2 control 43.60 3.85
Taxol 2 + MK571 47.45 4.36
Taxol 3 control 96.36 12.54
Taxol 3 + MK571 91.37 6.58
Table 3.14.1.3: Survival of the DLKP cell line in the presence of various 
concentrations o f Taxol and MK571. Survival is represented as a % of control 
untreated cells ± S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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A549 (P 98), Adriamycin and MK571
Adriamycin conc. 1 0.010 jxg/mL
Adriamycin conc. 2 0.005 |ig/mL
Adriamycin conc. 3 0.003 fig/rnL
MK751 conc. 1 15.10 (ig/mL
MK751 conc. 2 8.40 jj,g/mL
MK751 conc. 3 5.00 jig/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 62.83 8.85
MK571 conc. 1 control 16.63 1.57
Adriamycin 1 + MK571 12.35 2.60
Adriamycin 2 control 86.11 7.04
Adriamycin 2 + MK571 14.73 2.76
Adriamycin 3 control 95.95 5.70
Adriamycin 3 +M K571 15.16 3.08
Adriamycin 1 control 69.98 8.65
MK571 conc. 2 control 79.75 4.68
Adriamycin 1 + MK571 22.18* 6.80
Adriamycin 2 control 87.17 10.06
Adriamycin 2 + MK571 50.22 16.80
Adriamycin 3 control 94.94 8.42
Adriamycin 3 + MK571 64.72 24.99
Adriamycin 1 control 57.95 14.11
MK571 conc. 3 control 93.36 9.79
Adriamycin 1 + MK571 25.86* 3.41
Adriamycin 2 control 81.80 7.71
Adriamycin 2 + MK571 61.73 14.86
Adriamycin 3 control 85.92 8.71
Adriamycin 3 + MK571 77.48 20.87
Table 3.14.1.4: Survival of the A549 cell line in the presence of various 
concentrations o f adriamycin and MK571. Survival is represented as a % of 
control untreated cells ± S.D. Statistically significant results are indicated with an 
asterisk. Results are the average of triplicate determinations in a single 
experiment. Similar results were obtained in at least one additional experiment.
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A549 (P 98), VP-16 and MK571
VP-16 conc. 1 0.13 |ig/mL
VP-16 conc. 2 0.07 |ig/mL
VP-16 conc. 3 0.03 |ig/mL
MK751 conc. 1 15.10 jJ,g/mL
MK751 conc. 2 8.40 ¡ig/mL
MK751 conc. 3 5.00 jxg/mL
Treatment % Cell Survival S.D.
Cell control 100
VP-16 1 conlrol 54.55 6.81
MK571 conc. 1 control 12.42 2.03
VP-16 1 + MK571 11.59 1.67
VP-16 2 control 66.99 10.46
VP16 2 + MK571 12.58 2.56
VP-16 3 control 87.08 10.88
VP-16 3 +M K571 13.15 1.74
VP-16 1 control 51.07 7.56
MK571 conc. 2 control 78.35 9.56
VP-16 1 +M K571 22.72* 2.31
VP-16 2 control 81.27 8.91
VP16 2 + MK571 32.93* 3.92
VP-16 3 control 92.47 8.91
VP-16 3 +M K571 57.98 7.84
VP-16 1 control 66,87 4.81
MK571 conc. 3 control 93.59 7.88
VP-16 1 +M K571 29.67* 5.03
VP-16 2 control 54.05 4,51
VP16 2 + MK571 52.74 5.09
VP-16 3 control 68.15 6.12
VP-16 3 + MK571 70.88 6.21
Table 3.14.1.5: Survival of the A549 cell line in the presence of various 
concentrations o f VP-16 and MK571. Survival is represented as a % of control 
untreated cells ±  S.D. Statistically significant results are indicated with an asterisk. 
Results are the average of triplicate determinations in a single experiment. Similar 
results were obtained in at least one additional experiment.
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DLKP (P 32), Adriamycin and GF109203X
Adriamycin conc. 1 0.015 jxg/mL
Adriamycin conc. 2 0.008 (ig/mL
Adriamycin conc. 3 0.004 (ig/mL
GF109203X conc. 1 4.00 (ig/mL
GF109203X conc. 2 2.20 (Xg/mL
GF109203X conc. 3 0.90 ¡ig/mL
Treatment % Cell Survival S.D.
Cell control 100
Adriamycin 1 control 48.66 5.75
GF109203X conc. 1 control 101.86 15.27
Adriamycin 1 + GF109203X 8.07* 0.99
Adriamycin 2 control 98.01 15.67
Adriamycin 2 + GF109203X 69,51* 7.04
Adriamycin 3 control 101.32 12.46
Adriamycin 3 + GF109203X 99.51 15.95
Adriamycin 1 control 57.14 7.03
GF109203X conc. 2 control 101.07 9,59
Adriamycin 1 + GF109203X 10.70* 1.52
Adriamycin 2 control 101.60 12.91
Adriamycin 2 + GF109203X 96.00 12.53
Adriamycin 3 control 108.86 15.16
Adriamycin 3 + GF109203X 96.61 12.81
Adriamycin 1 control 70.08 7.97
GF109203X conc. 3 control 99.68 14.12
Adriamycin 1 + GF109203X 22.12* 2.56
Adriamycin 2 control 97.43 16.00
Adriamycin 2 + GF109203X 99.16 16.14
Adriamycin 3 control 103.84 16.38
Adriamycin 3 + GF109203X 101.33 16.28
Table 3.14.1.6: Survival of the DLKP cell line in the presence of various 
concentrations of adriamycin and GF109203 X. Survival is represented as a % of 
control untreated cells ± S.D. Statistically significant results are indicated with an 
asterisk. Results are the average of triplicate determinations in a single 
experiment. Similar results were obtained in at least one additional experiment.
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DLKP (P 27), VP-16 and GF109203X
VP-16 conc. 1 :- 0.13 mg/niL 
VP-16 conc. 2 :- 0.07 mg/mL 
VP-16 conc. 3 0.03 mg/mL
GF109203X conc. 1 :- 4.00 mg/mL 
GF109203X conc. 2 :- 2.20 mg/mL 
GF109203X conc. 3 0.90 mg/mL
Treatment % Cell Survival S.D.
Cell control 100
VP-16 1 control 84.00 12.62
GF109203X conc. 1 control 91.88 8.44
VP-16 1 + GF109203X 30.28* 3.26
V P-16 2 control 94.44 9.05
VP-16 2 + GF109203X 63.96* 6.37
VP-16 3 control 98.93 9.41
VP-16 3 + GF109203X 80.85 11.86
VP-16 1 control 87.24 7.63
GF109203X conc. 2 control 108.42 10.34
VP-16 1 + GF109203X 39.96* 3.36
VP-16 2 control 99.41 10.74
VP-16 2 + GF109203X 78.40 7.69
VP-16 3 control 105.48 12.33
VP-16 3 + GF109203X 103.34 12.95
VP-16 1 control 79.33 10.04
GF109203X conc. 3 control 109.71 10.76
VP-16 1 + GF109203X 59.73* 5.54
VP-16 2 control 94.84 9.13
VP-16 2 + GF109203X 94.54 9.10
VP-16 3 control 102.92 12.50
VP-16 3 + GF109203X 103.59 10.11
Table 3.14.1.7: Survival of the DLKP cell line in the presence o f various 
concentrations of V P-16 and GF109203X. Survival is represented as a % of 
control untreated cells ± S.D. Statistically significant results are indicated with an 
asterisk. Results are the average of triplicate determinations in a single 
experiment. Similar results were obtained in at least one additional experiment.
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DLKP (P 32), Taxol and GF109203X
Taxol conc. 1 1.20 ng/mL
Taxol conc. 2 0.60 ng/mL
Taxol conc. 3 0.30 ng/mL
GF109203X conc. 1 4.00 mg/mL
GF109203X conc. 2 2.20 mg/mL
GF109203X conc. 3 0.90 mg/mL
Treatment % Cell Survival S.D.
Cell control 100
Taxol 1 control 90.97 10.74
GF109203X conc. 1 control 97.19 11.69
Taxol 1 + GF109203X 48.33* 5.34
Taxol 2 control 99.98 12.05
Taxol 2 + GF109203X 93.96 7.56
Taxol 3 control 102.36 13.34
Taxol 3 + GF109203X 94.00 8.26
Taxol 1 control 90.47 10.16
GF109203X conc. 2 control 95.35 8.63
Taxol 1 + GF109203X 85.00 12.16
Taxol 2 control 93.81 9.70
Taxol 2 + GF109203X 98.01 10.88
Taxol 3 control 99.14 10.94
Taxol 3 + GF109203X 97.18 15.06
Taxol 1 control 100.08 17.94
GF109203X conc. 3 control 100.32 18.55
Taxol 1 + GF109203X 79.72 11.16
Taxol 2 control 96.54 15.16
Taxol 2 + GF109203X 102.23 14.48
Taxol 3 control 105.17 19.36
Taxol 3 + GF109203X 102.20 17.87
Table 3.14.1.8: Survival of the DLKP cell line in the presence o f various 
concentrations of Taxol and GF109203X. Survival is represented as a % of 
control untreated cells ±  S.D. Statistically significant results are indicated with an 
asterisk. Results are the average of triplicate determinations in a single 
experiment. Similar results were obtained in at least one additional experiment.
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3.14.2 Quantification of Vmax and Km parameters for LtC4 transport
in the DLKP and HL60-ADR cell lines.
The characteristic Vmax and Km values for [3H]-LtC4 transport have been reported 
for a variety o f MRP-expressing cell lines. In MRP-transfected HeLa cells, Km and 
Vmax for [3H]-LtC4 transport have been shown to be 105 nM and 530 
pmol/mg/min respectively, (Loe et al., 1996b). Experiments were conducted in 
order to use Lineweaver and Burk analysis to quantify these [3H]-LtC4 transport 
parameters in the DLKP and HL60-ADR cell lines. The protocol for these 
experiments and procedure used for calculation of kinetic parameters are detailed 
in Section 2.11.1 . As can be seen from Figure 3.14.2.1, transport o f LtC4 was 
concentration dependent and saturatable at high concentrations. Regression 
analysis performed for double reciprocal plots of 1/Vimtiai (Vimtiai being initial LtC4 
transport rate in pmol/mg/min) versus 1/S (S being substrate concentration) 
allowed more accurate determination o f the Vmax and Km values (Y axis intercept 
o f 1/Vmax and X axis intercept of -1/Km). From Figure 3.14.2.2, the regression 
equation for LtC4 transport by DLKP was found to be y = 4013.83x + 3 .14xl01() 
with a regression coefficient of 0.99. This is reflected in a Vmax value o f 32 
pmol/mg/min and Km of 127 nM for LtC4 transport in the DLKP cell line. When 
values were averaged for two independent experiments with a given IOY 
preparation, Vraax and Km values of 30 ± 2  pmol/mg/min and 114 ± 13 nM were 
obtained. Similar analysis was performed with HL60-ADR derived IOVs (Figures 
3.14.2.3 and 3,14.2.4). The regression analysis o f double reciprocal plots for this 
cell line yielded an equation of y = 472.16x + 8.08xl09 with a regression 
coefficient o f 0.99. This predicts Vmax and Km values for HL60-ADR o f 123 
pmol/mg/min and 58 nM respectively. When values were averaged for two 
independent experiments with a given IOV preparation, Vmax and Km values of 
211 ± 8 9  pmol/mg/min and 84 ± 26 nM were obtained. The Vmax value is 
particularly dependent on the quantity of MRP in the IOV preparation. DLKP and 
HL60-ADR transport LtC4 with a Vmax o f 30 ±  2 and 211 ± 8 9  pmol/mg/min 
respectively. From Western blotting experiments conducted with samples o f IO Vs 
from these cell lines (Figure 3.17.4.1), it was obvious that HL60-ADR derived
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IOVs contained very high levels of MRP relative to DLKP derived IOVs. The 
Vmax value was shown to be approximately 7 fold higher in HL60-ADR than in 
DLKP. This indicated that the LtC4 transporter in DLKP may be MRP. The Km 
values for DLKP and HL60-ADR are 114 ± 13 nM and 84 ± 26 nM respectively. 
As described above, there is significant variability in the Km values quoted in the 
literature for MRP mediated LtC4 transport. These values can vary from 35 nM 
(Paul et al., 1996c) to 120 nM (Pulaski et. al., 1996). The Km values found for 
LtC4 transport in DLKP and HL60-ADR derived IOVs show significant 
agreement with these values. This data is presented as the mean ± S.D. of 
duplicate determinations carried out with a given vesicle preparation on two 
separate occasions. It was found that it was not possible to obtain consistently 
repeatable results for Km and Vmax using different vesicle preparations from a 
given cell line. In these experiments it was found that a 3-fold variation in the 
values o f Km and Vmax could be found experimentally depending on the specific 
preparation of IOVs from a given cell line used. This was primarily a result o f the 
intrinsic experimental difficulties experienced in determining accurate transport 
parameters while working with relatively concentrated lipid solutions. In addition, 
the variation in the purity of separate IOV preparations also significantly 
influenced the accurate determination o f kinetic parameters. For this reason, the 
values for Km and Vmax described above for DLKP and HL60-ADR IOVs may 
only be regarded as being specific only for the actual IOV preparations analysed. 
The implications o f these results are discussed in Section 4.9.2.
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Figure 3.14.2.1: Effect of LtC4 concentration on initial rate of uptake of [?H]-LtC4 
into DLKP IOVs. Initial rate of uptake was determined after an incubation time of 1 
minute at 37°C over the range of substrate (LtC4) concentrations illustrated above. 
Data points represent the means (± S.D) of duplicate determinations in a single 
experiment.
Figure 3.14.2.2: Double reciprocal plot used for Lineweaver-Burk analysis o f [3H]- 
LtC4 uptake in DLKP IOVs and determination o f Km and Vmax transport parameters. 
Data points represent the means of duplicate determinations in a single experiment 
only.
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Figure 3.14.2.3: Effect o f LtC4 concentration on initial rate o f uptake o f [3H]-LtC4 
into HL60-ADR IOVs. Initial rate of uptake was determined after an incubation time 
o f 1 minute at 37°C over the range of substrate (LtC4) concentrations illustrated above. 
Data points represent the means (± S.D) of duplicate determinations in a single 
experiment.
O E * 0  11+0 2 E + B  3 E + 8  4 E + 0  6 E  + 8 fl K * ««
l / [ l . tc ;4 ]
Figure 3.14.2.4: Double reciprocal plot used for Lineweaver-Burk analysis o f [3H]- 
LtC4 uptake in HL60-ADR IOVs and determination o f Kra and Vmax transport 
parameters. Data points represent the means o f duplicate determinations in a single 
experiment only.
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3.15: Transport of cytotoxic drugs by MRP in HL60-ADR
IOVs
The glutathione conjugate pump, MRP is believed to play a role in drug transport 
but there has been little evidence o f direct transport o f the drugs to which this 
transporter is believed to confer resistance. Paul et al., (1996c) reported the 
MRP-mediated transport o f [3H]-labelled, unconjugated, natural product drugs 
such as VP-16, vincristine and daunorubicin but not o f Taxol into IOVs isolated 
from MRP-transfected 3T3 fibroblasts. Stride et al., (1997) demonstrated the 
transport into vesicles derived from MRP-transfected cells o f [3H]-vincristine in 
the presence of glutathione. Loe et al., (1996b) also reported the transport of 
[3H]-labelled vincristine into IOVs from MRP-transfected cells in the presence o f 
glutathione. This group also reported that colchicine, adriamycin, daunorubicin, 
Taxol, vincristine, vinblastine and VP-16 were poor inhibitors of [3H]-LtC4 
transport in MRP-containing IOVs. The inhibition o f [3H]-LtC4 transport by 
vincristine, vinblastine and Taxol was enhanced, particularly in the case of 
vincristine and vinblastine, in the presence of reduced glutathione (GSH). This 
was suggested to be a result co-transport of GSH and a suitable MRP substrate 
drug. The majority of studies in the area of drug transport by MRP are carried out 
using MRP-transfected cell lines rather than drug selected MRP-overexpressing 
cell lines. For this reason, a number of related studies were conducted using the 
MRP-overexpressing drug selected HL60-ADR cell line. The initial study 
investigated if cytotoxic drugs which have been proposed as being substrates for 
MRP, could be transported by MRP in HL60-ADR IOVs. The effect of GSH on 
this transport was then examined.
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3.15.1 Cytotoxic drug mediated inhibition of MRP activity.
It is practically impossible to conclusively define the cytotoxic drug substrate 
menu for MRP transport (Section 1.5.2.3). It is generally believed that MRP has 
the ability to transport drugs including adriamycin, vincristine, V P-16, 
daunorubicin and epirubicin. MRP-transfected or drug selected MRP- 
overexpressing cell lines often show low level resistance to Taxol (under 2-fold 
relative to the parental cells) but are generally sensitive to cisplatin. This suggests 
that MRP does not have the ability to transport cisplatin but may have low levels 
o f Taxol transport ability. If  a cytotoxic drug could be transported by MRP, one 
would predict that when added at the appropriate concentration, these compounds 
would compete for MRP-mediated transport to the interior of IOVs. The ability 
of vincristine, adriamycin, Taxol and cisplatin to inhibit transport of [(H]-LtC4 by 
MRP was investigated for this reason. These experiments involved co-incubating 
IOVs with [3H]-LtC4 and a suitable concentration o f cytotoxic drug. In all cases, 
efforts were made to maintain the final concentration of solvent containing the 
drug under 0.5%, a concentration above which interference in [3H]-LtC4 transport 
due to presence of solvent could occur. From Figure 3.15.1.1 it can be seen that 
106 (iM and 211 (iM vincristine inhibited the steady state, ATP dependent [3H]- 
LtC4 transport to the interior of HL60-ADR IOVs by approximately 50% relative 
to control IOVs incubated in ATP only. A  concentration of 27 |iM  vincristine 
inhibited this transport by under 15%. This was as expected as one would assume 
that an MRP substrate drug should interfere with MRP activity when added at an 
appropriate cellular concentration. Figure 3.15.1.2 illustrates that surprisingly only 
at 250 |xM adriamycin was significant inhibition o f [3H]-LtC4 transport achieved 
(approximately 20% of control). Cisplatin was completely ineffective at inhibiting 
[3H]-LtC4 transport into IOVs (Figure 3.15.1.4). As expected, Taxol (Figure
3.15.1.3) was not found to inhibit [3H]-LtC4 transport at 100, 50 or 1 |iM.
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Figure 3.15.1.1: Time course o f LtC4 transport into IOVs isolated from the HL60- 
ADR cell line in the presence of ATP, AMP or a combination of ATP and the 
individual concentrations o f vincristine indicated above. Data points represent the 
means (± S.D.) of duplicate determinations in a single experiment. Similar results were 
obtained in at least one additional experiment.
Figure 3.15.1.2: Time course o f LtC4 transport into IOVs isolated from the HL60- 
ADR cell line in the presence of ATP, AMP or a combination of ATP and the 
individual concentrations o f adriamycin indicated above. Data points represent the 
means (± S.D.) of duplicate determinations in a single experiment. Similar results were 
obtained in at least one additional experiment.
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Figure 3.15.1.3: Time course of LtC4 transport into IOVs isolated from the HL60- 
ADR cell line in the presence of ATP, AMP or a combination o f ATP and the 
individual concentrations o f Taxol indicated above. Data points represent the means (± 
S.D.) of duplicate determinations in a single experiment. Similar results were obtained 
in at least one additional experiment.
Figure 3.15.1.4: Time course o f LtC4 transport into IOVs isolated from the HL60- 
ADR cell line in the presence of ATP, AMP or a combination of ATP and the 
individual concentrations of cisplatin indicated above. Data points represent the means 
(± S.D.) o f duplicate determinations in a single experiment. Similar results were 
obtained in at least one additional experiment.
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3.15.2 Inhibition of MRP mediated transport of LtC4 in the presence
of cytotoxic drugs and glutathione in HL60-ADR lOVs.
The transport o f [3H]-LtC4 into HL60-ADR IOVs in the presence o f various 
concentrations o f glutathione was investigated in order to see if this tripeptide 
interfered with the activity o f the glutathione conjugate pump, MRP. From Figure
3.15.2.1 it can be seen that ATP-dependent MRP-mediated transport of LtC4 was 
practically completely inhibited in the presence of 5.6 mM reduced glutathione 
(GSH). The level of inhibition was 70% of the level of transport achieved for the 
ATP treated control in the presence of 3.7 mM GSH. Concentrations o f GSH 
below 1.9 mM had no inhibitory effects on [3H]-LtC4 transport. Previous evidence 
suggested that GSH in an unconjugated state is not a substrate for MRP 
transport. Leier et al. (1996) failed to show any direct transport of [3H]-labelled 
GSH into MRP containing IOVs, when added at a concentration of 100 (xM. 
Muller et al., (1994) demonstrated that 5 mM GSH did not affect [3H]-LtC4 
transport into IOVs isolated from MRP-transfected non-small cell lung carcinoma 
cell line SW1573/S 1. Loe et al., (1996b) stated that GSH in their experimental 
models did not inhibit IXC4 transport even at 5 mM, a concentration stated as 
being the highest intracellular concentration achievable in vivo. The results shown 
in Figure 3.15.2.1 obviously differ from the statements made by Loe et al., 
(1996b) and Muller et al., (1994).
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Figure 3.15.2.1: Time course o f LtC4 transport into IOYs isolated from the HL60- 
ADR cell line in the presence of ATP, AMP or a combination of ATP and the 
individual concentrations o f glutathione (GSH) indicated above. Data points represent 
the means (± S.D.) o f duplicate determinations in a single experiment. Similar results 
were obtained in at least one additional experiment.
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From Figure 3.15.2.1 it can be seen that a concentration o f 5 mM GSH totally 
inhibited LtC4 transport. I f  one co-incubated HL60-ADR IOVs with vincristine or 
cisplatin, one would predict that irrespective o f whatever drug was present, [3H]- 
LtC4 transport would be totally inhibited. From Figure 3.15.2.2 it can be seen that 
this was the case found experimentally. Cisplatin at 109 |lM  had no significant 
effects on [3H]-LtC4 transport but addition of 5 mM GSH completely inhibited 
LtC4 transport into HL60-ADR IOVs. The influence of 1 mM GSH, which has no 
significant effects on [3H]-LtC4 transport in IOVs, was then investigated in the 
case of vincristine, adriamycin, cisplatin and Taxol. In Figure 3.15.2.3 it can be 
seen that in the presence o f 1 mM GSH, [3H]-LtC4 uptake in the presence o f 1 1 0  
|iM  vincristine was significantly reduced from a steady state accumulation level of 
4.5 pmol/mg protein to below 2.0 pmol/mg protein. From Figure 3.15.2.4, it can 
be seen that the level o f [3H]-LtC4 accumulation in the presence o f 250 |iM  
adriamycin (a concentration o f drug which reduces LtC4 accumulation by 
approximately 15% relative to control IOVs) was only slightly affected by the 
addition o f 1 mM GSH. This was also found to be the case for 100 |xM cisplatin 
(Figure 3.15.2.5). [3H]-LtC4 accumulation in the presence o f 50 flM Taxol was 
unaffected by the presence o f 1 mM GSH (Figure 3.15.2.6). These results agree 
with a number of the findings o f Stride et al., (1997) and Loe et al., (1996b) for 
MRP-transfected cells. The importance of the illustration o f inhibition o f LtC4 
transport by vincristine but not adriamycin, cisplatin or Taxol is discussed in 
Section 4.10.1.
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Figure 3.15.2.2: Time course o f LtC4 transport into 10Vs isolated from the HL60- 
ADR cell line in the presence of ATP, AMP or a combination o f ATP and the 
concentrations the o f drugs indicated above. IOVs were also incubated in the presence 
o f 5 mM glutathione (GSH) and either ATP, ATP and vincristine, ATP and cisplatin or 
ATP and Taxol as indicated. Data points represent the means (± S.D.) o f duplicate 
determinations.
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Figure 3.15.2.3: Time course o f LtC4 transport into IOVs isolated from the HL60- 
ADR cell line in the presence o f ATP, AMP or a combination o f ATP and vincristine. 
IOVs were also incubated in the presence of 1 mM glutathione (GSH) and ATP, or 1 
mM GSH and ATP and vincristine as indicated. Data points represent the means (± 
S.D.) o f duplicate determinations in a single experiment. Similar results were obtained 
in at least one additional experiment.
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Figure 3.15.2.4: Time course o f LtC4 transport into IOVs isolated from the HL60- 
ADR cell line in the presence o f ATP, AMP or a combination o f ATP and adriamycin. 
IOVs were also incubated in the presence of 1 mM glutathione (GSH) and ATP, or 1 
mM GSH and ATP and adriamcyin as indicated. Data points represent the means (± 
S.D.) o f duplicate determinations in a single experiment. Similar results were obtained 
in at least one additional experiment.
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Figure 3.15.2.5: Time course o f LtC4 transport into IOVs isolated from the HL60- 
ADR cell line in the presence of ATP, AMP or a combination of ATP and cisplatin. 
IOVs were also incubated in the presence of 1 mM glutathione (GSH) and ATP, or 1 
mM GSH and ATP and cisplatin as indicated. Data points represent the means (± S.D.) 
o f duplicate determinations in a single experiment. Similar results were obtained in at 
least one additional experiment.
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Figure 3.15.2.6: Time course of LtC4 transport into IOVs isolated from the HL60- 
ADR cell line in the presence of ATP, AMP or a combination of ATP and Taxol. IOVs 
were also incubated in the presence of 1 mM glutathione (GSH) and ATP, or 1 mM 
GSH and ATP and Taxol as indicated. Data points represent the means (± S.D.) of 
duplicate determinations in a single experiment. Similar results were obtained in at 
least one additional experiment.
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3.15.3 Transport of natural product unconjugated cytotoxic drugs by
MRP in HL60-ADR IOVs.
As described earlier, MRP-overexpressing cell lines have been shown to be 
resistant to a range o f natural product cytotoxic drugs such as vincristine, 
adriamycin and V P-16. The mechanism by which MRP transports these drugs is 
unclear. MRP is a transporter of glutathione conjugates but natural product 
chemotherapeutic drugs are not believed to undergo glutathione conjugation. 
Stride et al., (1997) and Loe et al., (1996b) have shown that [3H]-labelled 
vincristine was actively transported in IOVs derived from MRP-transfected cells 
only in the presence of 1, 3 or 5 mM glutathione. These groups suggested that 
some form of co-transport o f vincristine and GSH into IOVs may have been 
responsible for the active transport of drug under suitable conditions. In order to 
investigate these findings in a drug selected MRP-overexpressing cell line, similar 
experiments were carried out using HL60-ADR IOVs.
The use of [3H]-vincristine in the IOV transport assay system required 
modification of the protocol used for [3H]-LtC4 transport analysis (Section 
2 . 1 1 .2 ) in order to minimise non-specific binding o f vincristine to the filters used 
to retain the IOVs. As can be seen from Figure 3.15.3.1, these modifications of 
the procedure did not significantly interfere with the detection o f ATP dependent 
transport o f [3H]-LtC4 to the interior of IOVs. The levels o f LtC4 transport found 
using the modified protocol were lower than obtained using the standard [3H]- 
LtC4 assay protocol. The reduction in detectable [3H]-LtC4 active transport 
(approximately 4 fold) caused by modification of the protocol to minimise non­
specific drug binding, was significantly less significant than the reduction in non­
specific binding o f [3H]-vincristine (reduced from 50% non-specific binding under 
standard assay conditions to under 2 % using the modified protocol) to the filters. 
The reduction in detectable [3H]-LtC4 active transport was primarily attributable 
to the filters used, which were of 1 (xm nominal pore size. The average size of 
IOVs is generally regarded as varying from 1.5 to 0.5 [lin and so one could 
assume significant losses of IOVs using these filters. As can be seen from Figure 
3.15.3.1, 10 mM GSH totally inhibited [3H]-LtC4 uptake into HL60-ADR IOVs.
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A concentration o f 0.5 mM GSH had no significant effects on LtC4 transport in 
the presence of ATP, but 2.7 mM inhibited transport by approximately 20%.
From Figure 3.15.3.2, it can be seen that HL60-ADR IOVs were not shown to 
transport [3H]-vincristine in a time dependent manner either in the presence of 
ATP or AMP. The addition of GSH at a concentration of 2.7 mM had no effect 
on [3H]-vincristine transport in the presence of ATP. All results have been 
corrected for non-specific binding of [3H]-vincristine to the filters. The conditions 
used in the experiment represented in Figure 3.15.3.2 were modified in a further 
experiment where [3H]-vincristine transport was studied in the presence of a low 
and high concentration of glutathione (0.5 and 10 mM). In addition, the quantity 
o f 10 V protein was increased (from 50 to 100 (lg) in order to see if this increased 
[3H]-vincristine transport to a detectable level. The results o f this experiment are 
summarised in Figure 3.15.3.3. As can be seen there were no significant 
differences in [3H]-vincristine transport between ATP and AMP treated HL60- 
ADR IOVs. The addition o f 0.5 mM GSH which has no effect on MRP activity or 
10 mM GSH which totally inhibits MRP activity had no significant effects on the 
transport o f [3H]-vincristine in the presence of ATP. The minor increases in 
vincristine accumulation shown in Figures 3.15.3.2 and 3.15.3.3 during the 
various treatments are not a result of any specific transport o f [3H]-vincristine.
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Figure 3.15.3.1: Time course o f LtC4 transport into 10Vs isolated from the HL60- 
ADR cell line in the presence of ATP, AMP or a combination of ATP and glutathione 
(GSH). Data points represent the means (± S.D.) o f duplicate determinations. 
Quantification o f uptake o f LtC4 was performed using glass fibre filters o f a 1 [Xm 
nominal diameter.
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Figure 3.15.3.2: Investigation into [:iH]-vincristine transport into HL60-ADR IOVs in 
the presence of ATP, AMP, 2.7 mM glutathione (GSH) or ATP and AMP in 
combination with 2.7 mM GSH. Quantification o f uptake of [3H]-vincristine was 
performed using glass fibre filters of a 1 |im nominal diameter. Data points represent 
the means (± S.D.) o f duplicate determinations carried out on two separate occasions.
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Figure 3.15.3.3: Investigation into [3H]-vincristine transport into HL60-ADR IOVs 
(100 |_Lg 10V protein) in the presence of ATP or AMP in combination with 0.5 or 10 
raM glutathione (GSH). Quantification of uptake of [3H]-vincristine was performed 
using glass fibre filters o f a 1 |im nominal diameter. Data points represent the means (± 
S.D.) o f duplicate determinations carried out on two separate occasions.
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3.16 Inhibition of LtC4 transport by MRP into HL60-ADR IOVs
due to the presence of cyclosporin A, verapamil or MK571.
In Section 3.15.1 and 3.15.2 it was shown that cytotoxic agents such as 
vincristine can inhibit [3H]-LtC4 transport when added at high concentrations. 
These concentrations are very high and may appear to be unlikely to reflect the 
cellular concentrations achieved with these agents. The circumventing agents 
cyclosporin A and verapamil are known to exert inhibitory activities on MRP 
activity. MK571 is believed to be the most potent inhibitor o f MRP available 
(Section 1.5.2.4). From studies in the DLKP cell line, (Section 3.14.1) it was 
known that MK571 enhanced the toxicity o f the MRP substrate drugs adriamycin 
and VP-16. The toxicity of the non-MRP substrate drug, Taxol was unaffected by 
the presence of MK571. In order to quantify the potency of MK571 as an 
inhibitor of MRP, the inhibition characteristics of this compound in the HL60- 
ADR IOV model for MRP activity was examined. From Figure 3.16.1 it can be 
seen that 50, 1 0  and 1 (JM concentrations of cyclosporin A inhibited [3H]-LtC4 
uptake into HL60-ADR IOVs by MRP by approximately 60, 50 and 40% 
respectively at steady state. Figure 3.16.2 illustrates that verapamil is relatively 
ineffective as an inhibitor of [3H]-LtC4 transport. Concentrations o f 50, 10 and 1 
LlM verapamil only achieve in the range of under 20%> inhibition o f [3H]-LtC4 
transport relative to control ATP treated IOVs. The levels o f inhibition of [3H]- 
LtC4 uptake into HL60-ADR IOVs achieved by cyclosporin and verapamil are 
significantly lower than achieved in the presence of the leukotriene receptor 
antagonist MK571. From Figure 3.16.3 it can be seen that 50 |0,M MK571 totally 
eliminates ATP dependent [3H]-LtC4 transport into HL60-ADR IOVs. 
Concentrations o f 50 |iM  MK571 reduced ATP-dependent transport by 
approximately 90-95% and 1 ¡.iM caused a reduction in [3H]-LtC4 uptake by 20- 
30%). These results show that cyclosporin A is a more potent inhibitor of MRP 
than verapamil. MK571 is significantly more potent an inhibitor o f MRP activity 
than either o f these circumventing agents.
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Figure 3.16.1: Time course o f LtC4 accumulation in HL60-ADR IOVs over time in 
the presence o f ATP, AMP or ATP and the concentrations o f cyclosporin A  indicated 
above. Data points represent the means (± S.D.) of duplicate determinations. Similar 
results were obtained in at least one additional experiment.
Figure 3.16.2: Time course of LtC4 accumulation in HL60-ADR IOVs over time in 
the presence o f ATP, AMP or ATP and the concentrations of verapamil indicated 
above. Data points represent the means (± S.D.) of duplicate determinations. Similar 
results were obtained in at least one additional experiment.
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Figure 3.16.3: Time course o f LtC4 accumulation in HL60-ADR IOVs over time in 
the presence o f ATP, AMP or ATP and the concentrations of MK571 indicated above. 
Data points represent the means (± S.D.) o f duplicate determinations. Similar results 
were obtained in at least one additional experiment.
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3.17 Investigation into the cytotoxic drug accumulation
characteristics of the DLKF-A10 multidrug-resistant human 
lung tumor cell line.
The DLKP-A10 cell line is a drug resistant variant of DLKP obtained by 
continuous adriamycin exposure of the multidrug resistant cell line, DLKP-A. 
DLKP-A10 cells can survive in 17 (10 (ig/mL) adriamycin, at cell densities
appropriate for drug selection in 75 cm2 flasks. The IC 5o of this cell line in a 
standard toxicity assay is approximately 6.5 |_iM, a factor o f over 800-fold more 
resistant than the DLKP parental cells. The MDR circumventing agents verapamil 
and cyclosporin A have been shown to significantly increase the level o f 
accumulation of adriamycin and vincristine in the DLKP-A10 cell line (Cleary el 
al., 1997). This level of accumulation is significantly higher than the levels present 
in DLKP-A10 in the absence of circumventing agent, but intracellular drug levels 
are still lower than the levels accumulated in the DLKP cell line. In the human 
lung squamous carcinoma cell line, SKMES-1/ADR it has been shown that both 
verapamil and cyclosporin A completely restored the accumulation deficit found 
in the resistant cells, to the levels o f the drug sensitive parental cells, SKMES-1. 
The DLKP-A10 cell line overexpresses the P-glycoprotein (Pgp) drug transporter, 
but if resistance was totally due to this resistance mechanism, one would predict 
complete reversal of the accumulation deficit upon addition of a suitable 
concentration o f verapamil or cyclosporin A (as found for the SKMES-1/ADR 
cell line). No significant increases in MRP protein were found in whole cell 
extracts of the DLKP-A10 cell line relative to the parental DLKP cells. This 
resistant cell line was noted to possess unusually high levels of vesicle formation 
within the cytosol (Cleary et al., 1997). It was found that drug became localised 
in these vesicles, which was believed to contribute to a reduction in nuclear 
accumulation of drug. The results of the studies conducted by Cleary et al., 
(1997) suggested that the DLKP-A10 cell line possessed an ATP-dependent 
vesicular sequesterisation system with contributed to the inability of verapamil and 
cyclosporin to reduce the accumulation deficit in this cell line. A number of MRP- 
expressing drug resistant cell lines have been shown to possess high levels of 
intracellular vesicles, (Marquardt and Center, 1992). For this reason, 10Vs were
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isolated from the DLKP-A10 cell line. Isolation o f plasma membrane derived 
1 0 Vs would not necessarily mean isolation o f the proteins present in the 
intracellular vesicles present in DLKP-A10, but because o f membrane trafficking 
to the plasma membrane, one could assume that a significant fraction of these 
vesicles would ultimately become retained in the plasma membrane. Analysis o f 
the MRP activity in the DLKP-A10 cell line could provide some indication as to 
whether or not MRP contributed to the drug accumulation deficit found in this 
cell line in the presence of verapamil or cyclosporin A. In advance of isolation of 
10Vs from DLKP-A10, drug accumulation studies were carried out in order to 
examine the specific details of the accumulation deficit in this cell line.
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3.17.1 Adriamycin accumulation characteristics in the DLKP,
DLKP-A10, SKMES-1 and SKMES-1/ADR cell lines.
Figure 3.17.1.1 illustrates that in the presence of 10 (iM adriamycin, DLKP cells 
accumulated high levels o f adriamycin (approximately 4 nmoles adriamycin per 
106 cells after 4 hours incubation in drug). No saturation in accumulation in this 
drug sensitive cell line was found even after 4 hours incubation in drug. The 
DLKP-A10 cell line accumulated very low levels of adriamycin relative to the 
parental DLKP cells. This resistant cell line only accumulated approximately 200 
pmoles adriamycin per 106 cells after 4 hours incubation in drug. Steady state 
accumulation was achieved after 1-2 hours incubation in drug. Addition of 
cyclosporin A ( 8  |xM) or verapamil (60 |±M) only partially reversed the 
accumulation deficit. Both of these MDR modulators increased cellular 
adriamycin accumulation levels in DLKP-A10 to approximately 1400 pmol per 
106 cells (35% of drug accumulation levels in the DLKP cell line). Steady state 
accumulation levels o f adriamycin in the presence of these MDR modulators was 
achieved by 3 hours incubation in drug. These results reflected the findings of 
Cleary, (1995). Cleary, (1995) also demonstrated that the accumulation deficit in 
DLKP-A10 was not affected by increasing the concentration of verapamil or 
cyclosporin. In Figure 3.17.1.2 it can be seen that in the Pgp-overexpressing cell 
line SKMES-1/ADR, cyclosporin A ( 8  (.iM) and verapamil (60 fiM) completely 
reversed the accumulation deficit to the levels achieved in the parental SKMES-1 
cell line. The SKMES-1/ADR cell line accumulated only approximately 300 pmol 
adriamycin per 106 cells after 4 hours incubation in drug. The parental SKMES-1 
cells accumulated approximately 1700 pmol per 106 cells after 4 hours incubation 
in 10 |_lM adriamycin. The drug resistance of SKMES-1/ADR is believed to be 
predominantly Pgp-mediated, (Cleary, 1995). As a result, drug accumulation 
levels in the presence of the potent Pgp modulators, verapamil or cyclosporin A 
were increased to the levels achieved in the drug sensitive SKMES-1 cells.
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Antimycin A is a metabolic inhibitor which inhibits ATP production by interfering 
with electron transport from ubiquinone to cytochrome C in the electron transport 
chain. Sodium azide is also an inhibitor of the electron transport chain (inhibits 
reduction of oxygen by cytochrome oxidase). Cleary et al., (1997) showed that 
under specific experimental conditions, antimycin A  but not sodium azide reversed 
the accumulation deficit in the DLKP-A10 cell line. The explanation given by 
Cleary et al., (1997) for the ability of the metabolic inhibitor antimycin A  but not 
sodium azide to reverse the drug accumulation deficit in DLKP-A10, involved the 
fact that antimycin A inhibited the electron transport chain at an earlier stage than 
sodium azide. For this reason, this was believed to result in elimination o f the 
adriamycin accumulation deficit in the DLKP-A10 cell line over the 3 hour time 
period studied. In order to investigate these findings, similar studies were 
conducted, the results of which are presented in Figure 3.17.1.3. The details of 
the protocol used in this experiment are provided in Section 2.15. This 
experimental protocol involved seeding cells at a density o f 0.5 x 106 cells per 75 
cm2 flask. Following an incubation period of 48 hours, cells were washed with 
PBS and incubated in glucose free media for two hours. After this time cells were 
treated with the relevant concentrations o f adriamycin (10 |xM), antimycin A  (20 
|iM) or sodium azide (10 mM) in glucose free medium. Cellular accumulation of 
adriamycin was then determined by HPLC as described in Section 2.15. From 
Figure 3.17.1.3 it can be seen that even in glucose free media, DLKP-A10 only 
accumulated approximately 500 pmol adriamycin per 106 cells after 3 hours 
incubation in drug. Steady state accumulation was achieved after 1 hour. The 
DLKP cell line accumulated approximately 1600 pmol adriamycin per 106 cells 
after 3 hours incubation. From Figure 3.17.1.3 it can be seen that 20 |_iM 
antimycin A caused a level of adriamycin accumulation in DLKP-A10 comparable 
to that achieved in the DLKP cell line. Sodium azide (10 mM) appeared to only 
partially reverse the accumulation deficit in DLKP-A10 (Figure 3.17.1.3). The 
primary reason for significant errors associated with the data is the toxicity of 
these metabolic inhibitors in glucose free media. Obviously interference with 
critical steps in the electron transport chain due to the presence of a metabolic 
inhibitor such as antimycin A has extremely detrimental effects on cellular
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metabolism. Even after 30 minutes incubation in antimycin A or sodium azide, 
cells appear shocked and after a period o f 4 hours, toxic effects begin to occur 
and cells undergo cell death. The differences between DLKP and DLKP-A10 
adriamycin accumulation are relatively small (approximately 3 fold difference after 
3 hours in glucose free media versus 20 fold in glucose containing media) and this 
makes the variation associated with the data quite significant. Due to the levels o f 
variation in analysis o f drug accumulation levels by HPLC, errors of ± 500 pmol 
adriamycin per 106 cells are possible at high drug concentration (such as in Figure
3.17.1.1 for DLKP at all timepoints). Even considering the levels of errors 
associated with the data it is clear that antimycin A reversed the accumulation 
deficit in DLKP-A10 and that sodium azide was only partially effective for this 
purpose. The potential ability of 2 |aM antimycin A to reverse the adriamycin 
accumulation deficit in the DLKP-A10 cell line in glucose containing media was 
also investigated. From Figure 3.17.1.4 it can be seen that under these conditions, 
antimycin A was totally ineffective for reversal of the drug accumulation deficit in 
the DLKP-A10 cell line. This suggests that the abilities o f antimycin A to increase 
adriamycin accumulation in the DLKP-A10 cell line were partially a result of the 
effects of this metabolic inhibitor on ATP production.
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Figure 3.17.1.1: The effect o f cyclosporin A ( 8  |iM ) and verapamil (60 ¡iM) on 
adriamycin accumulation in the DLKP-A10 and DLKP cell lines over time. Data points 
represent the means (± S.D.) o f duplicate determinations.
Figure 3.17.1.2: The effect o f cyclosporin A ( 8  |iM) and verapamil (60 (iM) on 
adriamycin accumulation in the SKMES-1/ADR and SKMES-1 cell lines over time. 
Data points represent the means (± S.D.) of duplicate determinations.
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Figure 3.17.1.3: The effect of antimycin A (20 (xM) and sodium azide (10 mM) on 
adriamycin accumulation in the DLKP-A10 and DLKP cell lines under glucose free 
conditions. Data points represent the means (± S.D.) of duplicate determinations.
Figure 3.17,1.4: The effect of antimycin A (2 (xM) on adriamycin accumulation in the 
DLKP-A10 and DLKP cell lines under glucose containing conditions. Data points 
represent the means (± S.D.) o f duplicate determinations.
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3.17.2 Transport of LtC4 into DLKP-A10 derived IOVs and
inhibition of this transport by antimycin A, sodium azide, 
cyclosporin A and verapamil.
DLKP-A10 IOVs were isolated using the protocol detailed in Section 2.10. The 
[3H]-LtC4 transporting abilities of this pump were then analysed and the results 
are summarised in Figure 3.17.2.1. As can be seen DLKP-A10 derived IOVs 
transported [3H]-LtC4 in an ATP dependent manner with an initial rate of 0.6 ±  
0 . 2  pmol per mg IOV protein per minute and achieved a [3H]-LtC4 accumulation 
level o f 1.8 ± 0.3 pmol/mg protein by 4.0 minutes. These values are the means ± 
S.D. of duplicate determinations carried out using two individually prepared 
vesicle preparations. The DLKP cell line transports [3H]-LtC4 with an initial rate 
o f 0 . 8  ± 0.2 pmol per mg IOV protein per minute (maximum accumulation o f 2.0 
± 0.2 pmol/mg) and the MRP overexpressing cell line HL60-ADR transports 
[3H]-LtC4 with an initial rate o f 4.0 ± 1.0 pmol per mg IOV protein per minute 
(maximum accumulation o f 7.0 ± 1.0 pmol/mg). Western blotting results 
demonstrated lower levels o f MRP in DLKP-A10 derived IOVs compared to 
levels found in DLKP IOVs (Section 3.17.4).
As described in Section 3.17.1, the metabolic inhibitor antimycin A but not 
sodium azide was shown by Cleary et al., (1997) to eliminate the accumulation 
deficit in the DLKP-A10 cell line. If  the effects o f antimycin A on ATP 
production were solely responsible for reversal of the accumulation deficit in 
DLKP-A10, one would expect sodium azide to have comparable effects. As this 
was not the case, an investigation was carried out to test if antimycin A had 
significantly different effects on [3H]-LtC4 transport and so MRP activity in 
DLKP-A10 IOVs. The effects of these agents on this activity was compared to 
the MDR modulators cyclosporin A and verapamil, which as shown in Section
3.17.1 were only partially effective as agents for reduction of the drug 
accumulation deficit in DLKP-A10. These circumventing agents exert inhibitory 
effects on Pgp and MRP, but are poor inhibitors of MRP relative to agents such 
as MK571 (Section 3.16). From Figure 3.17.2.2 it can be seen that 50 and 10 (iM
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cyclosporin A cause inhibition of ATP-dependent LtC4 uptake into DLKP-A10 
IOVs by approximately 80 and 60% respectively. A concentration o f 1 (iM 
cyclosporin A was without significant effects on [3H]-LtC4 uptake into these 
IOVs. Verapamil (Figure 3.17.2.3) was less potent an inhibitor o f [3H]-LtC4 
transport into DLKP-A10 derived IOVs as 50 and 10 |j,M reduced the levels o f 
uptake by less than 20%. A concentration of 1 |nM verapamil had no effects on 
[3H]-LtC4 uptake into DLKP-A10 IOVs. Antimycin A (as shown in Figure
3.17.2.4) was a potent inhibitor of [3H]-LtC4 transport activity at 50 [i,M 
(approximately 60% inhibition o f ATP dependent [3H]-LtC4 transport) and 10 |xM 
(over 30% inhibition of [3H]-LtC4 transport). This is relatively surprising as this 
compound was not previously believed to exert any direct inhibitory effects on 
MRP or other related transporter molecules. The fact that sodium azide (Figure
3.17.2.5) exerted minor inhibitory effects on [3H]-LtC4 transport into DLKP-A10 
IOVs (but only at a concentration of 50 |iM) indicated that these metabolic 
inhibitors could either interfere with the relevant [3H]-LtC4 transporter directly or 
simply interfere with the experimental model used (such as the ATP regenerating 
system involving creatine phosphate and creatine kinase). The investigations 
detailed in Section 3.17.3 demonstrated that antimycin A did not affect the ATP 
regenerating system in IOV transport assays. From Figure 3.17.2.6 it can be seen 
that the ability of antimycin A to inhibit [3H]-LtC4 transport is not restricted to the 
DLKP-A10 cell line. A concentration of 50 |iM  antimycin A was found to inhibit 
[3H]-LtC4 transport into HL60-ADR IOVs by 60-10%. This strongly suggested 
that this metabolic inhibitor exerted inhibitory effects on MRP-mediated transport 
of [3H]-LtC4 into DLKP-A10 and HL60-ADR IOVs.
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Figure 3.17.2.1: Time course o f LtC4 transport into IOVs from the DLKP-A10 cell 
line in the presence o f ATP or AMP. Data points represent the means (± S.D.) o f 
duplicate determinations.
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Figure 3.17.2.2: Time course of LtC4 transport into IOVs from the DLKP-A10 cell 
line in the presence o f ATP or AMP or ATP and 50, 10 and 1 [iM cyclosporin A. Data 
points represent the means (± S.D.) of duplicate determinations. Similar results were 
obtained in at least one additional experiment.
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Figure 3.17.2.3: Time course of LtC4 transport into IOVs from the DLKP-A10 cell 
line in the presence o f ATP or AMP or ATP and 50, 10 and 1 (iM verapamil. Data 
points represent the means (± S.D.) of duplicate determinations. Similar results were 
obtained in at least one additional experiment.
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Figure 3.17.2.4: Time course o f LtC4 transport into IOVs from the DLKP-A10 cell 
line in the presence of ATP or AMP or ATP and 50, 10 and 1 |iM  antimycin A. Data 
points represent the means (± S.D.) o f duplicate determinations. Similar results were 
obtained in at least one additional experiment.
Figure 3.17.2,5: Time course o f LtC4 transport into IOVs from the DLKP-A10 cell 
line in the presence of ATP or AMP or ATP and 50, 10 and 1 [iM sodium azide. Data 
points represent the means (± S.D.) o f duplicate determinations. Similar results were 
obtained in at least one additional experiment.
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Figure 3.17.2.6: Time course of LtC4 transport into lOVs from the HL60-ADR cell 
line in the presence o f ATP or AMP or ATP and 50 [.iM verapamil or antimycin A. 
Data points represent the means (± S.D.) o f duplicate determinations. Similar results 
were obtained in at least one additional experiment.
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3.17.3 Influence of verapamil and antimycin A on ATP levels during
LtC4 transport into HL60-ADR IOVs.
In order to investigate if the inhibition of [3H]-LtC4 transport caused by the 
presence of antimycin A was a result of interference with the ATP-regenerating 
system in the [3H]-LtC4 transport model, ATP levels in the system were 
monitored under a variety o f conditions. A bioluminescent ATP assay was used to 
quantify the levels of ATP present at various timepoints (Section 2.14). The ATP 
regenerating system in IOV transport assays involves the regeneration o f ATP 
using creatine phosphate, creatine kinase and ATP. From Figure 3.17.3.1 it can be 
seen that in the absence of creatine kinase, ATP levels in the reaction mixture 
were significantly reduced by 30 minutes, with levels reduced practically to zero 
by 3-5 hours. This experiment was only performed with HL60-ADR IOVs as it 
was known that antimycin A exerted comparable inhibitory effects on [3H]-LtC4 
transport into IOVs from both the DLKP-A10 and HL60-ADR cell lines. The 
HL60-ADR derived IOVs exhibited significantly higher capacities for [3H]-LtC4 
transport than found in DLKP-A10 derived IOVs (Section 3.17.2). For this 
reason, the rate o f ATP utilisation would be accordingly higher in HL60-ADR 
derived IOVs. This facilitated the rapid detection o f variations in ATP levels in the 
reaction mixture under various conditions. In the presence o f creatine kinase 
(Figure 3.17.3.1), ATP levels remained relatively constant in the reaction mixture. 
In the presence o f 50 ¡xM verapamil or 50 |iM  antimycin A, ATP levels appeared 
to remain relatively constant up to a period of 3 hours. After a period of 5 hours, 
ATP levels were slightly higher in reaction mixtures containing verapamil or 
antimycin A  treated IOVs, relative to a reaction mixture containing untreated 
IOVs. These results illustrated that antimycin A did not exert any specific effects 
on the ATP-regenerating system in the IOV transport model and so the influence 
of this metabolic inhibitor on [3H]-LtC4 transport into DLKP-A10 and HL60- 
ADR derived IOVs was a result of direct inhibitory effects on the [3H]-LtC4 
transport exhibited by IOVs from these cell lines.
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Figure 3.17.3.1: Time course of the effect o f 50 (iM verapamil and 50 (xM 
antimycin A  on ATP levels during LtC4 transport into HL60-ADR 10Vs. 10Vs 
were incubated in the presence of ATP and creatine kinase (CK), ATP and CK 
and verapamil, ATP and CK and antimycin A, or ATP without CK. Data points 
represent the means (± S.D.) of duplicate determinations.
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3.17.4 Western blot analysis of MRP levels in DLKP-A10 derived
inside-out vesicles.
The protein levels o f MRP in DLKP-A10 IOVs were analysed by Western 
blotting. As can be seen from Figure 3.17.4.1, DLKP, DLKP-A10 and HL60- 
ADR IOVs contained MRP protein. The HL60-ADR IOVs possessed extremely 
high levels of the 190 kDa MRP protein. As described in Section 2.9.6, the 
extremely sensitive Pierce SuperSignal Chemiluminescent substrate method was 
used for analysing MRP expression in DLKP and resistant variants of DLKP. The 
HL60-ADR IOVs contained such high levels of MRP that the Pierce SuperSignal 
Chemiluminescent substrate method was over sensitive as a strong signal was 
evident at all positions along the HL60-ADR IOV lane on the gel (Figure 
3.17.4.1). Reducing protein loading of HL60-ADR IOVs from 20 to 2 |0,g showed 
that the chemiluminescent signal was predominantly due to the 190 kDa protein, 
MRP. From Figure 3.17.4.1 it can also be seen that DLKP IOVs express 
significant levels of MRP. As predicted from the levels of [3H]-LtC4 transport 
activity exhibited by DLKP relative to HL60-ADR derived IOVs (Section 3.13), 
DLKP IOVs contain significantly lower levels o f MRP protein than found in 
HL60-ADR IOVs. DLKP-A10 derived IOVs also contain MRP but the levels 
present are lower than found in IOVs from DLKP. DLKP-A10 IOVs exhibit 
lower [3H]-LtC4 transporting abilities (initial rate of 0 . 6  ± 0.2 pmol per mg IOV 
protein per minute and maximum accumulation o f 1.8 ± 0.3 pmol/mg) than found 
in the case o f DLKP IOVs (initial rate of 0.8 ± 0.2 pmol per mg IOV protein per 
minute and maximum accumulation of 2.0 ± 0.3 pmol/mg). For this reason, one 
would have predicted from the [3H]-LtC4 transport characteristics of IOVs from 
the DLKP and DLKP-A10 cell lines, that DLKP-A10 IOVs possessed only 
slightly lower levels of MRP protein than DLKP derived IOVs. From Figure
3.17.4.1 it can be seen that the difference in MRP protein levels between DLKP 
and DLKP-A10 is larger than one would have assumed from the [3H]-LtC4 
transport characteristics of these cell lines. The presence o f the 116 kDa band in 
the DLKP, DLKP-A10 and HL60-ADR samples was not found to be present in a 
negative control blot performed using HL60-ADR IOVs.
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Figure 3.17.4.1: Western blot detection of MRP protein in IOVs isolated from 
the HL60-ADR (lanes 1 and 4), DLKP (lane 2) and DLKP-A10 (lane 3) cell lines. 
A quantity o f 20 |lg  protein was loaded in each case with the exception of lane 4, 
where 2 (ig HL60-ADRIOV protein was loaded. A negative control is shown in 
lane 5 where the nitrocellulose containing 20 |±g HL60-ADR IOV protein was 
exposed to TBS instead of primary antibody.
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3.18 MRP expression and LtC4 transport characteristics in clonal
populations isolated from the MDR cell line DLKP-A.
Heenan et al., (1997) isolated 9 clonal subpopulations from the Pgp 
overexpressing cell line DLKP-A. The drug resistant DLKP-A cell line 
(approximately 250-fold resistant to adriamycin relative to the parental DLKP 
cells) overexpresses Pgp and possesses reduced levels of topoisomerase II (Topo 
II) relative to levels found in DLKP. The clonal subpopulations isolated from the 
DLKP-A cell line exhibit various levels of drug resistance. The drug resistance 
mechanisms responsible for this drug resistance have been thoroughly studied by 
Heenan et al., (1997) and have been shown to primarily involve Pgp and Topo II. 
Until recently it was believed that DLKP did not express MRP protein, and this 
was also believed to be the case for DLKP-A and DLKP-A derived resistant 
clones. It is now known that DLKP expresses MRP and that this transporter is 
responsible for [3H]-LtC4 transport into IOVs from this cell line. The possible 
presence o f MRP protein in DLKP-A derived clones was investigated by means o f 
isolation of IOVs from the DLKPA2B, 1 IB, 6 B and 5F clones o f DLKP-A. These 
studies were carried out with two main objectives. Firstly these studies served as 
in investigation into MRP levels and activities in drug resistant variants o f DLKP. 
Resistant variants of the DLKP cell line preferentially overexpress Pgp protein 
rather than MRP protein. This study therefore served as an investigation into the 
possibility that MRP protein expression would become down-regulated as 
resistance and Pgp expression developed. The second main objective o f this study 
was to attempt to explain if MRP contributed to the findings o f Heenan et al., 
(1997) which showed that two clones (DLKPA6 B and 1 IB) which had practically 
identical drug resistance profiles, possessed significant differences in drug 
resistance mechanisms.
As can be seen from Figure 3.18.1, IOVs isolated from DLKPA2B transported 
[3H]-LtC4 in an ATP dependent fashion with an initial rate o f 0.5 ± 0.2 pmol/mg 
protein per minute with [3H]-LtC4 uptake saturated by 4 minutes at 1.5 ± 0.2 
pmol/mg protein. DLKP A l IB IOVs also transported [3H]-LtC4 in an ATP
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dependent fashion (Figure 3.18.2) with an initial rate o f 0.6 ±  0.3 pmol/mg 
protein/minute with [3H]-LtC4 uptake saturated by 3 minutes at 1.1 ± 0 . 2  
pmol/mg protein. DLKPA5F derived 10Vs exhibited relatively high levels of LtC4 
transport. [3H]-LtC4 transport occurred at an initial rate o f 1.3 ± 0.2 pmol/mg 
protein/minute with saturation at 2.3 ± 0.2 pmol [3H]-LtC4 per mg protein, 
occurring after 2 minutes (Figure 3.18.3). DLKPA6 B exhibited comparable levels 
of [3H]-LtC4 transporting abilities as was found in the case of DLKPA2B and 
11B. The DLKPA6 B derived IOVs transported [3H]-LtC4 with an initial rate of 
0.7 ± 0.3 pmol LtC4 per mg IOV protein per minute (Figure 3.18.4). Saturation in 
LtC4 uptake by DLKPA6 B IOVs occurred at a level o f 1.0 ± 0.2 pmol/mg 
protein. The rate and LtC4 accumulation data described above is the mean ± S.D. 
for duplicate determinations carried out using two separate IOV preparations 
from a given cell line.
As can be seen in Figure 3.18.5, IOVs from the DLKPA5F, 6 B, 2B and 1 IB cell 
lines express MRP protein. The levels of MRP protein present in DLKP derived 
IOVs are comparable to the levels found in DLKPA5F IOVs. Substantial levels of 
MRP were also found to be present in DLKPA6 B derived IOVs. In the case of 
IOVs from the DLKPA11B cell line, significant MRP protein expression was also 
found to be present but DLKPA2B-derived IOVs only expressed very low levels 
of this protein. The presence of the 116 kDa band in the case of all samples was 
not found to be present in a negative control blot performed using HL60-ADR, 
IOVs where the nitrocellulose was exposed to TBS instead of rat anti-MRP 
monoclonal antibody. A negative control with rat serum was not performed. No 
evidence was obtained to suggest that the 116 kDa was in any way specific for 
MRP or some degraded form of MRP and so was attributed to non-specific 
binding of the antibody to protein in the IOV preparations.
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Figure 3.18.1: Time course of LtC4 transport into IOVs isolated from the 
DLKPA2B cell line in the presence o f ATP or AMP. Data has been corrected for 
non-specific binding o f LtC4 which occurred in the absence o f ATP and AMP. 
Data points represent the means (± S.D.) o f duplicate determinations.
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Figure 3.18.2: Time course of LtC4 transport into IOVs isolated from the 
DLICPA11B cell line in the presence o f ATP or AMP. Data has been corrected for 
non-specific binding of LtC4 which occurred in the absence of ATP and AMP. 
Data points represent the means (± S.D.) o f duplicate determinations
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Figure 3.18.3: Time course o f LtC4 transport into IOVs isolated from the 
DLKPA5F cell line in the presence of ATP or AMP. Data has been corrected for 
non-specific binding of LtC4 which occurred in the absence o f ATP and AMP. 
Data points represent the means (± S.D.) of duplicate determinations.
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Figure 3.18.4: Time course o f LtC4 transport into IOVs isolated from the 
DLKPA6 B cell line in the presence o f ATP or AMP. Data has been corrected for 
non-specific binding of LtC4 which occurred in the absence o f ATP and AMP. 
Data points represent the means (± S.D.) of duplicate determinations.
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Figure 3.18.5: Western blot detection of MRP protein in IOVs isolated from the 
HL60-ADR (lane 1), DLKPA11B (lane 2), DLKP (lane 3), DLKPA5F (lane 4), 
DLKPA6 B (lane 5) and DLKPA2B (lane 6 ) cell lines.
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Discussion
4.1 General discussion
In cancer chemotherapy, tumors often develop resistance to the chemotherapeutic 
drugs with which they are being treated. Combination chemotherapy was initially 
introduced in an attempt to overcome this situation but it was found that in certain 
cases, tumors could develop which were cross-resistant to a range of structurally and 
functionally unrelated cytotoxic drugs. Multidrug resistance (MDR) is the. term given 
to the phenomenon in which cancer cells become resistant to a range of 
chemotherapeutic agents with dissimilar structures and mechanisms of action. Tumor 
cells can be selected in vitro for resistance to a particular cytotoxic drug by continual 
or pulsed exposure to the drug. In many cases these cells develop the multidrug 
resistance phenotype described above. MDR can be mediated by overexpression o f 
drug transporter molecules such as P-glycoprotein (Pgp). The Pgp molecule is a 170 
kDa plasma membrane protein with twelve transmembrane domains and two 
intracellular ATPase active sites (Section 1.5). It is an energy dependent broad 
specificity pump with the ability to transport drugs such as the vinca alkaloids 
(including vinblastine and vincristine), epipodophyllotoxins (such as V P-16), 
anthracyclines (including doxorubicin and daunorubicin), taxanes (such as Taxol) and 
miscellaneous drugs such as mitoxantrone and actinomycin D, (Fisher et al., 1996).
The calcium channel blocker verapamil was the first agent shown to be an effective 
inhibitor of Pgp-mediated drug efflux (Section 1.5.1.4). A number o f modulators of 
Pgp activity have subsequently been developed and a selection of these modulators 
have been studied in clinical trials, (Fisher and Sikic, 1995). The results o f these trials 
have been relatively disappointing as it has been found that the currently available Pgp 
modulators lack the potency to completely reverse the MDR phenotype at clinically 
achievable concentrations. One of the major factors in the failure o f Pgp modulators as 
potential drug resistance circumventing agents is the fact that these compounds can 
cause extreme toxic side effects at the high doses needed for inhibition o f the drug 
efflux activity of Pgp.
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Overexpression o f Pgp by tumor cells is by no means the only mechanism by which 
tumor cells can develop multidrug resistance. Cells that overexpress Pgp may 
simultaneously possess other resistance mechanisms including alterations in the nuclear 
enzyme topoisomerase II (Topo II) or expression of additional drug efflux pumps such 
as the multidrug resistance-associated protein, (MRP). Overexpression o f MRP is 
sufficient to confer multidrug resistance on cells in vitro, (Cole et al., 1992). MRP is a 
1531 amino acid, 190 kDa glycoprotein that is overexpressed in a number of non-Pgp 
expressing cell lines (Section 1.5.2). It has also been detected at the protein level in 
various normal human tissues such as the lung, bladder, stomach, colon, adrenal gland, 
ovary, pancreas, heart, placenta, kidney, spleen and liver, (Cole et al., 1992; Zaman el 
al., 1993). Only a limited number of efficient modulators o f MRP activity are currently 
available (Section 1.5.2.4). The tyrosine kinase inhibitor genistein has been 
demonstrated to modulate daunorubicin accumulation in human small cell lung cancer 
cells, (Versantvoort et al., 1994). The bisindoylmaleimide protein kinase C inhibitor 
GF109203X and the leukotriene D4 receptor antagonist MK571 have also been shown 
to modulate MRP activity, (Gekeler et al. 1995a, b). DL-buthionine-sulphoximine, 
(BSO) has also been shown to modulate MRP-mediated multidrug resistance. The y- 
glutamyl-cysteine synthase enzyme is strongly inhibited by BSO, and inhibition o f this 
enzyme can cause a depletion of cellular glutathione levels. Other compounds such as 
the ATPase inhibitor sodium orthovanadate and the organic anion transport inhibitor, 
probenecid, have also been shown to have MRP modulating activity, (Twentyman and 
Versantvoort, 1996).
The clinical relevance o f the MRP molecule in multidrug resistance in cancer has not 
been fully elucidated, but it has been shown that MRP can be present in abnormally 
elevated levels in various forms of chemotherapy resistant leukaemias (Zhou et al., 
1995). In addition, even if MRP is clinically important, it is not known if the MRP- 
modulating agents listed briefly above could be used to modulate MRP-mediated 
resistance in vivo. It is possible that these compounds could cause serious side effects 
particularly when added at the high concentrations required for modulation o f MRP 
activity (Section 1.5.2.4).
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This thesis describes the use of NSAIDs as modulators of the MRP drug efflux pump 
in drug sensitive MRP-expressing cell lines. NSAIDs are among the most commonly 
prescribed medicines and have been comprehensively characterised in vivo. For this 
reason these compounds are ideal candidates for use in practically any 
chemotherapeutic regime. The NSAIDs identified in in vitro toxicity screening assays 
as MRP-modulating agents were used at clinically relevant concentrations. This should 
be reflected in the concentrations of NSAID used for modulation of MRP in vivo being 
relatively non-toxic for normal cells. Modulation o f MRP-mediated efflux o f drug in 
vivo may cause similar side effects to those seen in trials involving modulation of Pgp 
mediated drug efflux due to the fact that MRP, like Pgp, is expressed in normal tissues. 
In addition, the therapeutic advantage of modulating MRP activity in tumors in vivo is 
not fully clear (Twentyman and Versantvoort, 1996), The use of non-toxic doses of 
well characterised agents such as NSAIDs, would be an effective tool with which to 
discover if modulating MRP activity could be significantly advantageous in cancer 
chemotherapy.
The illustration of NSAID-mediated chemotherapeutic drug toxicity enhancement in 
drug sensitive cell lines such as DLKP, confirms the importance of the activity o f drug 
efflux pumps in these cell lines. The identity o f these efflux pumps and their relevance 
in drug resistance in DLKP was investigated in detail in this thesis. The isolation of 
plasma membrane-derived inside out vesicles (IOYs) provided evidence for the first 
time that the DLKP cell line expresses significant levels of MRP. The existence o f 
MRP in drug resistant variants of the DLKP cell line could potentially explain the fact 
that the drug accumulation and resistance characteristics of many of these cell lines 
cannot be completely explained solely by the levels o f P-glycoprotein and 
topoisomerase II present. The DLKP cell line preferentially develops Pgp-mediated 
drug resistance during drug selection. The variation in MRP levels and activities during 
the development of Pgp mediated drug resistance in drug resistant variants o f DLKP 
was investigated in order to see if the expression and activity o f MRP became down- 
regulated as Pgp expression and drug resistance developed. The IOV assay system was 
also used to investigate the role o f MRP in the unusual drug accumulation 
characteristics found in a drug resistant variant o f DLKP, DLKP-A10.
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4.2 In vitro toxicity assay screening with indomethacin and sulindac
in combination with various chemotherapeutic drugs in the A549 
cell line.
Initial screening experiments in the A549 cell line demonstrated that the NSAIDs, 
indomethacin and sulindac, had the ability to enhance the toxicity of adriamycin 
(Tables 3.2.2 and 3.2.3). In an attempt to characterise if this effect was limited only to 
adriamycin, in vitro toxicity assay screening was expanded to include a variety of 
chemotherapeutic drugs from the various therapeutic categories (Table 3.2.1). It was 
found that indomethacin and sulindac enhanced the toxicity o f adriamycin, 
daunorubicin, epirubicin, vincristine and VP-16. This indicated that there were specific 
structural or mechanistic characteristics required for a drug to have toxicity enhanced 
in the presence of indomethacin or sulindac. All of the drugs listed above, which were 
found to have toxicity enhanced in the presence of indomethacin or sulindac, are 
believed to be substrates for Pgp and MRP, (Cole et a l ,  1994). Taxol is also a 
substrate of Pgp, but is not believed to be a high affinity substrate of MRP. This 
indicated that only MRP had a role in the toxicity enhancement effect, as only the 
toxicity o f MRP substrate drugs was enhanced in the presence of indomethacin or 
sulindac.
In order to partially validate this theory, the heavy metals sodium arsenate and 
potassium antimony tartrate were tested in combination with indomethacin and 
tolmetin in the A549 cell line (see Section 3.4 for details). These heavy metals are 
normally toxic to cells but they can also serve as substrates for MRP-mediated 
transport, (Cole et a l ,  1994). It was found experimentally that sodium arsenate 
toxicity was enhanced in the presence of indomethacin and tolmetin (an NSAID with 
the ability to enhance the toxicity o f a suitable cytotoxic drug as described in Section
3.3). This suggested that these NSAIDs inhibited the transport of the heavy metal out 
of the cell and so enhanced the level of cell kill achieved by a given concentration of 
sodium arsenate. This result was complicated by the fact that the toxicity of another 
heavy metal, potassium antimony tartrate, was unaltered by either indomethacin or 
tolmetin treatment. From Tables 3.4.3 and 3.4.4 it can be seen that there was an
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inconsistency in the level o f cell kill achieved between Tables 3.4.3 and 3.4.4 in the 
presence of all control concentrations o f potassium antimony tartrate used. This 
suggests that further investigations with potassium antimony tartrate would be 
required in order to conclusively answer if the toxicity o f this compound was affected 
by the presence of indomethacin or tolmetin. The fact remains that sodium arsenate 
toxicity was enhanced in the presence of indomethacin or tolmetin. This suggests that 
the toxicity o f an MRP substrate (not necessarily a chemotherapeutic drug) can be 
enhanced in the presence o f a suitable NSAID.
4.3 In vitro toxicity assay screening with NSALDs in combination with
adriamycin and vincristine in the A549 cell line.
The data from the in vitro toxicity assay drug screening experiments (Section 3.2), 
indicated that MRP-mediated transport was a critical factor in the NSAID-mediated 
chemotherapeutic drug toxicity enhancement effect. The precise nature of the 
relationship between MRP-mediated drug transport and NSAID treatment was not 
clear from the in vitro toxicity assay screening data. It also remained to be discovered 
if all NSAIDs had this toxicity enhancing ability or if there were specific structural or 
mechanistic characteristics required for an NSAID to have the toxicity enhancing 
abilities possessed by indomethacin and sulindac. For this reason an elaborate screen of 
a wide range of NSAIDs was performed (Section 3.3).
It was found that acemetacin, indomethacin, mefenamic acid, sulindac, sulindac sulfide, 
sulindac sulfone, tolmetin and zomepirac enhanced the toxicity of adriamycin and 
vincristine when present at an appropriate relatively non-toxic concentration. All but 
one of the NSAIDs found to have drug toxicity enhancing abilities, have common 
structural characteristics and were classified as heteroarylacetic acids by Korolkovas, 
(1988). The remaining NSAID with toxicity enhancing abilities, mefenamic acid is a 
fenamate NSAID. Not all heteroarylacetic acid NSAIDs possess toxicity enhancing 
abilities. For example, the heteroarylacetic acid, etodolac, did not enhance the toxicity 
of adriamycin or vincristine (Table 3.3.1).
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The potential for development o f additional toxicity enhancing NSAID analogues is 
quite encouraging. From the above list of toxicity enhancing NSAIDs, only 
indomethacin, mefenamic acid, sulindac and tolmetin were initially found to possess 
this ability. Acemetacin is a pro-drug of indomethacin, sulindac sulfide and sulfone are 
analogues of sulindac and zomepirac is a structural analogue of tolmetin. Screening o f 
these analogues demonstrated that these compounds also possessed chemotherapeutic 
drug toxicity enhancing abilities. This indicates that it may be possible to develop 
NSAID analogues from a suitable NSAID which may not necessarily possess potent 
anti-inflammatory or analgesic properties, but which may actually possess 
chemotherapeutic drug toxicity enhancing abilities.
There did not initially appear to be any mechanistic similarities between the activities of 
these specific toxicity-enhancing NSAIDs. All possessed varied abilities to inhibit 
prostaglandin H synthase (cyclooxygenase) activity and so prostaglandin synthesis. 
The level o f this ability varied from high levels of inhibitory activity, (indomethacin) to 
no inhibitory activity, (sulindac sulfone). In addition, NSAIDs with potent inhibitory 
activities on the cyclo oxygenase enzyme such as flurbiprofen did not possess the ability 
to enhance adriamycin or vincristine toxicity (Table 3.3.1). There did not appear to be 
any relationship between the ability of an NSAID to enhance toxicity and the ability of 
that NSAID to preferentially inhibit either the PGHS-1 or PGHS-2 isozymes. For 
example indomethacin preferentially inhibits PGHS-1 (IC5o ratio o f inhibition of 
PGHS-2 to PGHS-1 o f 9:1). Some NSAIDs which do not possess drug toxicity 
enhancing abilities (such as ibuprofen) have a similar preference for PGHS-1 (IC50 
ratio of inhibition o f PGHS-2 to PGHS-1 of 11:1). These ratios were developed by 
Gierse et al., (1995) in an in vitro cell-free enzyme system. The PGHS-l/PGHS-2 
ratios found for intact cells (Vane and Botting, 1996) show similarities to ratios 
developed using the cell free enzyme systems of Gierse et al., (1995). The other 
toxicity enhancing NSAIDs show varying levels of preferential inhibition of PGHS 
isozymes but no correlation was found between preferential inhibition o f PGHS-1 or 
PGHS-2 and ability of a given NSAID to enhance drug toxicity. Dexamethasone has a 
variety of effects in cells amongst which is the ability to inhibit PGHS-2 protein 
expression with little effect on PGHS-1. It was found experimentally that
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dexamethasone did not possess drug toxicity enhancing abilities (Table 3.7.1). This 
further indicated that the elimination o f PGHS activity was not sufficient to achieve the 
toxicity enhancement effect
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4.4 In vitro toxicity assay screening with various NSAIDs
for identification of NSAIDs with an ability to enhance the toxicity 
of adriamycin and vincristine in the DLKP cell line.
The in vitro toxicity assay screening results obtained using A549 were compared to 
results obtained in a second drug sensitive cell line, DLKP. It was found that as was 
the case in the A549 cell line, only acemetacin, indomethacin, mefenamic acid, 
sulindac, tolmetin and zomepirac enhanced the toxicity of adriamycin or vincristine in 
DLKP cells (Section 3.5). The ability of sulindac sulfide and sulfone to enhance 
adriamycin and vincristine toxicity was not investigated in the case of the DLKP cell 
line. The results indicated that the toxicity enhancement effect was not isolated to the 
A549 cell line. The NSAID-mediated chemotherapeutic drug toxicity enhancement 
effect must for this reason have involved a fundamental drug resistance mechanism 
found in drug sensitive cell lines. DLKP can be cultured in the presence of serum or 
alternatively in a fully defined serum free medium formulation, (Section 2.5). Screening 
was carried out under serum free conditions in order to investigate the possibility that 
the toxicity enhancement effect was serum or growth factor dependent. It was found 
that even under serum free conditions, adriamycin toxicity was enhanced in the 
presence of indomethacin, sulindac and tolmetin. Adriamycin toxicity was unaffected 
by naproxen treatment under serum free conditions, (Table 3.5.2).
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4.5 Investigation into the role of the arachidonic acid cascade in NSAID- 
mediated chemotherapeutic drug toxicity enhancement.
The NSAED-mediated toxicity enhancement effect was believed to be dependent on 
some form of inhibitory activity being exerted on the drug efflux activity of the M R P  
pump. The manner in which NSAIDs influenced MRP-mediated drug transport was 
not obvious from the in vitro toxicity assay screening results. From initial screening 
studies it was obvious that the effect was not totally dependent on PGHS inhibition as 
relatively potent PGHS inhibitors such as flurbiprofen did not enhance drug toxicity. 
As discussed in Section 4.3, there was also no relationship between the extent of 
preferential inhibition of PGHS isozymes and the ability of an NSAID to enhance drug 
toxicity.
A  number of reports have described an influence of cytotoxic drugs on the arachidonic 
acid cascade and this topic will be dealt with in more detail in Section 4.6. It is known 
that M R P  is a transporter of certain eicosanoids such as LtC4 and prostaglandin 
conjugates, (ledlitschky et a l , 1996; Ishikawa, 1992), and that eicosanoids such as the 
cytotoxic prostaglandin PgAi can interfere with M R P  activity, (Hollo et a l , 1996). 
Treatment of cells with a suitable NSAID could possibly enhance the production of an 
eicosanoid which may act as a substrate for MRP. Inhibition of PGHS could cause a 
decrease in prostaglandin production and a resultant increase in the synthesis of other 
eicosanoids due to increased arachidonic acid availability in the absence of PGHS 
activity. If these eicosanoids were substrates for MRP, then NSAID treatment would 
result in competition for MRP-mediated transport between the cytotoxic drug and the 
eicosanoid. This would ultimately result in an increase in cellular drug accumulation 
and an enhancement of chemotherapeutic drug toxicity. This theory was weakened by 
the fact that the potent PGHS inhibitors such as flurbiprofen did not enhance the 
toxicity of the M R P  substrate drugs in A549 (Table 3.3.1). A  number of related studies 
were carried out in an attempt to conclusively discount all possibilities of even a minor 
involvement of eicosanoids and PGHS in the toxicity enhancement effect. The first of 
these studies (results provided in Section 3.6) involved an attempt at reversing the
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toxicity enhancement effect by exogenous addition of prostaglandins. A549 
predominately produces PgE2 and so if NSAIDs had any significant effects on 
eicosanoid production in this cell line, it should reflect partially in an alteration in PgE2 
production. If the toxicity enhancement effect was not reversed by PgE2 addition, it 
indicated simply that this particular eicosanoid was not critical for the effect to occur. 
A  related investigation in this area involved the use of non-NSAID inhibitors of the 
arachidonic acid cascade. The major drawback of the study described above involved 
the fact that it examined only one particular eicosanoid namely PgE2. Inhibition of 
PGHS by non-NSAID agents could cause alterations in the eicosanoid profile formed 
by a cell, in a manner comparable to that achieved by NSAIDs. In this way it would be 
possible to investigate if alterations in the eicosanoid profile formed by a cell as a result 
of PGHS inhibition was involved in NSAID-mediated toxicity enhancement. This study 
involved using inhibitors of critical steps of the arachidonic acid cascade such as the 
liberation of arachidonic acid by phospholipase A 2. If PGHS inhibition and so 
eicosanoid synthesis inhibition was important for drug toxicity enhancement, then it 
would be probable that total elimination of eicosanoid synthesis by phospholipase A 2 
inhibition could also have an influence on drug toxicity. The final study in this area 
involved the use of sulindac sulfide (a potent PGHS inhibitor) and sulindac sulfone 
(devoid of significant PGHS inhibitory activity) in in vitro toxicity assay screening 
experiments (Section 3.9). If an NSAID analogue without PGHS inhibitory activity 
could enhance drug toxicity, this would provide conclusive proof that the toxicity 
enhancement effect was totally independent of NSAID-mediated inhibition of PGHS.
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4.5.1 Investigation into the potential reversal of NSAID-mediated drug
toxicity enhancement as a result of exogenous PgE2 or PgD2 
addition.
The results from these experiments are provided in Section 3.6. As can be seen from 
Table 3.6.1, PgE2 or PgD2 were unable to reverse the NSAID-mediated toxicity 
enhancement effect irrespective of whether adriamycin or vincristine were used in 
combination with indomethacin or sulindac. All experiments were repeated using a 
range of prostaglandin concentrations, which ranged from relatively low (60 ng/mL) to 
high PgE2 concentrations (up to 0.60 ¡j,g/mL). A549 cells in the stimulated state can 
produce 150 pg PgE2 per 105 cells per mL, (Croxtall and Flower, 1994). Obviously the 
concentrations of PgE2 added exogenously in these experiments are significantly higher 
than the concentrations to which A549 cells are exposed even after stimulation with an 
agent such as IL-1 p. Lowering the concentrations of exogenously added PgE2 or PgD2 
to a concentration of 150 pg/mL was also found to be without effect on NSAED 
mediated toxicity enhancement (data not shown). PgD2 was included as a negative 
control for these experiments as it is not normally produced by A549 cells under 
stimulated or unstimulated conditions (Hubbard et al., 1988). These results indicate 
that changes in extracellular levels of PgE2 have little if any influence on NSAID- 
mediated toxicity enhancement. These results were later confirmed by the results found 
by PgE2 ELISA, (Section 3.8).
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4.5.2 In vitro toxicity assay screening with non-NSAID inhibitors of the
arachidonic cascade
These experiments served to investigate if non-NSAID inhibitors of PGHS could also 
cause an enhancement of drug toxicity. Inhibitors of critical steps in the arachidonic 
cascade were combined with cytotoxic drugs in an attempt to see if altering the 
eicosanoid profile produced by the cells could also potentially contribute to enhancing 
drug toxicity. From Table 3.7.1 it can be seen that dexamethasone was screened in 
combination with adriamycin and vincristine. This glucocorticoid has a wide variety of 
effects in cells including inhibition of PGHS-2 protein synthesis (Masferrer et a l ,  
1994). It was found that dexamethasone did not affect the toxicity of adriamycin in 
toxicity assay screening experiments. This indicated that elimination of PGHS-2 
activity was not sufficient for achievement of enhancement of adriamycin toxicity. The 
limiting step in the arachidonic acid cascade involves the liberation of arachidonic acid 
from the cell membrane as a result of cytosolic phospholipase A 2, (PLA2) activity. 
Interference with the activity of this enzyme can cause a total block in eicosanoid 
synthesis by the cells. A  variety of PLA2 inhibitors were used in screening experiments, 
namely 4-bromophenacyl bromide, manoalide and quinacrine, and none of these 
inhibitors had any effects on adriamycin toxicity (Table 3.7.1). A  dual 5- and 12- 
lipoxygenase inhibitor, esculetin, was also screened in combination with adriamycin 
and vincristine. The 5-lipoxygenase enzyme is the critical enzyme in the pathway 
responsible for leukotriene synthesis (Section 1.3). Leukotrienes such as LtC4 can be 
transported out of cells by molecules such as M R P  but inhibition of this enzyme had no 
effect on adriamycin toxicity in the A549 cell line. This cell line is not believed to 
express significant levels of 5-, 12- or 15-LOX, (Claria et al., 1996) and so these 
findings svere as expected.
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4.5.3 Variations in PgE2 levels produced by A549 cells during the 
NSAID mediated toxicity enhancement effect.
Quantification of the levels of PgE2 produced by A549 in the presence of an NSAID 
and cytotoxic drug was performed using a PgE2 ELISA assay. From Table 3.8.1 it can 
be seen that there were no significant alterations in PgE2 levels produced by A549 cells 
in the presence of adriamycin or Taxol alone or in the presence of these drugs in 
combination with indomethacin or flurbiprofen. All compounds were added at a 
concentration equivalent to the concentration used for screening in the in vitro toxicity 
assays. Adriamycin toxicity in A549 cells is known to be enhanced in the presence of 
indomethacin but not flurbiprofen (Table 3.3.1). Taxol toxicity is known to be 
unchanged by indomethacin treatment (Table 3.2.1). There was no alteration in the 
levels of PgE2 formed by A549 cells treated with any of the agents listed above. The 
PGHS-2 stimulating compound IL-1 (3, served as a positive control for these 
experiments and caused significant stimulation of PgE2 synthesis, (Table 3.8.1). These 
results demonstrated that under the conditions examined, there were no unexpected 
alterations in the levels of PgE2 produced by A549 cells as a result of NSAID and drug 
treatment. These results agree with the results obtained from the prostaglandin reversal 
experiments, (Section 4.5.1).
4.5.4 In vitro toxicity assay screening with sulindac sulfide and sulfone in 
combination with adriamycin and vincristine in the A549 cell line.
As described earlier, sulindac sulfide is a potent PGHS inhibitor but sulindac sulfone is 
devoid of PGHS inhibitory activity. Section 3.9 provides the details of the screening 
experiments with these compounds. It was found that these sulindac analogues 
enhanced the toxicity of both adriamycin and vincristine to an extent comparable to 
that found in the case of sulindac (Tables 3.2.3 and 3.2.9). This result with sulindac 
sulfone is highly significant as it illustrates that a compound which is practically devoid 
of PGHS inhibitory activity can enhance the toxicity of adriamycin and vincristine. This 
obviously implies that the potential ability of NSALDs to inhibit PGHS is totally
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unrelated to their ability to enhance drug toxicity. This result, when combined with the 
results from the studies detailed in Sections 4.5.1 to 4.5.3 conclusively demonstrated 
that the arachidonic acid cascade had no involvement in the NSAID-mediated toxicity 
enhancement effect.
4.6 Effect of chemotherapeutic drug treatment on PGHS isozyme
expression and PgE2 production in the A549 cell line.
The results from the experiments discussed in Section 4.5 demonstrated that drug 
treatment had no effect on PgE2 production by A549 cells under the specific conditions 
examined. An investigation was subsequently conducted into potential relationships 
between the arachidonic acid cascade and chemotherapeutic drug treatment under a 
variety of conditions of tumor cell growth. It is widely known that tumor cells in vivo 
and in vitro can produce abnormally high levels of eicosanoids (Section 1.3.1). In 
many cases, tumors in vivo are treated with cytotoxic drugs but surprisingly few 
studies have examined the relationship between chemotherapeutic drug treatment and 
eicosanoid production. Tisdale, (1977) described the effects of a number of anti-tumor 
agents on the activity of PGHS from sheep seminal vesicles. It was shown that 
chlorambucil inhibited PgE2 and PgF2a synthesis by PGHS in a cell free system. A  
number of reports have indirectly carried out studies into the area of eicosanoids in 
cancer chemotherapy. One such study showed that an advanced human ovarian cancer 
which was unresponsive to chemotherapy, produced more eicosanoids than tumors 
responding to chemotherapy, (Bauknecht et a t , 1985). The involvement of PGHS in 
the bioactivation of various xenobiotics is discussed in Section 1.3,1 but there is some 
evidence to suggest that PGHS activity can be involved in bioactivation of a select 
number of chemotherapeutic drugs. Studies by Smith and Kehrer, (1991) suggested 
that PGHS activity could be involved in the bioactivation of cyclophosphamide. Lau et 
a t, (1987) investigated arachidonic acid metabolism in a variety of human lung tumor 
cell lines. This group found that two well differentiated non-small cell lung 
adenocarcinoma cell lines (NCI-H322 and NCI-H358) were shown to be relatively 
sensitive to the cytotoxic effects of mitoxantrone. These cell lines were shown to
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possess PGHS activity which resulted in PgE2 formation. Two small cell lung 
carcinoma cell lines (NCI-H69 and NCI-H128) were also analysed and shown to be 
devoid of PGHS activity and PgE2 synthetic ability. These cell lines which lacked 
detectable PGHS activity were shown to be unaffected by mitoxantrone treatment. 
This group also reported that PGHS present in ram seminal vesicular microsome 
preparations activated mitoxantrone to a highly reactive metabolite which had a strong 
affinity for binding to cellular macromolecules. Hamuro et a l , (1996) reported on 
PgE2 production by a number of sublines derived from a cyclophosphamide and 
lentinan (an anti-tumor polysaccharide used in immunotherapy) resistant murine 
fibrosarcoma. These sublines exhibited cyclophosphamide and lentinan resistance 
relative to the parental cells used to establish the original tumor in B10.D2 mice. In 
addition, these sublines were resistant to 5-fluorouracil. All chemo-immunotherapy 
resistant cell lines showed enhanced PgE2 synthesis relative to the parental cells. 
Observations of this nature have not been limited to chemotherapy or chemo- 
immunotherapy. Sochanowicz and Szumiel, (1996) reported that increased PgE2 
synthesis occurred in radiation resistant murine leukaemic lymphoblasts following 
radiation and ionophore stimulation. This PgE2 synthesis was not found to occur in the 
case of related radiation sensitive murine leukaemic lymphoblasts. This suggested that 
PgE2 was involved in cellular radio sensitivity modification which caused resistant cells 
to be protected against radiation damage by PgE2.
In order to investigate if chemotherapeutic drug treatment had any influence on the 
arachidonic acid cascade in human lung cell lines, a number of experiments were 
carried out using the A549 cell line. This cell line expresses negligible levels of PGHS- 
1 and is easily induced to express PGHS-2 and produce PgE2 (Asano et al., 1996). If 
there was an alteration in the level of eicosanoid production as a result of drug 
treatment, one would assume that in A549, the levels of PgE2 and PGHS-2 would vary 
accordingly. Three related experiments were carried out using the A549 cell line. The 
first experiment investigated if there were any differences in PGHS-2 expression or 
PgE2 production over a 24 hour time period as a result of treatment of cells with a 
relatively high dose of adriamycin (0.35 |0.g/mL). The second experiment involved 
treating cells with a variety of adriamycin concentrations for a period of 24 hours. The
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final experiment served as an investigation into the variations in the levels of PGHS-2 
and PgE2 during treatment with a range of VP-16 concentrations.
The results and experimental details of the first experiment are provided in Table
3.10.1. A  high concentration of adriamycin (0.35 |lg/mL) was used which was non­
toxic over 24 hours but which caused approximately 85% toxicity over a period of 7 
days. It was found that there were no significant alterations in PGHS-2 protein 
expression or PgE2 production during adriamycin treatment even after a period of 24 
hours (Table 3.10.1 and Figure 3.10.1). The time period of 24 hours was found to be 
sufficient for PGHS-2 and PgE2 (approximately 490 pg PgE2 per 106 cells) synthesis 
induction, as demonstrated by cells treated with EL-1(3 (Figure 3.10.1). As this time 
period was sufficient for PGHS-2 and PgE2 synthesis induction, a study was carried 
out to investigate if varying the concentration of adriamycin had any effect on PGHS-2 
protein or PgE2 levels. From Table 3.10.2, it can be seen that concentrations of 
adriamycin which caused 60-85% cell kill (0,25 and 0.35 |Xg/mL adriamycin 
respectively) over 7 days but which were non-toxic over 24 hours, had no significant 
effects on PGHS-2 protein synthesis induction or PgE2 synthesis. Combining 
adriamycin treatment with IL-] (3 treatment resulted in variable non-significant effects 
on PgE2 synthesis by A549 cells. The variation in PgE2 levels formed by A549 in the 
presence of adriamycin and EL-1(3 was a result of variations in PgE2 synthesising 
abilities of sub-populations of A549 cells. It was not a result of adriamycin influencing 
PGHS-2 activity in any way. From Figure 3.10.2 it was obvious that PGHS-2 levels 
were unchanged in the presence of EL-1(3 and adriamycin (at all concentrations 
analysed) from the levels present in IL-1(3 treated A549 cells.
The precise mechanism by which the epipodophyllotoxin, VP-16 exerts cytotoxic 
effects is unclear (Section 1.2.3). Loike and Horwitz, (1976) reported that the 
presence of a free 4’-OH group in the phenolic ring of VP-16 is essential for VP-16 
induced D N A  damage. It is believed that the metabolic activation of VP-16 occurs 
with the formation of a phenoxyl radical and ultimate conversion to a VP-16 quinone 
derivative, (Yalowich ei al., 1996). This bioactivation of VP-16 is critical for VP-16
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and topoisomerase II induced D N A  damage, and can be catalysed in part by the 
peroxidase activity of PGHS, (Haim et al., 1987). For this reason, an investigation was 
conducted into the influence of VP-16 treatment on PGHS-2 expression and PgE2 
formation in A549 cells (Table 3.10.3 and Figure 3.10.3). From this data it can be seen 
that treatment of A549 cells with concentrations of VP-16 which can cause 70, 40 and 
20% toxicity over a period of 7 days (2.5, 0.5 and 0.1 [J,g/mL VP-16 respectively) had 
no significant effects on PgE2 synthesis or PGHS-2 expression after 24 hours. IL-1P 
treated A549 cells produced high levels of PGHS-2 and PgE2. Co-treatment of cells 
with VP-16 (2.5 or 0.5 (xg/mL) and IL-1 (3 was found to have variable effects on PgE2 
synthesis. As was the case for adriamycin (Table 3.10.2), these effect were not VP-16 
specific but were simply a result of variations in PgE2 synthesising abilities of A549 
cells. In summary, these experiments demonstrated that cytotoxic drug treatment 
(either with adriamycin or VP-16) had no influence on the levels of PgE2 or PGHS-2 
protein synthesis by the human lung adenocarcinoma cell line, A549.
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4.7 Investigation into PGHS isozyme expression and PgE2 production
in DLKP and VP-16 selected drug resistant variants
Although the arachidonic acid cascade is reasonably well characterised for A549, this 
is not the case for the human squamous cell carcinoma cell line, DLKP. Drug selected 
multidrug resistant variants have been selected from DLKP, (Clynes et al., 1992). Two 
such variants, DLKP-VP3 and DLKP-VP 8 were selected by culturing the drug 
sensitive cell line, DLKP in gradually increasing concentrations of VP-16, (Heenan, 
1994). These drug resistant variants are sufficiently resistant to grow in concentrations 
of 3 and 8 [ig/mL VP-16 respectively. The IC5 0 values for adriamycin in the DLKP, 
DLKP-VP3 and DLKP-VP8 cell lines are 0.02, 1.30 and 3.90 (Ig/mL respectively. The 
DLKP-VP3 and DLKP-VP8 cell lines were used in a series of experiments to 
investigate if drug selected resistant cells showed alterations in their eicosanoid 
synthesising abilities relative to the parental drug sensitive DLKP cells (Section 3.11). 
The VP-16 selected resistant variants were chosen for analysis in preference to 
resistant variants selected with a different drug because of the potential role of PGHS 
in VP-16 activation (Section 4.6). If cells were selected for VP-16 resistance and if 
PGHS was involved in the activation of VP-16 to the form of the drug responsible for 
D N A  damage, then cells which were resistant to VP-16 could potentially possess low 
levels of PGHS protein. Alternatively PGHS activity could be in some way lower in 
VP-16 resistant cells than found in the parental drug sensitive cells. Either of these 
possibilities could result in a reduction in PGHS catalysed VP-16 activation in resistant 
cells and so permit survival of these cells in relatively high concentrations of VP-16. 
This effect could only be a relatively minor contributor to the drug resistance levels of 
these cell lines. Heenan, (1994) demonstrated that DLKP-VP3 and DLKP-VP8 
possess elevated levels of Pgp and reduced levels of Topo II protein relative to DLKP 
cells. Due to overexpression of the drug efflux pump Pgp, these resistant cells would 
accumulate low levels of drug relative to their sensitive counterparts. Reduced levels 
of Topo II would result in a reduction in efficacy of VP-16 induced D N A  damage and 
cell kill. For this reason, if VP-16 resistant cells overexpressed Pgp and possessed 
reduced levels of Topo II, the contribution of reduced levels of PGHS or low activity 
PGHS, to VP-16 resistance may be relatively small. Drug resistance is often dependent
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upon contributions from various drug resistance mechanisms. Even though a given cell 
may overexpress Pgp and possess reduced levels of Topo II, alterations in PGHS 
levels or activities could potentially be critical factors contributing in some way to this 
drug resistance.
As the eicosanoid synthesising capacity of DLKP had not been previously 
characterised, it was decided that as for A549, the levels of PGHS-2 protein 
expression and PgE2 production would be studied. The PGHS-2 isozyme and PgE2 are 
expressed in a large percentage of human lung cell lines (Asano et al., 1996; Hubbard 
ei al., 1988) and so the levels of PGHS-2 and PgE2 produced by DLKP and VP-16 
drug resistant variants were examined. No other aspects of the arachidonic acid 
cascade were examined. As can be seen from Table 3.11.1 and Figure 3.11.1, A549 
cells treated with IL-1(3 produced high levels of PgE2 (approximately 205 pg/106 cells) 
and PGHS-2 protein. DLKP did not produce significant levels of PgE2 or express 
PGHS-2 protein during IL-ip treatment. This result is quite significant with relevance 
to the NSAID mediated toxicity enhancement effect. If DLKP does not express 
PGHS-2, this indicates that NSAIDs enhance drug toxicity in DLKP independently of 
any effects on this PGHS isozyme. From Figure 3.11.1 and Table 3.11.1 it can be seen 
that the DLKP-VP3 and DLKP-VP 8 cell lines did not differ from DLKP in their 
PGHS-2 expressing or PgE2 synthesising abilities in the presence of IL-1 [5. This 
illustrated that VP-16 selected cells do not express PGHS-2 as a result of IL-lp 
treatment.
The DLKP-VP3 and DLKP-VP8 cell lines have been shown by Heenan, (1994) to be 
resistant to VP-16 (58 and 100-fold more resistant than DLKP) and adriamycin (90 
and 270-fold more resistant than DLKP). Interestingly these VP-16 selected cells 
developed a higher level of resistance to adriamycin than to VP-16. Both DLKP-VP3 
and DLKP-VP8 cell lines expressed higher protein levels of Pgp than the parental 
DLKP cell line. In addition, these resistant cells expressed less Topo II than DLKP. 
Relatively surprisingly, DLKP-VP3 cells expressed higher levels of Pgp and 
accumulated less adriamycin in drug accumulation experiments than the DLKP-VP8 
cell line (Heenan, 1994). The higher level of adriamycin resistance in DLKP-VP 8
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(approximately 3 fold higher than found for DLKP-VP3) was explained by Heenan, 
(1994) as being partially a result of lower levels of Topo II in DLKP-VP8 relative to 
DLKP-VP3. For this reason, in the presence of the Topo II poison adriamycin, DLKP- 
VP8 cells could survive high intracellular adriamycin concentrations because of the low 
levels of Topo II possessed by this cell line. DLKP-VP3 cells accumulate lower 
intracellular levels of adriamycin than DLKP-VP8 because of high levels of Pgp 
expression. These DLKP-VP3 cells are more sensitive to this relatively low 
intracellular adriamycin concentration than DLKP-VP8 cells are to a relatively high 
adriamycin concentration because of higher levels of the Topo II enzyme in the DLKP- 
VP3 cell line. The DLKP-VP3 and DLKP-VP8 cell lines are also resistant to 
vincristine (1090 and 1740 fold more resistant than DLKP). This vinca alkaloid is not 
associated with Topo II mediated toxicity and is believed to act as a substrate for the 
Pgp drug efflux pump. If Pgp and Topo II were the only explanations for the levels of 
drug resistance in DLKP-VP3 and DLKP-VP8 one would predict that DLKP-VP3 
would have lower levels of adriamycin and higher levels of vincristine resistance than 
found in DLKP-VP8. As this was not the case, it was possible that other mechanisms 
were involved in drug resistance in these cell lines. For this reason, an investigation 
was conducted into the potential involvement of the arachidonic acid cascade in this 
drug resistance. PGHS-2 protein synthesis is inducible by a wide variety of intracellular 
and extracellular stimuli including IL-1(3, lipopolysaccharide and retinoic acid 
(Williams and DuBois, 1996). The PGHS-2 promoter possesses a xenobiotic response 
element, but the compounds involved in influencing transcription by means of this site 
have not yet been fully characterised (Williams and DuBois, 1996). It was known from 
the experiment detailed in Table 3.11.1 that PGHS-2 did not appear to be expressed in 
DLKP or VP-16 selected variants. An investigation was then carried out to determine 
if cytotoxic drugs such as adriamycin rather than IL-ip, influenced PGHS-2 
transcription by influencing binding to the xenobiotic response element of the PGHS-2 
promoter. This had not been shown not to be the case in A549 (Section 3.10) but it 
was not known if this was the case in resistant cell lines such as DLKP-VP3 and 
DLKP-VP8 which were insensitive to IL-1 [3 stimulation of PGHS-2 synthesis (Figure 
3.11.1). As PGHS-2 protein synthesis induction was found to be reflected in PgE2 
synthesis (Section 3.10) it was decided to initially analyse PgE2 levels under a variety
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of treatment conditions. This would provide a general indication of any PGHS-2 
synthesis or activity and so if results were encouraging from initial experiments, then 
PGHS-2 protein levels could then be analysed.
From the resistance profiles of the DLKP-VP3 and DLKP-VP8 cell lines it was clear 
that even though these cells had been selected for VP-16 resistance, they exhibited a 
higher fold resistance to adriamycin. For these reasons, the investigation into the 
involvement of the arachidonic acid cascade in the unusual drug resistance 
characteristics of these cell lines was carried out using adriamycin rather than VP-16. 
The experiments with adriamycin involved treating DLKP, DLKP-VP3 and DLKP- 
VP8 cells with various concentrations of drug and IL-113 and then monitoring the 
resultant levels of PgE2 synthesis. From Table 3.11.2 it can be seen that treating DLKP 
with 0.15 or 0.25 |Xg/mL adriamycin had no effects of PgE2 production by this cell line. 
Treatment of this cell line with various IL-1P concentrations also had no effects on 
PgE2 production but treatment of A549 with 3 ng/mL IL-1 (3 stimulated significant 
PgE2 production by this cell line. Co-treatment of DLKP cells with adriamycin and IL- 
1P had no unexpected stimulatory effects on PgE2 synthesis. Similar results were found 
with DLKP-VP3 and DLKP-VP 8 cells treated with adriamycin, IL-ip or co-treated 
with adriamycin and IL-lp (Tables 3.11,3 and 3.11.4). The drug concentrations used 
in these experiments for DLKP, DLKP-VP3 and DLKP-VP8 were non-toxic over the 
period of analysis (24 hours) but caused 40 to 70% cell kill over 7 days. These results 
suggested that the aspects of the arachidonic acid cascade examined in these studies 
were not involved in the unusual drug resistance profiles of the DLKP-VP3 and 
DLKP-VP8 cell lines. As described in Section 1.5 the drug resistance profile of a drug 
selected cell line can be dependent upon the simultaneous influence of a wide variety of 
resistance mechanisms including Pgp, MRP, LRP, TAP, Topo II and GST. The 
unusual drug resistance profiles of the DLKP-VP3 and DLKP-VP8 cell lines should be 
explainable by further investigation into the influence of these mechanisms on the 
individual drug resistance levels of these cell lines.
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4.8 NSAID mediated drug toxicity enhancement studies in DLKP
As described earlier, it was known from the in vitro toxicity assay screening 
experiments that MRP-mediated transport of cytotoxic drugs was potentially a critical 
element of the toxicity enhancement effect. A  number of difficulties existed with this 
hypothesis, primarily that M R P  protein expression could not be detected in whole cell 
extracts of the DLKP cell line but yet the NSAID mediated drug toxicity effect could 
be demonstrated in this cell line. If M R P  was the critical factor in achieving the NSAID 
mediated drug toxicity enhancement effect in a given cell line, then this drug 
transporter should have been expressed in DLKP. The investigations into this area are 
described in Section 4.8.2. It was known that in non-MRP expressing drug resistant 
cell lines such as the Pgp overexpressing cell line DLKP-A the toxicity enhancement 
effect did not occur (Duffy et al., 1997). It was not known if this was totally due to 
Pgp pumping the cytotoxic drug out of the cell or if it was also a result of the NSAID 
not entering or alternatively being transported out of these resistant cells. A  series of 
experiments were performed to investigate the possibility that differences in NSAID 
transporting abilities between the drug sensitive cell line, DLKP and the drug resistant 
cell line. DLKP-A may have been involved in the inability of NSAEDs such as 
indomethacin to enhance drug toxicity in DLKP-A.
4.8.1 Assessment of extent of NSAID accumulation in the DLKP and
DLKP-A cell lines.
From Section 3.12 it was found that both DLKP and DLKP-A cells accumulated [14C]- 
indomethacin very rapidly and the level of this accumulation was saturated by 4 
minutes and unchanged from this level after a period of 4 hours. These results agree 
significantly with the results of Beaven and Bayer, (1980) who showed that rat 
hepatoma cells accumulated indomethacin very rapidly with a steady state 
accumulation level being reached by 3 to 10 minutes. The NSAID transport 
experiments detailed in Section 3.12 demonstrated that there were no significant
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differences in [14C]-indomethacin accumulation between D L K P  and DLKP-A. For this 
reason it was suggested that the toxicity enhancement effect could not be 
demonstrated in Pgp-overexpressing cells such as DLKP-A because NSAIDs such as 
indomethacin were without significant effects on Pgp activity. Pgp overexpressing 
drug resistant cells which were co-treated with a drug and NSAID mixture such as 
adriamycin and indomethacin would, if this was the case, continue to efflux drug to an 
extent comparable to that found in the absence of the NSAID.
4.8.2 Investigation into MRP expression and activity in DLKP.
As described in Section 4.4, Western blotting analysis failed to demonstrate expression 
of M R P  protein in whole cell extracts of DLKP. This obviously contradicted the 
suggestion that NSAIDs interfered with MRP-mediated drug efflux and in this way 
facilitated chemotherapeutic drug toxicity enhancement. In an attempt to explain the 
apparent absence of M R P  from the DLKP cell line, inside-out vesicles (IOVs) were 
isolated from this cell line. This was carried out firstly to see if targeting the analysis to 
a point of localisation of M R P  (in the plasma membrane) would permit detection of 
M R P  protein by Western blotting. In addition, the isolation of IOVs from DLKP 
would facilitate assessment of MRP-like activity in DLKP IOVs. It was found 
experimentally (Section 3.17.4) that M R P  was detectable by Western blotting in IOVs 
isolated from DLKP. The levels were relatively low in comparison to the levels present 
in IOVs isolated from the MRP-overexpressing cell line HL60-ADR. This suggests 
that DLKP possesses low levels of M R P  and that this level may be functionally 
effective for drug transport out of the cell. Inhibition of the drug efflux activity of 
M R P  due to treatment with a suitable NSAID ultimately resulted in the 
chemotherapeutic drug toxicity enhancement effect. The results illustrated in Figures
3.13.3 and 3.13.4 demonstrate that chemotherapeutic drug toxicity enhancing NSAIDs 
such as indomethacin significantly inhibit MRP-mediated transport of [3H]-LtC4 into 
HL60-ADR IOVs. NSAIDs which do not possess drug toxicity enhancing abilities 
such as naproxen, do not significantly affect M R P  activity. This was also found in the 
case of DLKP derived IOVs (Figures 3.13.5 and 3.13.6). This strongly suggests that
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the ability of NSAIDs such as indomethacin to enhance the toxicity of potential M R P  
substrate chemotherapeutic drugs, is a result of these NSAIDs inhibiting the drug 
efflux activity of MRP. From Section 3.13 it can also be seen that D L K P  IOVs actively 
transport [3H]-LtC4 to their interior at a lower initial rate and lower maximum 
accumulation than found in the case of HL60-ADR IOVs (initial rates of 0.8 ± 0.2 and 
4.0 ± 1.0 pmol LtC4 per mg protein per minute respectively and maximum 
accumulations of 2.0 ± 0.3 and 7.0 ±1.0 respectively). In order to verify that the [3H]- 
LtC4 transporter present in DLKP-derived IOVs was MRP, a number of further 
investigations were carried out as detailed in Section 3,14.
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As described in Section 4.8.2, DLKP exhibited MRP-like activity where [3H]- 
LtC4 was actively transported into IOVs isolated from this cell line. Western 
blotting analysis (Section 3.17.4), of the proteins present in these IOVs 
demonstrated that M R P  was present at low levels relative to IOVs from the M R P  
overexpressing cell line, HL60-ADR. The transporter responsible for [3H]-LtC4 
transport into DLKP derived IOVs could potentially be any of the isoforms of 
M R P  described in Section 1.5.2.5 or alternatively an unrelated leukotriene 
transporter. In order to identify the LtC4 transporter in D L K P  IOVs, a number of 
related investigations were conducted.
4.9.1 Enhancement of drug toxicity in the presence of inhibitors of MRP 
activity in the DLKP cell line.
As described in Section 3.14.1, experimental evidence suggests that the NSAID- 
mediated toxicity enhancement effect is achieved by means of NSAIDs interfering 
with transport of cytotoxic drugs by MRP. The drugs in question may, under 
normal conditions act as substrates for MRP-catalysed efflux out of the cell. The 
toxicity enhancement effect was known to occur in the DLKP cell line in the 
presence of a suitable cytotoxic drug and NSAID combination. If the transporter 
of [3H]-LtC4 into DLKP derived IOVs was MRP, then one may make the 
assumption that any agent which interfered with [3H]-LtC4 transport and so M R P  
transport activity, should also enhance the toxicity of a suitable cytotoxic drug in 
this cell line. This would be a result of the agent in question interfering with MRP- 
mediated drug efflux out of the cell. This would cause an increase in intracellular 
drug concentrations which ultimately would result in an enhanced cell kill for a 
given dose of cytotoxic drug. The leukotriene receptor antagonist MK571 is a 
potent inhibitor of [3H]-LtC4 transport by M R P  (Section 3.16), as shown in 
HL60-ADR IOVs. If the [3H]-LtC4 transporter in D LKP IOVs was M R P  then 
one would predict that MK571, which is believed to possess only leukotriene
4.9 Verification of the identity of the LtC4 transporter in IOVs from the
DLKP cell line.
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receptor antagonising activities, should interfere with M R P  activity and so give 
rise to an enhancement in the cell kill achieved by a suitable cytotoxic drug. From 
Section 3.14.1 it can be seen that MK571 enhances the toxicity of adriamycin and 
VP-16 in the DLKP cell line. These cytotoxic agents are believed to be substrates 
for M R P  and so MK571 mediated interference in their active efflux from the cell 
by M R P  would potentially result in enhanced cell kill for a given dose of drug. 
Taxol is not believed to be a high affinity substrate for MRP, and as shown in 
Table 3.14.1.3 the toxicity of this compound was unaffected by co-treatment with 
MK571. These results suggest that interference with M R P  activity in DLKP 
resulted in an enhancement of cell kill to an extent comparable to that found with 
NSAIDs such as indomethacin. In addition it was found that MK571 was found to 
be relatively toxic at the higher doses analysed (approximately 15 |ig/mL), as 
shown in Section 3.14.1. This may suggest that this leukotriene receptor 
antagonist interferes with a critical aspect of cellular metabolism in DLKP. This 
was also found in the case of the A549 cell line, where 5 |ig/mL MK571 (a non­
toxic dose) enhanced the toxicity of 10 ng/mL adriamycin and 7 ng/mL VP-16 
(Tables 3.14.1.4 and 3.14.1.5). Increasing the concentration of MK571 to 15 
(Xg/mL caused approximately 70-80% cell kill in the absence of cytotoxic drug. In 
summary, the in vitro toxicity assay results with MK571 provided evidence that 
the [3H]-LtC4 transporter in DLKP was MRP.
The bisindolylmaleimide GF109203X is also believed to exert inhibitory effects on 
M R P  activity due to effects on protein kinase C. It was found (Tables 3.14.1.6,
3.14.1.7 and 3.14.1.8) that this compound enhanced the toxicity of the M R P  
substrates adriamycin and VP-16 but also of the non-MRP substrate Taxol, in the 
DLKP cell line. Due to the effects of this compound on protein kinase C, one 
would predict a range of effects on cellular metabolism (including Pgp inhibition) 
in DLKP. This obviously is reflected in enhancement of the toxicity of drugs of 
various specificity’s for the various drug transport mechanisms possessed by 
DLKP.
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4.9.2 Comparison of Vmax and Km parameters for LtC4 transport in the
DLKP and HL60-ADR cell lines.
In Section 3.14.2 it was shown that HL60-ADR 10Vs transported LtC4 with a 
Vmax value of 211 ± 89 pmol/mg/min and K m of 84 ± 26 nM. The LtC4 transporter 
in DLKP derived 10Vs actively transported LtC4 with a V max value of 30 ± 2 
pmol/mg/min and K m of 114 ± 13 nM. The characteristic V max and K m values for 
LtC4 transport in M R P  expressing IOVs have been quoted in the literature for a 
variety of cell lines. Loe et. al., (1996b) demonstrated that M R P  transfected HeLa 
cells transport LtC4 with V max and K m values of 529 pmol/mg/min and 105 n M  
respectively. Pulaski et a l , (1996) found a K m value of 120 n M  for LtC4 transport 
by M R P  in human erythroleukemia cell derived IOVs. Paul et al., (1996c) found 
that M R P  transfected NIH 3T3 cells transported LtC4 with a K m of 35 n M  and a 
Vmax of 59 pmol/mg/min. The V max value is believed to be a reflection of the 
quantity of M R P  present in the IOV preparation. In the case of DLKP and HL60- 
ADR, one would predict that if M R P  was responsible for LtC4 transport in DLKP 
derived IOVs one would predict significantly higher protein levels of M R P  in 
HL60-ADR IOVs relative to DLKP derived IOVs. Western blotting protein 
analysis of IOVs from these two cell lines is described in Section 3.17.4. The fact 
that HL60-ADR IOVs accumulated LtC4 with a relatively low V max value 
compared to values quoted in the literature for M R P  transfected cell lines may 
simply result from differences in the protocol used for isolation of the IOVs. Only 
one individual IOV isolation procedure was used for the isolation of DLKP and 
HL60-ADR IOVs. For this reason, comparison of V max values for LtC4 transport 
into IOVs from these cell lines is justifiable for the purposes of attempting to 
approximately correlate M R P  protein levels in the IOVs and the V raax values of 
these IOVs. From the combination of the Western blotting data which showed 
significantly higher levels of M R P  in HL60-ADR IOVs relative to D L K P  IOVs, 
and the V niax data which is a factor of 7 times higher in HL60-ADR, the results 
provide some indication that M R P  is responsible for LtC4 transport in DLKP.
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A  wide range of values have been quoted in the literature for K m values in M R P  
mediated transport of LtC4 . These can range from 35 n M  (Paul el al., 1996c) to 
over 118 n M  (Pulaski et al., 1996) with significant errors (±30 nM) generally 
associated with the data. The K m values for DLKP and HL60-ADR are 114 ± 13 
n M  and 84 ± 26 n M  respectively. The K m value obtained for these cell lines are 
within the range of values quoted for M R P  mediated transport of LtC4 . The 
experiments performed for determination of K m and V max were performed in 
duplicate with a given vesicle preparation. Extremely high quality data is 
necessary in order to obtain accurate values for Lineweaver and Burk type 
analyses. Minor variability in data between replicates resulted in major shifts in the 
intercepts of the regression line with the X- and Y-axes. This ultimately resulted 
in significant variation in the K m and V max values found by regression analysis. 
There are considerable difficulties in obtaining accurate kinetic parameter data 
when using IOVs, due to the basic experimental difficulties encountered in 
working with concentrated lipid solutions. As described in Section 3.14.2, the 
datr. is represented as the mean ± S.D. for duplicate determinations in two 
separate experiments using one vesicle preparation from the relevant cell line. It 
was not found to be possible to obtain consistently repeatable results in 
subsequent experiments using separately prepared IOV preparations, as the values 
of K m and V max could in some cases vary by a factor of 3-fold between these IOV 
preparations from a given cell line. This may have been a reflection of the purity 
of the IOV preparations used in these experiments. Irrespective of the 
explanation, the lack of consistent repeatability in these experiments indicates that 
the accuracy of the K m and V max values described above may be questioned. Even 
considering this fact, this does not mean that the results shown above are not an 
accurate reflection of the kinetic parameters for a given high purity preparation of 
IOVs from a cell line such as analysed in the experiments described above. For the 
IOV preparations analysed in these experiments it may be reasonably justifiable to 
state from the kinetic parameter data determined experimentally that M R P  was 
responsible for [3H]-LtC4 transport in the preparation of HL60-ADR IOVs 
analysed. From the data, it could also be proposed that the [3H]-LtC4 transporter 
in the DLKP-derived IOV preparation analysed in this experiment was MRP.
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The design of the experiments described in Section 3.14.2 was relatively poor for 
the accurate determination of kinetic parameters. The Lineweaver-Burk plots in 
Section 3.14.2 have the disadvantage of compressing the data points at high 
substrate concentrations into a small region and emphasising the points at lower 
substrate concentrations. This may have contributed to significant variation in 
kinetic parameters between different IOV preparations from a given cell line as 
the majority of data points were determined using intermediate to high substrate 
concentrations. The experiment was designed so that saturation in LtC4 
accumulation at high substrate concentrations could be demonstrated (Figure
3.14.2.1 and 3.14.2.3). The direct use of this data which involved only a small 
number of lower substrate concentrations, for double-reciprocal plots resulted in 
the majority of the data being compressed into a small region (Figures 3.14.2.2 
and 3.14.2.4). For this reason, if further investigations were to be performed in 
this area, it would be necessary to design the experiment so that a sufficient 
number of low substrate concentrations were analysed for accurate Lineweaver- 
Burk analysis. An alternative would be to use an Eadie-Hofstee plot for analysis 
of the data (where initial rate of uptake is plotted against the rate divided by 
substrate concentration). This has not been performed for the data in Section
3.14.2, but it has the advantage of not compressing data obtained using higher 
substrate concentrations into a small region. The only conclusive way to identify 
the transporter responsible for [3H]-LtC4 transport in D L K P  IOVs would be to 
carry out photoaffinity labelling experiments. These experiments would involve 
incubating [3H]-LtC4 with IOVs and irradiating the mixture at 312 nm. Following 
a rapid freezing step, [3H]-LtC4 would become irreversibly bound to the relevant 
transporter molecule. The molecular weight of the [3H]-LtC4 bound protein in the 
IOVs could then be easily determined following gel electrophoresis of the proteins 
and autoradiography. If M R P  was responsible for [3H]-LtC4 binding, one would 
predict that all autoradiographic signal resulting from the presence of [3H] would 
be present at a position corresponding to a 190 kDa protein.
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4.10 Transport of cytotoxic drugs by MRP into HL60-ADR IOVs
The glutathione conjugate transporter M R P  is believed to be involved in the 
transport of cytotoxic drugs. There has been little evidence of transport of 
unconjugated cytotoxic drugs by M R P  with the exceptions of groups such as 
Stride et ah, (1997), Paul et ah, (1996c) and Loe et ah, (1996b). In addition, the 
M R P  pump is known to transport glutathione conjugates but drugs which are 
believed to be transported by M R P  are not known to readily undergo glutathione 
conjugation within cells. MRP-overexpressing cells are often sensitive to cisplatin, 
a drug for which glutathione conjugation is known to occur. In order to 
investigate the possible transport of cytotoxic drugs by M R P  in a drug selected 
rather than transfected cell line, two main approaches were taken. The first 
approach involved indirectly examining drug transport by M R P  by studying the 
inhibition of M R P  transport in HL60-ADR IOVs which occurred in the 
simultaneous presence of the high affinity M R P  substrate, [3H]-LtC4 and various 
cytotoxic drugs. The second and more direct approach involved monitoring the 
transport of [3H]-labelled vincristine into HL60-ADR IOVs by MRP.
4.10.1 Influence of glutathione and cytotoxic drugs on LtC4 transport into 
HL60-ADR IOVs by MRP.
From Section 3.15.1 it can be seen that vincristine, adriamycin, cisplatin and 
Taxol were examined for inhibitory effects on [3H]-LtC4 transport into HL60- 
A D R  IOVs. As described above, if a given drug was transported by MRP, one 
would predict that co-incubation of IOVs in [3H]-LtC4 and cytotoxic drug would 
result in competition for transport by MRP. Increasing the concentration of drug 
should cause a reduction in the accumulation of [3H]-LtC4 within the IOVs, due 
to increased competition for transport by MRP. The ability of a given drug to 
inhibit [3H]-LtC4 transport into IOVs should not be regarded as being solely a 
result of competition for transport. Addition of an agent to the IOV preparation 
could potentially influence any of the critical aspects of system necessary for M R P
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transport of [3H]-LtC4 . For this reason if an exogenously added agent interfered 
with the ATP regenerating system or osmotic pressure in the assay system, [3Hj- 
LtC4 accumulation in IOVs would be significantly reduced. In the case of this 
series of experiments and in all other experiments examining [3H]-LtC4 transport 
in the presence of inhibitory agents, the concentration of solvent used for 
dissolution of the compound of interest was maintained below 0.5% whenever 
possible. At this level, [3H]-LtC4 transport inhibition was affected only by the 
agent in question. It should be noted that comparison of inhibition of [3H]-LtC4 
uptake into IOVs by various agents is quoted in all subsequent discussions using 
steady state accumulation levels rather than initial rates although both initial and 
steady state accumulation levels were monitored. In order to fully characterise the 
inhibition of [3H]-LtC4 transport into IOVs by a particular agent it would be 
necessary to determine the initial rate of [3H]-LtC4 transport at a variety of [3H]- 
LtC4 and inhibitor concentrations so that Lineweaver-Burk plots could be 
developed for various concentrations of inhibitor. This would then allow 
elucidation of the Ki value (concentration of inhibitor which reduced maximum 
LtC4 accumulation rate by 50%) as well as the specific nature of the inhibition of 
LtC4 transport caused by the compound in question. In preference to carrying out 
an elaborate study of this nature, it was decided to express the inhibition of [3H]- 
LtC4 transport caused due to the presence of a compound as a percentage of 
steady state accumulation of [3H]-LtC4 in the absence of this inhibitor. This did 
not facilitate the determination of a K; value or the elucidation of the nature of 
inhibition caused by a particular compound but this method did permit the rapid 
approximation of the inhibitory effects of these compounds on [3H]-LtC4 
transport to the interior of IOVs.
Section 3.15.1 demonstrated that vincristine was found to be a relatively potent 
inhibitor of [3H]-LtC4 transport into HL60-ADR IOVs. A  concentration of 
approximately 100 (iM vincristine reduced ATP-dependent [3H]-LtC4 transport by 
approximately 50% relative to an ATP treated control. Adriamycin was a 
relatively poor inhibitor of [3H]-LtC4 transport, with 250 [iM adriamycin 
achieving only approximately 20%» inhibition relative to ATP treated control
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IOVs. Cisplatin was totally ineffective even at 220 ¡lM as an inhibitor of [3H]- 
LtC4 transport into IOVs. Taxol was ineffective as an inhibitor of [3H]-LtC4  
transport into HL60-ADR IOVs even at the high concentrations of 100, 50 and 1
H,M. The results obtained experimentally with the HL60-ADR drug selected M R P  
overexpressing cell line, agree significantly with the results reported by Loe et al., 
(1996b) for an MRP-transfected cell line. This group demonstrated that at a 
concentration of 100 |iM vincristine, M R P  activity was inhibited by 50% and that 
cisplatin was without effect on [3H]-LtC4 transport. Vincristine is believed to be a 
substrate for MRP-mediated efflux from cells and so the results found 
experimentally would suggest that this drug competed with [3H]-LtC4 for binding 
to the substrate binding site of MRP. This ultimately caused a reduction in 
detectable accumulated levels of [3H]-LtC4 in HL60-ADR IOVs. Cisplatin is not 
believed to act as a substrate for M R P  and for this reason had no effects on [3H]- 
LtC4 transport into IOVs. The relatively poor ability of adriamycin (believed to be 
an M R P  substrate) to inhibit [3H]-LtC4 transport is relatively surprising and differs 
from the results of Loe et a l , (1996b) where it was demonstrated that adriamycin 
at 100 ¡xM inhibited LtC4 transport by 60-70%. There is no evidence to suggest 
that M R P  has higher affinity for vincristine rather than adriamycin. These drugs 
are of comparable potency as anti-tumor agents. M R P  transfected cell lines often 
show comparable levels of resistance to adriamycin and vincristine (Section
I.5.2.3). The explanation for the inability of adriamycin to inhibit [3H]-LtC4 
transport to the same extent achieved by vincristine requires further investigation. 
Taxol was found to be an ineffective inhibitor of [3H]-LtC4 transport into HL60- 
A D R  IOVs. This also conflicts with the results found by Loe et a l , (1996b) in 
their MRP-transfected cell line model. This may be a result of differences between 
IOVs from MRP-transfected and drug selected MRP-overexpressing cells. In the 
experiment illustrated in Figure 3.15.2.6, Taxol was dissolved in ethanol, and final 
ethanol concentration was maintained below 0.5%>, a concentration which was 
without any influence on [3H]-LtC4 transport. Taxol is administered in vivo in a 
concentrate form containing dehydrated alcohol and polyethoxylated castor oil. It 
was found experimentally with HL60-ADR IOVs that Taxol in this form totally 
inhibited [3H]-LtC4 transport at 100, 50 and 1 (lM (data not shown). Although the
261
final concentration in the incubation mixture of ethanol and castor oil was below
0.5%, it was obvious that at the concentration added, these compounds caused 
significant alterations in incubation mixture viscosity and possibly osmotic 
pressure. An appropriate drug solvent control was not available in order to 
investigate the effects of the combination of ethanol and castor oil on [3H]-LtC4  
transport. For this reason, it was decided to use a Taxol stock which was 
dissolved in ethanol only in all further experiments. The details of the Taxol 
formulation used by Loe et al., (1996b) are not provided but it is possible that the 
Taxol used by this group in these experiments was the form which is provided 
dissolved in ethanol and castor oil. If this was the case, it could explain the high 
levels of M R P  transport inhibition achieved in the presence of low concentrations 
of Taxol. In the absence of data for a vehicle control it is not possible to state if 
this Taxol mediated inhibition was a result of Taxol acting as a substrate for M R P  
or simply a result of the Taxol formulation used.
Obviously the concentrations of cytotoxic drugs used in these studies are 
extremely high relative to the concentrations of these drugs used to treat cells in 
vitro. These concentrations may be relevant in terms of intracellular drug 
concentrations where drug becomes concentrated within the cell in intracellular 
compartments. Taxol is not regarded as a high affinity substrate for M R P  but is an 
extremely potent cytotoxic agent. For this reason, cells are normally treated with 
lower concentrations of Taxol to achieve a given level of cell kill, than would be 
added in the case of a less potent cytotoxic agent such as vincristine. For example, 
in the A549 cell line, 15 n M  vincristine and 40 n M  adriamycin achieve 
approximately 40% cell kill. A  dose of 0.5 n M  of Taxol (30 fold lower than 
vincristine) achieves a similar level of cell kill in this cell line. As a result of this 
fact, it would be more relevant to compare levels of inhibition of [3H]-LtC4  
transport due to the presence of a given cytotoxic drug at the relative intracellular 
concentrations to which cells are exposed. If vincristine causes a particular level 
of [3H]-LtC4 transport inhibition at a given concentration, then comparison of this 
concentration with a 30-fold lower concentration of Taxol may be more relevant 
for attempting to correlate with relevant intracellular concentrations of drug. The 
cytotoxic drugs examined in these studies were low potency inhibitors of [3H]-
262
LtC4 when examined in comparison to cyclosporin A  or MK571. As described in 
Section 3.16, cyclosporin A  is a relatively potent inhibitor (up to 60% of steady 
state accumulation levels) of M R P  mediated [3H]-LtC4 transport at 50, 10 and 1 
|lM. Verapamil was found to inhibit M R P  activity in HL60-ADR IOVs at very 
low levels at steady state even at a concentration of 50 (lM (Figure 3.16.2). There 
have been conflicting reports in the literature as regards the potency of verapamil 
and cyclosporin A  as inhibitors of M R P  activity as discussed in Section 1.5.2.4. 
Cole et a l , (1994) reported that cyclosporin A  enhanced adriamycin toxicity to a 
more minor extent in MRP-transfected HeLa cells than was found in the case of 
verapamil. Hollo et a l, (1996) reported that cyclosporin A  was two fold more 
potent than verapamil as an inhibitor of M R P  mediated transport of calcein into 
HL60-ADR cells. The results from Section 3.16 provide evidence that cyclosporin 
A  is more potent an inhibitor of M R P  activity. The potency of these non-selective 
M D R  modulating agents is extremely low when compared to the leukotriene 
receptor antagonist MK571. This compound practically completely inhibits [3H]- 
LtC4 transport into HL60-ADR IOVs at concentrations of 10 and 50 |xM. At a 
concentration of 1 |xM MK571, [3H]-LtC4 uptake into HL60-ADR IOVs was 
reduced by 20-30 %.
Relatively surprising results emerged from investigations into the effects of 
reduced glutathione (GSH) on [3H]-LtC4 uptake into HL60-ADR IOVs. As 
shown in Figure 3.15.2.1 a concentration of approximately 6 m M  G S H  was found 
to totally inhibit ATP dependent [3H]-LtC4 uptake. Only concentrations of G S H  
below 2 m M  were without inhibitory effects on the ATP dependent uptake of 
[3H]-LTC4 into HL60-ADR IOVs. It is believed that G S H  is not a substrate for 
M R P  transport (Leier et a l , 1996) which is relatively surprising considering the 
high affinity of GS-conjugates for transport by MRP. In addition G S H  was stated 
by Loe et a l, (1996b) and Muller et a l , (1994) to be without effects on M R P  at 5 
mM. The inhibitory effects of G S H  on [3H]-LtC4 accumulation could possibly be 
a result of active transport of this tripeptide by M R P  although there has been no 
previous evidence of transport of unconjugated G S H  by MRP. Alternatively, 
G S H  when added in high concentrations could simply bind to or block the
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substrate binding site of M R P  without necessarily being transported by the M R P  
molecule. This would then result in a reduction in accessibility for [3H]-LtC4 to 
the M R P  binding site, causing a reduction in [3H]-LtC4 accumulation. These 
possibilities require further investigation.
An investigation into the inhibition of [3H]-LtC4 transport into HL60-ADR IOVs 
in the presence of G S H  and various cytotoxic drugs was then conducted. As 
described earlier cytotoxic drugs in their unconjugated state have not been widely 
shown to be transported by the glutathione conjugate transporter MRP. In 
addition cytotoxic drugs which are believed to act as substrates for M R P  have not 
been shown to undergo glutathione conjugation in cells. It has been suggested 
that cellular G S H  metabolism is a critical element of M R P  activity in M R P  
expressing cells (Section 1.5.5.2) and for this reason, the inhibition characteristics 
of various concentrations of cytotoxic drugs on [3H]-LtC4 transport into HL60- 
A D R  IOVs was investigated. From Figure 3.15.2.2 it can be seen that in the 
presence of 5 m M  GSH, ATP dependent transport of [3H]-LtC4 was totally 
eliminated. In the presence of this concentration of GSH, vincristine and cisplatin 
treated IOVs also have all ATP dependent LtC4 transport eliminated as expected. 
In the presence of 1 m M  GSH, ATP dependent [3H]-LtC4 transport was 
unchanged from the levels achieved in the absence of 1 m M  GSH. The presence 
of 1 m M  G S H  had no effects on the uptake of [3H]-LtC4 into HL60-ADR IOVs 
treated with 100 |xM cisplatin. A  concentration of 100 (iM cisplatin in the absence 
of G S H  also had no effects on ATP dependent [3H]-LtC4 transport (Figure 
3.15.2.5). The addition of 1 m M  G S H  had no effects on the level of inhibition of 
[3H]-LtC4 uptake achieved by 50 p M  Taxol (Figure 3.15.2.6). From Figure
3.15.2.4 it can be seen that a concentration of 250 p M  adriamycin inhibited [3H]- 
LtC4 uptake into HL60-ADR IOVs by 15-20%. A  very small increase in inhibition 
of this transport was achieved in the presence of 1 m M  G S H  (Figure 3.15.2.4). 
The increase in inhibition of ATP dependent [3H]-LtC4 transport into IOVs was 
found to occur to a highly significant extent in the case of 110 p M  vincristine 
(Figure 3.15.2.3). In the presence of 110 jlM vincristine [3H]-LtC4 uptake into 
HL60-ADR IOVs was approximately 4 pmol per mg IOV protein at steady state.
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In the presence of 1 m M  G S H  and 110 (iM vincristine, this steady state ATP 
dependent accumulation was reduced by over 50% to under 2 pmol per mg IOV 
protein. As 1 m M  G S H  was without effects on ATP-dependent M R P  activity, one 
may assume (although there could be various possible explanations) that the 
synergistic inhibition of [3H]-LtC4 uptake in the presence of vincristine and 1 m M  
G S H  was a result of increased transport of vincristine, G S H  or some form of 
conjugate of both of these agents. The fact that 1 m M  G S H  was without effects 
on the levels of inhibition of [3H]-LtC4 uptake into 10Vs achieved by 100 jlM 
cisplatin and 50 (iM Taxol suggests that transport of vincristine by M R P  may 
explain the results of Figure 3.15.2.3. In the absence of the cellular enzymes 
required for glutathione conjugation, the IOV transport results suggest that 
glutathione conjugation is not strictly necessary to achieve transport of vincristine. 
It is possible that some form of co-transport of vincristine and G S H  occurs. 
Active transport of G S H  into IOVs is suggested from the data of Figure 3.15.2.1. 
Alternatively M R P  could possess a number of substrate binding sites, one of 
which recognises and binds to GSH. [3H]-LtC4 could be transported by M R P  
because of the high affinity of this glutathione conjugate for a specific substrate 
binding site on MRP. The G S H  binding site does not need to be occupied for 
transport of [3H]-LtC4 by M R P  to occur. When G S H  and an agent that could bind 
to one of the additional substrate binding sites on M R P  (such as vincristine but 
not Taxol) were present, this agent could be transported by M R P  because of the 
fact that both the G S H  and the substrate binding sites would be simultaneously 
occupied. This would then result in the overall level of [3H]-LtC4 transport into 
the IOVs to be reduced because of the increased competition between vincristine 
and [3H]-LtC4 for active transport by MRP. This synergistic inhibition of [3H]- 
LtC4 uptake by an MRP-substrate drug and G S H  may be specific for only a select 
number of drugs. Loe et al., (1996b) showed that in MRP-transfected cells, 1 m M  
G S H  caused an increase in the level of inhibition of LtC4 uptake caused by 100 
|XM vincristine and vinblastine but not adriamycin.
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4.10.2 Influence of glutathione on cytotoxic drug transport into HL60-ADR 
IOVs by MRP.
A  limited number of reports have shown the direct transport of unconjugated 
drugs by M R P  in MRP-transfected cells. In order to investigate this phenomenon 
in MRP-overexpressing drug selected cells, the transport of [3H]-vincristine into 
HL60-ADR IOVs was examined. As described in Section 3.15.3, the protocol 
used for these experiments was developed so as to minimise non-specific binding 
of [3H]-vincristine to the filters used to retain the IOVs. This modified protocol 
was still sufficient for detection of ATP dependent transport by M R P  of a suitable 
substrate (such as LtC4) into HL60-ADR IOVs (Figure 3.15.3.1). From Figure
3.15.3.2 it can be seen that no specific ATP-dependent active transport of [3H]- 
vincristine was found either in the presence or absence of 2.7 m M  GSH. This 
concentration of G S H  inhibited ATP-dependent M R P  activity by over 40% 
(Figure 3.15.3.1). The levels of transport of [3H]-vincristine were unchanged in 
the presence of this concentration of GSH. This strongly suggests that this drug 
was not actively transported by MRP. This absence of active transport of [3H]- 
vincristine by HL60-ADR IOVs was found to occur even when the levels of 10V  
were doubled from the levels normally used in the IOV assay system, to 100 (ig 
vesicle protein (Figure 3.15.3.3). Under these conditions, significant [3H]- 
vincristine uptake into HL60-ADR IOVs was negligible in the presence of ATP or 
AMP. The addition of a concentration of G S H  which totally inhibited M R P  
activity (10 mM) had no effects on [3H]-vincristine accumulation within HL60- 
A D R  IOVs. This was also found to be the case with 0.5 m M  GSH, a 
concentration of G S H  which is known to be without significant effects on M R P  
activity. The illustration of vincristine transport by the indirect study discussed in 
Section 4.10.1 in the presence of 1 m M  GSH, and the inability to detect this 
transport by the direct [3H]-vincristine method may have a relatively simple 
explanation. In the indirect studies, vincristine was added at a final concentration 
of 100 |jM. In the direct studies of Section 3.15,3, [3H]-vincristine was added at 
200 nM. Concentrations of vincristine over 200 n M  may be necessary to fulfil 
whatever criteria are required for active transport of drug in the presence or
266
absence of GSH. The use of a concentration of [3H]-vincristine of 100 [xM is not 
possible in practical terms as it would require very high levels of [3H] but as 
already described this concentration of drug may be relevant as an intracellular 
concentration of drug if drug became localised or compartmentalised in specific 
regions of the cell. This possibility could be relatively easily investigated using the 
ATP assay described in Section 2.14. As was demonstrated in Section 3.17.3, in 
the presence of a suitable substrate and in the absence of creatine kinase, ATP 
levels decrease because of active transport of the substrate by M R P  to the interior 
of the IOVs. In the absence of a suitable substrate, active transport would not 
occur and so ATP levels would remain constant. For this reason, it would be 
possible to monitor the active transport by M R P  of agents such as vincristine. For 
these experiments it would be necessary to include appropriate controls to ensure 
that ATP hydrolysis occurred as a result of active transport rather than as a result 
of non-specific degradation. The main advantage of using this system would be 
that it would eliminate the technical difficulties experienced in attempting to 
minimise non-specific binding of high concentrations of [3H]-vincristine to filters.
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4.11.1 Investigation into the cytotoxic drug accumulation characteristics of 
the DLKP-A10 multidrug-resistant human lung tumor cell line.
The DLKP-A10 cell line is a drug resistant variant of D L K P  and is derived from 
the DLKP-A cell line. This highly resistant cell line (over 800 fold more resistant 
to adriamycin than DLKP) was selected in 17 (iM adriamycin. The DLKP cell line 
accumulated over 4000 pmol adriamycin per million cells after 4 hours incubation 
(Figure 3.17.1.1). The resistant DLKP-A10 cells accumulated under 300 pmol 
adriamycin per million cells after 4 hours incubation in drug-containing media. 
Treatment of DLKP-A10 cells with 8 |iM cyclosporin A  or 60 (iM verapamil was 
only partially effective at reversing the drug accumulation defect in DLKP-A10. 
These compounds caused DLKP-A10 cells to accumulate over 1300 pmol 
adriamycin per million cells, with a steady state in drug accumulation levels 
reached after 3 hours incubation in drug. If the only mechanism of resistance 
responsible for resistance and so reduced drug accumulation levels in DLKP-A10 
involved Pgp, one would predict that addition of these circumventing agents 
would cause complete reversal of the drug accumulation deficit. This is illustrated 
in the case of the SKMES-1 and SKMES-1/ADR cell lines (Figure 3.17.1.2). The 
low levels of adriamycin accumulation in the SKMES-1/ADR cell line (250 pmol 
adriamycin per 106 cells) appeared to be solely a result of the Pgp-mediated drug 
efflux capabilities of this cell line. Inhibition of Pgp activity due to treatment of 
SKMES-1/ADR with 8 ¡iM cyclosporin A  or 60 |xM verapamil completely 
restored adriamycin accumulation levels to the levels achieved in the case of the 
SKMES-1 parental drug sensitive cell line. The SKMES-1 cell line is more 
resistant to adriamycin (IC50 of 25 nM) than the DLKP cell line (IC50 of 9 nM) 
and so this may explain the low levels of adriamycin accumulation found in the 
case of SKMES-1 when compared to D L K P  (2 nmol adriamycin per 106 SKMES- 
1 cells after 4 hours as compared to 4 nmol adriamycin per 106 DLKP cells after 4 
hours incubation in drug containing media). In summary, cyclosporin A  and 
verapamil were found to possess the ability to reverse the accumulation deficit in 
resistant cells where Pgp is believed to be solely responsible for drug efflux, such 
as in SKMES-1/ADR. The inability of these agents to reverse the accumulation
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defect in DLKP-A10 suggested that a non-Pgp-related mechanism of drug 
transport is active in this cell line. These results agreed with findings of Cleary el 
a l, (1997).
In order to investigate the ATP dependence of this drug transport mechanism in 
the DLKP-A10 cell line, transport was investigated in the presence of 10 m M  
sodium azide and 20 |iM antimycin A. It was found that these metabolic inhibitors 
were highly toxic at these and at even lower concentrations to DLKP-A10 and 
DLKP after a period of 4 hours. Exposure of the cells to these compounds for 
periods of under 3 hours did not cause any obvious toxic effects, but cells could 
be seen to be in a shocked state by 3-4 hours. The experiments with these 
metabolic inhibitors were conducted under glucose free conditions as described in 
Section 2.15. As can be seen in Figure 3.17.1.3, DLKP accumulated significantly 
more adriamycin after 4 hours incubation in 10 |iM adriamycin than the resistant 
DLKP-A10 cell line (1500 and 500 pmol adriamycin per 106 cells respectively). 
This illustrates that even within the glucose free conditions used in this 
experiment, the drug transport mechanisms responsible for the low levels of drug 
accumulation in the DLKP-A10 cell line continued to perform with comparable 
efficiency to that achieved under glucose containing conditions. From Figure
3.17.1.3 it can be seen that treatment of the DLKP-A10 cell line with sodium 
azide or antimycin A  under glucose deficient conditions, caused a significant 
increase in the accumulation of adriamycin in this resistant cell line. The metabolic 
inhibitor antimycin A  completely reversed the accumulation defect in the DLKP- 
A10 cell line by causing the cells to accumulate levels of adriamycin comparable 
to those found in DLKP in glucose free conditions. Sodium azide also caused a 
reasonably high level of adriamycin accumulation in the DLKP-A10 cell line under 
these conditions. These findings agreed with results of similar experiments 
performed by Cleary et al., (1997). The results described above demonstrated that 
the drug transport mechanism responsible for the low levels of adriamycin 
accumulation in the DLKP-A10 cell line was energy dependent and could be 
reversed completely in the presence of antimycin A. The effects of antimycin A  
were dependent on the ability of this compound to interfere with ATP production 
in DLKP-A10. Treatment of DLKP-A10 cells with this compound under glucose
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containing conditions had no effects on the accumulation of adriamycin as shown 
in Figure 3.17.1.4. As antimycin A  was believed to be more effective than sodium 
azide in achieving reversal of the accumulation deficit in DLKP-A10 and as both 
of these compounds should have comparable effects on ATP production, further 
experiments were conducted in order to see if antimycin A  and not sodium azide 
had some direct influences on the drug transport mechanisms in DLKP-A10.
4.11.2 Transport of LtC4 into DLKP-A10 derived IOVs and inhibition of 
this transport by antimycin A, sodium azide, cyclosporin A and 
verapamil.
A  number of drug resistant MRP-expressing cell lines have been shown to exhibit 
high levels of intracellular vesicle formation (Marquardt and Center, 1992). It has 
been suggested that M R P  can be involved in transport of drug into these 
cytoplasmic vesicles in order to facilitate eventual efflux of drug from the cell. 
The DLKP-A10 cell line was shown by Cleary et. al., (1997) to exhibit unusually 
high levels of vesicle formation within the cytosol. It was also found that drug 
became localised within these vesicles and that these vesicles were involved in 
sequestering drug away from the nucleus and potentially out of the cell (Cleary et 
al., 1997) The formation of intracellular vesicles by DLKP-A10 suggested that 
M R P  was present in this cell line. Cleary et al., (1997) demonstrated that M R P  
protein was not detectable in whole cell extracts of the DLKP-A10 cell line. As 
has already been described, M R P  protein had not been detected in the DLKP cell 
line until active M R P  protein was shown to be present in IOVs isolated from this 
cell line. This indicated that the isolation of IOVs from the DLKP-A10 cell line 
would illustrate if even very low levels of active M R P  protein were present in 
these cells.
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IOVs were isolated from DLKP-A10 in order to investigate if M R P  activity 
contributed to the unusual drug accumulation characteristics of this cell line. The 
results presented in Section 3.17.2 demonstrate that IOVs from the DLKP-A10 
cell line exhibit significant levels of [3H]-LtC4 transport and so MRP-like activity. 
From Section 3.17.2 it was demonstrated that IOVs from this cell line transport 
[3H]-LtC4 in an ATP dependent fashion with an initial rate of 0.6 ± 0.2 pmol per 
mg per minute. This transport becomes saturated by 2.5 minutes at a level of 1.8 
± 0.3 pmol/mg protein. From Section 3.13 it was demonstrated that DLKP 
derived IOVs transport [3H]-LtC4 with an initial rate of approximately 0.8 ± 0.2 
pmol per mg per minute (maximum accumulation of 2.0 ± 0.3 pmol/mg). From 
Section 3.17.4 it was shown that DLKP IOVs contained higher levels of the 190 
kDa protein MRP, than had been found in DLKP-A10 IOVs. The presence of a 
116 kDa band in all Western blots performed using the rat MRPrl monoclonal 
antibody (TCS Biologicals, ZUMC-201) had not been found previously with 
other batches of this antibody. A  negative control blot (with HL60-ADR IOVs) 
using PBS in place of primary antibody did not exhibit the 116 kDa or any other 
banding. A  negative control using rat serum was not performed. The low 
molecular weight of this protein indicates that the 116 kDa banding is unlikely to 
be attributable to the presence of MRP. For this reason the 116 kDa banding must 
be attributed to non-specific binding of the antibody.
Demonstration of the presence of active M R P  protein in the DLKP-A10 cell line 
suggested that this drug resistance mechanism may have exerted an influence on 
the unusual adriamycin accumulation characteristics of this cell line. As described 
in Section 4.11.1, these unusual adriamycin accumulation characteristics firstly 
involved the inability of cyclosporin A  and verapamil to completely reverse the 
drug accumulation deficit in DLKP-A10. In addition, the ability of antimycin A  
and the inability of sodium azide under glucose free conditions to reverse the 
accumulation deficit in DLKP-A10 could not be explained on the basis of the 
levels of Pgp possessed by this cell line. If M R P  activity in DLKP-A10 cells 
contributed to these adriamycin accumulation characteristics one would predict 
that antimycin A  was a more potent modulator of M R P  activity than sodium
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azide, cyclosporin A  or verapamil. This prediction was complicated by the fact 
that the ability of antimycin A  to reduce the accumulation deficit in DLKP-A10 
was partially dependent on the ability of this compound to inhibit ATP 
production. M R P  activity was analysed in DLKP-A10 derived IOVs in the 
presence of antimycin A, sodium azide, verapamil and cyclosporin A. From Figure
3.17.2.2 it can be seen that 50 and 10 |xM cyclosporin A  caused inhibition of [3H]- 
LtC4 uptake into DLKP-A10 IOVs by 80 and 60% respectively. Verapamil 
exhibited low levels of inhibitory effects on [3H]-LtC4 transport by DLKP-A10 
IOVs (Figure 3.17.2.3). A  concentration of 50 ¡xM antimycin A  inhibited LtC4 
accumulation in DLKP-A10 IOVs by approximately 50-60% and a 10 |xM 
concentration of this compound achieved 30-40% inhibition. From Figure
3.17.2.5 it can be seen that sodium azide also inhibited [3H]-LtC4 transport when 
present at a 50 |xM concentration (approximately 20% inhibition of transport). 
The inhibitory effects of antimycin A  on [3H]-LtC4 transport were not a result of 
interference in the ATP regenerating system (Figure 3.17.3.1) and so were a 
direct result of inhibitory effects on the M R P  transporter molecule.
The results of the studies on the effects of antimycin A  on [3H]-LtC4 transport 
into DLKP-A10 IOVs demonstrated that this metabolic inhibitor also exerted 
significant inhibitory effects on M R P  activity. The other metabolic inhibitor 
examined, sodium azide was significantly less potent an inhibitor of the activity of 
M R P  in IOVs from this cell line. The ability of antimycin A  to reduce the drug 
accumulation deficit in DLKP-A10 was partially dependent on the ability of this 
compound to inhibit ATP production. Under glucose containing conditions, 
antimycin A  had no effect on adriamycin accumulation in DLKP-A10 cells (Figure 
3.17.1.4). The results suggested that the abilities of antimycin A  to simultaneously 
inhibit ATP production and M R P  activity resulted in this compound reducing the 
drug accumulation deficit in DLKP-A10. Sodium azide only partially reversed this 
deficit because of the fact that although it inhibited ATP synthesis, this metabolic 
inhibitor exerted relatively insignificant effects on M R P  activity in DLKP-A10. 
The combination of the Western blotting results of Cleary et al., (1997), which 
showed very high levels of Pgp protein in DLKP-A10, and the Western blotting
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results of Figure 3.17.4.1 which showed relatively low levels of M R P  in DLKP- 
A10, suggest that Pgp overexpression is the dominant drug resistance mechanism 
present. The expression of low levels of M R P  may become influential on the drug 
accumulation characteristics of DLKP-A10 only when ATP levels in cells become 
depleted during growth under glucose free conditions in the presence of antimycin 
A  or sodium azide. The dual ability of antimycin A  to inhibit ATP production and 
to inhibit M R P  activity could potentially explain the ability of this compound to 
eliminate the drug accumulation deficit in DLKP-A10.
In order provide further evidence for this possibility, it would be necessary to 
perform three related experiments. In the first of these experiments, it would be 
necessary to demonstrate that IOVs from the SKMES- 1/ADR cell line did not 
possess M R P  activity. In the absence of MRP, the potent Pgp modulators, 
verapamil and cyclosporin A  would be predicted to eliminate the accumulation 
deficit in this cell line, as had been found experimentally (Figure 3.17.1.2). In the 
second experiment, it would be necessary to demonstrate that the levels of 
adriamycin accumulated in DLKP cells were significantly increased in the 
presence of antimycin A  under glucose free conditions. The D L K P  cell line is 
known to express active M R P  protein (Figure 3.17.4.1) and so significant 
interference in the activity of M R P  should result in an increase in drug 
accumulation in this cell line. Cleary, (1995) demonstrated that this is in fact the 
case. DLKP cells were found to accumulate approximately 444 pmol adriamycin 
per 106 cells after 3 hours incubation in 10 |iM adriamycin under glucose free 
conditions. Under these conditions and in the additional presence of 10 (iM 
antimycin A, DLKP cells accumulated approximately 980 pmol adriamycin per 
106 cells. In the third and final experiment, an established inhibitor of M R P  such 
as MK571 (Section 3.16) would be used under conditions where DLKP-A10 cells 
were deprived of ATP. If DLKP-A10 was deprived of ATP and if M R P  activity 
was simultaneously inhibited due to the presence of MK571, then one would 
predict that the drug accumulation deficit in DLKP-A10 would be eliminated. 
Under conditions where DLKP-A10 was not deprived of ATP, MK571 should 
have no effect on the levels of drug accumulated by DLKP-A10. This would be a
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result of the fact that Pgp activity would be unaffected by the treatment with 
MK571 and so would actively efflux drug from the cell.
The dual ability of antimycin A  to inhibit ATP production and to inhibit M R P  
activity may be proven to explain the ability of this compound to eliminate the 
drug accumulation deficit in DLKP-A10. This compound may have potential for 
use as an M R P  inhibitor as was demonstrated with HL60-ADR 10Vs in Figure 
3.17.2.6. This compound would be predicted to enhance the toxicity of drugs 
such as adriamycin in M R P  expressing cell lines such as DLKP. It would not 
significantly influence drug accumulation characteristics and drug toxicity in Pgp 
overexpressing cell lines under standard culture conditions as there is no evidence 
to suggest that this compound has any inhibitory effects on Pgp activity.
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4.12 MRP expression and LtC4 transport characteristics in clonal 
populations isolated from the MDR cell line DLKP-A.
As described in Section 3.18, Heenan et a l , (1997) isolated 9 clonal 
subpopulations from the Pgp-overexpressing cell line DLKP-A. This cell line is an 
adriamycin-selected variant of DLKP. The DLKP-A cell line (250-fold resistant to 
adriamycin relative to DLKP cells) overexpresses Pgp protein and possesses 
reduced levels of topoisomerase II (Topo II) protein. The drug resistance 
mechanisms responsible for the various levels of drug resistance in the DLKP-A 
clones had previously been believed to only involve Pgp and Topo II. It is now 
known that DLKP expresses M R P  in the plasma membrane (Section 3.17.4). The 
possible existence of M R P  in DLKP-A derived clones was investigated by means 
of isolation of IOVs from the DLKPA2B, 1 IB, 6B and 5F cell lines. These studies 
were carried out with two main objectives. The first objective involved an 
investigation into M R P  protein levels and activities in these drug resistant variants 
of DLKP. The DLKP cell line preferentially develops Pgp-mediated resistance 
rather than MRP-mediated resistance. This study therefore examined the 
possibility that M R P  expression would become down regulated if Pgp expression 
became up-regulated in a given clone. The second main objective of this study 
was to attempt to explain the findings of Heenan et a l, (1997) which 
demonstrated that the adriamycin accumulation characteristics of two clones two 
clones (DLKPA6B and 11B) did not correlate with the levels of Pgp protein 
possessed by these clones. The DLKPA6B cell line expressed extremely low 
levels of Pgp (lower than the levels present in DLKP) relative to DLKPA1 IB but 
yet after a period of 4 hours, DLKPA6B and DLKP Al IB accumulated 
comparable levels of adriamycin (approximately 200 pmol/106 cells). The levels of 
adriamycin accumulation in these clones were significantly less than the levels 
accumulated by DLKP over the same period (approximately 600 pmol/106 cells) 
which indicated the expression of an active drug efflux mechanism in these drug 
resistant clones.
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From the results presented in Section 3.18 it was demonstrated that IOVs from all 
clones examined exhibited ATP-dependent transport of [3H]-LtC4 to their interior. 
IOVs isolated from DLKPA2B transported [3H]-LtC4 in an ATP dependent 
fashion with an initial rate of 0.5 ± 0.2 pmol/mg protein/minute with [3H]-LtC4 
uptake saturated by 4 minutes at 1.5 ± 0.2 pmol/mg protein. DLKPA11B IOVs 
also transported [3H]-LtC4 in an ATP dependent fashion with an initial rate of 0.6 
± 0.3 pmol/mg protein/minute with [3H]-LtC4 uptake saturated by 3 minutes at
1.1 ± 0.2 pmol/mg protein. DLKPA5F derived IOVs exhibited relatively high 
levels of [3H]-LtC4 transport. [3H]-LtC4 transport occurred at an initial rate of 1.3 
± 0.2 pmol/mg protein/minute with a maximal accumulation of 2.3 ± 0.2 pmol 
LtC4 per mg protein, occurring after 2 minutes. The DLKPA6B cell line was 
found to possess comparable levels of [3H]-LtC4 transporting abilities to those 
found in DLKPA11B. The DLKPA6B derived IOVs transported [3H]-LtC4 with 
an initial rate of approximately 0.7 ± 0.3 pmol LtC4 per mg IOV protein per 
minute. Maximal accumulation (1.0 ± 0.2 pmol LtC4 per mg IOV protein) of 
[3H]-LtC4 by DLKPA6B IOVs occurred after an incubation period of 2 minutes. 
Western blotting protein analysis demonstrated that DLKP and DLKPA5F IOVs 
contained reasonably comparable levels of MRP. DLKPA6B IOVs contained 
marginally higher protein levels of M R P  than found in DLKPA11B IOVs. The 
protein levels of M R P  in DLKPA2B IOVs were found to be extremely low. The 
results of [3H]-LtC4 transport and Western blotting experiments are shown in 
summary in Table 4.12.1. All [3H]-LtC4 transport data is expressed as the mean ± 
S.D. of duplicate determinations carried out on two separate occasions, using 
different IOV preparations from the relevant cell line on each occasion.
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DLKP DLKP-
A2B
DLKP-
A11B
DLKP-
A5F
DLKP-
A6B
MRP protein levels in 
IOVs
High Very low Intermediate High Intermediate
Pgp protein levels in 
cclls*
Low Intermediate High Very high Very low
Initial LlC4 transport 
rate (pmol/mg/min)
0.8 ± 0 .2 0.5 ± 0 .2 0.6 ±  0.3 1.3 ± 0 .2 0.7 ± 0 .3
L1C 1 accumulation after 
4 minutes (pmol/mg)
2.0 ± 0 .3 1.5 ± 0 .2 1.1 ± 0 .2 2.3 ± 0 .2 1.0 ± 0 .2
Adriamycin fold
resistance
*
1 .0± 0 .1 37.0 ± 3 .7 84.0 ± 8 .4 331 ±33 .1 95.0 ± 9 .5
Adriamyein 
accumulation after 4 
hours (pmol/106 cells)*
618 ±  39 424 ± 3 1 204 ±  12 160 ±  12 232 ±  12
Cisplatin fold 
resistance*
1 .0± 0 .1 0.6 ± 0 .1 0.6 ± 0 .1 1.4 ± 0 .1 0.7 ± 0 .1
* Data obtained from Heenan et al., (1997)
Table 4.12.1: Summary of M R P  protein levels and LtC4 transport characteristics 
of IOVs isolated from DLKP and clonal subpopulations of the drug resistant 
DLKP variant DLKP-A. The levels of M R P  protein in IOVs from the various cell 
lines are illustrated in Figure 3.18.5. Densitometry has not been used to quantify 
the protein levels of M R P  or Pgp present but instead the level protein expression 
as determined by Western blotting is illustrated in the above table according to the 
band intensity at the position corresponding to the molecular weight of M R P  (190 
kDa) or Pgp (170 kDa).
The primary objective of this study was to examine if M R P  protein levels were 
related to the protein levels of Pgp in a clone with a known level of adriamycin 
resistance. From Table 4.12.1 it can be seen that DLKPA2B cells express higher 
levels of Pgp protein and lower levels of M R P  protein than is found to be the case 
for DLKP. DLKPA11B cells express higher levels of Pgp and M R P  protein than 
DLKPA2B. DLKPA5F cells express higher levels of Pgp and M R P  than is found 
to be the case for DLKPA11B and DLKPA2B. The levels of M R P  protein in 
DLKPA5F are higher than present in any of the other clones and these levels are 
comparable to the levels of M R P  present in DLKP. These results may be partially 
explained by the levels of adriamycin resistance of these clones (Table 4.12.1).
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The following discussion ignores the potential influences on drug resistance of the 
levels of Topo II protein possessed by the various clones. The primary aim of this 
study was to determine if M R P  protein expression was influenced in some way by 
the levels of Pgp protein expression in the various clones. It was not designed to 
determine the precise contribution of either of these transporters to the overall 
level of drug resistance of the various clones. The DLKPA2B clone was the least 
resistant of the clones (approximately 37 fold more resistant to adriamycin than 
DLKP). In this clone, Pgp overexpression may be sufficient to permit survival of 
DLKPA2B in relatively low adriamycin concentrations. For this reason, M R P  
protein synthesis could be down-regulated from the levels present in DLKP, as the 
levels of Pgp present would be more than sufficient for efflux of the levels of drug 
to which this cell line would be exposed. The DLKPA11B cell line was 
significantly (84-fold) more resistant to adriamycin than DLKP. In this clone, the 
levels of Pgp and M R P  protein were higher than was found in the case of 
DLKPA2B. Although increased levels of Pgp would facilitate a higher level of 
resistance in DLKP A 1 IB compared to DLKPA2B, an increase in the level of 
M R P  protein from the levels in DLKPA2B could also simultaneously contribute 
to an increase in the level of resistance to adriamycin. In the absence of significant 
M R P  protein expression by a clone with a level of adriamycin resistance 
equivalent to DLKPA1 IB, one would predict that the levels of Pgp in this clone 
would have to be higher than found in DLKPA1 IB. The DLKPA5F clone was 
highly resistant to adriamycin (330 fold more resistant than DLKP). This clone 
expressed higher levels of M R P  and Pgp protein than DLKPA1 IB. The higher 
levels of Pgp protein in DLKPA5F compared to DLKPA1 IB, contributed to 
DLKPA5F possessing a higher level of adriamycin resistance than DLKPA11B. 
The higher levels of M R P  protein in DLKPA5F could also simultaneously 
contribute to the relatively high level of adriamycin resistance of this cell line. In 
summary, the results suggest that in the low level adriamycin resistant clone 
DLKPA2B, increased levels of Pgp expression were sufficient to permit survival 
of these cells in low adriamycin concentrations. For this reason M R P  protein 
expression could be effectively down regulated without any detrimental effects on 
the ability of this clone to survive in the presence of low adriamycin 
concentrations. In clones with higher levels of adriamycin resistance such as
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DLKPA11B and DLKPA5F, high levels of Pgp protein expression contributed to 
the abilities of these clones to survive in high adriamycin concentrations. In 
addition, the simultaneous expression of increased levels of M R P  also contributed 
to this resistance. The significance as regards drug resistance, of small variations 
in M R P  protein levels between the various clones may be questionable because of 
the fact that only very low levels of the protein are present in any of the clones. It 
should be remembered that NSAID-mediated interference in the activity of the 
low levels of M R P  present in DLKP was sufficient to increase drug-induced cell 
kill. For this reason, even minor alterations in the levels of M R P  protein, when 
combined with alterations in the levels of other drug resistance mechanisms such 
as Pgp, could have significant influences on the level of resistance of a clone to a 
given drug.
The second main objective of these studies was to attempt to explain the 
adriamycin accumulation characteristics of the DLKPA6B and DLKPA1 IB cell 
lines. The DLKPA6B cell line was omitted from the previous discussion as the 
levels of adriamycin resistance of this clone were particularly unusual considering 
the levels of Pgp and Topo II possessed by this cell line. This cell line was shown 
by Heenan el a l , (1997) to express lower levels of Pgp protein than was found in 
the case of DLKP. In addition this cell line expressed similar levels of Topo II 
protein compared to the levels found in DLKP. It was surprising for these reasons 
to find that DLKPA6B exhibited comparable levels of adriamycin resistance to 
those found in the case of DLKPA1 IB (Table 4.12.1) as DLKPA1 IB was known 
to express more Pgp and less Topo II protein than DLKP. This suggested that a 
non-Pgp and Topo II related mechanism was involved in the levels of drug 
resistance of DLKPA6B. The fact that DLKPA6B and DLKP Al IB accumulated 
comparable levels of adriamycin after a period of 4 hours (Table 4.12.1) 
suggested that in the absence of significant levels of Pgp in DLKPA6B, a drug 
efflux pump may have been present in DLKPA6B which compensated for low 
levels of Pgp in this cell line. From Table 4.12.1 and Figure 3.18.5 it can be seen 
that DLKPA6B and DLKPA1 IB contain comparable levels of M R P  protein in 
their plasma membrane. For this reason it can be stated that M R P  is not 
responsible for the unusual drug accumulation characteristics of DLKPA6B. The
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identity of the drug transporter molecule involved in the active efflux of drug in 
DLKPA6B requires further investigation.
From Table 4.12.1 it can be seen that IOVs from a number of the clones exhibit 
significantly different levels of [3H]~LtC4 transport than was found in DLKP. If 
M R P  was totally responsible for [3H]-LtC4 transport in IOVs from these clones, 
one would assume from the [3H]-LtC4 transport data that M R P  protein levels in 
2B, 1 IB and 6B derived IOVs would be slightly lower than in DLKP IOVs which 
in turn would be lower than the levels found in DLKPA5F IOVs. From Figure
3.18.5 it was shown that this was not the case. These results could be used to 
suggest that a non-MRP 1 gene product LtC4 transporter was responsible for the 
unusual [3H]-LtC4 transporting abilities of IOVs derived from the various clones. 
From Figure 3.18.5 it can be seen that HL60-ADR IOVs possess extremely high 
levels of M R P  protein. A  study performed by Kool et al., (1997) demonstrated 
that HL60-ADR cells contained very high levels of MRP-1 m R N A  and practically 
negligible levels of the other M R P  analogues analysed. This suggested that the 
monoclonal antibody used for detection of M R P  (Figure 3.18.5) showed high 
affinity for the MRP-1 gene product (specificity for M R P  related isoforms not 
known). The presence of high levels of MRP-1 protein in HL60-ADR is reflected 
in an initial rate of [3H]-LtC4 transport of 4.0 ± 1.0 pmol/mg protein/minute with 
a saturation value of 7.0 ±1.0 pmol LtCVmg protein reached after 1-2 minutes. 
The only clone with a relatively high LtC4 transport ability was found to be 
DLKPA5F (Table 4.12.1). From Figure 3.18.5 it can be seen that IOVs from 
DLKPA5F contained slightly lower levels of MRP-1 protein than found in DLKP 
derived IOVs. Table 4.12.1 illustrates that DLKPA5F derived IOVs possess 
higher capabilities for [3H]-LtC4 transport than is found in the case of DLKP. The 
DLKPA6B cell line was found to express marginally lower protein levels of MRP- 
1 than found in DLKP or DLKPA5F. This was reflected in relatively low [3H]- 
LtC4 transport capabilities. IOVs isolated from the DLKPA2B cell line were 
found to possess very low levels of M R P  (Figure 3.18.5). Surprisingly these IOVs 
exhibited an initial rate of [3H]-LtC4 transport of 0.5 ± 0.2 pmol/mg/min, a rate 
comparable to that achieved in the case of DLKPA6B and DLKPA1 IB.
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The possible presence of a non-MRP 1 gene product [3H]-LtC4 transporter is 
strongly suggested by the [3H]-LtC4 transport and Western blotting results 
obtained in the case DLKPA5F and DLKPA2B. The various clones of DLKP-A 
are known from Western blotting studies to express the MRP-1 gene product, and 
so even if an additional [3H]-LtC4 transporter was present in any of these clones, 
the contribution of any individual transporter to overall [3H]-LtC4 transport and 
ultimately to drug resistance, becomes extremely difficult to conclusively 
determine. If a non-MRP 1 gene product, glutathione conjugate pump was 
involved in [3H]-LtC4 transport in the various clones, the specific identity of this 
transporter is not fully clear from the experimental data. The DLKPA2B, 1 IB, 6B 
and 5F clones are 0.6, 0.7, 0.6 and 1.39 fold resistant to cisplatin relative to the 
parental DLKP cell line (which is designated a fold resistance value of 1). The 
c M O A T  protein is a product of the MRP-2 gene and has been shown by Kool et 
al., (1997) to be elevated in several cell lines selected for cisplatin resistance and 
in a select number of adriamycin selected non-small cell lung cancer cell lines. 
This group provided some evidence that expression levels of this transporter 
correlated with the cisplatin but not adriamycin resistance levels of these cell lines. 
If the c M O A T  protein contributed to [3H]-LtC4 transport simultaneously with 
MRP-1 mediated [3H]-LtC4 transport in the clones one would predict that there 
was little c M O A T  in the DLKPA6B and DLKP 1 IB clones. This is due to the fact 
that the levels of [3H]-LtC4 transport in these clones were even lower than the 
levels predicted from the levels of M R P - 1 possessed by these clones relative to 
DLKP. The DLKPA5F clone possessed comparable levels of MRP-1 protein to 
those found in DLKP, but if c M O A T  was present, simultaneous MRP-1 and 
c M O A T  activity could have contributed to the higher levels of [3H]-LtC4 
transport in DLKPA5F than was found in the case of DLKP derived IOYs. The 
DLKPA2B cell line expressed very little MRP-1 in the plasma membrane and so if 
simultaneous c M O A T  and MRP-1 expression was found, then DLKPA2B 10Vs 
must be assumed to contain reasonably high levels of c M O A T  which resulted in a 
relatively high levels of [3H]-LtC4 transport into the IOVs. These assumptions 
would predict that DLKPA6B and 11B would possess a comparable level of 
cisplatin resistance to that found in the case of DLKP. In addition this would also
281
predict that DLKPA2B and DLKPA5F would be more resistant to cisplatin than 
was found in the case of DLKP. From Table 4.12.1 it can be seen that this is not 
found to be the case. Attempting to correlate levels of drug resistance with a 
specific drug resistance mechanism is questionable because of the many complex 
interacting systems involved in resistance to a given drug. It is particularly 
questionable in this particular case of cisplatin resistance of the DLKP-A clones 
because of the very small differences in fold resistance of these clones relative to 
DLKP (fold resistance ranging only from 0.6 to 1.4). For this reason there is no 
evidence currently available to suggest that c M O A T  in any way contributes to 
[3H]-LtC4 transport in the various clones. The potential contribution of M R P  
analogues to [3H]-LtC4 transport and to various aspects of drug resistance of the 
DLKP-A clones requires further investigation.
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Conclusions
The in vitro toxicity assay screening performed with the A549 cell line 
demonstrated that the toxicity of a specific group of chemotherapeutic drugs was 
enhanced in the presence of a suitable NSAID. A  number of key results were 
crucial in the elucidation of the mechanism involved in this effect. These results 
are summarised in the following points:
1. The cytotoxicity of adriamycin, vincristine, daunorubicin, epirubicin and 
VP-16 in A549 was enhanced in the presence of non-toxic levels of a 
suitable NSAID. The toxicity’s of carboplatin, Taxol and 5-fluorouracil 
were unaffected by the presence of these NSAIDs.
2. Only a limited number of NSAIDs were found to enhance the toxicity of 
this select profile of chemotherapeutic drugs namely indomethacin, 
sulindac, tolmetin, acemetacin, sulindac sulfide, sulindac sulfone, 
zomepirac and mefenamic acid.
3. This toxicity enhancement effect was found to occur to a comparable 
extent in the human lung squamous carcinoma cell line, DLKP. All 
NSAIDs found to enhance drug toxicity in A549 were also found to 
enhance drug toxicity in DLKP.
4. The chemotherapeutic drugs described above are believed to act as 
substrates for the multidrug resistance-associated protein (MRP). Heavy 
metals such as sodium arsenate are known to be transported by MRP.
The toxicity of this compound was found to be enhanced in the presence 
of an NSAID such as indomethacin.
5. The ability of the NSAIDs listed above to enhance chemotherapeutic drug 
toxicity was demonstrated to be independent of any effects on 
prostaglandin H 2 synthase (PGHS). This was conclusively demonstrated 
by the ability of sulindac sulfone, a metabolite of sulindac which is devoid 
of inhibitory effects on PGHS to enhance the toxicity of a suitable 
cytotoxic drug. The extent of chemotherapeutic drug toxicity 
enhancement was comparable to that achieved by the potent PGHS 
inhibitor, sulindac sulfide.
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6. Interference in MRP-mediated drug efflux by a given NSAID appeared to
explain the NSAID-mediated enhancement of chemotherapeutic drug 
toxicity. The major weakness in this theory was the fact that M R P  protein 
had not been detected by Western blot analysis of whole cell extracts of 
the DLKP cell line. As the toxicity enhancement effect was known to 
occur in this cell line, one would have predicted significant levels of M R P  
protein to be present in this cell line. Isolation of plasma membrane 
derived inside-out vesicles (10Vs) from DLKP demonstrated the presence 
of active M R P  protein in this cell line. It was found that NSAIDs such as 
indomethacin, which can potently enhance the toxicity of M R P  substrate 
drugs, have the ability to interfere with M R P  activity (as assessed by LtC4 
transport capabilities) in DLKP IOVs. NSAIDs without chemotherapeutic 
drug toxicity enhancing abilities such as naproxen, were demonstrated to 
be without effect on LtC4 transport in DLKP IOVs. These results 
suggested that M R P  was present in the plasma membrane of D L K P  cells 
and that this drug transporter was effective in aiding survival of these cells 
against the cytotoxic effects of chemotherapeutic drugs. Treatment of 
DLKP with NSAIDs such as indomethacin interfered with this drug 
resistance mechanism and ultimately caused an enhancement in 
chemotherapeutic drug toxicity.
The presence of an active drug resistance mechanism in DLKP may appear 
relatively surprising as this cell line is regarded as being drug sensitive.
The existence of low levels of M R P  in DLKP is not surprising when one 
considers that this cell line is also known to express Pgp protein at low 
levels (Heenan et al., 1997).
The use of NSAIDs such as indomethacin as modulators of MRP-related drug 
resistance in vivo, has the potential to be more successful for the development of 
clinically successful chemotherapeutic regimes than has been achieved with 
existing modulators of multidrug resistance such as cyclosporin A  or verapamil. 
M D R  modulators such as verapamil have not proven to be effective modulators of
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M D R  drug resistance mechanisms because these compounds are often required to 
be present at high concentrations to achieve their M D R  modulating effects. It has 
not been generally possible to achieve these high modulator concentrations in 
patient’s serum without unacceptable side effects. NSAIDs such as indomethacin 
have been shown in vitro to enhance chemotherapeutic drug toxicity at 
concentrations of even below 1 (ig/mL (3 pM). Indomethacin is rapidly absorbed 
from the gastrointestinal tract following ingestion. Once absorbed it is almost 
entirely bound to plasma proteins and can reach a peak plasma concentration of
0.5-1 |ig/mL, 2 hours after administration of a 25 mg dose, with a half life of 2-3 
hours, (Flower et al., 1980). Indomethacin has been chosen as an example, but 
from the in vitro data it may be suggested that it may be possible to achieve the 
NSAID concentrations in vivo that have been demonstrated to be sufficient for 
MRP-modulatory effects in vitro.
Although the explanation for the NSAID-mediated drug toxicity enhancement 
effect is based upon interference in drug efflux by MRP, the mechanism by which 
chemotherapeutic drugs are transported by M R P  is currently unclear. No evidence 
of direct transport of [3H]-vincristine by M R P  into HL60-ADR derived IOVs was 
found experimentally. It was demonstrated that vincristine significantly inhibited 
[3H]-LtC4 transport by M R P  into HL60-ADR IOVs, suggesting the occurrence of 
competition for transport by M R P  or competition for binding to the substrate 
binding site of MRP. The inability to demonstrate direct [3H]-vincristine transport 
in HL60-ADR IOVs was believed to be a result of the possibility that very high 
vincristine concentrations were required for M R P  to exhibit significant transport 
of this drug. Adriamycin was found to inhibit [3H]-LtC4 transport at high drug 
concentrations only, (200 (iM). Cisplatin and Taxol were not found to 
significantly inhibit [3H]-LtC4 transport by M R P  even when present at high 
concentrations. Taxol and cisplatin are not believed to be high affinity substrates 
for MRP, whereas vincristine and adriamycin are believed to be substrates for this 
glutathione conjugate pump. These results suggested that M R P  did possess some 
abilities to bind to unconjugated natural product drugs such as vincristine when 
present at very high concentrations. The HL60-ADR cell line was selected for
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resistance in 186 n M  adriamycin but only concentrations of over 200 
adriamycin were found to inhibit [3H]-LtC4 transport by MRP. Intracellular 
concentrations of 200 |xM adriamycin may appear to be extremely high for 
consideration as being an achievable intracellular concentration but these 
concentrations may be relevant if drug somehow became localised in a subcellular 
compartment or organelle. If M R P  was localised in a membrane adjacent to this 
region, it would effectively be exposed to this extremely high concentration of 
drug. The leukotriene D 4 receptor antagonist, MK571 was found to potently 
inhibit [3H]-LtC4 transport by M R P  at concentrations as low as 10 (J.M. This 
demonstrated that cytotoxic drugs such as vincristine are relatively poor inhibitors 
of [3H]-LtC4 transport by MRP.
It was previously believed that reduced glutathione (GSH) was not a substrate for 
transport by the glutathione conjugate pump MRP, (Leier et a l , 1996). Loe et a l, 
(1996b) stated that a concentration of 5 m M  G S H  was without effects on the 
[3H]-LtC4 transport activity of M R P  in IOVs isolated from MRP-transfected cells. 
It was found experimentally with HL60-ADR IOVs that M R P  activity was 
potently inhibited even in the presence of 4 m M  GSH. Concentrations of G S H  
below 1.9 m M  G S H  were found to be without significant effects on the [3H]-LtC4  
transport activity of MRP. These inhibitory effects of G S H  on [3H]-LtC4  
accumulation in HL60-ADR IOVs may have been a result of active transport of 
this tripeptide by M R P  although there has been no previous experimental evidence 
to suggest that this occurs. An equally possible alternative was that G S H  
competitively interfered with the binding of [3H]-LtC4 to the substrate binding site 
of MRP. The chemotherapeutic drug which was found to be most inhibitory for 
[3H]-LtC4 transport by M R P  was found to be vincristine. The inhibitory effects of 
vincristine on [3H]-LtC4 transport were found to be enhanced in the presence of 1 
m M  GSH. The inhibitory effects of the non-MRP substrate drugs Taxol and 
cisplatin were unaffected by the presence of 1 m M  GSH. This may suggest that 
co-transport of vincristine and G S H  may have occurred. An alternative 
explanation involves the possibility that M R P  possesses a number of substrate 
binding sites, one of which recognises GSH. Even in the absence of GSH, a
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glutathione conjugate such as [3H]-LtC4 could be transported by M R P  once 
bound to the relevant specific substrate binding site. When G S H  and an agent that 
could bind to one of the additional substrate binding sites on M R P  (such as 
vincristine but not Taxol) were present, this agent could be transported by M R P  
because of the fact that both the G S H  and the substrate binding sites would be 
simultaneously occupied. This ultimately would result in the overall level of [3H]- 
LtC4 transport into the IOVs to be reduced because of the increased competition 
between vincristine and [3H]-LtC4 for active transport by MRP. The specific 
mechanism responsible for the ability of G S H  to enhance the ability of vincristine 
to inhibit [3H]-LtC4 transport requires further investigation. The results do 
suggest that the presence of G S H  may cause active transport of drugs such as 
vincristine by MRP. The inhibitory effects of very high concentrations of 
vincristine and adriamycin may have been a result of these drugs simply binding 
M R P  and so blocking access for [3H]-LtC4. The non-MRP substrate drugs, Taxol 
and cisplatin did not possess the ability to bind to M R P  and so did not exert any 
effects on the level of [3H]-LtC4 transport There was no direct evidence to 
suggest that drugs such as vincristine were actually transported by M R P  under 
conditions where G S H  was absent. The increase in the ability of vincristine (due 
the presence of GSH), to exhibit relatively potent inhibitory effects on [3H]-LtC4 
transport by M R P  suggested that G S H  is required for transport of vincristine by 
MRP. These results may indicate that in the case of MRP-expressing cells, that 
glutathione metabolism may play a key role in the efficacy of M R P  as a drug 
transporter. Versantvoort et al., (1995) demonstrated that glutathione metabolism 
is a critical element in the drug efflux capabilities of MRP. It was shown that 
buthionine sulphoximine (BSO), an inhibitor of G S H  synthesis caused an 
inhibition in the drug efflux activity of M R P  in MRP-overexpressing cell lines. 
The results of the studies by Versantvoort et al., (1995) and the results of the 
studies described above suggest that one should consider G S H  metabolism when 
investigating the influence of M R P  on drug resistance of a given cell line. 
Examination of M R P  protein expression and activity in a given cell line may give 
some indication of the influence of this glutathione conjugate pump in the drug 
resistance of a cell line. If a cell line was in any way deficient in G S H  metabolism, 
then the ability of M R P  to transport drugs such as vincristine could be
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substantially reduced. For this reason, both M R P  protein expression and G S H  
metabolism should be examined in any experiments attempting to develop a 
conclusive explanation for the involvement of M R P  in the drug resistance of any 
given cell line.
The detection of active M R P  protein in DLKP cells suggested that some of the 
drug resistance characteristics of DLKP related drug selected cell lines may have 
been explainable by the presence of M R P  in these drug resistant cell lines. The 
DLKP-A10 cell line was established by exposure of DLKP-A cells to gradually 
increasing concentrations of adriamycin. This cell line was known to overexpress 
P-glycoprotein (Pgp) and to accumulate less adriamycin over time than DLKP 
cells. This was also known to occur in the case of the SKMES-1/ADR (drug 
resistant) cell line, which was derived from the drug sensitive, SKMES-1 cell line. 
The accumulation deficit was found to be reversed in SKMES-1/ADR cells by 
treatment with the modulators of P-glycoprotein (Pgp), verapamil and cyclosporin 
A. The accumulation deficit was found to be only partially reversed with these 
compounds in the case of DLKP-A10 cells. This indicated that non-Pgp-related 
drug efflux mechanisms were active in DLKP-A10 cells. The significant levels of 
intracellular vesicle formation by this cell line suggested that this highly resistant 
cell line may have possessed significant levels of M R P  as intracellular vesicle 
formation has been documented as being a feature of a number of MRP- 
expressing cell lines. The only compound identified as having the ability to 
completely reverse the accumulation deficit in DLKP-A10 was found to be the 
metabolic inhibitor, antimycin A. This effect could not be achieved using the 
metabolic inhibitor sodium azide and so the effects of antimycin A  on DLKP-A10 
cells were not believed to be solely dependent on inhibition of ATP production. 
The ability of antimycin A  to inhibit ATP production was necessary for 
achievement of reversal of the accumulation deficit in DLKP-A10 as antimycin A  
had no effects on drug accumulation under conditions where cells were not 
deprived of ATP. Isolation of plasma membrane derived IOVs from DLKP-A10 
demonstrated that this cell line expressed M R P  protein and that the levels of M R P  
were lower than those present in DLKP. IOVs from the DLKP-A10 cell line 
exhibited slightly lower levels of [3H]-LtC4 transport than found in the case of
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10Vs from the DLKP cell line. It was found that antimycin A  was a surprisingly 
potent inhibitor of M R P  activity in DLKP-A10 IOVs but was no more inhibitory 
of [3H]-LtC4 transport activity than cyclosporin A. Sodium azide was found to 
only slightly inhibit [3H]-LtC4 transport activities of DLKP-A10 IOVs at relatively 
high concentrations. The effects of the metabolic inhibitor antimycin A  were 
found to be independent of any inhibitory effects on the ATP regenerating system 
in the IOV transport assay model. The results suggested that the abilities of 
antimycin A  to simultaneously inhibit ATP production and M R P  activity resulted 
in this compound reducing the drug accumulation deficit in DLKP-A10. Sodium 
azide only partially reversed this deficit because of the fact that although it 
inhibited ATP synthesis, this metabolic inhibitor exerted relatively insignificant 
effects on M R P  activity in DLKP-A10. The expression of low levels of M R P  
protein in DLKP-A10 may be influential on the drug accumulation characteristics 
of DLKP-A10 only when ATP levels in these cells became depleted. The ability of 
antimycin A  to inhibit ATP production and M R P  activity reduced the influence of 
M R P  on the drug accumulation characteristics of DLKP-A10 and so under 
glucose free conditions, caused elimination of the drug accumulation deficit in this 
cell line. Antimycin A  was found to possess relatively potent inhibitory effects on 
M R P  and so may have potential for use as a modulator of M R P  activity in non- 
Pgp overexpressing cell lines. The possibility of using antimycin A  as a modulator 
of MRP-mediated drug resistance in vitro requires further investigation, but the 
extreme toxicity caused by even low concentrations of antimycin A  suggests that 
this compound may not be entirely suitable for this application.
The identification of active M R P  protein in DLKP suggested that M R P  may have 
an involvement in the drug accumulation and resistance characteristics of clonal 
subpopulations isolated from the DLKP-A cell line. It was found that all of the 
clones analysed contained active M R P  protein. In a clone with a low level of 
adriamycin resistance,(DLKPA2B) it was found that Pgp expression increased 
and M R P  expression decreased from the levels present in DLKP. It was suggested 
that this was a result of high levels of Pgp protein expression being sufficient to 
facilitate survival of DLKPA2B in low adriamycin concentrations. For this reason 
M R P  protein expression could be down-regulated without any detrimental effects
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on the ability of this clone to survive in low adriamycin concentrations. In clones 
of higher adriamycin resistance such as DLKPA11B and DLKPA5F it was found 
that Pgp and M R P  protein expression was upregulated from the levels present in 
DLKPA2B. The simultaneous upregulation of M R P  protein synthesis in these 
clones may have contributed to the level of adriamycin resistance of these clones. 
The differences in M R P  protein levels between the various clones were relatively 
small. None of the clones expressed more M R P  protein than DLKP. The fact that 
small levels of M R P  protein were found to exist in the various clones does not 
necessarily mean that M R P  did not influence the drug accumulation and drug 
resistance characteristics of these clones. Even though these clones generally 
contain Pgp protein, M R P  may simultaneously exert some influences on the ability 
of drugs to be retained within the various clones. The adriamycin accumulation 
characteristics of the DLKPA6B and DLKPA1 IB cell lines did not correlate with 
the levels of Pgp protein possessed by these clones, (Heenan et al., 1997). The 
DLKPA6B cell line expressed extremely low levels of Pgp relative to DLKPA1 IB 
but after 4 hours these clones accumulated comparable levels of adriamycin. 
These results suggested that a non-Pgp drug efflux pump may have been involved 
in the ability of DLKPA6B and DLKPA11B to accumulate comparable levels of 
adriamycin. It was found that these clones contained comparable levels of M R P  
protein. These levels were found to be lower than the protein levels present in 
DLKP. For these reasons, it was demonstrated that M R P  was not the reason for 
the ability of DLKPA6B and DLKPA1 IB to accumulate comparable levels of 
adriamycin despite large differences in Pgp protein expression. The presence of 
non-MRP 1 gene product LtC4 transporters was suggested from the levels of LtC4 
transport achieved by the DLKPA5F and DLKPA2B clones. The protein levels of 
M R P  in DLKPA2B were found to be extremely low but yet IOVs from this clone 
exhibited significant [3H]-LtC4 transport activity. The [3H]-LtC4 transporting 
properties of DLKPA5F were higher than would be predicted from the protein 
levels of MRP-1 in the IOVs from this clone. The specific identity of the putative 
non-MRP 1 gene product [3H]-LtC4 transporters in the various clones was not 
obvious from the experimental data obtained to date. Further investigation in this 
area will be required in order to elucidate if non-MRP 1 transporters are present in 
the DLKP-A related clones.
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The demonstration of NSAID mediated enhancement of chemotherapeutic drug 
toxicity in MRP-expressing cell lines may indicate that NSAIDs could potentially 
be used in the clinical treatment of certain cancers in order to selectively enhance 
the cytotoxicity of chemotherapy. The possibility of including NSAIDs in 
chemotherapeutic regimes is currently being intensively investigated by 
researchers at the NCTCC. The investigations into the role of M R P  in the 
NSAID-mediated enhancement of chemotherapeutic drug toxicity effect 
uncovered a number of potentially important features of the roles of drug efflux 
pumps in human cancer cell lines. These findings have already been discussed but 
some of the future work emanating from these findings are discussed briefly in the 
following points.
1. The mechanism of drug transport by M R P  remains to be fully elucidated.
No direct evidence for active transport of [3H]-vincristine was found either 
in the presence or absence of G S H  but this may have simply been a result 
of the concentrations of [3H]-vincristine used. These were the maximum 
concentrations of drug that could be used experimentally because at higher 
concentrations, non-specific binding of [3H]-vincristine to the filters 
became problematic. In preference to examining the transport of [3H]- 
vincristine, it could be possible to monitor transport of unlabelled 
vincristine into IOVs using the ATP assay described in Section 2.14. In 
the presence of active transport of a suitable substrate and in the absence 
of creatine kinase, ATP levels significantly decrease (Figure 3.17.3.1). For 
this reason, it would be possible to indirectly monitor the active transport 
of any possible substrate of M R P  such as vincristine. It would obviously 
be necessary to include appropriate controls for these experiments to 
ensure that ATP hydrolysis was specifically occurring as a result of 
transport of a substrate by MRP. This system would facilitate the rapid 
identification of compounds with an ability to be actively transported by 
MRP.
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2. The explanation for the apparent increases in vincristine transport in the
presence of G S H  requires further investigation. As already described this 
could be a result of some form of co-transport of G S H  and vincristine or 
alternatively a result of multiple substrate binding sites on MRP. If the 
apparent increases in vincristine transport in the presence of G S H  were a 
reflection of the situation found for drug efflux in cells, then this effect 
should not be limited to vincristine and should be shared by all potential 
M R P  substrate drugs. This suggestion needs to be examined in more 
detail.
3. The studies carried out into the involvement of M R P  in the drug 
accumulation and drug resistance characteristics of M R P  in DLKP-related 
drug resistant variants concentrated totally on protein levels and [3H]-LtC4  
transport abilities of this transporter. As already described, G S H  
metabolism appears to be a critical factor in the involvement of M R P  in 
drug resistance. For this reason it would be necessary to analyse the 
characteristics of G S H  metabolism in these drug resistant variants of 
DLKP if one was attempting to conclusively explain the involvement of 
M R P  in the drug resistance of one of these variants. The analyses carried 
out using the drug resistant DLKP-A10 cell line demonstrated that the 
metabolic inhibitor antimycin A  may have effects on M R P  activity. Further 
investigations will be necessary in order to identify if this compound could 
have effects on M R P  drug efflux activity in non-Pgp overexpressing cell 
lines.
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Appendices
Appendix 7.1 Abbreviations
AA Arachidonic acid
ABC ATP binding cassette
Ace Acemetacin
ADR Adriamycin
AMP Adeno sine 5 ’ -monopho sphate
ATCC American Tissue Culture Collection
ATP Adenosine triphosphate
BSA Bovine serum albumin
BSO DL-Buthionine-[S,R]-sulfoximine
CDK Cyclin dependent kinase
cDNA Complementary deoxyribonucleic acid
CHO Chinese hamster ovary
Cis Cisplatin
CK Creatine kinase
CML Chronic myelocytic leukaemia
COX Cyclooxygenase or Prostaglandin H synthase
CsA Cyclosporin A
Da Dalton
Dauno Daunorubicin
DMEM Dulbeccos modified Eagles medium
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
ECL Enhanced chemiluminescence
EDTA Ethylenediamininetetraacetic acid
ELISA Enzyme linked immunosorbant assay
Epi Epirubicin
FCS Foetal calf serum
GSH Reduced glutathione
GST Glutathione-S-transferase
HC1 Hydrochloric acid
Hepes 4-(2-hydroxyethyl)-l-piperazine ethane sulphonic acid
HETE Hydroxyperoxy fatty acid
HPLC High pressure liquid chromatography
IC50 Drug concentration sufficient for achievement of 50% cell kill
IL -lp Interleukin 1(3
IMS Industrial methylated spirits
Indo Indomethacin
IOY Inside-out vesicles
Kcl Potassium chloride
Km Substrate concentration which allows reaction to proceed at one 
half of maximum rate.
LRP Lung resistance-related protein
Lt Leukotriene
MDR Multidrug resistance
M ef Mefenamic acid
MEM Minimum essential medium
MgCl2 Magnesium chloride
MHC Major histocompatibility complex
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mRNA Messenger ribonucleic acid
MRP Multidrug resistance associated protein
MT Metallothionein
NaCl Sodium chloride
NADPH Nicotine adenine dinucleotide phosphate
NaOH Sodium hydroxide
NEAA Non-essential amino acids
NSAID Nonsteroidal antiinflammatory drugs
NSCLC Non-small cell lung carcinoma
OD Optical Density
P Passage
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
Pg Prostaglandin
PGHS Cyclooxygenase or Prostaglandin H synthase
Pgl2 Prostacyclin
PgP P-glycoprotein
PMSF Phenylmethylsulphonyl fluoride
psi Pounds per square inch
Rb Retinoblastoma protein
RNA Ribonucleic acid
rpm Revolutions per minute
RT-PCR Reverse transcriptase polymerase chain reaction
SCLC Small cell lung carcinoma
SD Standard deviation
SDS Sodium dodedecyl sulphate
Sul Sulindac
TAP Transporter associated with antigen presentation
TBS Tris buffered saline
TEMED N,N,N’ ,N’ -T etramethyl-ethylenediamine
TGF-ß Transforming growth factor ß
Tol Tolmetin
Topo II DNAtopoisomerase II
Tris Tris(hydroxymethyl)aminomethane
Tx Thromboxane
UV Ultraviolet
Vcr Vincristine
Ver Verapamil
VM-26 Tenopside
Vmax Maximum rate o f reaction when substrate present at saturation 
levels
VP-16 Etoposide
Zom Zomepirac
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Appendix 7.2 Molecular weights
Compound Molecular Weight
Acemetacin 414
Adriamycin 580
Antimycin A 549
Aspirin 180
ATP 509
Cisplatin 300
Cyclosporin A 1203
Daunorubicin 564
Epirubicin 572
Fenoprofen 523
5-Fluoruracil 130
Glutathione (GSH) 307
Indomethacin 358
Ketoprofen 254
Leukotriene C4 626
Mefenamic acid 241
Mitoxantrone 517
MK571 537
Naproxen 230
Prostaglandin D2 353
Prostaglandin E2 353
Sodium azide 65
Sucrose 342
Sulindac 356
Taxol 854
Tolmetin 315
Verapamil 455
Vincristine 825
V P-16 589
VP-16 589
Zomepirac 314
326
Appendix 7.3 ICso values for D L K P  and DLKP-A10
Cell line Cisplatin IC50, (M-M)* Fold resistance
DLKP 1.125 ±0.15 1
DLKP-A10 0.90 ±0.12 0 .8
*Values are the average of triplicate in vitro toxicity assays performed on two separate 
occasions.
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